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If they are to enter routine clinical application, new radiopharmaceuticals must have rapid and 
simple labelling procedures, ideally inserting the radionuclide at the last synthetic step with 
no need for further purification. This thesis describes the development of new targeted 
strategies for molecular imaging. Targeted nanoparticles have great potential for application 
as radionuclide molecular imaging agents but are subject to several limitations, including 
complex radiolabelling procedures, slow pharmacokinetics, low uptake in target tissue, and 
potential toxicity. We have discussed a targeted nanoparticle system comprising 
biocompatible materials with intrinsic affinity for readily-prepared radiotracers such as 18F-
fluoride and 99mTc-technetium bisphosphonate derivatives. Such a system would offer simple 
labelling, and signal amplification (each particle can deliver many radionuclides). To overcome 
slow pharmacokinetics we proposed to exploit pretargeting, whereby the radionuclide-
nanoparticle bond can form in vivo. Firstly, a large pretargeting agent (nanoparticle) that has 
affinity for both its target tissue and radionuclide probe, accumulates at the target site slowly 
over a period of time. This is followed by a chasing step, where a small radionuclide probe 
(18F-fluoride and 99mTc-bisphosphonate) distributes rapidly to the pretargeting agent, while 
untargeted circulating radionuclide probe clears rapidly from the blood pool. 
 
The reader is first introduced to the topics of radiopharmaceutical particulates and 
pretargeting, emphasing the requirement for novel radiopharmaceutical targeting methods. A 
literature review discussing fluoride affine materials was performed to guide initial screening 
experiments. We screened many inorganic nanoparticulate materials for binding to 18F-
fluoride. Of the materials tested, hydroxyapatite (HA) and Alhydrogel showed the most 
efficient binding to 18F-fluoride. The 18F-HA interaction was highly stable in serum, while the 
18F-Alhydrogel interaction was moderately stable in serum. 
 
HA materials were prepared via wet chemical precipitation. The effect of synthesis 
termperature and post-synthesis treatment was investigated. Stabilisation and 
functionalisation of HA nanoparticles with various ligands was discussed. Synthesis 
temperature did not greatly affect particle properties, while calcination and hydrothermal 
post-synthesis treatments controlled particle morphology and crystallinity. HA particles 




(SHMP) and polyethyleneglycol-bisphosphonates (PEG-BP). The bisphosphonate – 
Alendronate was used to link small molecules such as amino acids and fluorescein 
isothiocyanate to HA surfaces, for potential targeting applications.  Porous hollow silica 
particles were prepared using a novel templating method, using HA as core material. 
However, 18F-fluoride showed poor affinity for these materials.  
 
A novel bifunctional bisphosphonate chelator, N,N-bis(quinoylmethyl)pamidronate-amine 
(BQMPA) was prepared and its potential as  a probe for SPECT and fluorescence imaging was 
investigated. A DOTA like bisphosphonate – BPAMD (a literature compound) – and its novel 
64Cu radiolabelled complex were prepared. The preparation of 99mTc and Re-BQMPA 
complexes resulted in the formation of multiple products. The 64Cu-BPAMD complex was 
identified as a single complex and was kinetically stable in serum over 24 h. Both 99mTc-
BQMPA and 64Cu-BPAMD showed high affinity for HA materials. We screened inorganic 
nanoparticulate materials for binding to 99mTc- and 64Cu-bisphosphonates. We identified that 
99mTc(CO)3-DPA-Ale (
99mTc labelled dipicolylamine-alendronate) and 64Cu-BPAMD bind to a 
wide range of metal oxide materials with high efficiency. HA and Alhydrogel were chosen as 
lead materials for further in vitro and in vivo investigations. The 99mTc- and 64Cu-
bisphosphonate -HA and -Alhydrogel interaction was robust in biological media. In addition, 
functionalised HA particles were loaded with radiolabelled bisphosphonates in high efficiency.  
 
A series of in vitro and in vivo studies with prelabelled and pretargeted HA and Alhydrogel 
particles were performed. HA1, HA2 and Alhydrogel particles were sequestered within 
phagosomes inside macrophages. The HA and Alhydrogel-99mTc(CO)3-DPA-Ale interaction 
remained intact in vivo. HA particles functionalised PEG-bisphosphonates and SHMP were 
prelabelled with 99mTc(CO)3-DPA-Ale and showed high accumulation in the liver and spleen. 
Preliminary pretargeting studies with 99mTc(CO)3-DPA-Ale indicated that Alhydrogel particles 
can be radiolabelled in vivo. In conclusion, HA, Alhydrogel, bisphosphonate bioconjugates and 
bone-affine radiopharmaceuticals can be assembled into a targeted nanoparticulate 
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-  have low binding efficiencies to HA1. 
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Figure 6.14: Binding of 99mTc(CO)3-DPA-Ale to HA1 in different media over time. (A) 
H2O (B) TRIS-HCl buffer (pH 7.4) (C) PBS buffer (D) human serum 
 
268 
Figure 6.15: Binding of 99mTc(CO)3-DPA-Ale to Alhydrogel in different media over 
time. (A) H2O (B) human serum 
 
269 
Figure 6.16: Kinetic stability in water wash and incubation in serum of 99mTc(CO)3-
DPA-Ale-NPs. (Top) HA1 (Bottom) Alhydrogel 
 
269 
Figure 6.17: Binding of  99mTc(CO)3-DPA-Ale to functionalised HA Particles  
 
272 








Figure 6.20: Survey of 64Cu-(BPAMD) binding materials 
 
274 
Figure 6.21: Binding of 64Cu-BPAMD to HA1 in different media over time in TRIS-HCl 
buffer (pH 7.4) 
 
274 
Figure 6.22: kinetic stability of 64Cu-BPAMD labelled HA1, HA1HMP1 and 
HA1PEGBP1 in serum and water washing 
 
275 
Figure 7.1: TEM images of nanoparticle uptake in murine macrophages J744.1. (A) 
HA1 (B) HA2 (C) Control, (D) Alhydrogel*. The images show internalisation of HA 
nanoparticles via non specific endocytosis. Nanoparticle aggregates can be seen in 
endosome compartments, traversing though the cytosol. * Image D was provided 




Figure 7.2: Confocal Z-Stack images of HA2FITCBP uptake in murine macrophages 
J744.1. The blue regions are associated with the nuclear stain (DAPI), green regions 
in the cytosol are punctuate and can be attributed to phagocytosed HA2FITCBP 
nanoparticles within endosomes 
 
290 
Figure 7.3: Accumulation of 99mTc(CO)3-DPA-Ale  (Top) and  
18F-fluoride (Bottom) in 
particle treated macrophages (J774.1) 
 
291 
Figure 7.4: SPECT/CT images of intravenously injected 99mTc(CO)3-DPA-Ale-
Alhydrogel in normal mice at 30 minutes (Left) and 3 h (Right). There was no uptake 
in the lungs, high uptake in the liver and spleen 
 
293 
Figure 7.5: SPECT/CT images of intravenously injected 99mTc(CO)3-DPA-Ale-HA2PEG1 
in normal mice at 30 minutes (Left) and 3 h (Right) High liver and spleen uptake, less 
lung uptake than previously observed for untreated HA2 particles,1 suggesting 
disaggregation of HA2 when modified with PEG 
 
293 
Figure 7.6: SPECT-CT images of intravenously injected 99mTc(CO)3-DPA-Ale–
HA2HMP1 in normal mice at 30 minutes (Left) and 3 h (Right) High liver and spleen 
uptake, less lung uptake than previously observed for untreated HA2 particles,1 but 
more than the HA2PEGBP1 particles above. Less aggregated than HA2 but more 





Figure 7.7: Biodistribution of intravenously injected, radiolabelled nanoparticles in 
normal mice at 3 h, where n=1.  99mTc(CO)3-DPA-Ale labelled NP: (Top) Alhydrogel 
(Middle) HA2HMP1 (Bottom) HA2PEGBP1 
 
296 
Figure 7.8: Biodistribution spleen/liver ratios of intravenously injected, radiolabelled 
nanoparticles in normal mice at 3 h, 99mTc(CO)3-DPA-Ale-Alhydrogel, HA2HMP1 and  
HA2PEG1    
 
297 
Figure 7.9: Biodistribution of intravenously injected 99mTc(CO)3-DPA-Ale in  normal 
mice at 3 h, where n=3 mice. 
 
297 
Figure 7.10: Whole body SPECT/CT images of attempted pretargeting in normal 
mice at 1 h post radiotracer injection. Unlabelled nanoparticles were intravenously 
injected, then chased by i.v. injected tracer (99mTc(CO)3-DPA-Ale) 20 min later. (Left) 
Alhydrogel (Right) HA2PEGBP1. High bone uptake of the tracer is observed in both 




Figure 7.11: Biodistribution of attempted pretargeting in normal mice at 3 h post 
radiotracer injection. Unlabelled nanoparticles were intravenously injected, then 
chased by i.v. injected tracer (99mTc(CO)3-DPA-Ale) 20 min later. (Top) Alhydrogel  
(Bottom) HA2PEGBP1 (n=3 mice in both experiments) 
 
299 
Figure 7.12: Whole body SPECT/CT images of attempted pretargeting in normal 
mice at 1 h post radiotracer injection. Unlabelled Alhydrogel was intravenously 
injected, then chased by i.v. injected tracer (99mTc(CO)3-DPA-Ale) 2 min later. High 
bone, liver and spleen uptake is observed. Uptake in the liver and spleen indicates 
in vivo binding of 99mTc(CO)3-DPA-Ale to preadministered Alhydrogel 
 
300 
Figure 7.13: Sequential SPECT/CT images of attempted pretargeting in normal mice 
at (A) 6 min (B) 12 min (C) 18 min (D) 24 min (E) 30 min (F) 36 min post radiotracer 
injection. Unlabelled Alhydrogel was intravenously injected, then chased by i.v. 
injected tracer (99mTc(CO)3-DPA-Ale) 2 min later. High uptake is observed in the liver 
and spleen within 6 minutes, indicatating that the in vivo binding of 99mTc(CO)3-DPA-
Ale to preadministered Alhydrogel is rapid 
 
301 
Figure 7.14: Biodistribtuion of attempted pretargeting in normal mice at 3 h post 
radiotracer injection. Unlabelled Alhydrogel was intravenously injected, then chased 





Figure 7.15: Biodistribution spleen/liver and spleen/bone ratios of intravenously 
injected nanoparticles (Alhydrogel and HA2PEGBP1) chased by 99mTc(CO)3-DPA-Ale 
(2 or 20 minutes later),  in normal mice at 3 h post radiotracer injection. Includes 




Figure 7.16: (Top) Biodistribution of Intravenously injected 64Cu-BPAMD in  normal 
mice at 3 h, where n=3 mice.(Bottom) Biodistribution of intravenously injected 64Cu-
BPAMD labelled HA1PEGBP1 at 3 h, where n= 3 mice 
 
303 
Figure 7.17: PET/CT images of intravenously injected 64Cu-BPAMD in normal mice at 
45 minutes (Left) and 75 minutes (Right) post injection 
 
304 
Figure 7.18: PET/CT images of intravenously injected 64Cu-BPAMD-HA1PEGBP1 












List of Tables 
 
Table 1.1: Characteristics of PET, SPECT and MRI imaging techniques.1, 10, 13 
 
33 
Table 1.2: Summary of the range of particulate architecture currently available 
 
38 
Table 1.3: Radionuclide properties for synovectomy, adapted from ref.169 
 
50 
Table 2.1: FDA approved and PET radiopharmaceuticals under clinical 
evaluation. Highlighting the high frequency of 18F labelled radiotracers and the 
growing list of biological targets.  As of Dec 2011 an NDA (New Drug 
Application) is required for FDA approval. * denotes NDA approval. (table 
adapted from reference 6 
 
79 
Table 2.2: Materials used for fluoride removal in water. Please note that the 
fluoride removal capacities are highly dependent on experimental conditions, 
only an objective comparison of fluoride removal abilities can be made given 
the variation of experimental conditions 
 
83 
Table 2.3: Particulate and bulk materials surveyed for 18F- Fluoride binding, 
origin and particle size stated by manufacturer except, a measured by 
Transmission electron microscopy, b measured by Dynamic light scattering 
 
102 
Table 2.4: Binding characteristics of HA and Al(OH)3 nanoparticles for binding to 
18F-fluoride. Kd is the nanoparticle concentration at half-maximal % binding; 
Bmax is the maximal % binding. Al(OH)3 has the highest affinity as indicated by 
the low Kd value 
 
111 
Table 3.1: List of dispersing agents used for particle stabilization 
 
139 
Table 3.2: Ligands used to modify HA 
 
140 
Table 3.3: HA materials synthesised. Note (X) in material name represents 
concentration of ligand used in modification, listed in column 2 




Table 3.4: Crystallite size and crystallinity of HA samples calculated using 







Table 3.5: Particle and crystallite size measured by DLS, TEM and XRD. For TEM 
measurements a = length, b = width, of rod like particles. DLS measurements 




Table 3.6: Summary of HA1, HA2 and HA3 particle sizes by DLS, and zeta 
potential measurements. The polydispersity index indicates the spread of values 
in the distribution, thus the homogeneity of the dispersion, ranging from 0 to 1. 
A value closer to zero is more homogenous, a value above 0.3 is considered to 
have heterogeneity.111   
 
154 
Table 3.7: Particle sizes of HA1 in the presence different stabilizing agents. 
Measured by DLS. The particle size given is an average cumulant result (where 
n= 3). The polydispersity index indicates the spread of values in the distribution, 
thus the homogeneity of the dispersion, ranging from 0 to 1. A value closer to 
zero is more homogenous, a value above 0.3 is considered to have 
heterogeneity.111   
 
156 
Table 3.8: Particle sizes and zeta potential of HA1 functionalized with different 
ligands. The particle size given is an average cumulant result (where n= 3). The 
polydispersity index indicates the spread of values in the distribution, thus the 
homogeneity of the dispersion, ranging from 0 to 1. A value closer to zero is 
more homogenous, a value above 0.3 is considered to have heterogeneity.111   
 
163 
Table 3.9: TGA analysis. Weight loss observed between 150-650 oC. 
 
163 
Table 3.10: XPS table of peak binding energies for conjugation of pamidronate, 
lysine, glutamic acid and FITC to HA surfaces  
 
169 
Table 3.11: XPS table of % relative atomic content for conjugation of 
pamidronate, lysine, glutamic acid and FITC to HA surfaces.  
 
170 
Table 3.12: XPS table of total % relative atomic content for conjugation of 
pamidronate, lysine, glutamic acid and FITC to HA surfaces.  
 
170 
Table 3.13: TGA Analysis of HA1, HA1PAM1 and HA1PAMFITC 
 
170 
Table 4.1: HA and hollow silica particle dimensions and zeta potential 
 
186 
Table 6.1: Particulate and bulk materials surveyed for 99m Tc(CO)3 DPA-





manufacturer except, ameasured by transmission electron microscopy, b 
measured by dynamic light scattering 
 
Table 6.2: Comparison of 99mTc(CO)3DPA-Ale labelling efficiencies and published 
isoelectric points (IEP) 
 
259 
Table 6.3: Binding characteristics of HA and Alhydrogel nanoparticles for binding 
of 99mTc(CO)3-DPA-Ale and 
18F-fluoride (results from chapter 2). Kd is the 
nanoparticle concentration at half-maximal % binding; Bmax is the maximal % 
binding. A high Kd value implies weak binding, a low value implies strong binding 
 
264 
Table 6.4: List of functionalised HA particles and their labelling efficiency and 























AA – activated alumina 
ADEPT – antibody-directed prodrug therapy 
AES – affinity enhancement system 
APTES – 3-aminopropyltriethoxysilane 
BLG – NCA- benzyl-L-glutamate N-carboxyanhydride  
BQMPA – N,N-bis(quinoylmethyl)pamidronate-amine 
BP – bisphosphonate 
BPAMD – 4,7-Bis-carboxymethyl-10-[[(hydroxyphosphinoyl-phosphono-methyl)-carbamoyl]-
methyl] 1,4,7,10-tetraazacyclododec-1-yl-acetic acid 
bsMAbs – bispecific antibodies  
CBQCA – 3-(4- carboxybenzoyl)quinoline-2-carboxaldehyde 
CLIO – cross linked iron oxide nanoparticles  
CT – computed tomography 
CTAB – cetyltrimethylammonium bromide 
DIPEA – N,N-Diisopropylethylamine  
DLS – dynamic light scattering 
DMF – dimethylformamide 
DO3A  – 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid  
DOTA – 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DPA – dipicolylamine 
DPA – Ale -dipicolylamine-alendronate 
DTC – dithiocarbamate 
DTPA – diethylenetriaminepentaacetic acid 
EDAX – energy dispersive X-ray analysis 
EDTA – ethylenediaminetetraacetic acid  
EDTMP – ethylene-diaminetetramethylene- phosphonate  
EPR – enhanced permeability and retention effect 
ESI MS – electrospray ionisation mass spectrometry 
FDA – food drug agency 
FDG – 2-fluoro-2-deoxy-D-glucose 
Fmoc – fluorenylmethyloxycarbonyl 
FMT – fluorescence-mediated tomography 




FTIR – fourier transform infrared spectroscopy 
GAGS – glycosaminoglycans 
Glu – glutamic aicd 
HA – hydroxyapatite 
HEDP – hydroxyethylidene diphosphonate or etidronate 
HMDP – hydroxymethylene diphosphonate 
HMPAO – hexamethylpropyleneamine oxime 
HPLC – high performance liquid chromatography 
HSG – histamine-succinyl-glycine 
HT – hydrothermal treatment 
HVJ – hemagglutinating virus of Japan 
HYNIC – 6- hydrazinopyridine-3-carboxylic acid 
ICSD – inorganic crystal structure database 
ID/g  – injected dose per gram 
IEP – isoelectric point 
Ig – immunoglobulin 
IgG – immunoglobulin G 
Lys – lysine 
m – multiplet 
mAb – monoclonal antibody 
MAG3 – mercaptoacetylglycylglycylglycine 
MAMA – monoaminemonoamidedithiol  
MDP – methylene diphosphonate or medronate  
MES – 2-(N-morpholino) ethanesulfonic acid  
MORF – phosphorodiamidate morpholino oligomers  
MRI – magnetic resonance imaging 
MS – mass spectrometry 
NDA – new drug approval 
NHS – N-Hydroxysuccinimide 
NMR – nuclear magnetic resonance spectroscopy 
NOTA – 1,4,7-triazacyclononane-1,4,7-triacetic acid  
NP – nanoparticle 
PBLG – poly(g-benzyl-L-glutamate)  
PBS – phosphate buffered saline 




PEG – polyethyleneglycol 
PET – positron emission tomography 
PFPE – perfluoropolyether  
Pz – pyrazolyl-diamine 
PZC – point of zero charge 
RP – reverse phase 
RT – room temperature 
s – singlet 
scFv – single-chain variable antibody fragment 
SCK’s – shell cross-linked nanoparticles 
SDS – surfactant sodium dodecyl sulphate 
SHMP – sodium hexametaphosphate   
SLN – sentinel lymph node  
SMP – N-succinimidyl-3-maleimido propionate 
SPECT – single photon emission computed tomography 
t – triplet 
TATE  – Tyr3-octreotate 
TCP – tricalcium phosphate 
TEA – triethylamine 
TEM – transmission electron microscope 
TETA – 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid 
TLC – thin layer chromatography 
TOC –Tyr3-octreotide 
XPS – X-ray photoelectron spectroscopy 










1.1 Aims and Overview 
The opening chapter of this thesis describes the application of positron emission tomography 
(PET) and single-photon emission computed tomography (SPECT) using particulate 
radiopharmaceuticals and the requirement for novel targeting strategies in the field of 
diagnostic medical imaging and radiotherapy. 
 
 Although a review of aspects of the wider field of radiopharmaceutical particulates has been 
conducted, particular attention is paid to the preparation of nanoparticles and their potential 
radiolabelling strategies, reviewing pretargeting and bioorthogonal concepts. 
Radiopharmaceutical particulates have been used for decades, but are generally poorly 
defined and accumulate at their target by virtue of their size.  The expansion of modern 
nanomaterial technologies can be exploited to fulfill the requirement for novel, specific 
targeting strategies in nuclear medicine. There are numerous examples of radiolabelled 
nanoparticles for PET and SPECT in literature. However, we aim to develop a novel 
nanoparticle targeting strategy, exploiting the concept of pretargeting, to improve 
pharmacokinetics and introduce the maximum activity to target sites expressed in low 
quantities. The subject of this thesis is to investigate the nanoparticle binding properties of 
simple radiolabelled probes, such as 18F-fluoride and 99mTc labelled bisphosphonates. The aim 
is to identify novel materials and explore their in vitro and in vivo application towards the 
pretargeting strategy.  
 
The reader will be introduced to the principles of nanoparticles with particular focus on their 
in vivo application. The introduction includes a historical review of clinically used 
radiopharmaceutical particulates and novel radiolabelled nanoparticles. The purpose is to 
demonstrate the range of particulates in current use and the recent emergence of actively 
targeted nanoparticles with more finely tuned properties. The concepts of pretargeting and 
bioorthogonal chemistry are introduced, with a view to their application in nanoparticle 







The radionuclide imaging techniques of positron emission tomography (PET) and single-
photon emission computed tomography (SPECT) remain at the forefront of molecular imaging 
for non-invasive visualisation, characterisation and quantification of biological processes at 
the molecular and cellular levels in living systems.1-4 Advances in technology and imaging 
probe design have extended their use into the field of drug discovery and development.5, 6 
 
The principle of PET is based on positron emitting radionuclides. Positrons are emitted from 
decaying radionuclides and travel a short distance through tissues (known as positron range), 
before annihilation with an electron. Annihilation produces two 511 keV γ-rays, emitted 
simultaneously in opposite directions, essentially at 180o apart (Figure 1.1).7, 8 The γ-rays are 
detected by an array of surrounding detectors producing 2-D or 3-D images. SPECT imaging 
uses radionuclides that directly emit γ-rays, typically lower energy than PET isotopes, between 
30-300 keV. The single photons are emitted and detected using similar technology to PET.5, 6 
However, the major difference is the requirement of a physical collimator to restrict the 
travelling direction of the emitted γ-rays and provide directional information for image 
production.9 In contrast, PET requires only electronic “collimation” (coincidence detection) to 
obtain information on the origin of the two coincident γ-rays.  
 
In recent years the expansion of PET has been driven by the advent of 18F labelled 2-fluoro-2-
deoxy-D-glucose (FDG). FDG is used on a daily basis to pinpoint sites of high glucose 
metabolism for the diagnosis of diseases such as cancer. As a result, the worldwide growth of 
PET has significantly increased the availability of 18F and the potential for development of new 
tracers. While SPECT imaging continues to evolve alongside PET, each retains its respective 
advantages and disadvantages (Table 1.1).10, 11 From a physics viewpoint, the major advantage 
of PET imaging over SPECT is higher sensitivity, resulting in significantly improved image 
quality and quantification, and the feasibility of dynamic scanning of biological processes. The 
resolution of PET and SPECT is relatively low with poor anatomical detail in comparison to 
imaging techniques such as magnetic resonance imaging (MRI).9 The resolution of PET is 
limited by the positron range, typically 0.5-2.0 mm in human tissue,7 whereas SPECT is mainly 
limited by technology (i.e. collimator). However, the advent of dual PET/CT and SPECT/CT 
scans, and more recently PET/MRI, provides both anatomical and functional information fused 






Figure 1.1: Schematic representation of PET from positron emission and annihilation to gamma ray 




















Resolution(mm) ca. 5 ca. 10 ca. 0.1 
 




Chemical and biological properties also influence the choice of SPECT or PET isotope. For 
example, commonly used positron emitters, such as 11C, 13N, 15O, and 18F are covalently 
bonding elements that can be incorporated into small molecules, with no or only minor 
alterations in their chemistry. Alternatively, gamma emitters used for SPECT imaging are 
typically heavier elements, such as 99mTc, 67Ga and 111In, often requiring chelating ligands to 




their chemistry and biological behaviour, whereas the effect on labelling large peptides or 
proteins with heavier metallic radionuclides is less significant. In addition, the development of 
chemistry for PET is complicated by short lived isotopes such as 18F (T ½ = 110 mins), thus 
requiring challenging radiolabelling protocols. In contrast, the typically long half-life of SPECT 
isotopes can be advantageous; allowing for longer labelling protocols and increasing the 
imaging time window, making it possible to observe biological processes over several days. 
Nevertheless, longer lived PET isotopes are becoming more readily available, such as 64Cu (T ½ 
= 12.7 h).14 The availability of generator based SPECT isotopes, such as 99mTc has traditionally 
been considered cost effective and practical. However, as the number of cyclotrons available 
for producing PET isotopes increases, limitations in practicality become less apparent.     
 
For both PET and SPECT, new radiopharmaceuticals must have rapid and simple labelling 
procedures, ideally inserting the radionuclide at the last synthetic step with no need for 
purification, producing imaging agents with high radiochemical yield and purity. Developing 
strategies for targeted approaches in PET and SPECT chemistry is currently a hot topic of 
research.15 A problem for many biomolecule based imaging agents, such as antibodies and 
peptides, is their slow accumulation at target sites, particularly unfavorable for short lived PET 
isotopes. Another issue that ensues is that while FDG is taken up in great abundance by 
metabolising cells, the expression of new molecular targets at sites such as antigens or 
peptide receptors, is relatively low. For this reason, maximum specific activity delivering the 
maximum signal from the minimum number of target sites and tracer molecules must be 
achieved. To obtain high specific activity, several radionuclides may be attached to one probe. 
This can be achieved through the use of nanoparticle structures such as liposomes, 
dendrimers or nanocrystals, containing multiple binding sites. However, this will come at the 
expense of their large size and potentially poor biokinetics. With this in mind the concept of 
“pretargeting” may be applied (discussed later). Briefly, a “large” pretargeting agent, that has 
affinity for both its target tissue and radionuclide probe accumulates at the target site slowly 
over a period of time (e.g. bispecific antibody, bsMAb). This is followed up by a small 
radionuclide probe distributing rapidly to the pretargeting agent (e.g. hapten-chelate). 
Untargeted radionuclide probe is rapidly cleared from circulation, thus reducing the 
background signal. 
  
Within this thesis we aim to produce a novel pretargeting agent exploiting the availability, 
chemistry and simplicity of 18F and bifunctional chelating agents, such as 99mTc labelled 




material that is easily functionalised for targeting purposes and has high affinity for the 
simplest probes possible, i.e. 18F-fluoride. The 18F-fluoride ion is small and will distribute 
throughout the body rapidly, accumulating only in areas of high bone turnover such as bone 
metastases. We propose a pretargeting system that comprises three components: (1) a 
biocompatible nanoparticle that has high affinity for the selected bioorthogonal probe 
functionality; (2) a targeting functionality such as receptor targeting peptide or protein; and 
(3) a signal producing probe (e.g. radionuclide) capable of binding to the nanoparticles in vivo. 
Furthermore, the high affinity binding interaction of tracer with nanoparticles could also be 
useful in conventional targeting modes, where radiopharmacies prelabel particles before 
administration. In this sense, a rapid one step labelling protocol may be achieved, simply 
mixing particles with a tracer, requiring minimal purification. There are several advantages of 
pretargeted and prelabelled nanoparticles that we would like to exploit. For example, multiple 
binding sites (for high loading capacity of tracer, signal amplification), high affinity interactions 
(for rapid and stable binding), use of simple radionuclide tracers (e.g. 18F-flouride, can be used 
in aqueous solutions requiring no further modification), simple labelling protocols (i.e. one pot 
mixing with minimal purification required for prelabelled nanoparticles), and the avoidance of 
poor biokinetics of large molecules (in pretargeting strategies).   
 
Radiopharmaceutical particulates for imaging and therapy have been used for decades. 
However, they are generally poorly defined and consequently produce poor reproducibility. 
By exploiting modern nanoparticle technologies it is possible to produce well defined 
materials, with consistent particle size, morphology and surface properties. Initial studies 
within this thesis are focused on the synthesis and labelling of nanomaterials that have known 
affinity for 18F, such as silica, hydroxyapatite and aluminium hydroxide. 
 
Summary of Research Within this Thesis: 
 Identification of nanomaterials with high binding efficiency of simple radiolabelled 
probes. 
 Synthesis of nanoparticles and evaluation of their radiolabelling properties. 
 Development of nanoparticle derivatisation methodology. 







Figure 1.2: Schematic of proposed novel pretargeting strategy. (A) Pretargeting agent is administered 
(B) Pretargeting nanoparticle agent accumulates slowly at the target cell site (C) Radiolabelled probe is 
administered,  seeks out and targets its high affinity binding sites, then untargeted radiolabelled probe 
rapidly clears from the blood pool. 
 
1.3 Radiopharmaceutical Particulates 
Therapeutic and diagnostic radiopharmaceuticals can be divided into three main groups; 
molecular (18F-FDG, 67Ga-gallium citrate), macromolecular (125I-HSA, 125I-monoclonal 
antibodies), and particulate. Radiopharmaceutical particulates (also known as 
microparticulates, radiocolloids or radiofluids) vary in size from just a few nanometres to 
hundreds of microns in diameter, and have a variety of formulations, including colloids, 
liposomes, suspensions, aerosols and nanocrystals, summarised in table 1.2. Within this thesis 
“particulate” is a general term used to describe nanoparticle and microparticle formulations. 
Many microparticulates are radiolabelled with 99mTc, exploiting its excellent imaging 
characteristics for diagnostic purposes. However, microparticulates have been variously 
labelled with a variety of radionuclides for both imaging and therapeutic purposes, including 
186,188Re, 111In, 67Ga, 90Y, and 32P.  Some of these agents (and their clinical applications) are 
discussed below. 
  
Nanoscale devices in nanomedicine and biotechnology offer an attractive platform for the 
combination of biomedical imaging and nuclear therapeutic devices. Multifunctional 
nanocarriers capable of selectively targeting disease sites by virtue of targeting moieties on 
their surface could potentially be used for both diagnostic imaging and carrying large payloads 
of therapeutic drugs or therapeutic radionuclides.  These same agents could then be used in 
follow-up imaging to evaluate the effectiveness of their therapy. An increasingly common 




the respective advantages of different modalities to provide more powerful and accurate 
information. The combination of PET and MRI technologies into hybrid systems is still in its 
infancy, but the respective high sensitivities and high resolution of these two techniques are 
complementary; the development of dual PET/MRI microparticulate imaging agents to exploit 
this technology is a likely avenue of microparticulate research in the near future. 
 
1.3.1 Particulate Properties and Biodistribution 
When considering particulate biodistribution in vivo, surface chemistry, particle size, and 
morphology play important roles when interacting with cells and tissues of the body.  
Historically, non-uniformity in many of these parameters has been a significant problem in 
microparticulate manufacture, having implications for their labelling affinities and efficiencies. 
Ultimately, these non-uniformities result in variable biodistributions and rates of clearance 
from the body, which perhaps has limited the exploitation of particulate approaches to their 
full potential. The recent resurgence of interest in the nanomaterial field can be attributed to 
recent advances in techniques for nanoparticle synthesis, allowing greater control over 




Particulate size influences many aspects of their behaviour; a topic widely reviewed.17-20  The 
size of a particle determines its velocity in the bloodstream, and its capacity for diffusion 
across and adhesion to blood vessels and airways and the extracellular matrix. For example, 
the endothelial wall of tissues restricts nanoparticle uptake by virtue of their large size, since 
the diameter of paracellular transport pathways ranges between 0.5- 5 nm, depending on 
species.21 While small drugs can diffuse through capillary walls, larger nanoparticles rely on 
gaps to pass through the endothelial barrier to reach target tissues. Therefore, tissues with 
leaky endothelial walls such as liver, spleen and bone marrow display high particle uptake. 
Moreover, this property can be exploited to target tumours, since they contain leaky 
endothelial cells. This phenomenon is called the enhanced permeability and retention (EPR) 
effect (discussed later).22 The distribution of particles due to size is summarised as follows. 
Small particles (<10 nm) will be rapidly removed from circulation via renal excretion.23-25 
Larger particles (30-1000 nm) are taken up by the RES phagocytes in the liver, spleen and 
bone marrow. Particles in the range 30-150 nm can potentially cross blood vessel membranes 
and accumulate in bone marrow.26, 27 Nanoparticles in the range of 150-1000 nm typically 




lesser extent. Particulates larger than 10 µm are known to lodge in lung capillaries.29, 30 After 
administration by inhalation (a common approach for radioaerosol visualisation of lung 
ventilation) particles smaller than 2 µm in diameter have been shown to collect in alveolar, 
while those greater than 5 µm in diameter remain in the upper airway regions, bronchial 
tubes and trachea.31-33 
 
Nanomaterial ‘Nanomaterial’ means a natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, 
for 50 % or more of the particles in the number size distribution, one or more 






Spherical objects ranging from tens to hundreds of nanometres in size, composed 
of synthetic or natural polymers. The drug/agent of interest can be dissolved, 
entrapped, attached or encapsulated into or with the polymer matrix. 
Macroaggregates Aggregates of particles are defined as microaggregates if below 10 µm in diameter, 
and macroaggregates if they are larger. Often consisting of a range of sizes due to 
their preparation procedures, which include precipitation, coagulation or co-
precipitation. 
Microcapsules Microcapsules can be spherical, non-spherical, or aggregates. A core is surrounded 
by a wall or coating. The capsule or coating can improve pharmaceutical properties 
in various ways. 
Liposomes Liposomes are closed vesicles that form on hydration of dry phospholipids above 
their transition temperature. They can be classified by their size and number of 
bilayers. Multi-lamellar liposomes consist of several bilayers, each separated by 
aqueous spaces. Sizes range from a few hundred to thousands of nanometers in 
diameter.  Small unilamellar vesicles (SUV’s) are < 100 nm, while large unilamellar 
vesicles (LUV’s) are > 100 nm. Drugs/agents can be entrapped in the aqueous 
space or intercalated in the bilayer. 
Micelles An aggregate of molecules in solution, composed of hydrophilic and hydrophobic 
components generally arranged in a spherical shape, with  the hydrophobic core 
shielded by the hydrophilic groups from water 
Quantum dots Nanoscale crystalline structures that can transform the colour of light utilising 
quantum effects.  White light is absorbed, and re-emitted a couple of nanoseconds 
later at a different wavelength. Varying the size and composition of the quantum 
dot allows tuneable emission wavelength from blue to near infrared. 
Dendrimers Highly branched macromolecules with a number of chains radiating from a central 
atom or a cluster of atoms. They have controlled monodisperse 3D architecture, 
growing outwards from a central core in a series of polymerisation reactions, 
allowing precise control of their size. Folding and cavities in the core structure can 
create cages and channels. The surface groups of dendrimers can also be modified, 
allowing for a variety of applications. 






Surface Chemistry and Charge 
The interaction between microparticulates and the cells and tissues of the body is also highly 
dependent on microparticulate surface chemistry.  Opsonisation often takes place in the 
blood circulation, where blood serum components (commonly complement proteins C3, C4, 
C5 and immunoglobulins) bind to the particle surface, modifying them in such a way as to 
promote their recognition and phagocytic engulfment by macrophages of the RES 
(Reticuloendothelial system), thereby preventing the particle from reaching its desired 
target.34,35 Particulate surface characteristics such as charge are therefore important in 
determining particulate serum half life; neutral particles will have a slower opsonisation rate 
in comparison with those that are negatively charged.36 Negatively charged nanoparticles 
have been shown to adsorb proteins such as IgG, that promote phagocytosis.37, 38 Nanoparticle 
surfaces are therefore often decorated with groups that prevent or delay opsonisation to 
increase plasma half life, such as hydrophilic polymers and non-ionic surfactants like PEG 
(polyethyleneglycol).39, 40 
 
Functionalising surfaces with targeting agents can also be used to specifically direct 
nanoparticles to biologically relevant sites to demarcate a disease process. Antibodies, small  
molecules, carbohydrates and peptides are increasingly being used as targeting ligands for 
tissue or disease-specific accumulation in the brain, liver, spleen and tumours.41-43 These 
applications will be discussed in more detail later. The surface chemistry of nanoparticulates is 
also important when considering the interaction of particles with one another. Unchecked, 
many nanoparticulates in suspension tend to agglomerate, producing poor dispersity and 
inhomogeneous labelling. This issue is commonly combated by functionalisation with highly 
charged ligands so that particles repel each other, or branched polymers to sterically stabilise 
the particles in solution, although this must obviously be utilised with care to prevent 
problems associated with in vivo opsonisation. 
 
Nanoparticle Morphology 
Recent reviews have identified particulate shape as an important parameter controlling 
particle biodistribution.44-47 For example, shape may influence the flow of particles through 
blood vessels or phagocytic mechanisms may depend on shape recognition.21,  24 Specifically, 
worm-like, disc-like, and cylindrical shaped nanoparticles have been reported to evade 
phagocytic uptake more efficiently than spherical particles.24, 48 It is possible that mimicking of 
the distinctive shapes of bacteria, fungi and blood cells may ensure rapid and cell-specific 




lithography and microfluidics, it is now possible to produce a myriad of shapes, including 
boomerangs, doughnuts, cylinders and cubes for this purpose.44,  46 While particle shape seems 
to be one important determinant of uptake rate, it must be appreciated that it is only one of a 
range of particulate properties which determines uptake and biodistribution; thus it seems 
that a variety of particulate properties must be addressed to achieve the “ideal” 
nanoparticulate agent for a particular purpose.   
 
1.3.2 Synthesis of Particulate Structures  
The synthesis of nanoparticles can be achieved by a variety of methods, adopting both “top-
down” and “bottom-up” approaches.44, 46, 49 “Top-down” approaches such as ball milling (or 
attrition) or lithography, start with a material which is then sculpted down. Ball milling 
mechanically degrades a starting material to yield building blocks, which are subsequently 
converted into bulk materials. For example, this approach has been employed to achieve 
magnetic samarium cobalt particles as small as 25 nm,50 which can then be coated with gold 
for biological application.51 While attrition methods such as this can produce nanoparticles in 
a range of sizes, the size distribution is often wide, with variable particle morphologies.  
Photolithography uses light typically to etch a pattern or image onto a poly(ethyleneglycol) 
diacrylate polymer film, giving the capacity to generate microparticulates in a variety of 
shapes, which to date have included cubes, crosses and cylinders in the micrometre range.52  
Photolithography is currently the most widely used technology in the photelectronics industry, 
but it faces challenges with respect to its high cost and ability to reach sub-100 nm particle 
sizes.  A recent exciting prospect is the development of imprint lithography, produced at lower 
costs and capable of small sizes (e.g. <100 nm). Here, a mask mould is brought into contact 
with a liquid precursor or non-wettable substrate, which is cured by heat or UV light during 
the printing process. Gratton et al. have successfully used perfluoropolyether-based 
elastomers (PFPE’s) as moulds, which are relatively easy to then remove from the substrate, 
thereby generating nanoparticle cubes and cylinders with controllable size, shape and 
charge.47      
 
“Bottom-up” methods are currently more popular for nanoparticle synthesis due to their 
greater versatility and control over the resultant nanoparticle properties. Most approaches 
involve either self-assembly (creating liposomes, micelles or polymeric particles) or chemical 
synthesis (creating dendrimers or miniemulsions). These methods first take a nanomaterial 
building block, and assemble it into the final material, using either thermodynamic equilibrium 




supersaturation, nucleation and growth, while kinetic synthesis is achieved either by limiting 
the respective amounts of precursors available for growth, or confining the space available for 
growth, by utilising micelles, for example.  
 
Self-assembly occurs as a result of the spontaneous organisation of nanometre-scale building 
blocks, which may be organic, inorganic or polymeric materials, and is a common approach for 
the synthesis of vesicles or liposomes.53, 54 Liposomes consist of a phospholipid bilayer 
surrounding an aqueous or hydrophilic core. Under certain conditions the amphiphilic 
phospholipid structures will spontaneously arrange (self assemble) to form vesicles.  Not only 
can these vesicles be loaded with drugs, they are biocompatible and easily surface 
functionalised. Doxil® is a clinically available stealth liposome used in the treatment of ovarian 
cancer. Doxorubicin®, an anti cancer drug is encapsulated by a phospholipid layer coated in 
PEG polymer to help avoid the immune system uptake.55 Self assembly processes are highly 
dependent on the interaction between particles, their size and their shape. The surface 
properties of a particular particle/building block (such as charge and functionality) will affect 
how they interact, and thus govern the geometry and distances at which they will achieve 
equilibrium. 
   
The chemical synthesis of nanoparticulate materials is commonly achieved via precipitation 
reactions, while various other particulates have been obtained using suspension or emulsion 
polymerisation reactions and solvent evaporation. While both inorganic and organic methods 
have been employed in the past, the latter are most commonly used currently, due to recent 
advances in synthetic organic polymer chemistry. More recently a kinetic approach utilising 
microemulsion systems has been adopted, producing narrow particulate size distributions.56, 57 
Microemulsions consist of liquid mixtures of oil and water containing a surfactant. The 
surfactant forms a monolayer at the interface of the oil and water phases, with the 
hydrophobic tails facing the oil phase and polar heads facing the water phase. The resultant 
micelle “nanodroplets” formed can be used as reactors for chemical synthesis. A fission-fusion 
mechanism between the droplets results in a controlled micromixing process and in turn a 
more monodisperse particle synthesis. In this way, Munshi et al. have produced highly 
monodisperse polyacrylamide particles smaller than 100 nm in diameter, using reverse 







Nano and Micro-Particulates in Routine Use  
1.3.3 Lung Imaging 
The main function of the lung is to exchange inhaled oxygen with carbon dioxide from the 
blood. This gas exchange takes place in the alveoli, which are small densely capillaried sac-like 
structures which allow diffusion of gasses between blood and air. The flow of air into and out 
of the lungs is referred to as ventilation, and the flow of blood through the lungs as perfusion.   
Nuclear imaging of the lung (or lung scintigraphy) is widely used to visualise and quantify lung 
ventilation,  perfusion and mucociliary clearance to aid in the diagnosis of conditions such as 
pulmonary thromboemboli,59, 60 chronic obstructive pulmonary disease (COPD), interstitial 
pulmonary disease (IP), and asthma.61-63 While single photon emitting gases like 133Xe and 
81mKr may be used for measuring ventilation, radiolabelled aerosol suspensions including 
molecular 99mTc-DTPA and the particulate 99mTc labelled Technegas do not result in significant 
diagnostic differences, and have several advantages.63-66 First, microparticulate size can be 
tailored to target different regions of the lung;32 second, the greater retention time of 
microparticulates allows longer scan times, or sequential imaging to be performed; and third, 
labelling with 99mTc offers favourable radiopharmaceutical properties, such as a highly 
abundant 140 keV gamma ray, a short half-life (6.01 hours), and favourable dosimetry, as well 
as being cheap and readily available via 99Mo/99mTc generator production.   
 
99mTc-Macroaggregated Albumin (MAA) 
99mTc-macroaggregated albumin (MAA) is commonly used to measure lung perfusion,59, 61, 67, 68 
using a number of commercially available kits.69, 70 131I-MAA was the first radiolabelled MAA to 
be used in humans,71 but 131I was soon replaced by the more readily available 99mTc. MAA 
microparticles are formed by the thermal aggregation of human serum albumin; typically, a 
solution of human serum albumin is mixed with solution of stannous chloride to form Sn-MAA 
in a 0.1 M acetate solution buffered at pH 5.4. Sample solutions are then stirred before 
heating to 70-80 oC to form MAA aggregates. The aggregates are washed via centrifugation 
before resuspension in buffer solutions for labelling with 99mTc pertechnetate.29, 72, 73  Hunt et 
al. have produced an alternative formulation of MAA aggregates using a recombinant human 
albumin amid fears of contaminated blood derived agents spreading infections diseases.74  
Reproducible generation of MAA microparticulates of a specific size is fundamental to the 
accuracy of this technique. MAA size and labelling properties are highly dependant on 
temperature, stir time, pH, and reactant concentrations during preparations.29, 59 Adjusting 




properties. The introduction of a dispersing agent such as Tween 80, for example, before 
heating can produce a narrower size distribution.29 
 
For perfusion studies, it is recommended that 90 % of the particles are within the size range 
10-90 µm (although typically most are in the size range of 20-40 µm), and no particles should 
be larger than 150 µm.69, 70 The average diameter of lung capillaries is around 7 µm, while the 
average diameter of 99mTc-MAA is considerably larger. When injected intravenously, 99mTc-
MAA temporarily lodges in lung capillaries, providing the capacity to image the lung 
vasculature, and generate an index of lung perfusion.  If pulmonary flow is normal, 99mTc-MAA 
distributes to the entire pulmonary area.  Defects in perfusion indicate a high probability of 
pulmonary embolism.  99mTc-MAA is typically retained in the lung with a half-life of 1 to 5 
hours (with larger aggregates having a longer half-life), before being broken down 
mechanically by the pressure of the blood, metabolised by the RES, then excreted via the 
urine.75, 76 The number of particles administered per dose should be in the range 60,000 -
700,000 with a recommended average of 200,000. A typical injection would block 
approximately 1% of lung capillaries, and should not exceed 1.5x106 microparticles, carrying 
148 MBq of activity, resulting in an estimated whole body radiation dose of 0.60 mGy.69, 70  
Contraindications may include hypersensitivity to human serum albumin, and the technique 
may not be suitable for patients with pulmonary hypertension.69, 70, 77  
 
1.3.4 Ventilation Imaging with Particles 
Radioaerosols are inhaled by the patient via a nebuliser or special ventilation equipment to 
visualise lung ventilation; their lung distribution is dependent on particle size.  Droplets must 
be smaller than 2 µm to reach the lower regions of the lungs, and for uniform distribution 
throughout the lower lungs, particle sizes smaller than 0.5 µm are recommended.31-33 When 
targeting the central airways, particles greater than 5 µm are employed; in this way 
mucocilliary function can be studied in pathologies such as asthma and cystic fibrosis.  
Radioaerosols that have been routinely used include 99mTc-DTPA (diethylene triamine 
pentaacetic acid), 99mTc-Sn-Phytate, 99mTc-sulfur colloid, Technegas and Pertechnegas.60, 63, 66, 
78, 79 99mTc-DTPA is hampered by the fact that it crosses lung membranes too quickly, meaning 
that successive scans will differ, with knock-on effects on image quality.80 The radioaerosols 
99mTc-sulfur colloid and 99mTc-Sn-Phytate have slower lung clearance and help to overcome the 
image stability issue.81, 82 However, 99mTc-sulfur colloid and 99mTc-Sn-phytate are known  




Technegas and Pertechnegas, now most commonly used for ventilation studies consist of 
smaller carbon based particles. They remain stable to transmembrane transfer and have lower 
bronchial activity.  Technegas is a 99mTc-labelled aerosol produced by evaporating 
pertechnetate to dryness a graphite crucible.  The pertechnetate-coated crucible is then 
rapidly heated to 2500 oC in an inert atmosphere of argon to produce a fine dust of 99mTc-
labelled carbon particles.83-85 Faulty equipment may lead to large particles being produced 
which will impair the image quality. For a typical ventilation study, approximately 40 MBq of 
the radioaerosol is inhaled and up to 4-6 images of the lungs are taken with up to 200,000 
counts per view.60, 84 Technegas distributes to alveoli and distal non-ciliated airways, avoiding 
accumulation in the central regions of the lung,86 clearing very slowly, with a biological half life 
of up to 135 hours.61, 87, 88   
 
The morphology of Technegas was originally thought to resemble that of buckminster 
fullerene.87 However, since Technegas particle sizes larger than 1 nm have been reported, this 
is not necessarily the case. Lemb et al. described Technegas as agglomerated graphite 
particles (60-160 nm), comprised of hexagonal primary particles 7-23 nm in size.85 More 
recently, Senden et al. reported Technegas microparticles to be hexagonal platelets of 
metallic technetium contained within a thin layer of graphitic carbon 30-60 nm in size.83   
Pertechnegas is produced in a similar fashion to Technegas, but in the presence of oxygen.79 
As little as 0.1% oxygen leads to its formation rather than Technegas.79 The particulate size is 
comparable to those found in Technegas (30-100 nm) while mass spectrometry reveals the 
presence of a variety of gas phase Technetium oxides.89 In terms of image quality, 
Pertechnegas is much the same as Technegas. However, its distinguishing property is its rapid 
rate of clearance from the lungs, 7-10 minutes, which means that its biological behaviour is 
similar to 99mTc-pertechnetate.89, 90 In this respect it could be seen as advantageous to avoid a 
large radiation dose to the lungs, but may increase dose to other regions such as the thyroid. 
Both 99mTc-MAA and Technegas are routinely used in lung ventilation and perfusion and 
studies, often used sequentially with the images being matched.61 However, there are many 
non-particulate agents used for lung ventilation imaging, such as gases 133Xenon, 127Xenon, 
and 81mKrypton. The choice is highly dependent on cost, diagnostic quality, use and safety.66 
 
1.3.5 Reticuloendothelial System (RES) Imaging  
The reticuloendothelial system (RES) consists of organs containing phagocytic cells (Kupffer 
cells in the liver, reticular cells in lymph nodes, spleen and bone marrow, and tissue 




pathogens such as bacteria, protozoa and damaged cells as part of the immune response.93-95 
The liver, spleen and bone marrow contain 80-90, 5, and 5% of RES cells respectively.91, 92 
Their phagocytic nature makes them very amenable to imaging approaches utilising 
radiocolloids. Nanoparticles smaller than 150 nm accumulate in bone marrow, while those in 
the size range 150 nm to 1000 nm tend to accumulate in liver and spleen (see above 
discussion).96 A number of radiocolloids have been used for imaging the RES, including 198Au-
colloid, 99mTc-macroaggregated albumin, 99mTc-albumin colloid, 99mTc-sulfur colloid, 99mTc-Sn-
colloid, and 99m Tc-calcium phytate.97-100 
 
 198Au Gold Colloid 
Colloidal gold first appeared as a radiopharmaceutical in the 1940’s and was identified as a 
clinical tool for liver, bone marrow, lymph imaging in the 1950’s and 60’s.101-104 Colloidal gold 
has also been applied as a radiotherapeutic agent in the treatment of arthritis and certain 
cancers by intracavity injection.105, 106 Although still available commercially in some countries, 
it has largely been superseded by other radiocolloids for imaging purposes due to its 
undesirable beta and high gamma radiation doses. To this end, it is reviewed purely from a 
historical point of view as one of the first colloidal particulates.  
 
198Au decays with a half life of 2.7 days emitting a high energy gamma ray (412 keV) and beta 
particle (0.96 MeV). While the beta radiation has applications in radiation therapy, in terms of 
imaging, the high radiation dose may cause radiation necrosis and damage to organs such as 
the liver, kidney and spleen.107  
 
A comprehensive study and synthesis of colloidal gold particles from gold chloride and sodium 
citrate was first completed by Faraday in 1857.108 Methods remain much the same today, 
reducing chlorauric acid (Au3+, HAuCl4) to Au(0) with sodium citrate.
109, 110 The resultant  
particles are in the size range 10-30 nm,111 making them ideal for localisation in bone marrow 
and lymphoscintigraphy (discussed below). However, the use of 198Au gold colloid for bone 
marrow imaging has largely been replaced by preferable 99mTc colloids. Although originally 
attributed to pharmacological toxicity, the pathological effects of radioactive colloidal gold 
microparticles are actually mediated by the associated radiation exposure. Colloidal gold 
therefore still represents a versatile platform for biomedical applications.112,113 In the early 
90’s Geirsig and Mulvaney prepared stabilised gold particles capped with thiol groups, making 




also be used as an anchor for surface functionalisation with other ligands and molecules, in 
preparation for biological applications.115  
 
99m Tc-Sulfur Colloid  
99mTc-sulfur colloid has a blood clearance half life of 2-2.5 min by the RES.116-118 Uptake 
depends on blood flow to the particular organ and content of phagocytic cells. For liver and 
spleen imaging, the recommended dose is between 37 and 296 MBq, and for bone marrow 
imaging a dose of 111-444 MBq is recommended.119, 120 Around 90% accumulates in the liver, 
with 5-10% distributing to the spleen and bone marrow, dependent on kit formulation.118 
99mTc-sulfur colloid was first developed by Harper et al. in 1964. Their preparation involved 
bubbling hydrogen sulphide gas through an acidified solution of sodium pertechnetate, using 
gelatin as a stabilising agent.121 However, the requirement for purification made for an 
impracticably long synthesis. Today, commercial kits are based on methods developed by 
Stern and Larson et al.122, 123 Pertechnetate is reacted with sodium thiosulphate and acid in the 
presence of carboxymethylcellulose as a stabilising agent. Sulfur colloid kits are commercially 
available, with different formulations116,117,124 used for liver, spleen, marrow and 
lymphoscintigraphy.97, 99, 125-127  
 
Typically for thiosulphate kit procedures, 15% of particles generated are less than 0.1 µm,  
80% in the range 0.1 µm-1.0 µm, and 5% being greater than 1 µm.96 For lymphoscintigraphy, 
particle size is particularly important, requiring particles smaller than 0.1 µm to ensure uptake 
in the lymph nodes.127-129 In an attempt to produce narrower size ranges and smaller particle 
sizes, colloidal preparations have been filtered to achieve average sizes of 10 nm and 38 
nm.126, 127 Traditional labelling procedures currently involve heating to increase the rate of 
99mTc incorporation.122, 123 However, such heating encourages agglomeration, and is therefore 
a confounding factor when attempting to obtain appropriately small particle sizes.  As such, 
there is commonly a trade-off between particle size and rate of production.  
 
More recently alternatives for imaging the RES have become favourable. The labelling 
procedure and formulation of sulfur colloid kits is not straightforward, involving boiling, 
cooling, and neutralising. For this reason these particular kits are commercially undesirable, 
therefore alternative kits with simpler methods will be favoured. Bone marrow imaging with 
99mTc-albumin colloid (Nanocolloid®), antimony sulphide and 99mTc-phytate,130, 131 all produce 






Lymph node imaging has historically been used for imaging lymphatic obstruction, for 
example in cases of lymphoedema; however, sentinel lymph node (SLN) imaging has driven 
the most recent interest in colloidal particulates. Sentinel lymph nodes are the first lymph 
nodes receiving lymph draining directly from a tumour site, and are therefore the most likely 
to be involved in metastatic disease.132, 133 Many solid tumours, including breast cancer, 
malignant melanoma, head and neck cancers spread via lymphatic drainage and the presence 
of lymph node metastases is an important prognostic biomarker.  
 
The aim of SLN imaging is to find the precise location of the node for biopsy and to detect 
microscopic nodal disease by identifying all potentially involved nodes.  This approach offers 
significantly higher sensitivity than traditional blue dye methods.134 Selective biopsy of the 
sentinel node offers an alternative diagnostic procedure for tumour staging rather than 
removing all regional lymph nodes which often leads to lymphoedema.135, 136 A wide variety of 
radiopharmaceuticals have been used for SLN lymphoscintigraphy including 99mTc labelled 
dextran,137 99mTc-human serum albumin,138 198Au-colloid,103 99mTc-stannous-phytate,139 99mTc- 
sulfur colloid,126, 127 99mTc-antimony trisulphide colloid,135, 140 and 99mTc colloidal albumin.141  
After interstitial injection, particulates are transported by the lymphatic system, localising via 
drainage into the lymph nodes. For melanoma, colloids are administered intradermally or 
subcutaneously, while for breast cancer, intratumoral or peritumoral administration have also 
been successfully used.135 Both stability and particle size are again important factors here. 
Particles must be absorbed by peripheral lymph receptors before entering the lymph system 
and must be smaller than 100 nm to reach the lymph nodes,128, 129, 142 but larger than 5 nm to 
avoid penetration into capillary membranes and subsequent renal filtration and excretion.137 
Optimal uptake has been observed for particulates in the size range 5-15 nm.129   
 
1.3.7 Inflammation and Infection 
Inflammation scintigraphy is frequently used to identify and localise pulmonary and 
abdominal infections and fevers of unknown origin and to distinguish tumours from 
inflammation.143-145 Early approaches attempted to utilise leukocyte phagocytosis of sulfur, 
gold and albumin colloids, but poor labelling efficiency and label stability have generally 
proven to be significant limiting factors.146 Non-phagocytic approaches utilising 111In-Oxine 
and 99mTc-HMPAO have therefore largely replaced these early colloidal approaches. 111In-




of bowel disease145, 147; however, 111In radiopharmaceuticals are generally expensive 
compared to 99mTc. While radiolabelling yields are high, cell labelling in general involves 
lengthy procedures due to the non-specificity of labelling, requiring leukocyte separation from 
whole blood before labelling. Therefore, interest is returning to colloidal radiopharmaceuticals 
for leukocyte labelling using colloidal stannous fluoride (SnF2). 
99mTc-SnF2 is currently available 
in  Australia and Europe (less common in Europe), cheap to produce, and capable of directly 
and specifically labelling leukocytes in whole blood without the need for time consuming or 
complicated purification regimes.148  
 
Stannous Fluoride Colloid 99mTc-SnF2 
Stannous fluoride colloid, 99mTc-SnF2, is a commercially available radiopharmaceutical, 
primarily used to radiolabel leucocytes for imaging inflammation and infection; the mode of 
this labelling is currently unclear, but may involve phagocytosis, specific cell surface 
adherence, or even both.146, 149-153 The biological clearance of labelled leukocytes in the blood 
and lung is rapid, with biological half lives of 1.2 and 2.7 hours respectively. Clearance is slow 
in the liver, spleen and bone marrow remaining constant over 15 hours.   
 
99mTc-SnF2 colloids comprise aggregates of coiled and branched chains ranging from 0.1-3 µm 
in diameter, which can be narrowed to 0.33-1.12 µm using a 0.1 µm filter.154 Particle size has 
previously been shown to be single most important factor affecting phagocytic engulfment of 
99mTc-stannous colloid, with the optimal mean particle size being 2.1 µm.146 Various labelling 
procedures have been described;146, 148, 150, 155 but Hanna et al.’s work in 1984, demonstrating 
that using fresh stannous fluoride improved labelling efficiency,149 cell viability and reduced 
spleen and liver uptake, has endured as the core of most commercially available kits, such as 
the Radpharm Scientific Leukocyte Labelling Kit.156 The colloid is first prepared by mixing the 
aqueous sodium fluoride with stannous fluoride, filtered, and 99mTc-pertecnetate added. The 
mixture is incubated for 1 hour, producing radiolabelled stannous fluoride colloid in high 
radiochemical yield (99%).156 This colloid is then incubated in whole blood for 1 hour to 
specifically label leukocytes; however, reproducibility issues may be encountered.153  
 
1.3.8 Gastrointestinal Imaging 
Radionuclide imaging of the GI tract with microparticulates allows functional evaluation of 
oesophageal transit, gastro-oesophageal reflux and gastric emptying. Various particulates 




and MAA.157-159 The radiolabelled colloid is incorporated into specific liquid or solid foods (e.g. 
mashed potato, porridge, scrambled egg) and is ingested by the patient.   
 
1.3.9 Radionuclide Therapy  
Microparticulates have been previously employed to deliver a localised dose of beta-emitting 
radionuclides for the therapy of rheumatoid arthritis and cancer. Microparticulates can be 
directly injected into a desired target, such as a joint, a body cavity, or a tumour, so that they 
become trapped. While many of these approaches are non-specific, there is increasing 
research into site-specific targeting of nanoparticles to cellular or vascular receptors by 
conjugating particulates with peptides or antibodies.  
 
Synovectomy 
Inflammatory joint disease affects at least 1% of the world’s population.160 Synovial joints 
consist of a fibrous capsule, ligaments and articular discs. Inside the capsule is a synovial 
lining, composed of two cells types, phagocytic (type A) and fibroblast-like (type B) 
synoviocytes. In inflammatory conditions, the type A synoviocyte predominates, resulting in 
swelling and enlargement of the synovial membrane and increased synovial fluid secretion.161, 
162 
Rheumatoid arthritis and synovial disease are typically treated by systemic anti-rheumatic 
therapies such as non-steroidal  anti-inflammatory drugs (NSAIDS), glutocorticoids and 
disease-modifying antirheumatic drugs (DMARDs).163 When these traditional therapies fail, 
local articular radiotherapeutic treatments such as synovectomy can be applied. Radiolabelled 
particulates can be used for ablation of the synovial lining, thereby decreasing fluid secretion, 
and reducing intra-articular pressure. Since synoviocytes phagocytose particulates, they are 
also a useful target for microparticulate mediated irradiation.   
The importance of particle size is not completely understood, but generally, smaller particles 
tend to leak from the joint space; resulting in their undesirable accumulation in the 
reticuloendothelial system.164 Colloidal gold particles in the size range 20-30 nm result in a 
leakage of 3-18%,165 while a particle size of 300 nm results in a more acceptable leakage of 
only 1%.166  
 
Early examples of radiocolloids used for synovectomy include 32P-chromic phosphate167 and 
198Au-colloids,168 which have been superseded by 90Y colloids (e.g. silicate, resin, citrate), and 
more recently 186Re-sulphide,169 169Er-citrate,170 188Re-tin-colloid,171 177Lu-hydroxyapatite,172 




of radionuclide depends largely on its ability to penetrate tissues, and its half life, which must 
be sufficient to impart the prerequisite dose, but not so long as to cause damage to bone, 
cartilage or skin. Table 1.3 lists some properties of radionuclides used.169   
 
Isotope t ½ Penetration depth Joint Suitability 
90
Y 2.7 days 2.8 mm Large joints- Knee 
186
Re 9.4 days 1.0 mm Medium joints - Hip, shoulder, wrists 
169
Er 3.7 days 0.3 mm Small joints- fingers, toes 
 




Particulates in Cancer Imaging and Therapy 
The current use of particulates in tumour and cancer therapy is mainly limited to intracavity or 
intratumoural injection using 198Au-colloid,175 colloidal 32P-chromic phosphate.176 This 
approach is, however, significantly hampered by radionuclide leakage from the site of 
injection. As previously mentioned, the functionalisation of nanoparticles is a highly active 
field of research, with biological targeting molecules such as peptides, proteins and nucleic 
acids imparting specificity for a particular target. The large surface area of nanoparticulates 
has the potential to allow multiple imaging radionuclides or a high therapeutic payload to be 
conjugated to the particle surface. The surface can be functionalised by a variety of groups, 
offering the opportunity to introduce different agents simultaneously for multimodality 
imaging, for example, or for simultaneously delivering a drug or radionuclide payload, as well 
as providing biodistribution information by imaging.  
 
Liposomes in Cancer Therapy and Imaging 
Liposomes can be used as nanocarriers for the delivery of drugs or imaging agents.40,177-179  
Drugs/agents can be entrapped in the aqueous space or intercalated into the bilayer itself. It is 
also possible to modify the surface of the particles to alter their pharmacological profile or 
introduce a targeting functionality. Attachment of the hydrophilic polymer polyethylene glycol 
is a common modification to avoid degradation and minimise toxicity. Liposomes are typically 
in the diameter range of 80- 300 nm, and in this respect their passive uptake and 
accumulation in tumours may be limited due to their large size. They are therefore better 
suited to active targeting approaches in larger tumours.  Larger liposomes will accumulate in 




direction for future research is the generation and labelling of smaller unilaminar liposomes, 
which may overcome this problem.  
 
Two approaches can be taken for incorporation of the radionuclide. First, the radionuclide can 
be entrapped within the liposome aqueous space, either during liposome formulation or 
through the use of a suitable chelating agent that will pass through the lipid layer.  Examples 
of chelators used include hexamethylpropyleneamine oxime (HMPAO) and diethylene 
triamine pentaacetic acid (DTPA);180, 181 Second, the chelating agent can be derivatised with a 
hydrophobic anchor that will embed itself in the lipid bilayers, such that chelating agent is 
studded on the liposome surface ready for chelation. DTPA has been previously bound to long 
chain hydrocarbons (stearylamine-DTPA) and used to chelate 67Ga and 99mTc to the surface of 
liposomes in this manner.182 A great number of studies involving the development of 
liposomes  for nuclear imaging have taken place in recent years, most commonly including 
radiolabelling with 99mTc,179 111In,183 186Re,178 and  67Ga.184 Many of them demonstrate good 
accumulation in tumours and sites of inflammation,185 and are likely to become increasingly 
prevalent in clinical practice in the future.   
 
1.4 Targeting Strategies for Cancer Therapy and Imaging 
1.4.1 Passive Targeting  
Nanoparticles passively accumulate in tumours through an effect called enhanced 
permeability and retention (EPR).  The rapid and poorly controlled  growth of tumour blood 
vessels results in large gaps (up to 800 nm across) between tumour endothelial cells.186 
Tumours also lack an effective lymph drainage system. These effects combine to produce a 
leaky, tortuous vasculature which is predisposed to retaining nanoparticles in the range of 10-
100 nm.41,187 Utilising nanoparticles in this size range, and making them hydrophilic (to avoid 
plasma protein adsorption), optimises their capacity for passive uptake in small tumours of 
this type.  Further modification in terms of size and surface properties to avoid uptake by 
macrophages in the RES can also be used to optimise them for passive targeting approaches.  
 
1.4.2 Active Targeting 
In larger tumours with larger and more patent blood vessels, passive uptake is less prevalent. 
Nanoparticle accumulation is therefore augmented by conjugation of biological molecules 
that bind preferentially to specific tumour cell antigens or receptors. The folic acid receptor, 
angiogenic markers such as the αvβ3 integrins and specific antigens for monoclonal antibodies 




expression of receptors and antigens offers a pathway for nanoparticle/drug uptake via 
receptor-mediated endocytosis.  
 
To date, the use of nanoparticulates in nuclear medicine involving these targeted approaches 
is limited to research rather than clinical exploitation, but examples are becoming ever more 
frequent. Some more recent examples involving bioconjugates for both active and passive 
targeted delivery include the use of 211At,192 188Re,178 64Cu,193 18F,194 153Sm,195 and 111In.196  
 
Rossin et al. developed 64Cu-radiolabelled folate-conjugated shell cross-linked nanoparticles 
(SCK’s) to target tumours expressing the folate receptor. The SCK’s were functionalised with 
folate, fluorescein thiosemicarbazide, and 1,4,8,11-tetraazacyclotetradecane-N,N',N'',N'''-
tetraacetic acid (TETA).193 Preparation of the radiolabelled SCK’s required multiple steps; an 
aminated TETA precursor was prepared and conjugated to carboxylic acid groups on the SCK 
surface via an EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide) and s-NHS (N-
hydroxysulfosuccinimide) activated coupling reaction. The TETA-SCK particles were 
radiobelled by incubating them with 64Cu-acetate for 2.5 h at 43 oC, followed by centrifugal 
ultrafiltration for purification, resulting in a decay corrected yield of 15-20% and 
radiochemical purity >96%. Folate receptor mediated uptake was observed in small tumours.   
De Nardo et al. have prepared 111In-chimeric (ChL6) monoclonal antibody (MAb) bioprobes for 
thermal ablation of cancer cells.  111In-DOTA- (ChL6)-MAb was conjugated to polyethylene 
glycol (PEG) on an iron oxide core.  Specifically, 111In labelled antibody was prepared by 
conjugating 2-[p-(bromoacetamido)benzyl]-1,4,7,10-tetraazacyclododecane- N,N',N'',N'''-
tetraacetic acid (a benzyl DOTA) to ChL6 via a 2-iminothiolane, followed by incubation with 
111In chloride for 30 min and purification via molecular sieving chromatography. The 
radiolabelled antibody precursor was  conjugated to carboxylic acid groups on the iron oxide 
particles via an EDC and s-NHS activated coupling reaction over 1 h. The labelled particles 
were purified by dialysis to yield a brown solution with a specific activity of 1.0-2.0 mCi/110 
mg/20 mL. Anti-tumour monoclonal antibody (MAb) targets the particles to specific cancer 
cells where an alternating magnetic field can induce thermal therapy.196  
 
Many of these actively targeted nanoparticles are prepared by complex radiolabelling 
protocols and chemistry. Examples involving 18F-labelled nanoparticles will be discussed 
thoroughly in chapter 2 to highlight the complex nature of preparing prelabelled nanoparticles 
further. We aim to exploit the high affinity interaction of simple radionuclides (e.g. 18F-




mixing, requiring minimal purification. Ultimately we aim to exploit the high affinity 
interaction for a pretargeting strategy.   
 
1.5 Overview of Pretargeting Strategies  
The use of radiolabelled antibodies for targeting and treating cancer dates back to as early as 
the 1950’s and 60’s. These early studies showed that radiolabelled antibodies could 
specifically localise in target tissue.197-199 Goldenberg et al. reported the first clinical studies in 
1978: goat anti-CEA IgG was labelled with 131I for specific tumour localisation.200 However, 
imaging quality was poor due to the slow blood clearance of IgG, consequently a high 
percentage of untargeted radiolabelled antibody remained in the blood pool for long periods 
of time, interfering with image quality. The immunoglobulin type IgG is the most frequently 
used antibody for radioimmunoscintigraphy and radioimmunodetection. However, due to its 
lack of specific clearance mechanism and relatively large size (ca. 150 kDa), IgG remains in the 
blood pool for many weeks. In terms of targeted radiolabelled molecules, a high 
blood/tumour ratio is far from ideal. In addition, the radioactive dose given to healthy tissue is 
a concern.  
 
To combat the interference caused by the excessive antibody, various approaches were 
adopted.  These included computer aided background subtraction,200 local delivery of the 
antibody,201 and the use of a second antibody to aid clearance from the blood.202 With the 
development of monoclonal antibodies (MAb) and the use of smaller fragments such as 
F(ab’)2 (ca 100 kDa) and F(ab) (ca. 50 kDa), faster blood clearance has been achieved and 
imaging without the extra assistance is possible.203 Sharkey et al. compared tumour uptake of 
NP-4 IgG and fragments labelled with 90Y, 111In, and 131I.203 Although blood/tumour ratio was 
improved, 90Y labelled antibodies still had high normal tissue retention.  Most recently, smaller 
antibody fragments have been prepared, such as engineered single chain variable fragments, 
scFv’s (ca. 25 kDa). They have shown promising properties such as rapid clearance and 
increased tumour penetration. However, a consequence of the rapid clearance is that tumour 
localisation may not be sufficient.204  
 
With the apparent limitations of antibodies as therapeutic and diagnostic tools the concept of 
pretargeting was proposed. Firstly, a pretargeting agent, such as an antibody, that has high 
affinity for the tumour is delivered and allowed to accumulate slowly over a period of time; 
secondly, a small secondary targeting agent containing a radionuclide is delivered. The 




accumulation, and rapid clearance from circulation (Figure 1.3). The targeting antibody and 
radiolabel are administered separately, offering the opportunity to exploit high specificity 
through slow accumulation, and to introduce shorter lived PET isotopes such as 18F.  
 
The pretargeting concept was first proposed by Goodwin et al. (1984),205 who suggested that 
bifunctional agents could be used for pretargeting tumours, i.e. containing binding moieties to 
simultaneously  target the tumour and radiolabelled ligand. Reardan et al., one of the first to 
inspire the concept of pretargeting, reported bispecific antibodies (bsMAbs) that could target 
specific antigens and also recognise radiometal chelate complexes.206 The novel concept of 
preparing antibodies that had bispecificity, set the stage for the subsequently coined strategy 
of “pretargeting”.  
 
 
Figure 1.3: General pretargeting strategy. (A) Pretargeting agent (e.g. antibody) is administered; (B) 
Pretargeting agent accumulates slowly at the target cell; (C) Radiolabelled probe seeks out and targets 
its high affinity binding sites on pretargeting agent, while unbound radiolabelled probe clears rapidly.  
  
To date, pretargeting techniques can be divided into four catagories: (1) bispecific antibody 
bsMAb- hapten, (2) streptavidin/avidin- biotin, (3) complementary oligonucleotides bound to 
antibodies and (4) enyzmes bound to antibodies; each involving multiple steps. Of the above 
systems, the most commonly reported are streptavidin/avidin -biotin and bispecific antibody 
bsMAb recognition.  
 
The avidin/streptavidin-biotin strategies are versatile methods, first discussed by Hnatowich 
et al. in 1987207 and Pengelli et al. in 1988.208 Avidin is a glycosylated, positively charged 
protein that originates from the egg whites of birds, reptiles and amphibians. Streptavidin 




an extremely high affinity for biotin with a dissociation constant of 10-15 M, and can bind up to 
four biotin molecules with its tetrameric structure, thereby imparting signal potential 
amplification.207   
 
There are two distinct methods that have been developed from streptavidin/avidin–biotin 
systems. In the first example, the antibody(anti-tumour IgG) is conjugated to streptavidin, 
acting as the pretargeting agent, followed by the chasing injection of a radiolabelled biotin as 
a the targeting probe (Figure 1.4b).207 The conjugated antibody remains in the blood for a long 
time, thus, an additional clearance step may be required before a radiolabel can be injected. 
Even a small amount of antibody-StAv would interfere with tumour imaging. The high affinity 
for biotin works unfavourably in this instance. The clearance molecule may be a biontinylated 
agent, such as biotin conjugated to human serum albumin.209 After clearance, radiolabelled 
biotin can be injected to target the tumour bound IgG-StAv. The second method exploits 
biotin, rather than StAv or avidin, conjugated to IgG (Figure 1.4a).210 However, instead of using 
radiolabeled StAv or avidin, due to their unfavourable pharmacokinetics, radiolabelled biotin 
is the chasing targeting probe once again. To accommodate for this an additional step has 
been incorporated. After the initial injection of the IgG-Biotin conjugate, glycosylated avidin is 
injected to mop up the IgG in the blood, which is then rapidly cleared. Non-glycosylated StAv 
is then injected to target the tumour-bound biotin-IgG, consequently acting as a bridge for the 
chasing injection of radiolabelled biotin.  
 
Frequently cited examples of radiolabelled-biotin analogues are DTPA-biotin and DOTA-biotin. 
Hnatowich et al. first described 111In-DTPA-biotin, where a cyclic anhydride of DTPA was 
coupled to a lysine conjugate of biotin, containing a primary amine for bioconjugation.207 
Kalofonos et al. reported successful tumour imaging within 2 h using StAv-IgG and 111In-DTPA-
Biotin, with significantly reduced background levels.211 Clinical trials have shown some 
promising results, most notably with 90Y-DOTA-biotin.212, 213 Breitz et al. reported a 10 fold 
improvement for the tumour/blood ratio compared to a directly labelled antibody 90Y-NR-LU-
10 IgG.212, 213 In a comparison of 90Y-DTPA-biotin and 90Y-DOTA pretargeting avidin systems it 
was found that >5% of 90 Y had leaked from the DTPA and the dose received by bone was ten 
times greater than that of 90Y-DOTA-biotin, therefore it may be preferable to use the 
kinetically stable DOTA chelate.214  
 
With the growing interest in PET, biotin analogues with PET isotopes have been discussed, for 




probe at the target, given the traditionally shorter lived PET isotopes. While there are many 
advantages of using the StAv/avidin-biotin pretargeting method, there is one major 
disadvantage -StAv and avidin are nonhuman and have been shown to be immunogenic in 
clinical trials.216 
 
In contrast to the StAv/avidin-biotin protocols the bispecific antibody-hapten methods 
generally involve only two steps (Figure. 4c). First, bispecific antibody (bsMAb) is injected and 
allowed to accumulate at the tumour site over a period of a few days. Second, a radiolabelled 
effector containing a hapten-peptide to target the anti-hapten site of the bsMAb is 
administered.  
 
The bispecific antibody-hapten pretargeting methods utilise a bispecific antibody that is 
composed of two fragments; an antitumour antibody, and an antihapten-chelate fragment. 
The antitumour region targets tumours, while the antihapten can bind to radiolabelled 
hapten-peptides.  
 
The first antihapten bsMAb reported by Reardan et al. was against a 111In labelled 
benzyl(EDTA) fragment.206 Antibodies prepared in this way showed preference for indium 
chelates over metals such as gallium. Goodwin et al. pioneered some of the early hapten 
based pretargeting methods.218, 219A three step protocol was first described; (1) bispecific 
antibody (bsMAb) is injected and allowed to accumulate at the tumour site over a period 
time, maximising tumour uptake; (2) excess circulating non radioactive antibody is cleared by 
a “chase” step, usually i.v injection of a large molecular weight polyvalent hapten binds the 
circulating antibody and is rapidly cleared (3) a radiolabelled effector containing a hapten-
chelate to target the anti-hapten site of the bsMAb is administered, the radiolabelled hapten 
not bound to the antibody clears rapidly from circulation. Goodwin et al. showed that divalent 
88Y-DOTA-haptens could increase tumour uptake in comparsion to monovalvelnt 88Y-DOTA-
haptens, with  4.4% ID/g (tumour to blood ratio 21:1) and 1.7% ID/g (tumour to blood ratio 
16:1) respectively.219 Le Doussal et al. found that the divalent hapten structure had increased 
stability at the tumour site, attributed to the divalent hapten bridging across two bsMAb, and 
proposed a method known as the affinity enhancement system (AES).220,221 The pretargeting 
protocol is reduced to two steps, removing the requirement for a clearance step. The AES 
principle relies on the high affinity interaction of the bivalent hapten at the tumour site. The 
bivalent interaction requires two antibodies to bridge across, which is unlikely to occur in 




rapidly than the bivalent interaction at tumours. After the radiolabelled hapten is injected, 
there is a waiting period (e.g. 24 h) before imaging can take place, allowing for the circulating 
antibody-hapten to dissociate and clear while the bivalent interaction remains intact at the 
tumour site (Figure 1.4c). The AES concept remains the principal targeting method for bsMAb 
–hapten models to the present day. Although there is large difference in the affinity of the 
divalent hapten system (10-9 M) compared to (10-15 M for StAv/avadin-biotin) they are both 
sufficiently held within tumours.222 An advantage of the bsMAb-hapten methods over 




Figure 1.4: Schematic of common pretargeting strategies. (A) injection of antibody-biotin as 
pretargeting agent, followed by streptavidin and avidin clearance step, chasing injection of a 
radiolabelled biotin; (B) antibody-streptavidin as pretargeting agent, chasing injection of a radiolabelled 
biotin; (C) bispecific antibody (bsMAb) is injected, followed by chasing injection of radiolabelled hapten-
peptide; (D) antibodies–enzyme conjugate injected,  followed by chasing injection of prodrug, activated 




Current methods are focused on the use of an effector hapten known as HSG (histamine-
succinyl-glycine) to accommodate a more flexible design that can incorporate a variety of 
radionuclides by separating the peptide from the radiolabel. The antibody is directed against a 




addition the substance must be small, so it rapidly clears, and be amenable to radiolabelling. 
Separating the radiolabel from the targeting peptide moiety allows each to exclusively 
perform their respective jobs. A wide variety of isotopes have been incorporated using HSG 
peptides, including 111In, 99mTc, 188Re, 123I, 90 Y, and 177Lu223, 224, where DOTA and DTPA are the 
common choice of chelates.223, 224 A number of clinical trials have been performed using the 
antibody-hapten system. 131I labelled hapten peptide was used to study radioimmunotherapy 
of medullary thyroid carcinoma (MTC). In phase 1 trials the risk of hematologic toxicity was 
high, and in advanced MTC patients a maximum dose of 1.8 GBq/m2 was suggested. However, 
the therapeutic results were encouraging.225 
 
The third pretargeting model discussed involves the use of complementary oligonucleotides. 
In general a small DNA sequence is conjugated to the antibody, and a complementary DNA 
sequence is radiolabelled. The radiolabelled complementary sequence has affinity for the 
antibody-DNA conjugate when injected. Recently, phosphorodiamidate morpholino oligomers 
(MORF) have been investigated, primarily exploiting their water solubility and stability to 
nucleases.226 The antitumour antibody conjugated to MORF is administered as the 
pretargeting agent, followed by a chasing radiolabelled complementary MORF (cMORF) as the 
effector.227 A possible advantage of such oligomer systems is in their flexibility to vary chain 
length and base sequences to help improve pharmacokinetics. Jiang et al. have proposed a 
three step process for potential signal amplification.228 After administration of the antibody-
MORF, an additional step was incorporated, where a polymer containing multiple copies of 
cMORF was injected, and finally followed by the radiolabelled MORF chasing step. The 
principle is that one antibody bound to a target site (that is expressed in low quantities), can 
bind multiple copies of radiolabelled probe and amplify the signal. This is achieved via an 
amplifying agent, in this case it was a polymer containing ca. 15 copies of cMORF. In theory, 
the multiple cMORF copies should be available to bind radiolabelled probe. The multistep 
approach helps to overcome poor biokinetics. For example, when the antibody was bound to 
polymer-cMORF prior to administration, it showed poor diffusion into target tumours, 
attributed to large size and loss of functionality. Separating the administration of these 
components improves accumulation of antibody at the tumour site. The protocol was 
compared the two step method described above and a three fold amplification in tumour 
accumulation was observed. In addition, polymer-cMORF cleared by the RES was inaccessible 
to radiolabelled probe, thus reducing interference from non-targeted organs. However, there 
is increased blood signal interference from circulating amplifying agent and no evidence of 





The fourth pretargeting method involves the use of antibodies conjugated to enzymes to 
activate a prodrug at a target site (Figure 1.4 d). The principle is to deliver drugs selectively, 
for example, in cancer therapy it could avoid damage to normal tissues. The method is 
described as antibody-directed prodrug therapy (ADEPT). The antibody-enzyme conjugate 
targets specific tumour antigens; time is then allowed for unbound antibody to clear from the 
blood before a prodrug is administered. The prodrug targets the enzyme, which catalyses its 
conversion to its active cytotoxic form, concentrating the active drug in the local area of the 
tumour. 
 
 A variety of enzymes, antibodies and prodrugs have been designed for ADEPT and their 
clinical use is described as feasible.229-231 Bagshaw et al. reported the first clinical experience of 
ADEPT.229 A murine monoclonal antibody (A5B7) was conjugated to a bacterial enzyme 
(carboxypeptidase G2), injected and allowed to accumulate at a target tumour site.  After 
some time, a prodrug (4-[2-chloroethyl-(2 mesyloxyethyl)aminol]benzoyl-L-glutamic acid) was 
administered and converted to its active form at the localised enzyme site. The clinical trial 
concluded that ADEPT, in this form can offer effective treatment for colorectal cancer.     
Although 18F-FDG now dominates clinical oncology, pretargeting methods have proven 
clinically useful in tumour targeting for imaging and therapeutic purposes. A greater degree of 
specificity and signal amplification may be achievable using pretargeting methods, thus, there 
is scope for their development. Within this thesis we aim to adapt the existing pretargeting 
approaches, exploiting nanoparticle technologies and the affinity of simple radionuclide 
probes, such as 18F, for the nanoparticle (Figure 1.2). In theory, the nanoparticles provide a 
platform to introduce targeting moieties, such as antibodies, and introduce high payloads of 
radiolabelled probe for maximising specific activity at the target size. The use of nanoparticles 
should significantly enhance the potential for signal amplification in a pretargeting concept. In 
the above methods we have described potential signal amplifications of 4 fold and ca. 15 fold 
for StAv/avadin-biotin and complementary oligonucleotides pretargeting protocols. We 
envisage that the number of binding sites on nanoparticles, for the radiolablled probe will be 
in the order of 100’s-1000’s. Administering the radiolabelled probe in a second step could 
alleviate problems such as poor pharmacokinetics that maybe associated to nanoparticles, 





1.6 Bioorthogonal Chemistry 
The term bioorthogonal chemistry defines chemical reactions that can occur within a 
biological system without interference or interaction.232 Bioorthogonal groups must be able to 
react selectively under biological conditions, and without toxicity for in vivo application. The 
bioorthogonal approach to pretargeting typically involves two steps. First, an antibody, 
metabolic substrate, small molecules or enzyme containing a bioorthogonal group is 
introduced to a biological system. The active biomolecule is allowed to accumulate at its 
target site. The second step involves introduction of a bioorthogonal reactive molecule that 
contains a probe (e.g. fluorescent or radiolabel tag) to monitor the specific biological process 
in question. Essentially, these reactions work under the same principle as the pretargeted 
strategies described above. For example, they have been designed to overcome the poor 
pharmacokinetics of large labelled molecules. However, they aim to exploit the formation of 
covalent bonds (in contrast to avidin/biotin-non covalent) and the exclusive nature of 
reactions that do not occur naturally in biological settings. Bioorthogonal chemistry has 
traditional been used to monitor cellular processes that are not suitable for targeting methods 
involving labelled antibodies or genetically modified proteins (i.e. proteins are often large, and 
antibodies cannot be used to monitor intracellular processes). For example, lipids,233, 234 
nucleic acids,235 proteins,236 and enzymes,237 have been incorporated into bioorthogonal 
systems. The chemistry behind these systems has been dominated by the reaction of azide 
and its 1,3-dipolar cycloaddition with alkynes, including the “copper free” reaction of 
cyclooctynes (Figure 1.5).232, 233 However, the reaction rates of these systems are particularly 
slow, and the requirement for a copper catalyst, in some systems, raises issues of toxicity in 
biological systems. More recently, promising systems using cycloaddition between 1,2,4,5-
tetrazines and strained dienophiles such as norbornene, cyclooctyne, and trans-cyclooctene 
have been discussed (Figure 1.5).238-240  
 
Devaraj et al. describe the in vitro cycloaddition reaction between a tetrazine modified with a 
fluorescent tag and an antibody (herceptin) modified dienophile norbornene.238 The reaction 
was exploited to monitor targeting of the herceptin antibody to breast cancer cells; rapid and 
significant accumulation was observed. Intracellular studies with live cells were also 
successful. The in vivo application of this system was assessed by preparation of an 18F-
labelled dienophile, norbornene, which showed in vivo targeting in tumours preloaded with 
targeted tetrazine molecule. Most interesting, and of particular interest to our work was the 
notion that nanoparticles could be functionalised with bioorthogonal moieties, such as the 




with multiple fluorescent tags and tetrazine.239 The nanoparticles showed significantly 
increased targeting and signal amplification in cells pretargeted with antibody containing the 
dienophile norbornene, in comparison to antibodies directly labelled with fluorescent 
nanoparticles. Bioorthogonal chemistry and pretargeting are two concepts that are closely 
related. Naturally, as bioorthogonal chemistry evolves it will be incorporated into pretargeting 
strategies. Rossin et al. have recently (2010) described the first in vivo pretargeted example of 
bioorthogonal radioimmunoimaging in mice.240 A DOTA-like conjugate of tetrazine was 
radiolabelled with 111In and targeted to a tumour bound antibody containing a cyclooctene.240
tag















Figure 1.5: Bioorthogonal reaction schemes. (A) Cu(I) castalysed azide-alkyne cycloaddition (B) strain 




1.7 Summary and Aims  
In this chapter we have discussed some basic properties of nanoparticles with reference to 
their biological application. A review of radiopharmaceutical particulates in clinical use reveals 
that their use is restricted to “passive” targeting, e.g. they accumulate at their target site by 
virtue of their size. The formulations generally consist of poorly defined colloidal particles in 
the micrometer range. These large particles are sequestered by the RES, trapped in the lungs 
or trapped within cavities, such as joints (when directly injected). Inhomogeneous properties, 
such as particle size, are a significant problem that faces clinically used particles, affecting the 
consistency of labelling affinities and efficiencies.  
 
The recent expansion of nanoparticle technology has paved the way for developing materials 
with highly tuned properties. As our understanding of molecular mechanisms advances, the 
requirement for specific diagnostic tools increases. Therefore the design of active disease 
targeting strategies is currently a hot topic of research. In this chapter we have discussed 
some of the modern trends in active nanoparticle targeting systems for nuclear medicine. 
These examples typically consist of tightly controlled nanoparticles properties and have shown 
promising specific targeting capabilities. However, their preparation usually requires an 
additional step for synthesis of the radiolabelled ligand prior to conjugation of the 
nanoparticles, frequently accompanied by additional purification steps. Although often 
referred to as “one step” methods, in reality their preparation consist of multiple steps. The 
quest to address problems such as slow pharmacokinetics associated to large tumour 
targeting antibodies has led to the development of pretargeting strategies. In principle, 
introducing a targeting ligand and radiolabelled probe in separate steps can reduce 
background interference. 
 
Summary of Research Aims within this Thesis: 
 Develop a novel pretargeting concept and exploit the properties of nanoparticles, 
such as high surface area, to load multiple radiolabelled probes and achieve the 
maximum activity at a target site expressed in low quantities (signal amplification).  
 Identify nanomaterials with high binding efficiency of simple radiolabelled probes, 
such as 18F-fluoride or 99mTc containing bisphosphonates. 
 Develop selected nanoparticles, tailoring their size, shape and morphology.  
 Develop nanoparticle derivatisation methodology for conjugation of targeting vectors. 
 Explore selected nanoparticle biodistribution and pretargeting concept with 





 We propose to use the pretargeting concept and exploit the properties of nanoparticles, such 
as high surface area, to load multiple radiolabelled probes and thus achieve the maximum 
activity at a target site expressed in low quantities (signal amplification). Bioorthogonal 
chemistry offers an interesting platform for the formation of in vivo covalent bonds between 
pretargeted nanoparticles and radiolabelled probe. However, development of bioorthogonal 
chemistry is by no means simple, requiring components that react selectively and rapidly 
under biological conditions. For this reason, we have proposed a pretargeting strategy that 
avoids complex reactions, utilising the intrinsic affinity of nanomaterials for the simplest 
radiolabelled probes (this may be to some extent bioorthogonal- for example there is no 
endogenous aluminium), for example, 18F-fluoride or simple 99mTc containing bisphosphonates 
(See figure 1.2 for description of strategy).  
 
Further work within this thesis will focus on the identification and development of 18F-fluoride 
and bisphosphonate affine materials and their potential application in the proposed 
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A Survey of 18F-fluoride Avidity for Biocompatible Inorganic Materials 
 
2.1 Overview and Aims 
This chapter begins with an overview of basic fluorine-18 chemistry, highlighting the 
requirement to develop simple labelling methods to replace older, complex approaches. We 
aim to exploit the properties of nanoparticles (e.g. high surface areas) to develop rapid one 
step labelling chemistry. The search for new fluoride-affine materials was initiated with a 
review the current literature, with a view towards nanoparticle application. Herein we 
investigated the 18F-fluoride binding properties of nanoparticulate materials under various 
conditions. A survey was conducted to indentify nanomaterials with high fluoride loading rate, 
affinity, capacity and stability for potential in vivo application. Hydroxyapatite and Alhydrogel 
particulates were selected as lead materials for further study within this thesis, due to their 
promising 18F-fluoride binding properties. 
 
2.2 Introduction 
The chemistry of fluorine-18 reactions is discussed to highlight their complex nature. Our aim 
is to simplify these protocols, by introducing a one step nanoparticle labelling procedure. It is 
envisaged that simply mixing 18F-fluoride with fluoride-affine materials in a one pot/step 
reaction will reduce reaction times and require minimal purification. Ultimately, we aim to 
transfer the rapid one step labelling protocol to an in vivo pretargetting setting. To achieve 
that goal, the radiotracer probe will need to successfully compete with the bodies’ biological 
milieu.  
 
2.2.1 18F-Fluoride Chemistry  
Fluorinated compounds have long been used in pharmaceutical and chemical industries; their 
use continues to expand at a plethora of biological frontiers.1-3 Fluorine exhibits unique 
properties that can introduce significant and useful physicochemical and biological changes to 
organic compounds. The fluorine atom is small, and can often be considered as an isosteric 
replacement for hydrogen. However, fluorine is extremely electronegative and has hydrogen 
bonding abilities that make it more akin to substitution with a hydroxyl group. An important 
effect of the unique properties is the very high C-F bond energies, ultimately producing 
kinetically stable substitutions.    
The radioactive form, fluorine-18 continues the rich vein of useful physicochemical properties 




favourable properties that make it suitable for molecular imaging. A relatively long half life of 
109.7 minutes enables transport to locations away from the cyclotron production site, which 
is not possible for other common isotopes such as 11C (T1/2 = 20 minutes), 
13N (T1/2 = 10 
minutes, and 15O (T1/2 = 2 minutes). The relatively long half life also allows for lengthened 
synthetic procedures, and extended imaging protocols. 97% of fluorine-18 (18F) decay is a 
result of positron emission, with a relatively low maximum energy (635 KeV) that yields only a 
short range of positron emission (2.3 mm) in human tissue. Therefore, fluorine-18 is amongst 
the most favourable isotopes available for PET in terms of dosimetry and resolution 
properties.4 The growing availability of cyclotron produced isotopes is another advantage. It is 
estimated that there are around 650 biomedical cyclotrons supplying 2200 PET or PET/CT 
systems worldwide.5  
 
2.2.2 Clinical Uses of Fluorine-18  
This section highlights the growing range of 18F labelled radiopharmaceuticals, seeking a 
plethora of new biological targets. These new biological targets are often expressed in low 
abundance, thus it is essential that the radiotracer is delivered with high specific activity and 
affinity for its target site. We aim to exploit the large surface area of nanoparticles to deliver 
multiple radiolabelled probes to a target site. 
 
The development of PET imaging has largely been influenced by the emergence of 2-18F-
fluoro-2-deoxy-D-glucose (FDG). FDG is an FDA  (Food and drug administration) approved 
oncological PET tracer in routine use, and it is used in 90% of all PET scans.6 The first synthesis 
of FDG was reported in 1977 by Ido et al., developed with the intention of mapping glucose 
metabolism.7  In the following 30 years FDG has found clinical use in oncology, neurology and 
cardiology.8 The FDG success story has, in turn ignited the growing field of PET imaging and 
the development of new tracers for research and clinical purposes is now a hot topic. The 
increase in PET imaging research can be attributed to the demand for specific patient 
management and early diagnosis in disease. There is high demand to characterise and detect 
disease via new targets, reflected by the expanding list of PET labelled compounds, and 
growing number of publications related to PET in the past three decades.9  
 
Aside from FDG, the only FDA clinically approved PET imaging agents are 18F-fluoride (bone 
scans), 13N- NH4
+ (myocardial perfusion), and 82Rb-generator (myocardial perfusion) for use in 
the USA.6 This may seem a little underwhelming, yet as with any pharmaceutical, the clinical 




At present, there are a number of proprietary and non proprietary PET radiopharmaceuticals 
under clinical evaluation; nearly all are 18F labelled compounds (Table 2.1). Some of the 
biological targets and processes include: Aβ (senile plaques), amino acid transport (tumour), 
αvβ3 (angiogenisis), thymidine kinase (gene expression), hypoxic tissue (intracellular 
reduction and binding), and VMAT (dopaminergic neurons), representing an expanding list.  
 An emerging area of PET imaging is its use as a pharmalogical tool to aid drug design and 
development. Pharmacokinetic studies can provide direct in vivo information for 
biodistribution and drug occupancy using only very small doses of drug. 18F is a powerful tool, 
due to the fact that fluorine substitution is common place in many new pharmaceuticals and 
can provide direct analogues for assessment. For example, drug occupancy studies that 
quantitatively assess the number neurotransmitter receptors for dopamine, serotonin and 
benzodiazepines have been achieved using specific radiolabelled ligands.10 
 
Radiopharmaceutical Specific target  Clinical status 
18
F-Fluoride Bone imaging FDA approved (2000)* 
18
F-FDG Myocardial and tumour glucose 
metabolism, Epleptic foci.  




 Myocardial perfusion FDA approved (2000)* 
82
Rb-generator Myocardial perfusion FDA approved (1992)* 
18
F-Florbetapir (AV-45) Aβ (Beta Amyloid) FDA approved (2011)* 
18
F-Flutemetamol Aβ (Beta Amyloid) Phase III 
18
F-3′-FPIB Aβ (Beta Amyloid) Study complete 
18
F-Florbetaben (AV-1) Aβ (Beta Amyloid) Phase II 
18
F-BMS747158 Mitochondrial complex 1 inhibitor  Phase III 
18
F-FP-DTBZ (AV-133 VMAT2 
Pancreatic islet β-cells 
Phase I 
18
F-FACBC (Fluciclovine) AA  (amino acids) Phase II 
18
F-BAY 85-8050 AA  (amino acids) Phase II 
18
F-Fluciclatide αVβ3 integrins Phase II 
124
I-Girentuximab Carbonic anhydrase IX Phase III 
3′-
18
F-FLT Thymidine kinase Study not complete 
18
F-FMISO Intracellular reduction and binding Study not complete 
64
Cu-ATSM Hypoxic tissue, redox trapping Study not complete 
 
Table 2.1: FDA approved and PET radiopharmaceuticals under clinical evaluation. Highlighting the high 
frequency of 
18
F labelled radiotracers and the growing list of biological targets.  As of Dec 2011 an NDA 









2.2.3 Production and Chemical Reactions of 18F-Fluoride  
18F-Fluoride required for nucleophilic reactions can be produced in low energy medical 
cyclotrons (3-20 MeV proton beam) by a single nuclear reaction. Enriched 18O water in a metal 
target (such as silver) is irradiated with protons to induce a (p, n) nuclear reaction, producing 
the 18F-fluoride ion in aqueous solution.11 Currently, nearly all fluorine-18 is produced this 
way. The production of electrophilic 18F-F2 gas can be achieved using a two step method. The 
first step proceeds as the 18O irradiation above, using enrinched 18O gas. The second step is 
irradiation in the presence of carrier added fluorine (F2)in an inert gas. 
18F-F2 can also be 
produced by deuteron irradiation of neon gas (20Ne(d, α)18F), although this has not been 
common practice in recent years.11 
 
(i) Electrophilic Fluorination 
Methods for labelling organic molecules with 18F can broadly be divided into two categories - 
electrophilic and nucleophilic fluorinations. Electrophilic radiofluorinations may be carried out 
by forming 18F-F2 gas. Electrophilic fluorination faces some major drawbacks and has generally 
fallen out of favour. Firstly, 18F-F2 is produced by carrier-added methods, thus ensuing 
compounds labelled by electrophilic fluorinations have low specific activity,( generally less 
than 0.4 GBq/µMol).12 Secondly, the maximum radiochemical yield that is achievable is 50% 
because only one of the F atoms in 18F-F2 will be labelled with 
18F. Lastly, the fluorinating agent 
18F-F2 gas is highly reactive, and often needs to be converted into a secondary agent such as 
18F acetyl hypofluorite for easier handling. 13 In spite of the shortcomings 18F-F2 still finds use in 
some labelling processes. For example, the labelling of 18F-fluoroDOPA is mainly by 
electrophilic methods due to the fact a more efficient nucleophilic method has not yet been 


















(ii) Nucleophilic Fluorination 
Nucleophilic fluorination is the most common 18F labelling method. Nucleophilic fluorination 
requires production of the 18F-fluoride ion, this is a major advantage as the enriched 18O water 
irradiation (described above) is a one-step “no carrier added” process that yields high specific 
activity. Typically, the specific radioactivity is greater than 185 GBq/µmol.15  However, the 18F-
fluoride ion is a poor nucleophile in the aqueous solution produced and requires further 
manipulations to become reactive. The first step involves drying, achieved through trapping 
the aqueous 18F-fluoride on an ion exchange cartridge. The 18F-fluoride is then eluted in a 
small volume of weak aqueous base. Removal of the additional water is achieved by repeated 
cycles of azeotropic evaporation with acetonitrile. In addition, a phase transfer catalyst is 
added, such as the cryptand (1,10-diaza-4, 7, 13, 16, 21, 24-hexaoxabicyclo-[8.8.8]-hexacosane 
= Kryptofix® = K222) reacted with an aqueous potassium solution to provide a cationic counter 
ion. Once the dry active residue is produced, it can be solubilised in a suitable solvent ready 
for chemical synthesis.13, 15   
 
The active fluoride ion, in this form, can be used for fluorinations via aliphatic SN2 and 
aromatic SNAr reactions. Aliphatic SN2 substitutions occur through displacement of suitable 
leaving groups, such as Br, I, mesylates, and tosylates. Aromatic substitutions are often 
accompanied by neighbouring activating groups, such as electron withdrawing NO2 and 





Figure 2.2: Generic reaction scheme for nucleophilic fluorinations with 
18
F-fluoride, where, AG= 





2.3 Towards New 18F-Fluoride Binding Sites  
As the demand for new radiolabelled compounds increases, novel methods to incorporate 
and improve labelling properties are sought. This leads us to look beyond the traditional C-F 
bond formation and search for new fluoride binding sites. Our aim is to exploit the intrinsic 
affinity of the fluoride ion for the nanomaterial surfaces.  
 
The range of new biomolecular targets is a diverse, growing list; including cell surface 




processes demands the development of distinct, specific targeting agents. The targeting 
methods currently include a wide range of small molecules, peptides and antibodies with 
diverse labelling strategies.17 The radiolabelling of amino acids and peptides has been an 
intense area of focus for developing new molecular imaging agents. These smaller compounds 
are often favoured over larger proteins and antibodies that can have low signal to background 
ratios.19 Methods are diversifying to incorporate new fluorine binding sites, in addition to C-F 
bond formation. Some approaches include silicon,20 phosphorus,21 aluminium22 and boron23, 24 
as binding sites. For example, non carbon binding sites can be incorporated into peptides or 
small biomolecules and directly labelled with 18F-fluoride in one step reactions under aqueous 
conditions.20, 23 Ultimately, the use of fluoride coordination could provide means to developing 
one pot “kit like” chemistry for radiofluorinations. 
 
 The development of new imaging probes requires them to have some key properties- 1) High 
specific activity, 2) high target specificity, 3) high binding affinity, 4) high signal to noise ratio, 
5) simple labelling protocol 6) low toxicity and immunogenicity.  We propose a novel targeting 
method using nanoparticles as a platform to deliver multiple radiolabelled probes to a target 
site (pretargeting concept described in chapter 1). To do this, we aim to exploit the high  
affinity interaction of the 18F-fluoride ion with a range of different or inorganic materials in a 
simple, rapid one step reaction, to deliver a high payload of activity to the target site with 
reduced background signal. 
 
2.4 Fluoride Binding Materials 
Herein we review potential fluoride binding materials to indentify leads for our initial fluoride 
binding survey. The avidity of fluoride for inorganic or organic materials has been widely 
investigated for use in water purification.  Low cost materials with efficient fluoride binding 
kinetics are sought after to minimise fluorine toxicity in water (limits must be kept between 
0.5-1.0 mg L-1 in drinking water).25 As a starting point, the following section will give a short 
review on some of the materials that have been utilised for fluoride ion capture. Due to 
simplicity and cost effectiveness, adsorption is one of the most commonly used water 
purification methods. Others include: ion exchange,26 precipitation,27 or physical removal, 
such as  electro dialysis and diffusion dialysis.28, 29 An extensive list of materials with fluoride 
capturing abilities used in water purification is displayed in table 2.2. From this table we have 
indentified key materials including- alumina, calcium based materials and other metal oxides 
(such as iron oxides). These materials are discussed in detail below, highlighting the trend 









Experimental conditions Reference 




Activated Carbon  





4.46  pH 6.5, Concentration 19 mg/L @ 25
o
C 31 
Al2O3/ Carbon nano 
tubes 
14.9 pH 6, Concentration 12 mg/L @ 25
o
C 32 
Activated Carbon 1.1 pH 6, Concentration 12 mg/L, @ 25
o
C 32 
γ Al2O3 3.6 pH 6, Concentration 12 mg/L, @ 25
o
C 32 
Zn/Al hydrotalcite 13.43 pH 6, Concentration 10 mg/L @ 30
o
C 33 
Mixed Rare earth 
oxides 





1.45 pH 7, Concentration 2.5-14 mg/L 35 
KMnO4-modified 
activated carbon 





7.0 pH 6.0-7.0, Concentration 1-100mg/L, @ 25
o
C 37 
Nano-ALOOH 3.26 pH 7.0, Concentration 3-35 mg/L @ 25
o
C 38 
CaO nanoparticles 163.3 pH <8.0, Concentration 100 mg/L @ 25
o
C 39 















2.23 pH 6.4, Concentration 10 mg/L @ 30
o
C 42 
Magnetic Chitosan 20.96-23.98 pH 7.0, Concentration 5-140 mg/L, @ 18-20
o
C 43 
Hydrous MgO coated 
activated Alumina 






















Table 2.2: Materials used for fluoride removal in water. Please note that the fluoride removal capacities 
are highly dependent on experimental conditions, only an objective comparison of fluoride removal 









Table 2.2 continued: 





Experimental conditions Reference 
Nano HAp-Chitin 
Composite 





1.560 pH 7.0, Concentration 10 mg/L @ 30
o
C 49 
Nano Hap 1.296 pH 7.0, Concentration 10 mg/L @ 30
o
C 48 
Nano Hap 1.845 pH 3.0, Concentration 10 mg/L @ 30
o
C 50 
Iron Oxide 20.4 pH 4.0, Concentration 6 mM, @ rt 51 
Al exchanged Zeolite 
F9  
37.54 pH Neutral (6.34 optimal), Concentration 10-








































Table 2.2: Materials used for fluoride removal in water. Please note that the fluoride removal capacities 
are highly dependent on experimental conditions, only an objective comparison of fluoride removal 
abilities can be made given the variation of experimental conditions. 
 
2.4.1 Activated Alumina (AA) 
Activated alumina (AA) is a commonly used material for removal of fluoride from water.35, 54, 55 
Activated alumina is an aluminium oxide (partially hydrated) formed by dehydroxylating 
aluminium hydroxide yielding a highly porous material with a large surface area.56 The binding 
of fluoride to AA is  described predominantly as an ion exchange process, see equations 2.1-
2.3.35    
(2.1) *AlOH + F-  ↔ *AlF + OH-  
(2.2) *AlOH2 + F
- ↔ *AlF + H2O 
(2.3)*AlOH + 2F- ↔ *AlF2 + OH
- 
Equations (2.1-2.3): Binding of fluoride to AA surface. *Al denotes the Alumina surface and the over bar 




Ghorai et al. describe the use of a fixed bed adsorber system to assess the performance of 
AA.35 Fluoride containing water was passed through a column packed with AA. During a 




alkali/acid treatment. For example, the AA column is flushed with NaOH to remove the bound 
fluoride. To reactivate the column, it is flushed with acid (H2SO4) to restore the positive charge 
on the surface alumina.20 In the same study, the loss of fluoride adsorption is shown to be 
only 5% after five cycles of regeneration.35 The adsorption capacity at pH 7 was 1450 mg/kg 
(fluoride per unit mass of material). 
 
Many factors affect the fluoride binding capacity of AA. These include adsorbent 
concentration, fluoride concentration, pH, and ion competitors. 54, 55 Tang et al. found the 
maximum adsorbance of AA occurred at pH 5.5-7 (10-54 mg/L fluoride concentration for 
10g/L [AA]).54 The effect of increasing fluoride ion concentration was to lower the maximum 
binding pH. At high fluoride concentrations, such as 106 mg/L, using 10g/L adsorbent the 
optimal efficiency was reached at a pH lower than 5.5. At lower pH practical applications 
become limited and the toxicity from leaching aluminium is a health concern. The effect of 
competing ions such as Cl- , HPO4
2-, HCO3
-, and SO4
2- is well documented.54, 55 The greatest 
effect was observed with phosphate as a competing ion, with a reduction from 76% to 50% 
fluoride binding under the following conditions (300 mg/L of [HPO4
2-], 150 mg/L [fluoride], 10 




2- > Cl-.54  The adsorption kinetics are also important. It was found that adsorption of 
fluoride on AA was rapid in the first few hours, then significantly slowed to reach equilibrium 
in about 10 hours.54 The study of factors influencing fluoride adsorption can be applied to a 
wider field of biomedical applications. For example, fast adsorption kinetics and optimal 
biological pH ranges for fluoride adsorption would be ideal for our in vivo pretargeting 
concept, or the removal of unwanted fluoride after radiolabelling protocols.   
 
The shortcomings of AA, such as narrow pH limits and slow binding kinetics have led to the 
search for new fluoride affine materials. The growing list includes; amorphous alumina,32 
mesoporous alumina,57  rare earth metal oxides (in the form, M2O3 or M(OH)3),
34 
hydroxyapatite (HA) ,50, 53 chitosan beads,41 clays, 58 activated carbons,36 zeolites,52 and layered 
double hydroxides33 (Table 2.2).  
 
2.4.2 Metal Oxides for Fluoride Binding 
It is well known that many hydrous metal oxides have high fluoride affinity. The high 
electronegativity and small ionic size of fluoride ions favour their affinity to electropositive 
multivalent transition and rare earth metal ions such as Al(III), Fe(III), Ti(IV), Zr(IV), La(III) and 




binding, such as iron(III) oxide,51 zirconium(IV) oxide,59 iron(III)-zirconium(IV) hybrid oxide,47 
iron(III)- aluminium(III) mixed oxide,46 iron(III)- tin(IV) mixed oxide,45 manganese oxide coated 
alumina,44 copper oxide coated alumina,42 and trimetal oxide Fe-Al-Ce.31 All have shown 
promising fluoride retention, displaying properties such as improved fluoride adsorption, 
faster kinetics and favourable pH binding ranges compared to AA.  
 
Mixed metal oxides provide a platform to manipulate adsorption affinities. New metal ions 
can be incorporated into metal lattice structures to influence their binding properties. For 
example, introducing hard metal ions such as tin(IV), that have high a positive charge, can 
increase fluoride adsorption.45 Rare earth metal hydroxide/oxides have been widely reviewed 
as potential materials for fluoride binding, utilising their selective high affinity fluoride binding 
properties, easy preparation, and environmental compatibility.34, 60, 61, 62 Ion exchange with 
inorganic cation/anion exchange resins such as silica gels, alumina gels and chelating agents 
containing high valence metal ions, such as Fe(III), La(III) , Zr(IV) and Ce(III) has also been well 
reviewed.26, 63  
The mechanism of fluoride adsorption on metal oxide surfaces can be explained through the 
affects of pH. Firstly, the point of zero charge (pHpzc), (the point at which the electrical charge 
density on the surface is zero) must be considered. It is well described that in acidic medium 
the metal oxide surface will be highly protonated, the net result is a positive surface 
increasing the attractive forces between it and negative fluoride ions.37, 44, 45 However, in some 
examples it has been seen that fluoride adsorption decreases at low <pHpzc, explained by the 
formation of HF at acidic pH, reducing the electrostatic interaction between the surface and 
fluoride ion.25 As we move above and beyond the pHpzc the metal oxide surface becomes 
negatively charged, causing repulsion of the fluoride ion. In addition, there will also be OH- 
competing for potential F- binding sites. Typical adsorption mechanisms for fluoride on 
hydrous metal oxides in aqueous solution is summarised by equations 2.4-2.7.45 
 
(2.4) MOH(S) + H3O
+ + F− → MOH2
+----F−(S) + H2O 
(2.5) MOH(S) + H3O
+ + F− → M+----F−(S) + 2H2O 











− → MO−----Na+----F− + H2O 
Equations (2.4-2.7): A typical adsorption mechanism for fluoride to hydrous metal oxides.
45
Equation 2.4 
describes the electrostatic interactions that may occur on positively charged surfaces. Equation 2.5 and 
2.6 represent the anion exchange mechanisms that might occur predominantly around pHpzc or neutral 
pH. The suggested anion exchange mechanism between OH/F is further supported by increased pH 




 Equation 2.7 represents formation of a 
primary adsorption sphere on a negatively charged surface, subsequently fluoride and hydroxyl ions 




2.4.3 Calcium Containing Materials 
It is well known that fluoride ions bind avidly to the bone-like material hydroxyapatite (HA). 
For example, 18F-NaF is recognised as an excellent bone scanning agent.64-66 HA has also been 
used to remove fluoride in water purification processes.49, 50, 53 Other calcium based materials 
are also known for their fluoride removal abilities, such as limestone (calcite)67, 68 and 
fluorspar.53 
 
 Fan et al. described the favourable adsorption kinetics of fluoride on HA and other low cost 
materials, including, fluorspar, calcite and quartz. 53 18F-fluoride was used to study the kinetics 
of each material. The fluoride binding capacities recorded were: HA (90%), fluorspar (25%) 
and calcite (12%). The fluoride uptake on calcite and fluorspar was considered to be via 
surface adsorption. It was thought that calcite (CaCO3) can scavenge fluoride in two ways; 
First, through releasing the calcium ion and forming a CaF2 precipitate,
68 secondly, by 
replacing the CO3
2- ion with F- (Equation 2.9). Fan et al. provide evidence that an adsorption 
process was mainly taking place. Fluorspar (CaF2) may contain unsaturated calcium sites and 
exchangeable fluoride anions (caused by distorted fluorine positions in its crystal structure). 
The fluoride adsorption equilibrium for calcite and fluorspar was reached in 2 minutes, in 
contrast to the HA, which reached equilibrium at a much slower rate, in 150 minutes. The 
difference in adsorption capacity and kinetics was explained through different adsorption 
mechanisms. Firstly, the fluoride adsorbs onto the HA surface, followed by ion exchange with 
OH groups nearest the surface, and finally fluoride exchange continues with mobile charge 
carrying hydroxyl ions in the internal HA structure (Equation 2.8).50, 53 HA has been identified 
as an electronically conductive material, where OH- can act as a charge carrier moving in 
electric fields.69, 70 The internal exchange of mobile OH- with F- is proposed to significantly 
increase the binding capabilities of HA. 
 
The studies reported by Fan et al. consider only small concentrations of fluoride. At higher 
concentrations the adsorption behaviour reported may not be the same.  For example, Fan et 
al. report fluoride removal as a poor adsorption process on the surface of calcite. However, at 
higher concentrations, dissolution of CaCO3 and precipitation of CaF2 can occur.
67, 68 Turner et 
al. provide evidence that both surface adsorption and precipitation mechanisms take place 
dependent on calcite surface area and fluoride concentration.68 These findings highlight the 
importance of experimental conditions, such as fluoride concentration when studying 




concept will rely on adsorption of fluoride ions at very low concentrations in the presence of 





2−----Fn  (a)  
 Ca10(PO4)6(OH)2+nF
− = Ca10(PO4)6F2 -2OH
−  (b) 
Ca10(PO4)6(OH)2+nF
− = Ca10(PO4)6(FOH) -OH
−  (c) 
(2.9)  2F−+CaCO3(s)  =  CaF2(s)+CO3
2 
Equations 2.8-2.9: (2.8) Possible mechanism of HA- fluoride binding. Scheme (a) Electrostatic interaction 
at low/acidic pH with positively charged surface. (b,c) anionic exchange mechanisms.
50, 53
 (2.9)possible 




2.5 Nanomaterials for Fluoride Binding  
Herein we review the avidity of fluoride for nanoparticulate materials reported in water 
purification processes. The majority of the fluoride binding materials reported hitherto have 
been in the micron size range. More recently it was thought that combining the high affinity 
fluoride interactions with nanotechnology could enhance fluoride ion capture. Nanoparticle 
materials are known for their high surface area to volume ratio and enhanced reactivity.  
Binding or adsorption sites often occur at the surface of nanoparticles, offering a platform for 
increasing the fluoride binding capacity (increased surface area) and shorter diffusion routes 
for fast adsorption kinetics.71, 72As chemistry and technology in the nanoparticle field evolves, 
the ability to tailor properties to specific size, shape and charge, can be exploited to design 
materials fit for their intended use.  Some examples of nanoparticle materials used in the field 
of fluoride water purifaction include nano scale aluminium oxide hydroxide,38 nano-alumina,25 
HA,50 HA/chitosan composites,49 CaO NPs,39 Fe3O4/Al(OH)3 NPs,
73 Fe-Al-Ce hydroxide nano-
adsorbent. 74 
 
2.5.1 Aluminium Based Nanomaterials 
Herein a comparison between bulk aluminium based materials and their nano scale counter-
parts is made. Due to the fact that fluoride loading capacity is dependent on many factors 
such as, pH, fluoride concentration, adsorbent concentration, and temperature, direct 
comparisons are difficult to make. Kumar et al. assessed the fluoride loading capacities of 
nano alumina (Al2O3).
25 The maximum adsorption estimated was 14.0 
mg[fluoride]/g[adsorbent] at pH 6.15, 298K, with initial fluoride concentrations ranging from 
1-100 mg/L. Wang et al. assessed the fluoride adsorption properties of aluminium oxide 
hydroxide (nano-ALOOH).38 A Maximum adsorption of 3.259 mg/g was estimated, at pH 6.8, 
298K, with initial fluoride concentrations ranging from 3-35 mg/L. Wang et al. found that 




equilibrium at ca. 6 hours for fluoride concentrations of 11.59, and 24.04 mg/L. At lower 
fluoride concentrations (6.06 mg/L) faster reaction kinetics were observed, reaching 
equilibrium within 100 minutes. In a study under similar conditions, Maliyekkal et al. report 
the fluoride binding capacity of activated alumina (bulk material) to be 1.077 mg/g, 
approximately three times less.72 A study by Tang et al. reports a loading capacity of activated 
alumina in a range between 1-10 mg/g (adsorbent 10g/L, initial fluoride concentrations were 
between 5-106 mg/L at 298K).54 Maximum adsorption was observed in the pH range 5.5-7.5 
reaching equilibrium less rapidly, ca. 10 hours. 
 
An interesting study compares fluoride binding properties of bulk mesoporous alumina(MA2), 
and commercially available activated alumina’s, pseudo boehmite and γ-Al2O3.
57Although 
these mesoporous materials are not nano, they represent a large increase in surface area, 
similar to that observed in nanomaterials. The maximum adsorption capacities were 
estimated at 14.26, 6.13, and 6.36 mg/g for, MA2, boehmite, and γ-Al2O3 respectively, 
(measured at pH 6, 298K, initial fluoride concentrations were between 20-250 mg/L, 
adsorbent 12 g/L). The initial adsorption rate for MA2 was 45 times that of γ-Al2O3, reaching 
equilibrium in 15 minutes and ca. 2 hours respectively. The maximum absorption capacity of 
MA2 was 2.3 times that of boehmite, corresponding well to a surface area increase, where 
MA2 is 2.6 times larger than boehmite. 
  
In conclusion, both ALOOH and Al2O3 nanoparticles offer improved fluoride loading capacities 
over bulk activated alumina. The initial rate of adsorption is evidently faster than the 
unfavourable slow reaction kinetics of activated alumina. The slow reaction kinetics of AA 
have been explained by its poor interparticle diffusion in the solute, thus restricting the 
absorbent coming into contact with fluoride ions.72 The increased surface area of nanoparticle 
and mesoporous preparations plays a critical role in improving fluoride binding capacities of 
these materials.  
 
2.5.2 Calcium Based Nanomaterials 
Calcium coated particles have received much interest due to their high binding capacities, 
economical preparations, and biocompatibility. Sundaram et al. prepared nano scale 
hydroxyaptite via a simple low cost wet chemical precipitation process.50 A maximum 
defluoridation capacity of 1.845 mg/g (pH 3, 303K and fluoride concentration 10 mg/L was 
reported). Fluoride saturation on the particles was reached ca. 30 minutes. The same group 




maximum fluoride loading 1.911 mg/g, (pH3, 303K fluoride concentration 10 mg/L).49 In 
comparison, a study reporting bulk hydroxyaptite properties measured lower binding 
capacities and slower kinetics. The measured defluoridation capacity was 0.022 mg/g, (at pH 
6, and initial fluoride concentration of 0.064 mg/L) and adsorption equilibrium was achieved 
ca. 150 minutes.53 However, the experimental conditions are vastly different, such as pH and 
fluoride concentration making any comparison difficult. Patel et al. synthesised colloidal CaO 
nanoparticles with a large fluoride removal capacity of 163.3 mg/g, at pH <8.0, and initial 
fluoride concentration 100 mg/L, 298K. The results suggest that nano-CaO and HA have 
potential as a fluoride adsorbing agents, with favourable reaction kinetics and loading 
capacities. 
 
The above discussion has been based on materials used for fluoride removal in water 
purification processes; a useful resource for identifying lead materials that may be applied to 
our search for a fluoride-affine material. The review has indentified the trend towards 
developing novel nanomaterials to obtain maximum fluoride loading capacities. Below we 
review the current trends for incorporating fluorine-18 into nanoparticles for PET imaging 
applications.  
  
2.6 Fluorine-18 Labelled Nanoparticles 
Nanoparticles in the field of medical imaging/therapy have been widely discussed. The older 
and clinically used methods (reviewed in chapter one), often involve microparticles or large 
aggregates that accumulate in target sites by virtue of their size. However, many do exploit 
simple surface interactions as binding sites for radiolabelling probes. As nanotechnology has 
advanced the ability to tailor particles to a specific size, shape and surface chemistry has 
dominated research, producing defined particles with active targeting strategies in mind. The 
simplistic view has been overlooked, as many novel nanoparticle designs incorporate 
complicated surface functionalisation with ligands acting as linkers to provide binding sites for 
radiolabels. Herein we provide some examples of fluoride-nanoparticle linking methods 
discussed in literature. We aim to apply the fluoride avidity for nanomaterials to a simple one 
step labelling protocol. In this section we discuss the complex nature of many modern 
nanoparticle labelling protocols.   
 
2.6.1 Fluorine-18 Labelled Liposomes 
Oku et al. describe one of the earliest examples of fluorine-18 labelled nanoparticles in 1996.75 




and develop liposomal systems their characteristics need to be considered, including: lipid 
composition, size, and surface properties. Imaging of in vivo trafficking utilising PET can help 
evaluate the pharmacological profile of the lipsomes. The incorporation of 18F for in vivo 
trafficking of long circulating liposomes was achieved through encapsulation of 18F-FDG.75 
Liposomes were composed of dipalmitoylphosphatidylcholine, cholesterol, and a modifier, 
specifically- ganglioside (GM1), distearoylphosphatidylethanolamine-polyethyleneglycol 
(DSPE-PEG) or palmityl-D-glucuronide (PGlcUA) to prolong blood circulation times. 18F-FDG 
was incorporated into the aqueous cavity of the liposome during its formation. The liposomes 
were then extruded through a polycarbonate membrane filter (100 nm pore size), washed and 
purified with saline via centrifugation. 18F-FDG was encapsulated with about 10% efficiency in 
all preparations. The modified 18F-FDG labelled liposomes remained in blood circulation longer 
than their unmodified counterparts, reducing liver trapping. Enhanced tumour accumulation 
of the modified liposomes was also observed, attributed to the EPR effect. The authors 
identify the modified liposomes as potential tumour imaging and therapeutic agents. 
However, improvement of the low encapsulation efficiency would be a significant 
development in this chemistry.   
 
The same group, have developed a labelling method on preformed liposomes, improving 
labelling efficiency and occupational dosimetry. Although referred to as a one step protocol, it 
clearly requires a two step labelling protocol; a precursor is radiolabelled then incorporated 
into the liposomes. The new method involves incorporation of 18F labelled amphiphilic 
compounds into the phospholipid bilayer of the preformed liposome, described as the “solid 
phase transition method”.76  The approach identifies a generic method that can be applied to 
a variety of nanocarriers, such as micelles or microbubbles. A series of novel 18F amphiphilic 
compounds were developed and assessed for liposome labelling suitability. 18F-fluoro-3,6-
dioxatetracosane (18F-SteP2) (Figure 2.3) was selected as the most promising in vivo liposome 
imaging agent. The 18F label was introduced via nucleophilic substitution of its corresponding 
toluene sulfonate with 18F-KF/K[2.2.2] (Figure 2.3). The radiochemical purity and decay 
corrected radiochemical yield were 100% and 42.9% respectively. The amphiphilic 18F-SteP2 
compound was dried to make a thin film. Next, liposomes were added to the solvent free 
compound, incubated for 15 minutes at 65 °C and purified by ultracentrifugation. The 18F label 
was incorporated with ca. 90% efficiency. Liposomes of different sizes were labelled with 18F-
SteP2, and assessed via PET imaging. Whole body In vivo mice imaging revealed 18F 




recently 18F-SteP2 labelled liposomes have been used as brain tumour imaging agents in rats, 








F-SteP2 (1). (a) NaH, THF, 0 °C to room temp, then 
TsCl, room temp, 40–70% yields, (b) 
18




Marik et al. describe the preparation of the 18F labelled amphiphilic diglyceride 18F-
fluorodipalmitin (18F-FDP).78 However, the 18F-FDP incorporation was achieved during 
liposome formation rather than on preformed liposomes. 18F-FDP was prepared via the 
reaction scheme in figure 2.4, with a decay corrected radiochemical yield of 43%. 
Radiolabelled liposomes were purified by gel chromatography to remove unincorporated 18F-
FDP. The radiolabelled liposomes were obtained with a decay-corrected radiochemical yield of 
70%. 18F-fluorodipalmitin has more recently been incorporated into microbubble shells, 
demonstrating for the first time full body microbubble in vivo biodistribution.79 Although the 
liposomes are prepared post 18F-FDP preparation, the total synthesis time is not significantly 
affected in comparison to the preformed liposome labelling method discussed above, with 
reaction times of 10 (18F-SteP2, see above) and 15 (18F-FDP) minutes for 18F-liposome labelling 
steps. However, the newly synthesised liposomes do require purification using gel 
chromatography. Dynamic PET studies provided pharmacokinetic information, valuable for 
assessing potential drug delivery applications using ultrasound and microbubble formulations.  
 
(a) (b)
Figure 2.4: Radiochemical synthesis of 
18
F-FDP (a) TsCl, pyridine, 16h, RT (b) K222/K-
18
F, MeCN, 100°C, 
20 min.  
 
2.6.2 Fluorine-18 Labelled Quantum Dot Micelles 
Ducongé et al. have synthesised bifunctional 18F labelled phospholipid quantum dot (QD) 
micelles.80 QDs were encapsulated with phospholipid micelles covalently labelled with 18F-
fluoride for fluorescence and nuclear imaging. CdSe/CdZnS Core-Shell QDs were encapsulated 
with PEG-phospholipid micelles and coupled to 18F (Figure 2.5). To achieve encapsulation, QDs 
were dissolved in chloroform with a mixture of 1,2-dipalmitoyl-sn-glycero-3-




PEG2000-NH2 and heated. The resultant QDs were purified through ultracentrifugation in a 
sucrose solution. Terminal amine groups were converted to active thiol moieties using 
sulfosuccinimidyl6-(3-[2-pyridyldithio]-propionamido)hexanoate (Sulfo-lc-SPDP) as a 
heterobifunctional linker. The QDs were labelled using a 18F-maleimido reagent, 18F-FPyME (1-
[3-(2-fluoropyridin-3-yloxy)propyl]pyrrole-2,5-dione). 18F-fluoride was incorporated into the 
pyridinyl moiety via nucleophilic heteroaromatic substitution, prior to surface conjugating via 
thiol and maleimide coupling. The particles were loaded with 370-750 GBq/(QD)µmol in a 
total synthesis time of 145 min.   The QDs were employed for in vivo confocal and PET imaging 
in mice. The biodistribution results indicate these QDs have potential imaging applications, 
such as tumour targeting, as they exhibit long  blood circulation time, T1/2 is approximately 2 
h. After 90 minutes there was relatively low liver and spleen accumulation 10% and 6% ID/g 
respectively. In future targeted studies, using long blood circulating particles may require 
incorporation of longer lived isotopes for biodistribution assessment.  
 
2.6.3 Viral Envelope Encapsulation of Fluorine-18 
Flexman et al. report the encapsulation of fluorine-18 and superparamagnetic iron oxide 
(SPIO) nanoparticles in viral envelopes.81 Viral gene or drug delivery vehicles are of particular 
interest due their ability to interact with cellular membranes and hence perform drug or DNA 
delivery with high efficiency. Evaluating the in vivo biodistribution of the viral agents can help 
design and improve their targeting abilities. The hemagglutinatin virus of Japan (HVJ) has been 
used effectively in gene therapy as a reconstituted envelope (HVJ-E).82 The HVJ-Es are 
approximately 300 nm in diameter and were used to co-encapsulate SPIO nanoparticles and 
the fluorine-18. The encapsulation procedure was optimised using a range of cationic 
polypeptides. From the polypeptides investigated the positively charged poly-L-lysine (PLL) 
(MW 66.7 kDa) exhibited the best labelling efficiency of the viral envelopes (0.1507% ± 
0.0242%). The 18F-fluoride ions were first incubated with a solution of polypeptide, to form an 
18F-peptide complex. Next, a solution containing the 18F-peptide complex and SPIO particles 
was mixed with the HVJ-Es. The solution contained a detergent to open the cell membrane 
and allow 18F-peptide complex and SPIO particles to penetrate. It was hypothesised that the 
cationic polypeptides formed a bridge between the negatively charged fluoride ions and iron 
oxide particles, thus preventing leakage of the free ions from the viral membrane. The in vivo 
biodistribution and magnetic targeting of the loaded HVJ-Es was assessed in rats. PET imaging 
was able to show that the bifunctional HVJ-Es cleared the liver and spleen and could be 
magnetically targeted using externally placed magnets. However, the labelling efficiency of 
the HJV-Es was very low, which could potentially limit the effectiveness of potentially longer 













2.6.4 Cross Linked Iron Oxide Nanoparticles (CLIO) “Click Chemistry” 
Devaraj et al. present, perhaps the most frequently cited example of fluorine-18 labelled 
nanoparticles.83 Cross linked iron oxide nanoparticles (CLIO) were radiolabelled with fluorine-
18 using 18F labelled PEG3 conjugated to azide containing CLIOs via “click chemistry”. Since the 
discovery of a Cu(I) catalyzed version of the Huisgen 1,3-dipolar cycloaddition of terminal 
alkynes and azides,84, 85 (Figure 2.6) “click chemistry”, its applications have been widely 
reviewed.86-88 In particular, several radiolabelled PET tracers have utilised this chemistry.89-93 
18F radiosynthesis methods have exploited the rapid, high yielding, chemoselctive nature and 
aqueous mild reaction conditions of click reactions. 
 
Many 18F-peptide synthetic approaches require harsh reaction conditions and lengthy, 
complicated procedures. The same can be said for labelling functionalised nanoparticles with 
fluorine-18.  In recent years a plethora of “click chemistry” based bioconjugations examples 
has inspired its investigation as a potential nanoparticle derivatisation method.94 Although the 
click chemistry reaction is mild, preparation of the labelled click reagent may still be 







Figure 2.6: (Top) The Huisgen 1, 3-diploar cyclo-addition yields two triazole regioisomers (bottom) Cu (I) 
catalysed “click reaction” yields one isomer.  
 
Devaraj et al. prepared multimodal 18F-nanoparticles; firstly, aminated CLIO nanoparticles 
were functionalised with a NHS derived fluorescent tag (VT680). Next, the remaining amine 
groups were reacted with the NHS ester of 1-azido-13-oxo-3,6,9-trioxa-12-azaheptadecan-17-
oic acid, followed by the chemoselective “click” reaction of 18F-PEG3 (Figure 2.7). The synthesis 
of fluorescent aminated CLIO nanoparticles had been reported previously.95 
 
3-(2-(2-(2-18F-fluoroethoxy)ethoxy)ethoxy)prop-1-yne (18F-PEG3) was prepared via nucleophilic 
substitution of 18F-fluoride with an alkynyl tosylate PEG precursor, in 57% average decay 
corrected radiochemical yield. The “click” reaction yielded 18F-CLIO particles in an average 
decay corrected radiochemical yield of 58%, and average specific activity of 1.1 mCi/0.1 mg of 
nanoparticles. The overall synthesis time from start to finish was 140 minutes. In vivo dynamic 
PET studies revealed the nanoparticles had a blood half life of 5.8 h before being sequested by 
the RES system in mice. The sensitivity of 18F-CLIO for PET-CT was 200 times greater than MRI 
detection thresholds, 0.025 μg Fe/mL for PET-CT and 5 μg Fe/mL for MRI.96 The PET-CT 
detection threshold was also greater than 64Cu-labelled CLIO nanoparticles, approximately 4 
times greater (0.1 μg Fe/mL). However, it can be attributed to the higher abundance of 
positron emission of 18F (97%) compared to 64Cu (19%). The authors also describe the 18F 
shorter half life as an advantage in comparison to 64Cu labelled nanoparticles. This may not 
always be the case, nanoparticles with longer blood half life might require longer times to 
accumulate at their target sites, and subsequently a shorter lived isotope will decay and 





             
 






A later publication from the same group reports the fluorescent imaging capabilities of the 
particles.97 The multimodality particles were assessed via optical measurements 
[fluorescence-mediated tomography (FMT)] and PET/CT. The FMT and PET data sets 
conformed to each other, indicating that multichannel FMT/PET CT fusion can be integrated 
and visualised. The detection threshold for FMT (1.25 μg Fe/mL) was 50 times higher than 
PET/CT. The use of a dual PET/fluorescent particle could be applied to a clinical setting. PET 
could be used to identify and stage tumours preoperatively. Short lived isotopes such as 18F 
can decay to a safe level, while the particles remain fluorescent and could be used as an 
intraoperative tool guiding surgery. Fluorescent imaging in vivo faces some major obstacles, 
such as animal tissue adsorbing and scattering photons, obscuring and interfering with signal 
collection. However, recent advances in imaging strategies and probe design have significantly 
improved signal sensitivity and fluorescence potential as an in vivo imaging modality.98 
 
2.6.5 Cross Linked Micelles, 18F MORF Nanoparticle 
Matson et al. described the synthesis of fluorine-18 labelled cross linked micelles using 
amphiphilic block copolymers as scaffolds. The polymers self assemble to form micelles of 
controllable size and shape, dependent on block lengths and relative ratios of hydrophilic and 
hydrophobic parts. Ring opening metathesis polymerization (ROMP) provides a method for 




produced consisted of cross-linking and 18F labelling functionality. Hydrophobic and 
hydrophilic monomers were synthesised as described in figure 2.8.  The monomer units were 
prepared from exo norbornene molecules. The exo nobornene has the ability to undergo 
ROMP and more specifically, consists of an exo anhydride moiety that can be modified with 
amines to form a range of monomers, presented in the paper. A cinnamoyl moiety was also 
incorporated as a cross linking agent, and a mesylate group for nucleophilc substitution with 
18F-fluoride. 
 
Copolymerization of monomer units was achieved utilising a ruthenium olefin metathesis 
catalyst (H2IMes)(pyr)2(Cl)2Ru=CHPh in THF. The reaction was quenched with ethyl vinyl ether 
and precipitated in ether/hexane (1:1). Micelles were formed by dissolving the polymer in 
THF, followed by the addition of water. Cross linking was achieved under irradiation with UV 
light, the cinnamoyl groups undergo a [2 + 2] dimerization to yield a tetra-substituted 
cyclobutane ring. Micelles were in the size range 47.4-142.5 nm, measured by DLS. The 18F 
radiolabel was incorporated into the nanoparticles via nucleophilic substitution with its 
mesylate moiety. Nanoparticles were suspended in acetonitrile and reacted with 18F-fluoride 
in a sealed vessel for 1 h at 120 oC. The particles were purified on a neutral aluminium and 









Figure 2.8: Synthesis of ROMP monomers. Reaction conditions: (i) H2NCH2CH2OH, NEt3, toluene, DS-trap; 
(ii)trans-cinnamic acid, EDC, DMAP, CH2Cl2, rt; (iii) H2N(CH2CH2O)13OH,C6H6, DS-trap; (iv) MsCl, NEt3, -30 
°C. 
 
 The flexibility of size control of the nanoparticles could allow for in vivo biodistribution 
studies on tumour targeting via the enhanced permeability retention effect (EPR effect).  
However, no such studies have been reported yet. The 18F-fluoride nanoparticle labelling 
procedure is comparable to the click chemistry procedure reported above, requiring 1 h 





The targeting strategies reported above have exploited the passive accumulation of 
nanoparticles at their target site, hence accumulating by virtue of their size via the EPR effect.  
Cheng et al. report actively targeted anti Her2 nanoparticles labelled with 18F and 99mTc tags, 
comparing the performance of micro PET and SPECT.99 The nanoparticles were prepared from 
a biotinylated phosphodiamidate morpholino (MORF) oligomer terminated with amine 
groups. Although the MORF particles have been repeatedly labelled with 99mTc via MAG3 for 
antisense imaging,100 this was the first report of fluorine-18 labelled MORF particles. After 
radiolabelling, the particles were linked to biontinylated Trastuzumab (Herceptin) anti Her2 
via streptavidin on the nanoparticle surface. 18F labelling was achieved via the linkage of N-
succinimidyl-4-18F-fluorobenzoate (18F-SFB) to the aminated surface. 18F-SFB was prepared via 
the reaction scheme in figure 2.9, from ethyl 4-(trimethylammonium)benzoate 
trifluoromethane sulfonate. The final 18F-SFB product was purified using C18 Sep Pak 







Figure 2.9: Synthesis of 
18
F-SFB . (i) K222/K-
18
F, MeCN, 90 °C, 5 min (ii) NaOH/HCl, 90 °C, 5 min, (iii) TSTU 
(O-(N-succinimidyl) N,N,N′,N′-tetramethyluronium tetrafluoroborate), MeCN, 90 °C, 5 min. 
 
The nanoparticles were prepared by mixing the MORF oligomer with 18F-SFB for 40 min at 
room temperature. The 18F MORF was mixed with a 2 fold excess of strepavidin for 30 min at 
room temperature. Next, biotinylated Trastuzumab was mixed with the MORF/strepavidin 
particles in 1:1 ratio for 30 min at room temperature and purified. Preparation of the 99mTc 
labelled nanoparticles followed a similar protocol. However, NHS-MAG3 was conjugated to the 
MORF oligomer and subsequently labelled directly with 99mTc pertechnetate, excluding the 
need for a prelabelled intermediate. The nanoparticle formation was performed post MORF 
oligomer radiolabelling, since it required heating, which could affect the integrity of the 
incorporated streptavidin. The synthesis of 18F MORF and 99mTc MORF nanoparticles yielded 




In vivo biodistribution studies in mice reveal both nanoparticles exhibited similar tumour 
accumulation (around 10% ID/g). Aside from the sensitivity and resolution advantages of PET, 
the authors describe the 99mTc labelling protocol to have clear advantages over the 18F 
method. For example, the 18F-MORF nanoparticle required the preparation of a prelabelled 
intermediate, extending the total synthesis time to 4 h in comparison to 2 h.  99mTc chelation 
does indeed offer a more efficient, simple labelling protocol in this example. However, you 
cannot rule out the development of simpler 18F-fluoride protocols. 
 
2.6.6 Direct Labelling of Nanoparticle Surfaces with 18F-Fluoride 
The above discussion highlights that the labelling of nanoparticles with fluorine-18 is often 
complex, requiring the complicated synthesis of a labelled precursor and multiple steps. These 
approaches involve either encapsulation or bioconjugation via a linker and an 18F-labelled 
precursor. A concept that is consistently overlooked in these examples is the direct labelling of 
nanoparticle surfaces with the 18F-fluoride ion. Our survey above indicates that fluoride ions 
have affinity for a variety of materials. For simplicity, nanoparticles can be directly labelled 
exploiting the high affinity interaction with metal ions, removing the additional step of 
synthesising an 18F-labelled precursor before conjugation. We aim to exploit the simplicity of a 
radiolabelling protocol that requires only one step, using the simplest probe-18F-fluoride, 
which can be mixed and bound to nanomaterials in a one pot reaction. Our pretargeting 
concept envisages that this interaction will take place in vivo.  
 
Recently, a number of publications have reported rare earth metal oxides (in the form M2O3 
and M(OH)3) or rare earth metal doped nanoparticles and their ability to adsorb the 
18F-
fluoride ion.60, 101, 102 The unique optical and magnetic properties of rare earth metal 
nanoparticles has promoted intense research interest in recent years,103-105 including the 
development of luminescent lanthanide doped upconversion (UC) nanocrystals for optical 
imaging104 and gadolinium based nanoparticles for MRI.105 Sun et al. surveyed the 18F-fluoride 
ion binding capacities of a range of rare earth nanoparticles. The labelling procedure was a 
simple, rapid one step method. The nanoparticles (10 mg/mL) were incubated in aqueous 18F-
fluoride for 1 minute, reporting 18F-fluoride incorporation of 89.8, 90.1, 97.3, 96.4 and 88.7% 
onto Y2O3, NaYF4, Y(OH)3, Gd(OH)3 and UC NPs (NaYF4: Yb, Tm), respectively. The radiolabelling 
process of UC NPs was optimised with regard to NP concentration and incubation time. An 
optimal time of 5 minutes and a concentration of 1.25 mg/mL was chosen. The stability of the 
particles was measured in PBS, exhibiting a 18F-fluoride dissociation rate of 11.34% in 2 hours 
for UC NPs. In vivo PET/CT and biodistribution studies were performed on mice. 




45.2% ID/g at 5 minutes. Ex vivo UC luminescence microscopy of liver and spleen sections 
exhibited intense UC luminescent signals with counts greater than the detection threshold, 
implying high sensitivity for optical imaging is achievable. Additionally, 18F-UC NPs were 
injected subcutaneously into the paw footpad of mice, where lymph node imaging was the 
objective. PET/CT images were acquired, exhibiting an intense signal in the sentinel lymph 
node after 30 minutes. The authors do not refer to the 6.20% ID/g accumulation in bone after 
5 minutes. It is not clear if this is due to loss of weakly adsorbed fluoride ions on the particle 
surface or bone marrow accumulation of the labelled particles. However, there is not a 
significant increase in bone accumulation after 2 h (8.8% ID/g), suggesting the 18F-NP 
interaction is sufficiently stable for in vivo nuclear imaging. Both the in vivo PET/CT imaging 
and biodistribution results suggest that the UC NPs have potential as PET and optical imaging 
agents. 
  
Other examples exploiting the avid rare earth metal 18F-fluoride interaction include; UC NPs 
(NaYF4: Yb,Er) doped with Gd
3+ and functionalised with ligands such as folic acid for multi 
modality PET/MRI/UCL (upconversion luminescent) in vivo imaging .101, 102 Future experiments 
should investigate the in vivo targeting ability and evasion of RES system uptake through 
further functionalisation of the particles.  
 
2.7 Aims 
This review has revealed that there are many fluoride affine materials, capable of removing 
fluoride from aqueous solutions, with calcium and aluminium based materials at the forefront 
of water purification processes. There is a trend towards the use of nanomaterials to increase 
the fluoride removal capacity for water purification. We aim to reflect this trend in our 
labelling protocol to introduce the maximum payload of radiotracer to a biological target site 
that is expressed in low abundance. The incorporation of fluorine-18 into nanoparticle 
preparations for PET imaging is often complex and requires multiple steps. Our strategy aims 
to simplify this process by exploiting fluoride–affine materials in a rapid one step labelling 
protocol without the need for further modification or purification 
 
Experimental Aims 
 To identify and select materials that have high fluoride loading rate, affinity, capacity 
and stability for potential in vivo application. 
2.8 Materials 
All chemicals were obtained from commercial sources as analytical reagents and used without 




obtained from an ELGA Purelab Option-Q system. Human serum, male AB plasma (H4522) was 
purchased from Sigma-Aldrich. Trizema base, sodium phosphate, sodium chloride, sodium 
carbonate, sodium hexametaphosphate, sodium fluoride, were all purchased from Sigma-
Aldrich. Sodium citrate dihydrate was purchased from Fischer Scientific. 18F-fluoride was 
produced at the Clinical PET Centre, St. Thomas’ Hospital, London, UK, by proton irradiation of  
97% 18O-enriched water from Isochem Ltd, Hook, UK (18O (p, n) 18F nuclear reaction); 11 MeV 
protons from a CTI RDS 112 cyclotron, beam current 30 µA. This solution, in 18O-water was 
used without further purification. The 18F is nominally in the form of no carrier-added fluoride 
ions, although typically 19F is also present and it is impossible without further analysis to 
confirm the absence of minor contaminants such as trace metals that might interact with 
fluoride ions in solution. 
 
2.9 Methods 
Note: The synthesis of HA materials HA2 and HA3 is described in chapter 3.  
Alhydrogel labelling experiments discussed within this chapter were performed by Dr. Maite 
Jauregui-Osoro. A full discussion and comparison of HA and Alhydrogel labelling properties is 
necessary as these materials form the basis of our research within this thesis. Our published 
paper provides full details of this work. “Biocompatible inorganic nanoparticles for 18F-fluoride 
binding with applications in PET imaging”.106  
 
2.9.1 Initial Screening for 18F-Fluoride Binding 
Initial 18F-fluoride labelling studies were performed on HA nanoparticles, assessing optimal 
conditions for incubation time and media type. Cyclotron produced 18F-fluoride (20 µL, 3-6 
MBq), direct from cyclotron target, (untreated by ion exchange, kryptofix or azeotropic 
distillation) was added to a 1 mg/mL suspension of HA in water (1 mL). The suspensions were 
incubated for 5, 10, 20, and 60 minutes with continuous shaking at RT.  Consequently, a 
standard incubation time of 5 minutes was selected for all samples (see table 2.3 for materials 
tested). Each sample was tested in triplicate and nanoparticle free standards were used to 
measure the baseline supernatant activity and any non specific binding to centrifuge tubes. To 
measure the binding of radioactivity to particulates the solution was centrifuged (5 min at 
14000 rpm). An aliquot of each sample supernatant (100 μL) was removed and counted for 
activity using a gamma counter. The amount of activity associated to the particles was 
calculated as a percentage of the total input activity (Equation 2.10). 
Labelling efficiency % = [1- (Activity in supernatant aliquot/ activity in standard aliquot)] x 100   





Table 2.3: Particulate and bulk materials surveyed for 
18
F- fluoride binding, origin and particle size stated 
by manufacturer except, 
a
 measured by Transmission electron microscopy,
 b
 measured by Dynamic light 
scatterin. 
 
To assess binding capabilities of small quantities (i.e. injectable in vivo quantities) of HA could 
sufficiently bind 18F-fluoride, a series of different particle concentrations (0.01 mg/mL – 2 
mg/mL), were incubated with 18F-fluoride. No carrier added 18F-fluoride (20 μL, 3-6 MBq) was 
added to each suspension of particulate material (1 mL) in water. The mixture was incubated 
Material Origin Particle size 
CeO2 Sigma-Aldrich (544841) < 25 nm 
ZrO2 Sigma-Aldrich (544760) <100 nm 
Co3O4 Sigma-Aldrich  (637025) < 50 nm 
MgO Sigma-Aldrich  (549649) < 50 nm 
Bi2O3 Sigma-Aldrich  (637871) 90-210 nm 
Y2O3 Sigma-Aldrich  (544892) <50 nm 
Fe2O3 Sigma-Aldrich  (544884) < 50 nm 
HA1 Sigma-Aldrich  (677418) <200 nm 
HA2 This work 41.6± 1.8 nm
a
 
HA3 This work 107.5 ± 6.2 x 25.8 ± 0.9 nm
a
 
Er2O3 Sigma-Aldrich (637343) <100 nm 
Eu2O3 Sigma-Aldrich (634298) <150 nm 
SiOH/Al2O3 Sigma-Aldrich (643084) <50 nm 
Al(OH)3-Alhydrogel Brenntag Biosector 1211 ± 64 nm
b
 
Al Sigma-Aldrich  <75 µm 
Ag Sigma-Aldrich <100 nm 
CaO Sigma-Aldrich <160 nm 
Dy2O3 Sigma-Aldrich  (289264)  
Al2O3 Sigma-Aldrich   (544833) < 50 nm 
CaCO3 Acros (40381100)  
Ho2O3 Sigma-Aldrich( 229679)  
Yb2O3 Sigma-Aldrich  (637300) <100 nm 
ZnO Sigma-Aldrich (544906) < 100 nm 
CaHPO4 Sigma-Aldrich  (100931751)  
Ca3P2O8 Fluka (2318408)  
TiO2, Rutile/Anatase mixture Sigma-Aldrich  (634662) < 100 nm 
CaC2O4 Acros (403880050)  
SnO2 Sigma-Aldrich (549657) < 250 nm 
CuO Sigma-Aldrich  (544868) < 50 nm 
Sb2O3 Sigma-Aldrich  (537173) < 100 nm 
Gd203 Alfa Aesar (11290)  
Mn2O3 Alfa Aesar (87791) <45  µm 
In2O3 Sigma-Aldrich  (632317) < 100 nm 




at room temperature with continuous shaking for 5 minutes. To measure the binding of 
radioactivity to the particulates the solution was centrifuged (5 min at 14000 rpm). An aliquot 
of each sample supernatant (100 μL) was removed and counted for activity using a gamma 
counter. Labelling efficiency was calculated using equation 2.10. 
  
A semi quantitative method for assessing and comparing the fluoride binding affinity for 
different materials was developed. We selected a particle concentration at half-maximal % 
binding after 5 min incubation with no-carrier-added 18F-fluoride with suspensions containing 
different concentrations of particles. The data were fitted to equation 2.11, a sigmoid function 
from which the maximum binding (Bmax) and the particle concentration at half-maximal % 
binding (Kd) were obtained, using OriginLab Pro 8.5 curve fitting software. 
 
Y = Bmax(Xn)/(Kdn+Xn) 
Equation 2.11: Sigmoid function fitted to binding efficiency data.  Y = labeling efficiency (%), X = particle 
concentration mg/mL), Bmax= Maximum binding, Kd= concentration of NPs at half-maximal % binding. 
 
2.9.2 Competition Studies  
For the principle of pretargeting to work, the nanoparticle-fluoride interaction must take place 
rapidly and efficiently in vivo. Inhibition of binding could occur via competition from the 
bodies’ abundant endogenous proteins, peptides and circulating ions. HA (HA1) (1 mg) (unless 
stated otherwise) was suspended in water (0.5 mL). Potential competitor solutions in water 
(0.5 mL) were added to the suspension. At the same time, an aliquot of aqueous no-carrier-
added 18F-fluoride (20 μL) was added to each suspension of particulate/competitor material. 
The mixture was incubated at room temperature with continuous shaking for 5 min. To 
measure the binding of radioactivity to the particulates the solution was centrifuged (5 min at 
14000 rpm). An aliquot of each sample supernatant (100 μL) was removed and counted for 
activity using a gamma counter. Labelling efficiency was calculated using equation 2.10.  
To study the fluoride loading capacity of HA (HA1), particle solutions of different 
concentrations (0.1, 0.5, 1 mg/mL) were labelled in the presence of a series of fluoride (non-
radioactive) solutions of different concentrations. Labelling was performed as the competition 
experiment described above. 
 
2.9.3 Kinetic Profile in Different Media 
A series of time course experiments in different media were carried out to assess the kinetic 
profile and behaviour of 18F-fluoride binding in the presence of binding competitors. HA (HA1) 




carrier added 18F-fluoride (20 μL) was added to each suspension of particulate material. The 
mixture was incubated at room temperature with continuous shaking for 5, 10, 20, and 60 
minutes (unless otherwise stated). To measure the binding of radioactivity to the particulates 
the solution was centrifuged (5 min at 14000 rpm). An aliquot of each sample supernatant 
(100 μL) was removed and counted for activity using a gamma counter. Labelling efficiency 
was calculated using equation 2.10. 
 
2.9.4 Kinetic Stability in Serum 
HA (HA1) (1 mg) was suspended in water (1 mL). No carrier added 18F-fluoride (20 μL) was 
added to the suspension. The mixture was incubated at room temperature with continuous 
shaking for 5 minutes. To measure the binding of radioactivity to the particulates the solution 
was centrifuged (5 min at 14000 rpm). An aliquot of each sample supernatant (100 μL) was 
removed and counted for activity using a gamma counter. Labelling efficiency was calculated 
using equation 2.10. The remaining supernatant was discarded. The labelled particles were 
collected and washed with water (1 mL) via centrifugation x4 ( 5 min at 14000 rpm). The 
pellets were re-suspended in human serum (1 mL). The re-suspended pellets were divided 
into 200 μL aliquots. The mixtures were incubated at 37 oC with continuous shaking for 30, 60, 
120, 360, 1080 min. Samples were prepared in triplicate for each time point. To measure the 
radioactivity associated to the particulates the solution was centrifuged (5 min at 14000 rpm). 
An aliquot of each sample supernatant (100 μL) was removed and counted for activity using a 
gamma counter. The percentage binding was calculated with respect to the standard input 
activity using equation 2.10. The input activity was 200 μL of the serum suspended particle 
solution.  
 
2.9.5 Kinetic Stability in Water 
To ensure that the HA-18F-fluoride labelling interaction was stable in water; the activity 
associated to particles during a washing procedure was measured.  HA1 (1 mg) was suspended 
in water (1 mL) and labelled, in triplicate, with 18F-fluoride as described above. The particles 
were pelleted via centrifugation (5 min at 14000 rpm) and 100 μL of the supernatetant was 
collected for labelling efficiency measurements, using equation 2.10. The remaining 
supernatant was discarded and pellets were subjected to a washing protocol. The labelled 
particles were re-suspended in water (1 mL) and incubated at room temperature with 
continuous shaking for 5 minutes. The particles were collected via centrifugation (5 min at 
14000 rpm). At each washing step 100 μL supernatant was removed and counted for activity. 




initial activity of the nanoparticles, before washings. The % activity associated to the particles 
after washings was calculated using equation 2.12.  
 
Activity associated with particles % = 
[1- ((Activity in washing aliquot x10)/ activity of standard nanoparticles)] x 100 
Equation 2.12: Equation to calculate activity associated with particles %. 
 
2.10 Results and Discussion 
2.10.1 Initial Screening for 18F-Fluoride Binding 
Preliminary binding studies using HA (HA1, HA2, HA3) and 18F-fluoride in water revealed the 
general trend that binding equilibrium was reached within 5 minutes in solutions of 1 mg/mL. 
Prolonging the incubation time up to 60 minutes did not significantly alter or increase the 18F-
fluoride labelling efficiency. Thus, for subsequent screening experiments an incubation time of 
5 minutes was adopted for all materials. The materials (Table 2.3) were chosen based on the 
known fluoride affinity for electropositive hard metal ions, with additional materials included 
for comparison and contrast (see introduction). Various solid state materials have been used 
in ion exchange purification for capture of fluoride,107 such as alumina,108, 109 HA110, 111 and 
titanium112. Polar molecular materials containing silicon, boron, phosphorous and complexes 
of aluminium can form highly stable Si-F,20 B-F,23 P-F21  and Al-F22 bonds. Iron oxide and 
lanthanide nanoparticles have interesting MR and optical imaging properties respectively, 
presenting potential as multimodal agents when combined with PET isotopes. Alhydrogel is an 
aluminium hydroxide gel (Al(OH)3) used clinically as an adjuvant, thus it is a well known 
biocompatible material (see chapter 6 for further discussion).113 Our pretargeting concept 
aims to exploit nanoparticle properties to improve radioisotope delivery and targeting. 
Precisely defined nanoparticulate materials are required to ensure reproducible radiolabelling 
and bio-distribution. The capacity to derivatise and the biocompatibility of particulates is 
extremely important for in vivo targeting applications. For example, silica nanoparticles are 
well defined materials that can be derivatised with fluorescent probes and have been 
proposed as a useful biomedical tool.114, 115 An initial survey of 18F-fluoride binding properties 
to a range of materials is displayed in figures 2.10 and 2.11.  
 
HA showed very high binding efficiency while surprisingly, other calcium salts did not. Fan et 
al. report similar findings at low fluoride concentrations.53 The vastly different binding 
efficiencies of HA and other calcium salts, such as CaCO3 can be attributed to different fluoride 




replacing hydroxyl groups with fluoride ions, while other calcium salts bind through a surface 
adsorption process only. The surface adsorption processes have much lower capacity for 
fluoride uptake. Alhydrogel also showed very high binding %, in accordance with high fluoride 
binding seen for aluminium hydroxide materials used for water purification (Table 2.2).116, 117 
The rare earth metals, CeO2 and Er2O3 showed high binding %. Unsurprising as binding of 
fluoride with hard electropositive lanthanide metal ions has been reported previously.34, 60, 101, 
102 Our results showed 18F-fluoride loading in the order CeO2> Er2O3> Y2O3> Eu2O3 >Dy2O4 
>Yb2O3 with binding efficiencies of 87, 86, 62, 34, 24, and 11% respectively. Aluminium oxide 
(Al2O3), and magnesium oxide (MgO) showed high affinity, while zirconium oxide showed low 
binding % despite the well known affinity of soluble zirconium for fluoride.118 The low affinity 
could be attributed to non optimal pH for fluoride adsorption. For example, the surface charge 
of material in solution is affected by pH. There is a point at which there is no net surface 
charge, referred to as the isoelectric point (IEP) or point of zero charge (pzc). The pH at which 
this occurs is related to the electronic character of the metal oxide bond and surface 
stoichiometry.119, 120 If a metal oxide has a low IEP (e.g. pH 2) and it is in a solution above this 
pH it would typically carry a negative charge (related to dissociation of hydroxyl groups), thus 
repelling negative charged fluoride ions. However, we choose not to control pH in these initial 
experiments to avoid interference from competing ions, therefore relating results to IEP and 
surface charge would be purely speculative in this instance. 
  
Takahashi et al. reported most effective fluoride exchange takes place at pH 4.5-6.0 for a 
Zr(IV)-EDTA complex.118 The low binding efficiency of Iron(III) oxide may also be improved by 
altering pH, Huang et al. report fluoride adsorption on iron oxide reaches a maximum near pH 
4.51 Given the highly polar nature of silica, the lack of fluoride uptake is surprising. This may be 
explained by the predominant adsorption mechanism being surface adsorption rather than 
ion exchange of surface hydroxyl groups. Fan et al. report similar findings for quarzt (SiO2) at 
low concentrations.53 In addition, silica typically has low IEP (ca. pH 2), therefore we speculate 
the charge repulsion mechanism described for the IEP affect above.119 Based on these initial 
results, HA and Alhydrogel (Al(OH)3) were chosen for further investigation. Not only were 
these particles selected for high fluoride binding potential but they are also highly 
biocompatible, a requirement for in vivo application. The ideal nanomaterial will have well 
defined properties, such as size and morphology to ensure reproducible radiolabelling and 
biodistribution. The particles must also provide a platform to load targeting functionalities. 
The development of hydroxyapatite materials will be investigated and discussed within this 












2.10.2 Binding Efficiency of Hydroxyapatite and Alhydrogel in Water   
Several preparations of HA nanoparticles were synthesised (discussed in chapter 3). The HA 
materials were commercially available, calcined, and hydrothermally treated, named as HA1, 
HA2, and HA3 respectively. The effect of preparation on fluoride binding properties of HA was 
assessed. In addition the commercially available Alhydrogel was tested. 
 
To provide an objective measure of fluoride binding affinity allowing semi-quantitative 
comparison between materials, a particle concentration at half-maximal % binding after 5 
minutes incubation with no carrier added 18F-fluoride was adopted. It is assumed that the 
system is close to equilibrium based on time course experiments discussed later. The data 
were fitted to equation 2.11, using OriginLab Pro 8.5 curve fitting software. A sigmoid 
function, where maximum binding (Bmax) and concentration of NPs at half-maximal % binding 
(Kd) can be obtained.  
 
                                                                 Y= Bmax (X
n) /(Kd
n + Xn)  
 
Equation 2.11: Sigmoid function fitted to binding efficiency data.  Y = labeling efficiency (%), X = particle 
concentration mg/mL), Bmax= Maximum binding, Kd= concentration of NPs at half-maximal % binding.  
 
The concentration of the particles was varied between 0.01 and 2 mg/mL, see figures 2.12-
2.15 and table 2.4 for results. A high (Kd) value implies low affinity (weak binding), a low (Kd)  
value implies high affinity (strong binding). The results showed that the binding affinity varied 
depending on preparation methods of HA. Commercial HA1 and calcined HA2 had binding 
affinities ca. 3 times stronger (lower Kd values) than hydrothermally treated HA3. This could 
be related to a decrease in particle surface area as the HA3 particles become smoother, larger 
and more regular after hydrothermal treatment (the properties of HA1, HA2, and HA3 are 
discussed fully in chapter 3). Overall efficient binding was observed for all materials at 
concentrations below 1 mg/mL. The binding affinity of Alhydrogel was equivalent to HA1 and 
HA2, and ca. 3 times stronger (lower Kd values) than HA3. The maximum labelling efficiency 
measured for the commercially obtained HA1 is ca. 5% lower than the in house prepared 





                              Figure 2.12: 
18
























Material Bmax (%) Kd (mg/mL) n r
2
 
HA1 92.04 0.038 1.43 0.9700 
HA2 100 0.042 1.24 0.9976 
HA3 100 0.113 1.31 0.9266 
Alhydrogel 92.47 0.038 1.23 0.9836 
 
Table 2.4: Binding characteristics of HA and Al(OH)3 nanoparticles for binding to 
18
F-fluoride. Kd is the 
nanoparticle concentration at half-maximal % binding; Bmax is the maximal % binding. Al(OH)3 has the 
highest affinity as indicated by the low Kd value. 
 
To assess the amount of fluoride that can be loaded on to the particles, cold (non radioactive) 
fluoride (NaF) was used as a competitive inhibitor. The fluoride loading capacities of HA1 and 
Alhydrogel were measured using varying concentrations of cold (non radioactive) fluoride and 
particulates. The fluoride loading capacity of Alhydrogel was markedly higher than that of HA1 
at the same particle concentrations. The fluoride loading capacity of HA1 was ca. 0.1 
µmol/mg, (Figure 2.16), equivalent to (1.9 g/kg) (Figure 2.16) comparable to values reported 
in literature for HA nanoparticles (Table 2.2). The fluoride binding capacity of Al(OH)3 was 
approximately ca. 10 µmol/mg, equivalent to (190 g/kg) about 2 orders of magnitude higher 
than that of HA (Figure 2.17). This is about 1 order of magnitude higher than values reported 
in literature for alumina based materials (Table 2.2).  The relatively high capacity of Alhydrogel 
may be due to its permeable gel-like nature. At these levels of affinity and capacity it is clear 
that for both HA and Al(OH)3 , at quantities likely to be used in vivo (e.g. >>0.1 mg) no carrier 












F-fluoride binding of Alhydrogel in the presence of NaF. 
 
2.10.3 Binding of 18F-Fluoride to Hydroxyapatite and Alhydrogel in the Presence of 
Competitors 
For the application of the nanoparticles in a biological setting, 18F-fluoride binding must take 
place in the presence of a number of competing substances. A series of potential competing 
solutions were prepared and 18F-fluoride binding was assessed in their presence (Figure 2.18 
and 2.19). The solutes included simple anions (chloride, phosphate, carbonate, and citrate) 
and components which could be used for particle derivatisation and stabilisation, such as 
amino-bisphosphonate alendronate and hexametaphosphate (HMP). An 18F-fluoride 
incubation time of 5 minutes was chosen for comparison to previous results in water. The 
normal serum concentrations for Cl- , HCO3
2-, and HPO4
2-are  ca. 103, 27, and 1 mM 
respectively,121 therefore the concentration of competitor was studied in the range- 0.01-100 
mM. For HA and Alhydrogel, the binding of 18F-fluoride in the presence of NaCl and the amino-
bisphosphonate Alendronate had little or no effect at concentrations up to 100 mM. This is a 
remarkable result for the amino-bisphosphonate considering the high affinity of 
bisphosphonates for HA.122 For HA, the inhibitory effect observed in TRIS buffer was modest, 
while binding in the presence of phosphate and carbonate was significantly inhibited at 
concentrations as low as 1 mM. The greatest inhibitory effect was observed in the presence of 
hexametaphosphate, even at low concentrations (0.1 mM), less than 30% labelling efficiency 
was observed for HA1. The anionic nature of HMP, and affinity for HA has been exploited to 
stabilise HA particles in solution.123 Given the presence of negative charge and the bulky HMP 
molecules it is unsurprising that the polyphosphate provides an inhibitory affect, presumably 
through both steric and electrostatic repulsion. The inhibitory effect of HMP was less 
pronounced for Alhydrogel, although still significant at 1 mM. Citrate also has a marked effect 




concentrations as low as 1 mM. For HA, surprisingly high concentrations of citrate (100 mM) 
were required for fluoride binding to be reduced to half the maximum binding observed in 
water. The low binding of Alhydrogel can be related to its dissolution in high concentrations of 
citrate.   
 
For these materials to be used in vivo, binding must occur rapidly and efficiently in biological 
conditions. The biological environment may contain components that exhibit inhibitory 
effects.  A series of time course experiments were performed in different media to assess the 
binding profile of 18F-fluoride on HA materials (HA1, HA2, HA3) (Figure 2.20). The binding 
efficiency was measured at time points up to 1 hour. The 18F-fluoride binding equilibrium in 
water was reached rapidly within 5 minutes of incubation (as described above). There was 
little change over a period of 1 hour. The binding of 18F-fluoride in TRIS-HCl (50 mM) pH 7.4 
buffer had little effect on the binding profile, reaching equilibrium within 5 minutes. For HA1 
and HA2, the binding profile of fluoride in PBS is surprising, initially reaching a maximum at 5 
minutes; however, after 10 minutes binding decreases, then slowly increasing up to 1 hour. 
This implies that initial fluoride binding occurs at a faster rate than phosphate binding and 
that phosphate can compete with, and dissociate surface adsorbed fluoride ions. Therefore, 
implying the initial fluoride surface adsorption may be a weaker interaction than the binding 
observed with longer incubation times, perhaps correlating to an ion exchange process with 
hydroxyl groups. However, this initial rapid adsorption was not observed with HA3, and may 
be related to the lower affinity constant measured in (Figure 2.14). The fluoride binding in 
DMEM and human serum is markedly slower than in water, although given time the binding % 
approaches that comparable to water. DMEM contains a mixture of amino acids, proteins, and 
inorganic salts. The slow binding profile is unsurprising, since DMEM contains sodium 
bicarbonate up to 3.7 mg/mL (44 mM), a known fluoride binding inhibitor (Figure 2.18). It 
must be noted that the human serum used in these experiments contains added citrate (10 
mM) another known fluoride binding inhibitor (Figure 2.18). The rate of fluoride binding for 
HA samples in serum was slow, but tended towards the maximum values observed in water 
over 1 hour.   
 
The effect of labelling of Alhydrogel in serum was more marked and the % binding was 
severely reduced in serum even when incubated for 3 hours (See reference106). The highly 
reduced serum binding could be due dissolution of Al(OH)3, forming soluble AlF3.
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Figure 2.20: Binding of 
18
F-fluoride to HA competitors over time HA1 (Top), HA2 (Middle), HA3 (Bottom). 
 
 
2.10.4 Kinetic Stability of 18F-Fluoride Labelled HA and Alhydrogel 
For radiolabelled nanoparticles to be used for in vivo imaging, the nanoparticle-fluoride bond 
must be kinetically stable in biological media. Repeated washing of 18F-fluoride labelled 
nanoparticles (HA and Al(OH)3) did not remove a significant fraction of radiolabel (see 
appendix). The stability of labelled HA was measured in serum, after 3 hours minimal fluoride 
dissociation was observed. However, the loss of fluoride from labelled Alhydrogel was much 
more severe, losing up to 50% in 30 minutes of incubation in serum (Figure 2.21). The rapid 
dissociation may be caused by the high citrate concentration in serum used, resulting in 





Figure 2.21: Kinetic stability of 
18
F-fluoride labelled HA1 and Alhydrogel in serum. 
 
2.11 Conclusion 
Designing new molecular imaging agents based on nanoparticles requires a material that fits a 
number of criteria: efficient and rapid labelling under facile conditions, functionalisable for 
targeting and stabilising purposes, homogenous nature to provide consistent labelling and 
biodistribution, means of attaching a stable radiolabel, and biocompatibility. Our aim within 
this thesis is to identify and develop nanomaterials that can be loaded with a high affinity 
radiolabelled probe (e.g. 18F), in a rapid one step reaction. Initial studies have focused on 18F-
fluoride because of its simplicity and availability. Our review identified a number of fluoride 
binding materials that are used in water purification, such as aluminium oxides, HA and rare 
earth metal oxides (in the form M2O3 or M(OH)3). Many examples of 
18F-labelled nanoparticles 
examples exist, including QD’s, liposomes, and cross linked iron oxide (CLIO). However, these 
approaches require multiple, complicated labelling steps. We aimed to directly label 




identified HA and Alhydrogel as promising materials, providing facile rapid labelling with 18F-
fluoride. They have bound 18F-fluoride efficiently at low concentrations, applicable for in-vivo 
studies.  Efficient labelling has been achieved in the presence of various biological and 
potential competitors. In particular, the 18F-HA interaction has proven robust under biological 
conditions, with only minor dissociation seen over time in serum. However, the serum stability 
of 18F-fluoride bound to Alhydrogel appears less robust, and may only be suitable for shorter 
molecular imaging studies, unless further modified to curtail degradation. Both HA and 
Alhydrogel provide a promising nanoparticle base, with biocompatibility and low toxicity, for 
the development of new molecular imaging agents. Further work in this thesis will describe 
the development, primarily of HA, to produce non-aggregated, functionalisable nanoparticles 
for in vivo pretargeting applications. For example, we will look at the well known HA-
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Synthesis and Functionalisation of Hydroxyapatite Materials 
 
3.1 Overview 
The experiments discussed in chapter 2 highlight the potential of hydroxyapatite (HA) as a 
fluoride binding material. These results prompted the development of HA nanoparticles 
discussed within this chapter. This chapter begins with an introduction to hydroxyapatite 
materials, reviewing their chemical properties, synthesis and application. We aimed to adopt 
HA nanoparticles as lead materials for application as a primary targeting agent in our 
pretargeting strategy. This chapter presents the synthesis and characterisation of various 
hydroxyapatite materials. The effect of reaction temperature and post-synthesis treatment is 
discussed. We have investigated the ability to stabilise HA preparations with a variety of ionic 
and non-ionic surfactants. Furthermore, a successful pretargeting concept requires HA 
nanoparticles to be readily functionalised with targeting moieties, aiding disease specific 
targeting. We investigated the functionalisation of HA nanoparticles with a variety of 
molecules, including bisphosphonates and other small anionic ligands. The chemical 
properties and behaviour of the prepared materials are discussed. We aimed to produce a 
stable, functionalisable HA preparation suitable for radiolabelling and ultimately, pretargeting.  
HA nanoparticles were prepared via wet chemical precipitation. Synthesis temperature did 
not greatly affect particle properties, while calcination and hydrothermal post-synthesis 
treatments controlled particle morphology and crystallinity. HA particles formed stable 
colloidal solutions when functionalised with sodium hexametaphosphate (SHMP) and 
polyethyleneglycol-bisphosphonates (PEG-BP). The bisphosphonate Alendronate was used to 
link small molecules such as amino acids and fluorescein isothiocyanate to HA surfaces, for 
potential targeting applications.  
 
3.2 Introduction  
3.2.1 Hydroxyapatite 
Hydroxyapatite (HA) (Ca10(PO4)6(OH)2) is a biocompatible ceramic, chemically similar to the 
mineral component of bones and teeth.1, 2 HA has been used as a bone substitute in 
orthopedic and orthodontic implants, exploiting the excellent biocompatible and 
osteoconductive properties.3-7 Furthermore, HA nanomaterials have been used as local drug 
delivery systems; including, proteins, antibiotics, anti cancer drugs and enzymes.8-13 HA is also 




HA is a member of a large family of apatite crystals that consists of a variety of complex 
structures and bonding types.15 However, the term apatite is generally used to describe a 
group of phosphate minerals with a similar hexagonal crystal structure.1, 16-19 The general 
formula for calcium apatite materials is given by Ca10(PO4)6(X)2, representing the number of 
ions needed for each structural unit of the crystal. Apatite materials exist in range of 
compositions; where X  is most commonly, OH, F, Cl, or Br.16 The crystals are composed of six 
unconnected PO4
3- tetrahedra, surrounded by ten Ca2+ cations filling the spaces between 
them, with two X- ions located along the c-axis helping to balance charge (Figure 3.1). 
Fluorapatite (FA) and bromoapatite (BrA) consist of hexagonal crystal structures; however, 
chloroapatite (ClA) and HA are said to consist of hexagonal and monoclinic structures.16-18 For 
HA, the major difference between the two structures is the orientation of the hydroxyl 
groups.18 The monoclinic system is structurally more stoichiometric than the hexagonal HA.17, 
18 However, the hexagonal HA structure has received most attention, since even small 
amounts of impurities will destabilise the structure of monoclinic HA.18 It is possible to 
exchange  HA surface ion groups, for example, OH- can exchange with F-, or PO4
3- with CO3
2-.20-
22 When OH- is replaced with a fluoride ion, a more stable complex is formed, due to stronger 
electrostatic attractions.20, 21 Thus, fluoride ions are often used as a supplement in water or 
toothpaste to help strengthen enamel. Furthermore, it is possible to exchange the Ca2+ cation 
with ions of a similar size, such as Sc2+.23, 24 However, this generally only occurs during 
formation of the crystal.  The Ion exchange of Ca2+ on the crystal surface in solution has also 
been reported, expanding the group of possible substitutes to include ions, such as, Mg2+ and 
Ba2+.23, 24  
 
In addition to ion exchangeable surfaces, the polar chemical nature of HA results in high 
affinity towards various biological or polar molecules. Therefore, HA materials may be an ideal 
platform for developing nanoparticles functionalised with targeting moieties and radiolabelled 





                                     




3.2.2 The Synthesis of Hydroxyapatite Materials 
HA has been used as a bioactive clinical bone grafting material for more than 30 years.2, 26 
However, its poor mechanical properties make it unsuitable for high load bearing applications. 
The development of new HA materials has been driven by the need for hard tissue substitutes 
in surgical and dental implants, and more recently for its drug delivery potential.2, 27 While HA 
is bioactive (forming strong bonds with bone through inducing bone formation), it has the 
undesirable properties of brittleness and low tensile strength, and is not suitable for load 
bearing applications.2 To improve load bearing properties, HA/alloy composites have been 
prepared, such as HA/titanium composites.2, 28 HA has been used to coat load bearing 
materials for surgical implants, such as titanium alloys; helping promote bioactivity, enhance 
biocompatibility, and improve implant stability.29, 30 Numerous HA-composite materials have 
been prepared: HA/collagen, HA/chitosan, and HA/gelatin. The composites attempt to 
combine the positive bone grafting properties of each material.2, 31 In recent years, the search 
for HA materials with improved bone grafting properties has turned to nano scale materials. 
Nano HA powders have unique properties that can be exploited, such as large surface areas, 
high surface reactivity, and porosity. Compared to micro HA, nano HA has shown improved 
bioactive properties.32 Nano HA has been shown to enhance bone densification, strengthen 
fracture toughness, and stimulate osteoblasts.32-36 Composites of nano HA have also been 





The preparation of HA nanomaterials is an area of growing interest, based on its demand for 
bone grafting and drug delivery applications. The combination of high biocompatibility and 
surface reactivity make HA nanoparticles an intriguing prospect for various biomedical 
applications. A variety of synthetic approaches have been developed: mechanochemical,37, 38 
combustion,39 electrochemical deposition,40 sol gel,41-46 hydrothermal,47-49 emulsions,50-52 and 
wet chemical precipitation.53-61 
  
Wet chemical precipitation is the most frequently used method of HA preparation, and has 
been widely reviewed.53-61 The method is preferred due to its ease, versatile nature, low cost 
and level of repeatability. Herein, the wet chemical precipitation method is reviewed in detail. 
HA can be precipitated from the acid-base reaction of a variety of calcium and phosphate 
salts. The precipitation reactions require the addition of phosphate ions to a solution 
containing calcium ions. The reaction is highly dependent and sensitive to reactions 
conditions, such as addition rate, temperature, pH, reactant concentrations, and ripening 
times.56-58 The preparation of precipitated HA nanoparticles proceeds via nucleation of a 
supersaturated solution of Ca2+ and PO4
-3 ions, followed by growth and agglomeration 
phases.62 Ordered aggregation of the primary precipitated nanocrystals is responsible for 
particle formation. The most common routes of precipitating HA are described by schemes 3.1 
and 3.2.  Scheme 3.1 represents the reaction between calcium hydroxide and orthophosphoric 
acid.55, 57 Scheme 3.2 is the reaction between calcium nitrate and ammonium dihydrogen 
phosphate.35, 49  
 
3.1) 10Ca(OH)2 + 6H3PO4                                            Ca10(PO4)6(OH)2 +18H20 
 
3. 2) 10Ca(NO3)2 + 6(NH4)H2PO4                                 Ca10(PO4)6(OH)2  +12H20 +20NH4NO3 
 
Schemes 3.1 and 3.2: HA precipitation methods. 
 
Bouyer et al. and Kumar et al. describe preparations based on scheme 3.1.55, 57  An advantage 
of scheme 3.1 is that the only by product is water. Typically, reactant solutions containing 0.5 
M calcium hydroxide and 0.3 M phosphoric acid in H2O are prepared, with a molar ratio of 
1.67 Ca/P to obtain stoichiometric HA. Orthophosphoric acid is added to the calcium 
hydroxide solution in a dropwise fashion, usually at pH 7.4 (at time of addition). The reaction 
mixture is vigorously stirred at 60 oC and left to age (stand in reaction mixture without further 
stirring) for a period of time, then washed and dried. Specifically, Kumar et al. stirred the 





mixture was aged for 15 h, and precipitate was washed and dried in an oven at 60 oC.55 The 
particles produced were either needle like or spherical, depending on reaction conditions.   
 The effects of reaction temperature and addition rate were studied.55, 57 Bouyer  et al. found 
that varying the reaction temperature and addition rates could control particle  size and 
morphology,57and   a transition temperature of 60 oC was suggested. There was a tendency to 
form monocrystalline structures at low temperatures (<60 oC), above the transition 
temperature, nanoparticles become polycrystalline. At 60 oC particles reached a maximum 
size. The morphology tended towards spherical at temperatures above 60 oC and needle like 
below 60 oC. Kumar et al.55 hypothesise that the driving force for precipitation is the 
supersaturation level. The solubility of calcium hydroxide in aqueous solutions is reduced with 
increasing temperature; thus, the growth rate at lower temperatures is faster resulting in rod 
like particles.  Spherical or needle-like particles were produced when the acid addition rate 
was fast or slow respectively. Conversely, the precipitation of HA via scheme 3.2 has a growth 
rate that increases with temperature. At higher temperatures needle like, large nanocrystals 
are formed. Calcium nitrate is highly soluble in aqueous solution at high and low 
temperatures; thus, the solubility dependence is less important and temperature is the driving 
force for growth.   
     
Scheme 3.2 proceeds through the addition of (NH4)H2PO4 to a Ca(NO3)2  solution. In an 
example by Loo et al.,49 solutions of Ca(NO3)2  and (NH4)H2PO4 in H2O were prepared. The Ca/P 
ratio was set to 1.67, to achieve stoichiometric HA. In addition, NH4OH was added to the 
Ca(NO3)2 solution to ensure pH >11. The (NH4)2H2PO4 solution was added to the mixture in a 
dropwise manner. In general, the precipitates were formed and left to age, then washed via 
centrifugation. The effect of reaction temperature and duration was explored. At a synthesis 
temperature of 25 oC, increasing the synthesis time (1-96 h) did not alter the low particle 
crystallinity. However, at 80 oC the particles became highly crystalline after 3 h of reaction. 
Increasing synthesis temperature (between 5 oC to 80 oC), resulted in a linear increase in 
particle size, ranging from 20 nm-200 nm. The particles produced were a needle like 
morphology. Although, at 5 oC the particle morphology is not distinguishable in the 
transmission electron microscope (TEM) image presented, implying highly aggregated 
samples. The crystallinity of the particles increased significantly when the synthesis 
temperature was 80 oC. The results imply that particle growth and crystallinity are dependent 





To improve shape and surface morphology, the nanoparticles were subjected to a post-
synthesis hydrothermal treatment (HT). Hydrothermal describes the chemical reaction of 
substances in a sealed heated solution above ambient temperature and pressure (described 
below). The HA suspension was placed in an acid digestion bomb, heated in an oven at 200 oC 
for 24 h, and freeze dried, where upon the particle morphology became rod-like and smooth. 
There was a decrease in surface area compared to untreated particles, attributed to the 
increased regularity of these particles. The particle size was seen to increase with increasing 
temperature. Conversely, Kumar et al.55 describe slower growth rates at high temperatures 
via scheme 3.1 (see above). Thus, highlighting the choice of reaction scheme can affect 
particles properties.   
 
3.3) 10CaCl2 + 6(NH4)2HPO4                                  Ca5(PO4)3(OH) +6H20 +20NH4Cl 
 
Scheme 3.3: HA precipitation with calcium chloride and diammonium phosphate. 
 
Scheme 3.3 is a precipitation method that uses calcium chloride as the calcium source.58 The 
properties of the reaction scheme are similar to scheme 3.2. Pang et al.58 prepared 0.5 M and 
0.3 M solutions of CaCl2 and (NH4)2HPO4, respectively. Equal amounts of the solutions were 
mixed, adjusting to pH 10 throughout the reaction with ammonium hydroxide. The precipitate 
was stirred, aged, washed and dried. The particles were subjected to a post-synthesis 
treatment of calcination (discussed below). The effect of temperature, ripening time and 
calcination was investigated. In conclusion, as temperature and ripening time increased, both 
crystal size and crystallinity increased. When subjected to calcination at 650 oC for 6 h, the 
crystallinity greatly improved and crystallite sizes ranged from 20 nm-50 nm. 
 
Wet chemical precipitations of HA are prone to carbonate impurities. Carbonate substitution 
of HA can be defined as type A and type B, where CO3
-2 replaces OH and PO4
-3 respectively. 
Carbonate substitution exist in natural bone, where type B substitution is predominant.63 In 
this respect, it may be useful to design carbonated HA to mimic biological apatites. However, 
the affect that carbonate substitution has on HA properties, such as decreased thermal 
stability and dissolution must also be considered.63 It is difficult to remove all carbonate 
impurities from synthetic HA, especially in wet chemical preparations. For example, carbonate 
species may be obtained from impurities in reagents or dissolved CO2 from the atmosphere. 
Kumar et al. reported that carbonate substitution decreased with increased temperature,55 
while Loo et al. reported increased carbonate content for longer reaction times.49 The 





carbonate species in the reaction process. For example, NH4HCO3 and NaHCO3 have been 
added to wet chemical precipitation schemes.63 The substitution of carbonate may be 
considered as an advantage or disadvantage depending on the intended use of HA.  
 
3.4) Ca10(PO4)6(OH)2                                   3Ca3(PO4)2 + CaO + H20 
Scheme 3.4: Decomposition of HA to tricalcium phosphate. 
 
Cao et al. investigated the effect of Ca2+ ion concentration via precipitation methods,64 and 
found that the concentration of reactant ions used can affect the stoichiometry and 
crystallinity of HA particles.  HA was prepared via Scheme 3.2, and precipitation was aided by 
ultrasonic irradiation. Solutions were prepared with varying Ca/P molar ratios (1.2-2.5).64 
Monophase HA could be formed at Ca/P molar rations between 1.2 and 2.5. However, the 
best crystallinity was observed when the Ca/P ratio was 1.67 (a stoichiometric amount for 
HA). The formation of non-stoichiometric HA may be a problem, in terms of preparing stable 
nanoparticles, since it can lead to poorer mechanical properties and chemical stability. The 
low thermal stability of HA results in its decomposition to alpha or beta tricalcium phosphates 
(TCP), Ca3(PO4)2 and CaO. Sung et al. found that HA prepared at Ca/P molar ratios > 1.7, had a 
greater tendency to thermally decompose to Ca3(PO4)2 and CaO via scheme 3.4.
35 
 
HA particles prepared by wet chemical precipitation are often subjected to post-synthesis 
treatments to alter properties such as crystallinity or particle morphology. Thus, post-
synthesis treatments and reaction conditions may play an important role in the development 
of new HA nanoparticles. Herein we review calcination and hydrothermal post-synthesis 
treatments.    
 
3.2.3 Post-Synthesis Treatment: Calcination 
Calcination refers to the thermal treatment of solid materials in air to induce thermal 
decomposition or phase transition.  Calcination is also applied to remove volatile fractions. 
Materials will often be subjected to high temperatures for a prolonged time. Calcination is a 
common heat treatment applied to HA synthesis, and can transform amorphous materials to 
highly crystalline materials.22, 35, 56-58, 63, 65-67 For example, calcination and sintering of HA 
materials is often in the range of 500-1250 oC for a duration as little as 15 minutes or as long 
as 6 h.57, 65, 67 It has been reported that above 700 oC decomposition products such as β-TCP 
begin to form.22, 35, 66 It is thought that the heat treatment allows crystal growth to continue in 




crystallisation takes place through the HA molecules in solution packing on formed nuclei in 
the ripening process. The crystals are free to grow in any direction on the surface; hence, 
larger more irregular particles are produced until equilibrium is reached. During calcination, 
nucleation and crystal growth can take place throughout the particle rather than just the 
particle surface, thus, more crystallites can be formed with greater phase transition. The 
crystal shape can also be more regular due to the confinement of growth within the 
precipitate. 
 
Raynaud et al. describe the morphological transformation of uncalcined needle-like particles 
to spherical upon calcination treatment.67 In the same paper it is reported that the sintering 
process (densification and coalescence of HA particles) begins at 700 oC. The Coalescence of 
particles is said to occur in three stages: the rounding of particles, formation of necks between 
the particles, and finally coalescence.67 Studies have shown that increasing the calcination 
temperature results in increased crystallinity, increased crystallite size and decreased specific 
surface areas.22, 65, 67 The decrease in specific surface area is related to a sintering process as 
the particles begin to adhere to each other, creating larger grains of tortuous morphologies.  
Particle coalescence and agglomeration are undesirable when considering HA for 
radiolabelling or loading with small molecules. Agglomeration promotes inhomogeneity and 
can reduce surface areas (potential binding sites), thereby reducing labelling repeatability 
reduced efficiency. With these properties in mind, a relatively low calcination temperature of 
550 oC was selected for our work, envisaging morpholigcal and crystallinity modifications 
without thermal decomposition and coalescence of HA particles.    
 
3.2.4 Post-Synthesis Treatment: Hydrothermal Treatment 
Hydrothermal treatment (HT) refers to the chemical reaction of substances in a sealed heated 
solution above ambient temperature and pressure.5 Hydrothermal techniques have been 
applied to the synthesis of HA during reaction68-70 or as a post-synthesis treatment.49, 71, 72  
Hydrothermal methods have been used to control the morphology of HA particles to produce 
nanorods,68, 69, 73, 74 nanofibers,75 nanoplates,76 and aggregated nanospheroids70 with high 
crystallinity. Organic modifiers or additives are commonly used to control particle growth and 
morphology during hydrothermal reactions.48, 68, 73, 76 For example, cetyltrimethylammonium 
bromide (CTAB) can be used to elongate nano-rod lengths.74 
 
HA crystallites preferentially grow along the c-axis (002) crystal plane, and form rod-like 




dissolve and grow into bigger crystals, and the process of crystal growth and dissolution 
reaches equilibrium after 12 h.68, 77 The initial pre-treatment reaction involves the formation of 
small nuclei in a supersaturated medium. When transferred to the sealed reaction vessel at 
high pressure and temperature, smaller particles can dissolve, the irregular particles vanish 
and larger rod shaped particles are formed.  During HT the irregular contours of pre-treated 
particles become smooth and well defined shapes are formed, resulting in a decreased surface 
area.49  
 
HT is affected by synthesis temperature and reaction time. Liu et al. report  hydrothermal 
temperatures less than 120 oC result in monetite (Ca(HPO4) phase impurities.
69 Manafi et al. 
have reported highly crystalline HA synthesised at a HT temperature of 200 oC, and showed 
that particle size increased with increasing HT temperature.73 Balasundaram et al. have 
prepared amorphous HA via a post-synthesis hydrothermal treatment at 70 oC.72 
 
3.2.5 Stabilising and Functionalising HA Nanoparticles       
A major problem with HA nanoparticles is their inherent tendency to agglomerate.49, 54, 78 It is 
important that nanoparticles have colloidal stability if they are to be used as radiolabel or 
drug carrier systems. For example, aggregation of particles will affect properties such as 
particle size and surface area in solution, thereby influencing their biological behaviour in vivo 
and radiolabelling properties. The colloidal stability of HA may be enhanced through steric and 
electrostatic stabilisation. The zeta potential (electrokinectic potential) in colloidal systems is 
recognised as a measure of colloidal stability. Colloidal solutions or dispersions will tend to 
aggregate at low zeta potentials, for example, systems <30 mV are typically considered 
colloidally unstable.79 The zeta potential of unfunctionalised HA was 7 mV at pH 7.4, measured 
by Welzel et al.80 The relatively low zeta potential of HA can be related to poor colloidal 
stability of HA nanoparticles.  
 
To combat the issue of poor colloidal stability, the surface of HA can be functionalised with 
molecules that are highly charged, or offer steric stability. Welzel et al. functionalised HA with 
different compounds: an anionic surfactant sodium dodecyl sulphate (SDS), cationic surfactant 
cetyltrimethylammonium bromide (CTAB), non-ionic surfactant octylphenoxy 
polyethoxyethanol (Triton-X100), and DNA.80 All of the functionalised particles helped to form 
stable colloidal solutions and prevent agglomeration. Wezel et al. postulated that the 
positively charged surface of HA results in the high efficiency of absorbed anionic surfactants, 




surfactant was able to produce highly positively charged particles, despite the theory that 
positive charge on the HA surfaces attracts negative ions, thereby implying a positively 
charged surfactant may be repelled via electrostatic repulsion. Particle sizes measured via 
dynamic light scattering (DLS) were ca. 14 nm and several 100 nm for particles prepared with 
ionic and non-ionic surfactants respectively. In conclusion, it appeared that electronic 
stabilisation was much more important than steric stabilisation.  Another ionic surfactant that 
has been used as a HA dispersing agent is sodium hexametaphosphate (SHMP). According to 
Loo et al., SHMP provided better colloidal stability than CTAB and SDS due to greater 
electrostatic repulsion.49 SHMP contains cationic phosphate groups that can directly react 
with the HA surface, presumably resulting in a more efficiently-bound dispersant.    
 
Many attempts have been made to fine tune the surface properties of HA nanoparticles. 
Examples include conjugating peptides or ligands to prevent aggregation: glycosaminoglycans 
(GAGS),78 maleic acid,71 citric acid,81, 82 zirconyl  salts,83 polylactide84 chitosan,85  aminosilanes86 
and bisphosphonates.87  
 
 











Figure 3.2: HA functionalised with 3-aminopropyltriethoxysilane (APTES). 
 
Organosilane functionalisation has been used routinely for surface modification for various 
nanoparticles. Herein we described their use with respect to HA materials. Aminosilane type 
molecules can provide a stable linker for further functionalisation of HA (Figure 3.2).48, 88,86, 89, 
90 Free hydroxyl groups on the surface of HA are ideal for the hydrolysis of organosilane 
compounds. The surface of HA may be covered through the self assembly of the organosaline 
layers. The hydroxyl groups will attack and displace the alkoxy groups of the saline molecules, 






Early interest in organosilane coupling agents for use with HA based materials was driven by 
their application as adhesion promoting agents in surgical and dental implants. Dupraz et al. 
coated HA powder surfaces with a variety of coupling agents.88 For example, the silane 
coupling agents investigated possessed vinyl, methacryloxy, amine and diamine moieties. The 
presence of silane treated surfaces was confirmed through X-ray photoelectron spectroscopy 
(XPS), and the measurement of zeta potentials. The aminosilane coatings formed were 
chemically stable and resistant to water.88 Durrie et al. and Balasundaram et al. describe the 
grafting of RGD peptides to HA surfaces via aminosilane linkers.72, 86 The HA compacts were 
designed to enhance osteointegration of HA bone implants. RGD peptides have been shown 
to enhance osteoblast adhesion through their interaction with proteins such as fibronectin 
and vitronectin.72 Durrie et al.  grafted the aminosilane (APTES) to the HA surface,86 then 
coupled the surface bound terminal amine group to a heterobifunctinal cross linker, N-
succinimidyl-3-maleimido propionate (SMP). The SMP functionality contains a maleimide 
moiety that can be reacted with free thiol groups contained in the RGD peptide.86 
Balasundarum et al. used a fluorescent tag, 3-(4- carboxybenzoyl)quinoline-2-carboxaldehyde 
(CBQCA) that can react with amine groups, to indentify free amine groups on the HA surface.72 
Nelson et al. used the SMP linker to conjugate Lysine-arginine-serine-arginine sequences and 
enhance osteoblast adhesion for HA bone implants.34 HA nanoparticles have also been 
functionalised with the polypeptide, poly(g-benzyl-L-glutamate) (PBLG) via APTES linkage.90 
Surface amino groups were used in the ring opening polymerization of benzyl-L-glutamate N-
carboxyanhydride (BLG-NCA). The PBLG-g-HA particles showed enhanced biocompatibility, cell 
adhesion, and proliferation of osteoblasts.  In addition the colloidal stability of the HA 
nanoparticles was greatly improved.  
 
3.2.6 Radiopharmaceutical Examples of Hydroxyapatite 
HA microparticles have been labelled with various beta emitting isotopes for the treatment of 
arthritis, for example, 166Ho, 90Y, 153Sm, and 186Re.91-94  The choice of radionuclide depends 
largely on its ability to penetrate tissues, and its half life, which must be sufficient to impart 
the prerequisite dose, but not so long as to cause damage to bone, cartilage or skin (see 
chapter 1 for discussion on radiopharmaceutical particulates arthritis treatment). The 
radiolabelled particles are typically injected into the joint cavities, and remain there by virtue 
of their size.  The HA formulations described here are typically in the µm range, for example, 
15 µm to 40 µm was reported by Chinol et al., who labelled HA with 166Ho and 153Sm.92  
Typical labelling procedures for conjugating radionuclides to HA surfaces involve the use of 




chelating agent.94 A 166Ho-citrate complex was formed by dissolving citric acid in 0.1 M HCl. 
The HA particles were simply mixed with the 166Ho-citrate complex to form the radiolabelled 
166Ho-HA. Radiolabelling yields of over 98% were achieved. The radiolabelled 166Ho-HA 
particles were clinically safe and stable for use in synovectomy, where negligible joint leakage 
and no toxicity were observed.92, 94  
 
More recently, the development of small nanoparticles with controlled size, morphology and 
surface chemistry has led to their application as drug delivery tools. HA nanoparticles have 
been labelled or loaded with proteins, DNA and drugs. 8-12 Ong et al. have described the 
labelling of HA nanoparticles with bisphosphonate derived compounds.87 HA nanoparticles 
were labelled with 99mTc-methylene diphosphonate (99mTc-MDP) and Clodronate (a bone 
cancer treatment). The aim was to produce injectable HA nanoparticles that could be used for 
the delivery of therapeutic agents for the treatment of cancer. The labelling procedures were 
fast and simple, exploiting the high affinity bisphosphonate-HA interaction. In addition, the HA 
surface required no modification prior to labelling. In both instances efficient labelling was 
achieved within 5 minutes (>80 %).  
 
Han et al. have prepared HA nanoparticles doped with  ethylene-diaminetetramethylene-
phosphonate (EDTMP), where the size and morphology were  controllable, as a model for 
producing 153Sm-EDTMP-HA particles.95 The HA-EDTMP nanoparticles were formed via a co 
precipitation method. A solution of (NH4)2HPO4 was doped with various concentrations of 
EDTMP and added to a Ca(NO3)2 solution. After precipitation, the particles were subjected to 
HT. EDTMP was successfully incorporated into the nanoparticle and Han et al. suggest that the 
153Sm3+ ion will chelate to EDTMP and form 153Sm-HA-EDTMP particles. These nanoparticles 
could have therapeutic applications, for example, at targeted cancer sites. A point stressed is 
that EDTMP is doping the nanoparticles rather than tagging the surface, therefore the surface 
of particle will remain relatively clear for the addition of targeting ligands.   
HA nanoparticles have also been developed for other medical imaging fields. These 
preparations have exploited the ability to dope HA materials. For example, MRI active and 
fluorescent HA has been prepared, doping HA with Fe or Eu for MRI and fluorescent imaging 
applications respectively.96-98  
 
3.3 Aims 
HA nanoparticles have shown potential in orthopedic, drug delivery, radiotherapy and imaging 




binding properties make HA nanoparticles an ideal platform for developing a pretargeting 
nanomaterial. However, the highly aggregated nature of HA nanoparticles is a major issue that 
will need to be assessed. In this chapter the synthesis of HA nanomaterials is described. We 
aimed to stabilise and develop novel methods for linking small molecules or targeting 
peptides to HA nanoparticles for use in our pretargeting method.   
      
Experimental Aims 
 Prepare HA nanoparticles via wet chemical precipitation and investigate the effects of 
synthesis temperature and post-synthesis treatment on particle properties. 
 Reduce HA aggregation using stabilsing ligands.  
 Functionalise HA surfaces with small molecules for targeting purposes. 
 
3.4 Materials  
All chemicals used in these experiments were obtained from commercial sources as analytical 
reagents and used without further purification unless otherwise indicated.  Deionised water 
(Type I, 18.2 MΩ·cm) was obtained from an ELGA Purelab Option-Q system. Trizma base, 
hydroxyapatite nanoparticles (HA1), calcium nitrate tetrahydrate, ammonium dihydrogen 
phosphate, Fmoc-Lys-OH hydrochloride, Fmoc-Glu(OtBu)-OH, sodium hexametaphospate, 
sodium dodecyl sulfate, Tween® 20, Triton® X-100, phytic acid, oleic acid, malic acid, 3-
aminopropyl triethoxysilane (APTES) were all purchased from Sigma Aldrich. Sodium citrate 
dihydrate was purchased from Fischer Scientific. Alendronate, Pamidronate, and PEGBP 
MW5000 (a polyethyleneglycol containing a bisphosphonate moiety) were prepared in house, 
supplied by Dr Rafael Torres (Division of Imaging Sciences, Kings College London).  
 
3.5 Characterisation   
Fourier transform infrared spectroscopy (FTIR) studies were performed using either a Perkin-
Elmer spectrum RXI FTIR spectrometer or a Perkin-Elmer Spectrum 100 spectrometer 
equipped with a universal attenuated total reflectance (UATR) sampling accessory. 
Transmission electron microscopy (TEM) was performed with an FEI Tecnai T12 instrument at 
120 kV (Centre for Ultrastructural Imaging (CUI), Kings College London). The samples were 
prepared by evaporation of a drop of the aqueous colloidal suspensions onto a carbon-coated 
copper grid (Agar Scientific 200 mesh). Elemental analysis was performed by energy dispersive 
X-ray spectroscopy using an EDAX spectrometer in conjunction with the same microscope. X-
ray powder diffraction (XRD) was recorded on a PANalytical X’Pert Pro Multi Purpose 




Simultaneous TGA-DSC (ITRI Labs, St Albans). Zeta potential and hydrodynamic particle size 
measurements were performed using a Delsa Nano C particle analyser; all measurements 
were performed at 25 oC. X-ray photoelectron (XPS) analysis was performed on a Kratos Axis 
Ultra DLD Spectrometer with monochromatised Al Kα (1486.6 eV) radiation and a 
hemispherical energy analyser. The spectrometer was also equipped with a hybrid lens 
(electrostatic and magnetic together) and a charge neutralization system. High resolution 
scans were acquired at pass energy 20 eV with ranges relevant to the elemental core levels of 
interest, step sizes of 0.1 eV. The XPS data were acquired at photodetector take-off angle of 
90°. The service was kindly provided by The University of Nottingham under the Engineering 
and Physical Sciences Research Council (EPSRC) grant EP/F019750/1 "A Coordinated Open-
Access Centre for Comprehensive Materials Analysis". 
 
3.6 Methods 
3.6.1 Synthesis of Hydroxyapatite  
HA1 is commercially available HA, purchased from Sigma Aldrich (<200 nm) catalogue number 
677418.  
  
Preparation of HA2 (Calcined Hydroxyapatite) 
To a solution of 0.5 M Ca(NO3)2.4H2O in H2O (30 mL) was added 0.3 M (NH4)2HPO4 in H2O (30 
mL) drop-wise. The solutions were adjusted to pH 10 with NH4OH (28%) prior to mixing. The 
reaction mixture was stirred for 4 h at 60 oC, and left to stand overnight. The precipitate was 
washed four times with water (20 mL) with centrifugation at 8,000 rpm to remove the 
washings. The product was dried at 60 oC overnight and sintered in a furnace at 550 oC for 6 h, 
yielding a fine white powder.  
 
Preparation of HA3 (Hydrothermally Treated Hydroxyapatite) 
To a solution of 0.5 M Ca(NO3)2.4H2O in H2O (30 mL) was added 0.3 M (NH4)2HPO4 In H2O (30 
mL) drop-wise. Solutions were adjusted to pH 10 with NH4OH (28%) prior to mixing. The 
reaction mixture was stirred for 4 h at 60 oC, and left to stand overnight. The precipitate was 
washed four times with water (20 mL) with centrifugation at 8,000 rpm to remove the 
washings. After washing and drying at 60 oC overnight the HA powder was suspended in water 
(15 mg/mL) and placed in an acid digestion bomb (Parr), and heated in an oven at 200 oC for 
24 h. Water was removed from the suspension by freeze drying, yielding a fine white powder. 
*To investigate the effect of reaction temperature, calcined and hydrothermal preparations 




3.6.2 Stabilisation of HA Particles 
HA nanoparticle preparations are inherently unstable in solution, forming large aggregates. 
The ability to disaggregate and stabilise HA particles was assessed. HA particles were 
suspended in series of solutions containing cationic, anionic and non-ionic surfactants. In 
addition, a series of experiments, attaching cationic, anionic or sterically stabilising agents 
directly to the particle surface were conducted. The surface functionalisation and dispersing 
ability was assessed by FTIR, DLS, zeta potential, and TGA analysis. For DLS and zeta potential 
measurements, a solution of 0.2 mg/mL particles was prepared. In general, 3 mg of dried 
particles was resuspended in 3 mL of 50 mM TRIS-HCl buffer (pH 7.4). Particles were sonicated 
for 5 min before diluting to 0.2 mg/mL in 50 mM TRIS-HCl buffer (pH 7.4). 
 
Method 1: Preparation of Stabilised Dispersions of HA Particles 
Particle material (HA1, HA2 or HA3) (3 mg) was suspended in dispersing agent (10% -0.01% 
wt/vol) in H2O (3 mL), see table 3.1 for a list of dispersing agents. The particles were sonicated 
for 5 min before measuring particle size via DLS.  
Dispersing Agent Concentrations used (wt/vol) 
Sodium hexametaphosphate 10 -0.01%  
Sodium dodecyl sulfate 10 -0.01% 
Tween
®
 20 10 -0.01% 
Triton
®
 X-100 10 -0.01% 
 
Table 3.1: List of dispersing agents used for particle stabilisation. 
Method 2: Modification of Particle Surfaces 
General Modification Procedure 
HA1 or HA2 (100 mg) was suspended in H2O (10 mL) containing surface modifying agent (10% 
-0.1% wt/vol). See table 3.2 for a list of modifying ligands. In the case of malic acid, phytic acid, 
and citrate dihydrate, the solution was made in 0.1 M 2-(N-morpholino) ethanesulfonic acid 
(MES) buffer (pH 6.15) to avoid the dissolution of the nanoparticles at lower pH. Sodium 
hexametaphosphate was prepared in 100 mM TRIS-HCl buffer (pH 7.4).  The suspension was 
sonicated for 5 min, followed by shaking at RT overnight (12 h), followed by an additional 2 h 
of shaking at 50 oC. The suspension was washed five times with H2O (5 mL) by centrifugation 




samples. The particles were referred to as HA(X)Mal(A), HA(X)Phytic(A), HA(X)Citrate(A) and 
HA(X)HMP(A), where X = either HA1 or HA2 and A = the concentration of ligand used (wt/vol). 
 
Preparation of Bisphosphonate Functionalised HA Particles.  
HA1-Alendronate 
 HA1 (100 mg) was suspended in 50 mM TRIS-HCl buffer (pH 7.4) (10 mL) containing 
Alendronate (1% -0.01% wt/vol). The suspension was sonicated for 5 min, followed by shaking 
at RT for 2 h. The suspension was washed five times with H2O (5 mL) by centrifugation at 
15,000 rpm to remove washings. The resulting solid was freeze dried producing a fine white 




*PEGBP is a polyethylene glycol polymer containing a bisphosphonate moiety,  MW 5177.  
HA1 or HA2 (10 mg) was suspended in 50 mM TRIS-HCl buffer pH7.4 (1 mL) containing PEGBP 
(10% -0.01% wt/vol). The suspension was sonicated for 5 min, followed by shaking at RT for 2 
h. The suspension was washed four times with H2O (5 mL) by centrifugation at 15,000 rpm. 
The resulting solid was freeze dried, producing a fine white powder. The particles were 
referred to as HA(X)PEGBP(A), where X = either HA1 or HA2 and A = the concentration of 
ligand used (wt/vol). 





10 -0.1% 100 mM (TRIS-HCl) 
buffer (pH 7.4) 
Sodium citrate dihydrate 10 -0.1% 100 mM (MES) 
buffer (pH 6.15) 
Phytic acid 10 -0.1% 100 mM (MES) 
buffer (pH 6.15) 
Malic acid 10 -0.1% 100 mM (MES) 
buffer (pH 6.15) 
PEGBP 10-0.01% 50 mM (TRIS-HCl) 
buffer (pH 7.4) 
Alendronate 1-0.01% 50 mM (TRIS-HCl) 
buffer (pH 7.4) 




Surface Derivatisation of Hydroxyapatite with 3-aminopropyltriethoxysilane (APTES) and 
Bisphosphonate Molecules 
It was thought that bisphosphonate molecules bearing amino or other linking functionalities 
could provide a method for conjugating peptides or small molecules to the surface of HA 
nanoparticles. Aminosilane type molecules have previously been used for HA surface 
modification, acting as a linking for further modification (discussed above).  3-
aminopropyltriethoxysilane (APTES) modified HA1 has been prepared for a comparison of the 
radiolabelling capabilities of these particles (See chapter 6). Furthermore, the ability for 
bisphosphonate molecules to act as “bifunctional linkers” on HA surfaces is assessed. The 
conjugation of small molecules to HA surfaces via the free amino group available on 
pamidronate functionalised HA nanoparticles has been studied using lysine, glutamic acid and 
fluorescein derived molecules.  
 
Preparation of APTES Functionalised HA1 
APTES solutions- 1, 2, and 4% (wt/vol) were prepared in hexane. HA1 (50 mg) was suspended 
in each APTES solution (20 mL) under a nitrogen atmosphere. The suspensions were stirred 
overnight at RT and washed four times by centrifugation (5 min at 14000 rpm) with hexane (5 
mL). The pelleted samples were left to dry in air overnight, producing a white powder. The 
particles were referred to as HA1APTES(A), where A = the concentration of ligand used 
(wt/vol). 
 
Preparation of Pamidronate Functionalised Hydroxyapatite 
To a suspension of HA1 or HA2 (100 mg) in H2O (5 mL) was added a solution of pamidronate 
(100 mg) in H2O (5 mL). The reaction mixture was stirred for 2 h at RT and washed four times 
by centrifugation (5 min at 8000 rpm)  with water (5 mL), or  until no further bisphosphonate 
could be identified in the supernatant. Ninhydrin spray was used to identify the presence 
pamidronate amine groups. The solid was freeze dried to remove water. The particles were 
referred to as HA1PAM1 and HA2PAM1. 
 
3.6.3 Using Pamidronate Functionality to Conjugate Small Molecules to HA 
Preparation of HA-Pamidronate-Lysine Nanoconjugates 
HA1PAM1 (50 mg) was suspended in water (2.5 mL). N,N-diisopropylethylamine (DIPEA) (11.5 
mg, 88.9 µM) was added to the suspension.   Next, a solution of Nα-Fmoc-L-lysine 
hydrochloride (30 mg, 74.1 µM) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 




The mixture was allowed to stir overnight at RT and washed four times via centrifugation (5 
min at 8000 rpm) with water (5 mL), or until no Nα-Fmoc-L-lysine hydrochloride amine groups 
could be identified in the supernatant. Ninhydrin spray was used as an identification 
technique; a purple/blue spot indicated Nα-Fmoc-L-lysine hydrochloride was present. The solid 
was freeze dried to remove water, yielding (30 mg) of white powder. The particles were 
referred to as HA1PAMLys. 
 
Preparation of HA-Pamidronate-Glutamic Acid Nanoconjugates 
HA1PAM1 (50 mg) was suspended in dimethylformamide (DMF) (2.5 mL), and DIPEA (10.9 mg, 
84.6 µM) was added to the suspension. Next, a mixture of Fmoc-L-glutamic acid 5-tert-butyl 
ester EDAC (15.6 mg, 84.6 µM) in DMF (5 mL) was added with continuous stirring. The mixture 
was allowed to stir overnight at RT and washed four times via centrifugation (5 min at 8000 
rpm) with DMF (5 mL), and three times with water (5 mL) (5 min at 8000 rpm). The solid was 
freeze dried to remove water, yielding (24 mg) of white powder. The particles were referred 
to as HA1PAMGlu. 
 
Preparation of FITC Labelled HA 
HA1PAM or HA2PAM (35 mg) was suspended in DMF (5 mL), and DIPEA (8.1 mg, 62.7 µM) was 
added to the suspension. Next, fluorescein isothiocyanate (FITC) (10 mg, 25.7 µM) in DMF (2 
mL) was added to the suspension with continuous stirring. The mixture was protected from 
light and stirred for 12 h at RT. Unbound FITC was removed via centrifugation, (5 min at 8000 
rpm x 4) with DMF (5 mL), and water (5 mL) (5 min at 8000 rpm x 4). The product was freeze 
dried to remove water, yielding an orange powder. The particles were referred to as 
HA1PAMFITC or HA2PAMFITC.  
 
The reaction was repeated for unfunctionalised HA1 to compare any HA-FITC binding without 
the pamidronate functionality. After washing there was no obvious colouration of the powder, 
indicating that if any, only a minimal amount of FITC are bound to the HA surface. The 









HA1Citrate(X) 10, 1, 0.1% 
HA1Malic(X) 10, 1, 0.1% 
HA1Phytic(X) 10, 1, 0.1% 
HA1HMP(X) 10, 1, 0.1% 
HA2HMP(X) 10, 1, 0.1% 
HA1PEGBP(X) 1, 0.1, 0.01% 
HA2PEGBP(X) 10, 1, 0.1% 
HA1APTES(X) 4, 2, 1% 








Table 3.3: HA materials synthesised. Note (X) in material name represents concentration of ligand used 
in modification, listed in column 2. 
*Commercially prepared HA nanoparticles (Sigma Aldrich) are referred to as HA1. 
 
3.7 Results and Discussion 
3.7.1 Synthesis of Hydroxyapatite  
HA has been prepared via numerous synthetic routes, discussed above. We chose to adopt a 
method based on wet chemical precipitation due to its simplicity and versatile nature. More 
specifically, we chose the aqueous addition of (NH4)H2PO4 to Ca(NO3)2, due to promising size 
and morphology control reports using similar methods.49, 56, 63, 71, 99 Our approach was adapted 
using methods previously published.49, 56, 63, 71, 99 The literature review on HA nanoparticle 
synthesis (see above) revealed that precipitation methods are highly dependent on 
temperature, addition rate, precipitation time and pH; controlling the size, morphology and 
composition of particles.49, 54, 55, 57, 58, 100 We have investigated the effect of reaction 
temperature and post-synthesis treatment on HA particle properties. (NH4)H2PO4 (0.3 M) was 
added to a Ca(NO3)2 (0.5 M) solution in a dropwise fashion. The molar ratio was set at 5:3 to 
achieve a 1.67 Ca/P stoichiometric HA ratio. HA is known to be the predominant and stable 




mixtures of HA containing calcium phosphate apatite and CaHPO4 were present when using 
Ca/P molar ratios <1.5, or Ca(OH)2 at Ca/P molar ratios >1.67).
66 This chapter presents the 
synthesis of monocrystalline HA materials. The presence of impurities such as β-TCP can 
seriously damage mechanical and chemical stability.101 We decided to prepare pure crystalline 
HA to ensure chemical stability in an in vivo setting for pretargeting schemes. However, small 
amounts of impurities (e.g. TCP or carbonate) have been shown to enhance bone resorption 
properties, and may be considered useful for grafting to natural bone.101 These materials may 
also provide interesting radiolabelling properties, but are not reported within this thesis.  
 
The Ca(NO3)2 solution was heated to the desired temperature before adding (NH4)H2PO4 (not 
heated). To ensure temperature remained constant, a dropwise addition rate was chosen. The 
rate of addition has been known to influence precipitation methods.  For example, when 
phosphoric acid H3PO4 is added to a Ca(OH)2 solution, (Scheme 3.1) fast addition of the acid 
may result in a sharp decrease in pH. At high addition rates incomplete dissociation of the 
phosphate salt has been observed, resulting in HA containing phosphate impurities.57  
 
The effect of addition rate on morphology has been reviewed with conflicting results. Bouyer 
et al. report elongated and spherical particles at rapid and slow addition rates respectively.57 
In contrast, Zhang et al. report spherical and rod-like particles at rapid and slow addition 
rates.99 Zhang et al. postulate that rapid addition results in a more homogeneous nucleation 
process, thus preferential growth of the c-axis (002) does not occur resulting in spherical 
particles. However, we chose a slow addition rate to maintain constant temperature.   
 
For our initial HA preparation studies, an intermediate reaction temperature of 60 oC, 
followed by an aging period of 12 h was chosen. These conditions have proven sufficient in 
literature to produce monocrystalline materials.49, 57, 58 In an attempt to control particle size 
and morphology we have investigated the effect of reaction temperature on particle 
properties. Furthermore, the effect of post-synthesis treatment was assessed. After aging for 
12 h the particles were washed and dried in an oven at 60 oC overnight. The dried particles 
were subjected to either calcination or hydrothermal treatment. The resultant nanoparticles 
were characterized with X-ray diffraction (XRD), Fourier transform infrared spectroscopy 





3.7.2 The Effect of Synthesis Temperature 
The synthesis temperature prior to post-synthesis treatment was varied to study the effect on 
particle properties. It was thought that by varying the temperature, particle size, morphology 
and crystallinity could be tailored.49, 55, 57, 58 The particles were prepared by the addition of 
(NH4)H2PO4 to Ca(NO3)2, at 4, 25, 40, 60, 80 and 100 
oC. The preparations were subjected to 
calcination or hydrothermal post-synthesis treatments. The resultant nanoparticles were 
characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM) and dynamic 
light scattering (DLS). 
 
 
Figure 3.3: TEM of as prepared (pre-treated) HA particles prepared at different reaction temperatures. 
(A) 4 
o
C (B) 25 
o
C (C) 60 
 o
C (D) 80 
 o
C, with scale bars of 100 nm.  
 
TEM analysis of the as prepared pre-treated particles revealed that particle morphology varied 
with synthesis temperature (Figure 3.3). At low temperatures (4 oC and 25 oC) the particles 
appeared to be approximately spherical but poorly defined and connected by an aggregated 
framework.  At higher temperatures (60 oC and 80 oC) the particles were elongated needle-like 
shapes. The growth pattern of spherical particles to needle-like particles with increasing 
synthesis temperature has been described previously.55, 99 The preferential growth of particles 
along the c-axis of HA crystals has been reported by various authors.49, 58, 99, 100 This 
observation is explained by temperature being the driving force for particle growth, as the 





The TEM of calcined particles presents highly aggregated samples at all temperatures. In 
comparison to untreated particles (Figure 3.3) the morphology appears more rounded (Figure 
3.4), notably different to the needle-like particles seen at higher temperatures for particles 
without thermal treatment (Figure 3.3). At lower temperatures (4 oC and 25 oC) there 
appeared to be significant coalescence of the particles, attributed to thermal instability. The 
increased rounding and smoothness can be related to the induced crystal growth under 
thermal conditions. The TEM of HT preparations revealed smooth regular shapes rod shapes 
(Figure 3.5), with less aggregation seen in comparison to calcined particles. Presumably, the 
milder aqueous conditions of HT prevent particle coalescence, even for the particles prepared 
at low synthesis temperatures (e.g. 4 oC and 25 oC). The smooth nature of HT particles can be 
associated to thermally induced crystal growth.   
 
 
Figure 3.4: TEM of calcined HA particles prepared at different temperatures. (A) 4 
o







C (E) 80 
 o







Figure  3. 5: TEM of HT HA particles prepared at different temperatures(A) 4 
o
C (B) 25 
o
C (C) 40 
 o
C (D) 60 
 
o
C (E) 80 
 o




The XRD patterns of calcined and HT HA particles prepared at different temperatures are 
shown in figures 3.6 and 3.7. At synthesis temperatures above 60 oC, peaks correspond well to 
pure HA standard diffraction patterns for both calcined and HT particles. The HA phase was 
confirmed by standard ICSD (inorganic crystal structure database) reference.102 Below 40 oC a 
biphasic mixture was observed for both post-synthesis treatments. The biphasic mixture 
consisted of HA and β-TCP phases, highlighted in figures 3.6 and 3.7. The β-TCP phase was 
confirmed through comparison with a standard ICSD references.103, 104 The occurrence β-TCP 
phases can be explained by the thermal instability of HA samples prepared at lower reaction 
temperatures. The β-TCP phase is more prominent in the calcined samples, which correlates 
well with the high temperature of calcination treatment, inducing thermal decomposition. The 
crystallite size and crystallinity of the HA samples can be calculated for the XRD results, using 
peak broadening, according to the Scherrer equation (Equation 3.1).22, 57, 58, 105 
 
XS= Kλ/(FWHMcosθ) 
Equation 3.1: Where XS is the crystallite size (nm), K is a constant related to crystallite shape, λ the 
wavelength of x-ray beam (λ= 0.15406 nm for CuKα radiation), FWHM the full width at half maximum 





Figure 3.6: XRD patterns of calcined HA prepared at different temperatures. TCP= β tricalcium 
phosphate. TCP impurities are labelled, all other peaks correspond to HA. 
 
The diffraction peak at 2θ = 26.10° was chosen for calculation of the crystallite size, since it is 
sharper and isolated from the others. The peak can be assigned to the (002) miller’s plane, 
and represents growth along the c-axis of the crystal.58, 100, 105 The calculated values of 
crystallite size are presented in table 3.4. For calculations, a shape factor (k) of 0.9 or 1 was 
applied for the rod-like HT and irregular calcined rounded particles respectively.64, 105, 106 The 
FWHM value was calculated by peak fitting to a gaussian function using OriginLab 8.5 
software. In general, an increase in sharpness and intensity of peaks is indicative of larger 
crystallites and increased crystallinity. The crystallinity of samples can be calculated using 
equation 3.2.107 The crystallinity value corresponds to the fraction of crystalline apatite phase 









Equation 3.2: Where XC is the crystallinity degree, KA is a constant found to be 0.24 for a large number of 
HA powders,
107





Figure 3.7: XRD patterns of HT HA prepared at different temperatures. TCP= β tricalcium phosphate 






















4 Calcined 0.52422 324.32 16.87 0.10 
25 Calcined 0.38450 490.10 23.18 0.24 
40 Calcined 0.61497 229.03 14.39 0.06 
60 Calcined 0.37908 309.60 23.50 0.25 
80 Calcined 0.38273 473.35 23.12 0.25 
100 Calcined 0.35024 515.41 25.26 0.32 
4 Hydrothermal 0.32407 677.74 27.30 0.41 
25 Hydrothermal 0.24574 1674.97 35.99 0.93 
40 Hydrothermal 0.32276 626.28 27.39 0.41 
60 Hydrothermal 0.28505 915.22 31.03 0.60 
80 Hydrothermal 0.23895 2319.96 37.01 1.01 
100 Hydrothermal 0.23984 2322.51 36.87 1.00 
HA1 - 0.35479 559.92 24.95 0.31 
 
Table 3.4: Crystallite size and crystallinity of HA samples calculated using Scherrer equations 1 and 2.  A 
high value represents a higher degree of crystallinity.  
 
The calculated values for crystallinty (XC) are presented in table 3.4. The crystallinity of 
hydrothermal preparations was significantly higher than that of the calcined samples. This 
observation can be coordinated with the increased regularity and smoothness of HT particles 
indicated by TEM analysis (Figure 3.4 and 3.5). For both calcined and hydrothermal particles, 
the calculated crystallite size increased with increasing temperature, at synthesis 
temperatures above 40 oC. The crystallite size of HT particles was larger than calcined 
preparations, corresponding to preferential growth along the c-axis of the rod-like particle 
crystal structure. An explanation of the smooth rod-like transition from the irregular pre-
treated particles (Figure 3.3) is offered above (see introduction). Briefly, the dissolution of 
small particles that can then form larger particles, and growth along the c-axis of the crystal is 
promoted at high temperature and pressure. The transition is particularly evident for samples 
prepared at 4, 25 and 40 oC. 
  
The crystallinity of calcined and HT samples prepared at 4, 25 and 40 oC does not follow the 
trend of increased crystallinity with increased temperature. The pattern is highlighted by a 
decrease in crystallinity from 25 oC to 40 oC seen in both HT and calcined particles. This may be 
related to the biphasic nature of these materials interfering with crystallite size and 




phases. The crystallinity measurements above 40 oC corresponded to increased crystallinity of 
HA with increased reaction temperature.  
 
A comparison of particle size and crystallite size measured by TEM, DLS and XRD is given in 
table 3.5 and figure 3.8. The general trend of increased crystal growth with increased 
synthesis temperature appears to be observed above 40 oC. The main observation is that 
particle size measurements vary greatly depending on the method of measurement. XRD 
measurements are related to crystallite size, where “crystal” or “crystallite” size generally 
refers to a discrete diffracting domain that coherently scatters x-rays.95 Therefore, it is not a 
direct measurement of particle size, and does not account for the joining or aggregation of 
particles in polycrystalline samples. Furthermore, the values for crystallite size calculated 
herein are an approximation. The crystallite size is not the only factor that affects peak 
broadening. For example, there are instrumental and lattice strain contributions to consider 
for more accurate results.105 Instrumental error could not be factored into our results due to 















by XRD (nm) 
4 Calcined - 822.5 ±254.6 16.9 
25 Calcined - 463.5 ±3.0 23.2 
40 Calcined 33.0  ±14.7 216.2 ±8.2 14.4 
60 Calcined 37.3 ±16.2 105.1 ±6.1 23.5 
80 Calcined 47.5 ±20.3 119.6 ±6.6 23.1 
100 Calcined 50.9 ±17.8 222.7 ±31.9 25.3 






95.6 ± 2.2 27.3 






85.6 ±1.8 36.0 






90.1 ±3.6 27.4 






145.4 ±4.5 36.9 






126.5 ±3.9 37.0 






126.9 ±3.2 31.0 
HA1 - 65.8 ±29.7 224.3 ±4.4 25.0 
 
Table 3.5: Particle and crystallite size measured by DLS, TEM and XRD. For TEM measurements a = 
length, b = width, of rod like particles. DLS measurements were performed in the presence of a 






TEM particle sizes were calculated using ImageJ processing software, where n=100-150. The 
largest diameter of the irregular calcined particles, and length and width measurements were 
taken for rod-like particles. DLS measurements were taken by suspending particles (0.2 
mg/mL) in a solution 0.1% sodium hexametaphosphate (SHMP), as a dispersing agent. The DLS 
measurements are expected to be larger than TEM, as the hydrodamic radius of the particle in 
solution is being measured. There may also be an increase in particle size due to the 
adsorbtion of SHMP to the surface of HA. For calcined particles synthesised at 4 and 25 oC it 
was not possible to measure the particle size via TEM due to coalescence of the particles, 
individual particles were not visible. The observation of particle coalescence is in agreement 
with the large particle size measurements found by DLS, 823 and 464 nm for 4 and  25 oC 
respectively (omitted from graph in figure 3.8 for clarity). However, these results are not 
reflected by crystallite size calculated from XRD diffraction peaks. The crystallite size was 
considerably less, which can be attributed to particle coalescence and aggregation not being 
accounted for. For HT HA particles, DLS and TEM measurements were relatively similar. 
However, XRD crystallite sizes were greatly reduced in comparison. As particles become larger 
the Scherrer equation becomes more error prone. The peak broadening effect due to 
crystallite size becomes smaller. Therefore, instrumental and lattice strain effects become 
more significant. At particle sizes >100 nm the Scherrer equation may be less applicable.108, 109 
 
In conclusion, calculating crystal size using the Scherrer equation may not be applicable in this 
instance. Further modifications to include other peak broadening effects are required for 
more accurate results.109, 110 The results reported are an approximation that may not hold true 
at particle sizes >100 nm. However, the general trend in crystal and particle size growth 
observed by TEM, DLS and XRD was similar. For all subsequent studies we selected calcined 
and HT particles prepared at 60 oC. At this temperature the treated particles were 
monocrystalline. We chose the intermediate temperature of 60 oC to avoid particle growth at 
higher temperatures. The particles were referred to as HA2 and HA3 for calcined and HT 
samples, respectively.  TEM images, and particle size measurements for HA2 and HA3 are 
summarised in figure 3.9 and table 3.6. The DLS measurements of HA1, HA2 and HA3 particles 
(without dispersing agent) indicate that they are highly aggregated in solution. The HA particle 
sizes ranged between ca. 2-4 µm. Therefore, indicating that dispersing agents, such as SHMP 
are required to prepare colloidally stable HA. The rest of our discussion will focus on 






Figure 3.8: Graphs comparing particle size measurement of HA samples via different techniques, XRD, 









Material Dispersing Agent 
(wt/vol) 





HA1 HMP(0.1%) 224.3 ±4.4 0.279 ±0.006 - - 
HA2 HMP(0.1%) 105.1 ±6.11 0.284 ±0.003 - - 
HA3 HMP(0.1%) 145.4 ±4.5 0.269 ±0.003 - - 
HA1 - 2829.3 ±59.4 0.266 ±0.093 -4.41 ±0.32 
HA2 - 4479.3 ±307.5 0.587 ±0.041 1.82 ±0.13 
HA3 - 1686.9 ±55.3 0.188 ±0.062 -16.13 ±0.38 
 
Table 3.6: Summary of HA1, HA2 and HA3 particle sizes by DLS, and zeta potential measurements. The 
polydispersity index indicates the spread of values in the distribution, thus the homogeneity of the 
dispersion, ranging from 0 to 1. A value closer to zero is more homogenous, a value above 0.3 is 
considered to have heterogeneity.
111   
   
3.7.3 Stabilisation and Functionalisation of Particles 
HA nanoparticle preparations are inherently unstable in solution, and form large aggregates. 
The ability to disaggregate and stabilise HA particles is discussed herein. HA particles were 
suspended in series of solutions containing cationic, anionic and non ionic surfactants (Figure 
3.10). In addition, a series of experiments, attaching cationic, anionic or sterically stabilising 
agents directly to the particle surface were conducted (Figure 3.10). The surface 
functionalisation and dispersing ability was assessed by FTIR, DLS, zeta potential, and 
thermogravimetric analysis (TGA) (TGA was performed on select samples). For DLS and zeta 
potential measurements; a solution of 0.2 mg/mL particles was prepared. In general, 3 mg of 
dried particles was resuspended in 3 mL of 50 mM TRIS-HCl buffer (pH 7.4). Particles were 
sonicated for 5 min before diluting to 0.2 mg/mL in of 50 mM TRIS-HCl buffer (pH 7.4).  
There have been many attempts to stabilise HA nanoparticles, using; 
cetyltrimethylammonium bromide (CTAB),80 sodium dodecyl sulphate  (SDS),80 sodium 
hexametaphosphate (SHMP),49 glycosaminoglycans (GAGS),112 malic acid,71 poly(lactide),84 
chitosan,85 and phytic acid.113 However, none report the requirement of colloidal stability and 
subsequent loading of HA particles. Herein we investigated the colloidal stability of HA 
preparations, with a view towards further functionalisation or labelling for pretargeting 
purposes. 
  
As a starting point for our investigations we selected some well known biological dispersing 
agents.80  HA1 samples were suspended in a series of solutions containing different dispersing 
agents; the cationic surfactants, SDS and SHMP, and non-ionic surfactants, tween-20 and 
triton-X100 (Figure 3.10). The concentration of the dispersing agent was varied between 10-
0.1% (wt/vol). All concentrations of SDS, triton-X100, and tween-20 were prepared above 




assessed by hydrodynamic size measurements using DLS (Table 3.7). For non ionic surfactants, 
triton- X100 and tween-20, there was little or no evidence of particle stabilisation, as particle 
size measurements were in the µm range, similar to that observed for unfunctionalised 
particles. However, the anionic surfactants, SHMP and SDS displayed ability to stabilise 
(disaggregate) the HA1 particles in solution. Remarkably, SHMP showed stabilising potential at 
concentrations as low as 0.01 % (wt/vol), while SDS showed stabilising potential at 
concentrations down to 0.1% (wt/vol). The reduced stabilising ability of SDS at 0.01% w/v can 
be attributed to the fact that this concentration is on the boundary of the CMC, thus, SDS 
micelle formation may be limited and prevent its HA stabilising properties.116 The ability of 
charged particles to bind to the surface of HA1 appears to be an important mechanism for 
particle stabilisation. It was thought that SHMP can adsorb directly onto the particle surface, 
interacting with Ca2+ cations. Loo et al. suggested that surface phosphate anions are replaced 
with anionic phosphate groups of SHMP in an anion exchange process.49 However, we suggest 
that the former is most likely, since the large structure of SHMP is not suitable for replacing 
small phosphate groups in the HA structure. In conclusion, SHMP solutions were found to be 
the best at stabilising HA1 particles. Therefore, for HA particle size measurements (unless 
otherwise stated), an SHMP dispersant concentration of 0.1% (wt/vol) was chosen.  
 
3.7.4 Functionalising HA nanoparticles 
The ability to functionalise HA and calcium phosphate nanoparticles with small molecules such 
as malic acid,71 citric acid,81, 82 phytic acid,113 and SHMP49 has been discussed previously. 
Herein, we describe the preparation HA nanoparticles functionalised with malic acid, citrate, 
phytic acid, SHMP and the bisphosphonates; pamidronate, alendronate and PEGBP. The 
ligands were chosen based on previous results discussed in literature and the well-known 
affinity of bisphosphonates for HA.87 The purpose was to investigate the colloidal stability of 
re-dispersed functionalised HA powders. Confirmation of HA functionlisation was provided by 
FTIR, zeta potential, and TGA analysis.  
 
HA1 was suspended in a series of solutions containing different concentrations of 
functionalising agent (Table 3.3). The suspensions were incubated for a period of time, then 
washed by centrifugation and freeze dried (the particles prepared are described in tables 3.3 
and 3.8). The FTIR spectrums for all samples can be seen in figures 3.11-3.17. All samples 
showed peaks that can be attributed to HA, PO4
3- ions at 1085 cm-1,1010 cm-1, 960 cm-1, 600 
cm-1, and 560 cm-1 and OH- stretch at 3570 cm-1 (Figure 3.11). Additional bands at 1456 cm-1 
and 1414 cm-1 may correspond to CO3




agent had similar FTIR spectrums. Malic acid was identified by a characteristic C=O vibration at 
1550 cm-1 (Figure 3.12).71 The presence of citrate was indicated by a characteristic band 
corresponding to carboxylate groups at 1550 cm-1 (Figure 3.13).81, 117 The presence of phytate 
was indicated by characteristic bands at 1650 cm-1assigned to the C–O–P vibrations from 
phytate, as seen for the phytate standard (Figure 3.14).113 Surface bound SHMP was not 
identifiable by FTIR, since characteristic bands that were expected at 1264, 1085 and 877 cm−1 
were hidden by the PO4
3- ion bands from HA.118, 119 Alendronate functionalised particles were 
identified by characteristic amine bands at 1640 cm-1 (Figure 3.15). The PEGBP functionalised 
particles had characteristic bands corresponding to the standard PEGBP at 2875 cm−1 (Figure 
3.16). The APTES functionalised particles were identified by characteristic Si-O bending at ca. 
800 cm-1 and Si-O asymmetric stretching at ca. 1200 cm-1, and amine bands at 1635 cm−1 
(Figure 3.17).  
 
Dispersing Agent Concentration 
(wt/vol) 
Particles Size (nm) PDI 
(polydispersity index) 
SHMP 10% 577 ±27.9 0.260 ±0.033 
SHMP 1% 277.3 ±3.5 0.304 ±0.006 
SHMP 0.1% 264 ±2.3 0.306 ±0.006 
SHMP 0.01% 224.3 ±4.4 0.279 ±0.006 
SDS 10% 520 ±13.8 0.286 ±0.011 
SDS 1% 327 ±1.5 0.279 ±0.004 
SDS 0.1% 406 ±15.6 0.249 ±0.030 
SDS 0.01% 1809.7 ±8.8 0.322 ±0.016 
Tween-20 10% 1512.7 ±58.3 0.225 ±0.038 
Tween-20 1% 1563.7 ±31.7 0.227 ±0.056 
Tween-20 0.1% 1358 ±32.8 0.177 ±0.035 
Tween -20 0.01% 1301 ±63.5 0.083 ±0.044 
Triton-X100 10% 3072 ±73.8 0.753 ±0.036 
Triton-X100 1% 1347.7 ±46.2 0.232 ±0.018 
Triton-X100 0.1% 1529.3 ±43.7 0.216 ±0.056 
Triton-X100 0.01% 1240 ±26.1 0.206 ±0.016 
 
Table 3.7: Particle sizes of HA1 in the presence different stabilizing agents. Measured by DLS. The 
particle size given is an average cumulant result (where n= 3). The polydispersity index indicates the 
spread of values in the distribution, thus the homogeneity of the dispersion, ranging from 0 to 1. A value 
closer to zero is more homogenous, a value above 0.3 is considered to have heterogeneity.
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Figure 3.10: Structures of dispersing and functionlising agents. (A) Alendronate (B) Pamidronate (C) 
Citric acid (D) Phytate anion (E) Hexametaphosphate anion (F) PEGBP (MW5177) (G) Triton-X100, n = 9-







Figure 3.11: FTIR of (Top) HA1, (Middle) HA2 and (Bottom) HA3. HA was identified by characteristic 








Figure 3.12: FTIR of (Top) malic acid and (Bottom) magnified region of characteristic malic acid 





Figure 3.13: FTIR of (Top) citrate acid and (Bottom) magnified region of characteristic citrate acid 





Figure 3.14: FTIR of (Top) phytic acid and (Bottom) magnified region of characteristic phytic acid C-O-P 





Figure 3.15: FTIR of (Top) Alendronate and (Bottom) magnified region of characteristic Alendronate 







Figure 3.16: FTIR of (Top) PEGBP, (Middle) magnified region of characteristic PEGBP bands in 




Figure 3.17: FTIR of HA1APTES4. (Top) Full FTIR, where Si-O bands are observed, and (Bottom) magnified 
region of characteristic APTES amine band. 
 
Zeta potential measurements were taken to further confirm the surface functionalisation of 




colloidal stability. Colloidal solutions or dispersions will tend to aggregate at low zeta 
potentials, for example, systems <30 mV are typically considered colloidally unstable.79 Herein 
the zeta potential measurements have been exploited to identify changes in surface charge, 
related to functionalisation of the HA surface. For all concentrations of, malic acid, citrate, 
phtyic acid and SHMP, negative zeta potentials were measured, ca. -21,-20, -35, and -50 mV 
respectively. In comparison unfunctionalised HA1 had a zeta potential of -4.4 mV. The 
increased negative potential was associated to the anionic nature of the functionalising 
agents. In an attempt to assess the degree of functionalisation (i.e. a greater degree of 
functionalisation might be indicated by variation in zeta potential), a series of ligand 
concentrations were incubated with HA1 particles. However, the change in zeta potential was 
unremarkable. Phytic acid was an exception to this observation. The zeta potential reduced 
from -50 mV to -43 mV for 10 and 0.1% wt/vol of functionalising solutions respectively. Zeta 
potential measurements for the alendronate coated particles did not vary greatly from 
unfunctionalised HA1. Alendronate consists of separate bisphosphonate and amine moieties 
(Figure 3.10a). The bisphosphonate part that is expected to interact with the HA surface, while 
the amine group is left free to suspend in the solution (a discussion of bisphosphonate-HA 
interactions is given in chapter 5). It could be reasoned that these particles will carry a positive 
charge, due to the free amine groups available. However, zeta potential measurements are 
highly dependent on pH, and at pH 7.4 (used in these experiments) the free amine moiety will 
not be protonated, resulting in little or no change in the measured values. In addition, there 
was little change in zeta potential measured for PEGBP functionalised particles.  
 
DLS analysis of resuspended particles indicated that only SHMP, phytic acid and PEGBP 
functionalised HA1 particles had improved colloidal stability, as shown in table 3.8. The highly 
negative zeta potentials of HA1HMP and HA1Phy particles can be correlated to electrostatic 
stabilising properties, as indicated by the low DLS particle size measurements. SHMP showed 
better stabilising abilities than phytate, indicated by the smaller particle sizes measured. This 
was remarkable given the greater zeta potential of HA1Phy particles. The extra stabilisation 
for HA1HMP particles may be provided by additional steric stabilisation from SHMP.118 The 
HAPEGBP particles showed good stabilising potential; however, their low zeta potential 
confirmed that HAPEGBP stabilisation was due to steric properties rather than electrostatic. 
The poor stabilising abilities of malic acid, citrate and alendronate corresponded to their 









Particles Size/nm Polydispersity Index 
(PDI) 
Zeta potential  
(mV) 
Citrate 10% 1635 ±50.1 0.156 ±0.04 -20.87 ±0.06 
Citrate 1% 1361 ±52.6 0.121 ±0.05 -16.70 ±0.04 
Citrate 0.1% 1541.7 ±92.9 0.151 ±0.06 -18.45 ±0.16 
Malic acid 10% 1147.7 ±29.4 0.298 ±0.03 -21.20 ±0.11 
Malic acid 1% 1363 ±39.6 0.215 ±0.02 -21.58 ±0.07 
Malic acid 0.1% 1412.7 ±76.8 0.245 ±0.01 -20.12 ±0.39 
Phytic acid 10% 430 ±14.6 0.182 ±0.01 -50.28 ±0.52 
Phytic acid 1% 391 ±7.2 0.190 ±0.01 -48.47 ±0.22 
Phytic acid 0.1% 565 ±91.0 0.237 ±0.03 -42.54 ±0.26 
SHMP 10% 140 ±1.5 0.165 ±0.01 -34.23 ±0.02 
SHMP 1% 195.6 ±6.8 0.255 ±0.02 -34.13 ±0.07 
SHMP 0.1% 276.7 ±9.0 0.270 ±0.01 -35.94 ±0.10 
PEGBP 1% 203 ±5.0 0.173 ±0.02 -5.72 ±0.04 
PEGBP 0.1% 491.7 ±8.4 0.277 ±0.01 -4.60 ±0.21 
PEGBP 0.01% 1141.3 ±8.0 0.174 ±0.02 -13.09 ±0.24 
Alendronate 1% 790 ±17.2 0.175 ±0.05 -12.70 ±0.18 
Alendronate 0.5% 1061.3 ±32.9 0.214 ±0.02 -10.14 ±0.06 
Alendronate 0.1% 1201.3 ±53.9 0.146 ±0.02 -6.97 ±0.21 
Alendronate 0.01% 1269.7 ±22.7 0.130 ±0.01 -5.26 ±0.19 
APTES 4% 1734.1 ±150.1 0.208 ±0.08   
APTES 2% 2057.86 ±232.6 0.106 ±0.03   
APTES 1% 1937.8 ±42.3 0.440 ±0.057   
Table 3.8: Particle sizes and zeta potential of HA1 functionalized with different ligands. The particle size 
given is an average cumulant result (where n= 3). The polydispersity index indicates the spread of values 
in the distribution, thus the homogeneity of the dispersion, ranging from 0 to 1. A value closer to zero is 
more homogenous, a value above 0.3 is considered to have heterogeneity.
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Thermogravimetric analysis (TGA) analysis was performed on selected samples to investigate 
the degree of functionalisation (Table 3.9 and figure 3.18). The % of weight loss was most 
significant for HAPEGBP and APTES functionalised particles. The % weight loss of SHMP 
functionalised particles did not vary much compared to unfunctionalised HA samples, 
presumably due to the inorganic nature of SHMP, and therefore lack of volatile organic 
components <650 oC.   



















Figure 3.18: TGA analysis of HA1PEGBP10 and HA2PEGBP10. 
 
The promising colloidal stability of HA1PEGBP and HA1HMP samples prompted further 
investigation. Dispersions of HA1PEGBP and HA1HMP particles were prepared and their 
colloidal stability was studied over a period of 24 h (Figure 3.19). In addition, HA2PEGBP and 
HA2HMP samples were prepared and analysed (Figure 3.19). HA1HMP particles functionalised 
with 10-0.1% wt/vol SHMP were stable up to 24 h, while HA1PEGBP1 particles also retained 
their stability in solution for 24 h. The respective functionalised HA2 particles were stable up 
to 1 h. At 24 h all HA2HMP and PEGBP particles had formed aggregates in solution. This result 
indicates that functionalised HA2 particles are more prone to aggregation in solution. The TEM 
of HA1 and HA2 -PEGBP and -HMP functionalised (Figure 3.20) showed a decrease in 
aggregation compared to unfunctionalised HA samples (Figure 3.9). In summary, HA1 and HA2 
particles that were functionalised with either PEGBP or SHMP ligands showed promising 
stabilising abilities (disaggregation) in solution. Furthermore, we need to confirm that these 




Figure 3.19: Stability of HA1 (Top) and HA2 (Bottom) PEGBP and HMP particles in solution overtime.





3.7.5 Conjugation of Amino Acids and Small Molecules  
Herein, we have investigated the use of bisphosphonate molecules as bifunctional linkers on 
HA surfaces. The aim was to introduce peptides or small molecules to the HA surface for in 
vivo targeting purposes. In principle, the bisphosphonate moiety will anchor to the HA surface 
while the second moiety, such as an amino group is free for conjugation to small molecules or 
peptides (Figure 3.21). We proposed that the bisphosphonate pamidronate could be used as a 
linking agent. Pamidronate is composed of a bisphosphonate and amine moieties (Figure 
3.10b). The amine moiety was used to conjugate FMOC protected amino acids, lysine and 
glutamic acid via amide coupling. In addition, we described the reaction of fluorescein 
isothiocyanate (FITC) with the amine functionalised surface (Figure 3.22). It was thought that 
labelling HA particles with a fluorescent tag could be a useful tool for evaluation of their in 
vitro behaviour. The functionalised particles were prepared in two steps- first, HA1 and HA2 
particles were functionalised with pamidronate, and second, the pamidronate functionalised 
particles were reacted with either FITC, Fmoc-L-glutamic acid 5-tert-butyl ester or Nα-Fmoc-L-
lysine hydrochloride. The products were washed and dried at each stage. The reactions were 
monitored by X-ray photoelectron spectroscopy (XPS) (Tables 3.10-3.13). XPS can provide 
information about chemical bonding and atomic concentrations on the particle surfaces. In 
addition, the final products were analysed by FTIR.  
PEPTIDE
HA
Figure 3.21: Schematic of pamidronate acting as a linker for targeting peptides or other small molecules 
to functionalise HA surfaces.  
 
The amide bond formation between carboxylic acids of Fmoc-L-glutamic acid 5-tert-butyl ester 
and Nα-Fmoc-L-lysine hydrochloride and pamidronate amine is depicted in figure 3.22. The 
carbodiimide, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride (EDAC) was 
chosen as an activating agent for amide coupling, selected due to its water soluble properties. 
Furthermore, the coupling reaction by-products can be removed via extraction in aqueous 




In addition, to identify any non specific binding of FITC to the HA surface, unfunctionalised HA 
was incubated in with FITC. Fluorescein is a fluorescent molecule commonly used to evaluate 
the biological behavior of peptides, antibodies, and nanoparticles.120-123 FITC is a fluorescent 
derivative that consists of fluorescein and isothiocyanate moieties. The flourescein part is 
responsible its fluorescent properties and the isothiocyanate moiety can be used to conjugate 
small molecules or peptides.  Isothiocyanates can react with amine groups to form thioureas 
under mild conditions. The advantages of using FITC include its reactivity towards amine and 
sulfhydryl groups. We aimed to react the FITC isothiocyanate groups with pamidronate amine 
moieties, to from a stable thiourea linkage.  
Figure 3.22: Thiourea and amide bond formation between pamidronate (on HA surface) and (A) 
fluorescein isothiocyanate (FITC), (B) Nα-Fmoc-L-lysine hydrochloride or (C) Fmoc-L-glutamic acid 5-tert-
butyl ester.  
 
XPS analysis 
XPS results are displayed in tables 3.10-3.12. The expected Ca, P, and O core HA peaks were 
observed for all samples.124-126 It was found that the Ca/P ratio was significantly lower than 
fluorescein isothiocyanate 
(FITC) 










those expected for stoichiometric HA. This trend has been observed previously, attributed to 
the instability of HA powders during prolonged exposure to the X-ray source, leading to 
decomposition of the Ca substituent.124, 125 Notably, for unfunctionalised HA samples, C and N 
impurities were present. The carbon impurities were attributed to “adventitious carbon” due 
to adsorption of hydrocarbon impurities.124, 126 The observed N impurities seen in HA2 samples 
may be accounted for by NH4NO3 by-product and excess NH4OH in its precipitation route. 
McLeod et al. have reported N impurities, suggesting that adsorbed ammonia contamination 
is responsible.127 Furthermore, NH4NO3 can be assigned to the peak present at 401.7 eV.
128  
Since phosphate is inherently present in HA, in large quantities, it was thought that the N % 
atomic content would be a better guide to pamidronate functionalisation. The appearance of 
peaks at 399.2 and 399.6 eV for HA1PAM1 and HA2PAM1 respectively, provided evidence of 
R-NH2 groups on the surface of HA.
127-129 In addition, the overall nitrogen content was more 
than doubled for both HA1PAM1 and HA2PAM1 (Table 3.13). The % atomic content of the N 
1s peaks seen at 401.5 eV (previously associated to NH4NO3 impurities) also increased, which 
can be assigned to the protonated C-NH3
+ form of pamidronate.128, 130  
 
Conjugation of glutamic acid and lysine residues to HA1PAM1 was identified by further 
increases in N % atomic content (Table 3.13). The conjugation of Fmoc-L-glutamic acid 5-tert-
butyl ester to pamidronate should correspond to the formation of an amide bond. High 
resolution scans of the C 1s region was fitted to four peaks: 284.8, 285.6, 286.6, and 287.7 eV, 
which were attributed to  –C-C-,  -C-N or -C-O , and –NHCO- respectively.128, 131-133 In addition, 
a fifth peak present at 289.1 eV was attributed to carbonate impurities.134 The N 1s region was 
fitted into three peaks at 399.3, 400.5 and 401.5 eV. The unreacted pamidronate primary 
amine groups (R-NH2) were assigned to 399.3 eV.
127-129 Amide peaks are expected in the 
region 399.7-400.9 eV, and were assigned to 400.5 eV.86, 128, 133, 135 There was also an N 1s peak 
seen at 401.5 eV, which was assigned to the protonated C-NH3
+ form of pamidronate.128, 130 
The conjugation to Nα-Fmoc-L-lysine hydrochloride presented similar C 1s peaks to the 
glutamic acid functionalisation described above. Moreover, there was a large increase in N % 
atomic content related to the additional R-NH2 provided by lysine. The N 1s region was fitted 
to three peaks at 399.3, 400.1 and 401.6 eV. The large increase in N % atomic content of the N 
1s peak at 399.3 eV was assigned to additional R-NH2 provided by the lysine moiety.
127-129 The 
protonated amine signal observed at 401.6 eV was also moderately increased.127, 129 The peak 
at 400.1 eV was asigned to an amide bond.116, 127, 132, 134 The results for FITC conjugation to 
HA1PAM1 and HA2PAM1 are very similar to each other. There was an increase % atomic 




the N 1s peaks appeared at 401.6, 400.0 and 398.7 eV. The most notable peak appeared at 
398.7 eV, and a sift of the potential amine peak to 400.0 eV (from 399.6 eV in HA2PAM)  was 
observed. The peak appearing at 398.7 eV (or 399 eV for HA1PAMFITC) was associated to –C-
NH-C- formation,128 while the peak at 400.0 eV could also be related to unprotonated –C-N-C-
.130 The S 2p3/2 peaks assoicated with thiourea type molecules should appear at 162-162.6 
eV.136, 137 However, given the increase in % atomic content of N, it is suprising that there was 
no significant increase in sulfur content observed.  This could be related to the instability of 
the sulfur linkage under prolonged X-ray exposure. Alternatively, sulfur may not be present. 
Therefore, FTIR analysis was performed to confirm the presence of FITC on the HA surface. 
Further evidence for FITC conjugation was provided by the highly fluorescent nature of the 
particles observed under confocal microscopy (discussed in chapter 7). TGA analysis of 
unfunctionalised HA1, HA1PAM1,  and HA1PAMFITC gave the following weight loss results: 
0.5, 1.28, and 2.44% (over 150-650 oC) respectively (Table 3.13). The reaction of HA1 with FITC 
resulted in minimal additional weight loss (0.74%). There was a significant increase in weight 
loss for the HA1PAMFITC particles in comparison to the attempted HA-FITC reaction, 
indicating that pamidronate functionlaised particles promote the addition of FITC, while there 
is little non-specific binding to HA1.  












O 1s A 530.8 530.8 530.7 530.7 530.8 530.8 530.7 530.7 
O 1s B 532.4 532.5 532.4 532.5 532.5 532.6 532.4 532.5 
N 1s A 402.4 401.5 401.6 401.5 401.5 401.6 401.6 41.7 
N 1s B 401 399.6 399.2 399.6 400.5 400.1 399.6 400 
N 1s C     396.1 397.2 399.3 399.3 398 398.7 
Ca 2p 3/2 347.1 347 346.9 347 347 346.9 346.9 346.9 
Ca 2p 1/2 350.6 350.5 350.4 350.5 350.5 350.4 350.4 350.4 
C 1s A 284.8 284.9 284.9 284.6 284.8 284.8 284.4 284.4 
C 1s B 285.5 285.5 285.4 285.3 285.6 285.5 285.6 285.5 
C 1s C 286.6 286.5 286.4 286.3 286.6 286.4 286.5 286.5 
C 1s D 288.1 288.2 287.5 287.5 287.8 287.7 287.8 287.6 
C 1s E 289.3 289 288.5 288.8 289.1 288.9 289.1 288.7 
Cl 2p 3/2 198.9 199.4 197.7 198.6 198.7 198.6 198.5 198.3 
Cl 2p 1/2 200.8 201.2 201.3 200.1 200.4 200.2 200.2 200.1 
P 2p 3/2 A 132.8 132.9 132.7 132.8 132.8 132.8 132.7 132.7 
P 2p 1/2 A 133.7 133.9 133.7 133.7 133.8 133.7 133.7 133.7 
P 2p 3/2 B 134.1   135.3 135.1 134.6       
P 2p 1/2 B 135.1   136.2 136.1 135.5       
 
Table 3.10: XPS table of peak binding energies for conjugation of pamidronate, lysine, glutamic acid and 

















O 1s A 41.6
4 
43.18 41.52 42.06 43.34 40.2 38.68 40.12 
O 1s B 4.38 4.08 5.06 5.11 5.86 5.1 5.28 4.88 
N 1s A 0.38 0.78 1.63 1.75 1.73 1.83 2.31 2.26 
N 1s B 0.72 0.29 0.69 0.84 0.38 0.8 1.04 0.89 
N 1s C - - 0.02 0.14 0.46 1.41 0.16 0.46 
Ca 2p 3/2 10.3 10.83 10.43 9.77 10.21 9.22 9.4 9.37 
Ca 2p 1/2 5.15 5.41 5.22 4.88 5.1 4.61 4.7 4.68 
C 1s A 13.3
8 
16.52 14.13 8.87 9.94 13.73 15.05 13.33 
C 1s B 8.94 4.38 4.6 9.17 5.82 6.33 6.22 6.89 
C 1s C 2.76 2.21 3.56 4.15 3.32 4.02 4.3 4.72 
C 1s D 1.37 1.09 1.14 1.35 1.26 1.84 1.75 1.67 
C 1s E 0.68 0.55 1.07 0.85 0.71 0.88 0.68 0.81 
Cl 2p 3/2 0.18 0.05 0.02 0.17 0.14 0.13 0.15 0.04 
Cl 2p 1/2 0.09 0.02 0.01 0.08 0.07 0.06 0.07 0.02 
P 2p 3/2 A 5.46 7.09 7.42 7.09 7.43 6.56 6.82 6.58 
P 2p 1/2 A 2.73 3.54 3.71 3.55 3.71 3.28 3.41 3.29 
P 2p 3/2 B 1.23 - 0.13 0.12 0.35 - - - 
P 2p 1/2 B 0.62 - 0.06 0.06 0.17 - - - 
Table 3.11: XPS table of % relative atomic content for conjugation of pamidronate, lysine, glutamic acid 
and FITC to HA surfaces.  
 
Peak HA1 HA2 HA1PAM HA2PAM HAPAMGlu HA1PAMLys HA1PAMFITC HA2PAMFICT 
O1s 46.02 47.26 46.58 47.17 49.2 45.3 43.96 45 
N1s 1.1 1.07 2.34 2.73 2.57 4.04 3.51 3.61 
Ca 2p 15.45 16.24 15.65 14.65 15.31 13.83 14.1 14.05 
C 1s 27.13 24.75 24.5 24.39 21.05 26.8 28 27.42 
Cl 2p 0.27 0.07 0.03 0.25 0.21 0.19 0.22 0.06 
P 2p 10.04 10.63 11.32 10.82 11.66 9.84 10.23 9.87 
Table 3.12: XPS table of total % relative atomic content for conjugation of pamidronate, lysine, glutamic 
acid and FITC to HA surfaces.  
 
 







Table 3.13: TGA Analysis of HA1, HA1PAM1 and HA1PAMFITC. 
 
FTIR analysis confirmed the presence of pamidronate, glutamic acid, lysine, and FITC on the 
particle surface  (Figures 3.23-3.26). For HA functionalised with pamidronate, an amine band 




pamidronate sample (Figure 3.23). HA1PAMLys formation was identified by bands associated 
to amide formation at 1688 cm-1 and 1530 cm-1 for amide C=O and N-H bands respectively 
(Figure 3.24).HA1PAMGlu formation was identified by bands associated to amide formation at 
1598 cm-1 and 1492 cm-1 for amide C=O and N-H bands respectively (Figure 3.25). FITC was 
identified on the surface of HA1PAMFITC and HA2PAMFITC in  comparison with unconjugated 
FITC standard. Notably, the isothiocyanate band at 2008 cm-1, seen for free FITC dissapeared 
for the HA1PAMFITC and HA2PAMFITC spectrums, and bands corresponding to thiourea 
formation (N-CS-N stretching) at ca. 1389 cm-1 were present (Figure 3.26).138, 139 
 
 
Figure 3.23: FTIR of (Top) pamidronate and (Bottom) magnified region of characteristic pamidronatate 
amine band in HA1PAM1. 
 
 






Figure 3.25: FTIR of (Top) Fmoc-L-glutamic acid 5-tert-butyl ester and (Bottom) HA1PAMGlu, indicating 
amide bond formation. 
 
 
Figure 3.26: FTIR of (Top) fluorescein isothiocyanate (FITC) (Middle) HA1PAMFITC and (Bottom) 







3.8 Conclusion  
In this chapter we have prepared monocrystalline HA samples via a wet chemical precipitation 
route. Low synthesis temperatures correlated to thermal instability of HA preparations. Post-
synthesis treatment induced morphological and crystallinity changes in HA preparations. 
Hydrothermally treated particles were rod-like and highly crystalline, while calcined particles 
were crystalline and possessed a rounded irregular morphology. Calcined particles prepared 
at low temperatures were particularly vulnerable to thermal instability, indicated by the 
presence of biphasic mixtures observed by XRD analysis. In addition, calcined preparations 
appeared most prone to particle aggregation. The general trend of increased particle size with 
increased temperature was observed at temperatures above 40 oC, for both post-synthesis 
treatments. However, only moderate size changes were observed. For further studies within 
this thesis, calcined and hydrothermally treated particles will be prepared at 60 oC, at this 
temperature the treated particles were monocrystalline. Moreover, the intermediate 
temperature of 60 oC was chosen to avoid particle growth at higher temperatures; smaller 
particles will be beneficial to the pretargeting concept, helping to evade uptake by the 
reticuloendothelial system for in vivo biodistribution.  The particles were referred to as HA2 
and HA3 for calcined and hydrothermally treated samples, respectively.   
 
DLS studies revealed that unfunctionalised HA particles: HA1, HA2 and HA3 were highly 
aggregated in solution (ca. 2-4 µm). The particles were stabilised in 0.1% sodium 
hexametaphosphate (SHMP) solutions, and HA1, HA2, and HA3 were measured at 224, 105 
and 145 nm respectively. Furthermore, particles functionalised with SHMP and PEGBP were 
stable in solutions over a period of 24 h and 1 h for HA1 and HA2 respectively. XPS analysis 
indicates that peptide conjugation via pamidronate amine groups on HA surfaces is possible. 
Therefore, bisphosphonates provide a potential, simple one step method for functionalisation 
of HA surfaces with peptide linking moieties. This approach provides a valuable pathway for 
derivitising HA nanoparticles for in vivo targeting purposes. Future investigations will need to 
confirm the ability to radiolabel both stabilised and functionalised HA preparations (Chapter 
6). Results in chapter 2 have already indicated promising 18F-fluoride binding in the presence 
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4.1 Overview and Aims  
Silica encapsulation of nanoparticles is a technique that has been routinely used to stabilise 
and modify nanoparticles. We aimed to exploit silica encapsulation of hydroxyapatite (HA) 
nanoparticles to stabilise them in solution. In addition, hollow porous silica shells were 
prepared as a novel material that may provide interesting radiolabelling properties for 
application in our pretargeting strategy. Herein we discuss the silica encapsulation of HA 
nanoparticles and removal of HA core to form hollow silica shells.  
 
Porous spherical and rod-like hollow silica structures were obtained via a surfactant 
templating method, adopting HA nanoparticles as core materials. Hollow structures were 
formed via self assembly of cetyltrimethylammonium chloride (C16TAC) and silica species on 
the HA surface, followed by a calcining and etching process in dilute HCl to remove the HA 
core. Shape controlled silica structures were formed corresponding to the morphology of their 
HA template. The “as prepared” particles were characterised by transmission electron 
microscopy (TEM), energy dispersive X-ray spectroscopy (EDAX), fourier transform 
spectroscopy (FTIR) and dynamic light scattering (DLS). HA core/shell nanoparticle or hollow 
silica structures may provide a platform for loading radiolabelled ligands or drugs. However, 
low 18F-fluoride labelling efficiency was observed for the silica based materials prepared 
herein. Therefore they showed no promise for application in the pretargeting strategy within 
this thesis.  The content of this chapter has been published in chemical communications.1 
 
Experimental Aims 
 Prepare silica encapsulated HA for stablisation purposes. 
 Prepare hollow porous silica shell nanoparticles for potential use in pretargeting.  
 Assess the 18F-fluoride binding properties of porous silica materials.  
 
4.2 Materials 
All chemicals used in these experiments were obtained from commercial sources as analytical 
reagents and used without further purification unless otherwise indicated.  Deionised water 




nanoparticles (HA1), cetyltrimethyl ammonium chloride 25% (C16TAC) and tetraethyl 
orthosilicate (TEOS) were all purchased from Sigma Aldrich. Sodium citrate dihydrate was 
purchased from Fischer Scientific. 
 
4.3 Characterisation 
The morphology and structure of the products was analysed by transmission electron 
microscopy (TEM) using an FEI Tecnai T12 instrument at 120 kV. Samples were drop cast and 
dried on carbon film copper grids. Elemental analysis was performed by energy dispersive X-
ray spectroscopy using an EDAX spectrometer in conjunction with the same microscope. X-ray 
diffraction patterns (XRD) were recorded on a PANalytical X’Pert Pro Multi Purpose 
diffractometer. Zeta potential and hydrodynamic particle size measurements were made 
using a Delsa Nano C particle analyser. Particles were suspended in water (1 mg/mL) at pH 7. 
All measurements were performed at 25 oC. Samples were also analysed by infrared 
spectroscopy (FTIR) using a Perkin-Elmer Spectrum RXI FTIR spectrometer.  
 
4.4 Methods 
HA1 refers to hydroxyapatite obtained from Sigma Aldrich (<200 nm) catalogue number 
677418. HA2 (calcined hydroxyapatite) and HA3 (hydrothermally treated HA) were prepared 
as described in chapter 3.  
 
4.4.1 Preparation of Porous Hollow silica Particles (HSP): General Method 
Hydroxyapatite (HA) nanoparticles, HA1, HA2 or HA3 (30 mg) were added to ethanol (4 mL) 
and sonicated for 10 min. To the sonicated suspension was added cetyltrimethyl ammonium 
chloride 25% (C16TAC) (0.08 mL) followed by stirring for 10 min and the addition of H2O (0.34 
mL), ammonium hydroxide 28% (0.15 mL), and tetraethyl orthosilicate (TEOS) (0.41 mM, 0.08 
mL). The reaction mixture was stirred at room temperature for 3 h and washed four times 
with ethanol (5 mL) with centrifugation at 15,000 rpm to remove washings. The particles were 
left to dry in air overnight and calcined in the presence of air in a furnace at 550 oC for 6 h. The 
powder thus prepared was suspended in dilute HCl (0.1 M) and stirred for 12 h to remove the 
core HA. The suspension was washed four times with H2O (5 mL) by centrifugation at 15,000 







4.4.2 Preparation of HA4 – Citrate Coated Hydroxyapatite 
HA1 (200 mg) was suspended in sodium citrate dihydrate 0.2 M (50 mL), adjusted to pH 6 with 
HCl (0.1 M), and stirred for 12 h at RT. The suspension was washed four times with H2O by 
centrifugation at 8,000 rpm to remove unbound citrate. The resultant white powder was 
freeze dried to remove water. 
 
4.5 Results and Discussion 
Mesoporous silica has attracted significant interest since the discovery of surfactant 
templating methods.2, 3 Having large surface areas and a high capacity to adsorb a variety of 
biological molecules, mesoporous materials offer an ideal platform for application in various 
fields such as drug delivery,4 catalysis,5 sensing,6 separation7 and electrical insulation.8 
Mesoporous silica particles with hollow interiors have a number of useful attributes including 
low density, high surface area, thermal and mechanical stability, and potentially unique 
optical and chemical properties. 
  
The most successful synthetic approaches to hollow shell particles are based on template 
methods, involving latex,9 gold,10 silica,11 polystyrene12 and carbon13 templates. Other routes 
include emulsion14 or vesicle-based15 systems, in which the emulsion droplets act as 
templates. Other notable systems that have produced high quality materials (comprised well-
defined pores) via the template route include the preparation of mesoporous amorphous 
calcium silicate via mesoporous silica templates.16 A notable report describes the synthesis of 
rod-like hollow titania using HA as a template.17 The preparation of hollow nanoporous silica 
shells via surfactant templating methods has been investigated elsewhere, and the effects of 
varying solvent composition, hydrolysis catalyst and surfactant reported.18, 19 Existing methods 
have employed calcium carbonate,20, 21 polystyrene12 and latex9 particles as core templates to 
produce hollow silica nanostructures. These methods often require strictly controlled 
synthetic conditions and produce large particles with poor monodispersity and uncontrolled 
morphology. The morphology and properties of hard core template methods can be exploited 
to generate hollow structures in a variety of shapes and sizes.21 The Stöber22 method for 
preparing silica nanoparticles has been further modified by employing organic surfactant 
templates to produce nanoporous materials with controlled dispersity and morphology.17, 19 
For a detailed review on HA materials see chapter 3.  
 
Herein we highlight some properties that make HA amenable to core template methods.  HA 




with a high level of monodispersity and reproducibility.23-25 Most importantly, It can be etched 
easily via dissolution with dilute acids.26 It also has high adsorbability and affinity for various 
biological molecules.27-32 Exploiting this property, HA has been used in drug delivery systems 
for proteins,28 antibiotics33 and anti-cancer drugs.27 It is also well known for its use in protein 
purification and extraction via column chromatography.34 We have investigated the use of 
various HA nanoparticles as templating materials for hollow silica nanostructures, defining 
some effects of particle morphology, size and surface properties. We report a simple route to 
mesoporous spherical and rod-like hollow silica particles, using cetyltrimethylammonium 
chloride (C16TAC) as a directing agent for the formation of mesoporous channels. 
 
Several different HA nanoparticle preparations were compared (Figure 4.1 and table 4.1) 
including commercially available HA1 (Figure 4.1A) and samples prepared in our laboratory: 
HA2 (prepared via wet chemical synthesis and calcination, figure 4.1B), HA3 (via wet chemical 
synthesis with hydrothermal treatment, figure 4.1C), and HA4 (citrate treated particles, figure 
4.1D). The preparation of samples HA2 and HA3 are described in detail in chapter 3. Briefly, 
HA2 was prepared via wet chemical precipitation followed by a post-synthesis treatment of 
calcination, producing crystalline particles with an irregular morphology (Figure 4.1B). HA3 
was formed via wet chemical precipitation (as HA2) followed by hydrothermal treatment, 
producing highly cystalline nanoparticles with a rod-like morphology (Figure 4.1C). The citrate 
treated particles of HA4 were prepared by suspending HA1 in a solution of sodium citrate (0.2 
M) at pH 6 overnight, followed by washing and drying steps.35 FTIR spectra showed a new 
band at ca. 1382 cm-1 corresponding to citrate carboxylate groups36 (Figure 4.6) and zeta 
potential measurements show a large increase in negative charge, indicating presence of the 
citrate anion in the sample. 
 
All HA materials were subjected to the same silica encapsulating and core etching processes. 
In a typical synthesis HA nanoparticles were dispersed in ethanol and sonicated. Next, C16TAC 
25%  was  added and the suspension stirred vigorously for 10 minutes before adding water, 
ammonium hydroxide 28%, and finally tetraethyl orthosilicate (TEOS), in a dropwise fashion. 
The suspension was stirred for 3 h and the particles were washed with ethanol and left to dry 
in air. The surfactant was removed by calcination of the silica-HA composites at 550 oC for 6 h. 
TEM analysis of the resultant composite material revealed its porous nature, shown in figure. 
4.2. Energy dispersive X-ray spectroscopy (EDX) for elemental analysis confirmed the presence 
of Ca, P, Si and O (Figure. 4.4). FTIR spectroscopy was consistent with the presence of both 







Figure 4.1: TEM images of HA used in this study. (A) commercially available HA1 (B) calcined (HA2) (C) 







Figure 4.2: TEM of HA-silica composites. (A) HA1-Silica  (B) HA2-Silica (C) HA3-Silica (D) HA4-Silica (E) 










Figure 4.3: TEM images of hollow silica nanoparticles prepared using different templates (corresponding 
to those in Figure 4.1). (A) HSP1 (B) HSP2 (C) HSP3 (D) HSP4. 
 
To prepare the hollow silica shells, the core-shell composites were suspended in dilute HCl 
(0.1 M) overnight, for complete dissolution of the HA core. The suspension was centrifuged, 
washed with water, and freeze dried. The resulting hollow silica particles are referred to as 
HSP1-4, corresponding to their respective template materials HA1-4. Particle sizes and shell 
thicknesses are displayed in table 4.1.  
 
Material Particle size measured 
by TEM (nm) 
Shell thickness measured 
by TEM (nm) 
Particles size 





HA1 65.8±29.7  2829.3±59.4 -4.41±0.3 








 1686.9±55.3 -16.13±0.1 
HA4 59.8± 2.2   -41.8  ±0.7 
HSP1 68.0± 2.8 6.5± 0.3 2076.6 ±154.1 -32.2 ±0.5 







12.2± 0.4 1070.5 ±95.2 -26.5 ±0.5 
HSP4 71.3 ±2.3 18.6±0.9 2311.1 ±141.3 -36.0 ±0.6 




The contrast between the dark outer rings and light inner circles, seen in TEM images (Figure 
4.3), is convincing evidence for the hollow nature of the particles. The spherical and rod-like 
shapes of the light inner core voids corresponded well to the morphology of their HA 
templates (Figure 4.1). The TEM of well-defined porous hollow nanorods HSP3 provided 
compelling evidence that shell morphology is controlled by HA morphology. Elemental 
analysis using EDAX established the disappearance of Ca and P leaving only Si an O detectable 
in all HSP samples (Figure 4.4). The Fourier transform Infra-red (FTIR) spectroscopy study 
confirmed the calcination and etching procedures, indicating removal of inner core templates 
for all samples (Figures 4.5 and 4.6). HA core materials were identified by characteristic bands 
due PO4
3- ions at 1085 cm-1,1010cm-1, 960 cm-1, 600 cm-1, and 560 cm-1 and an OH- stretch at 
3570 cm-1. Additional bands at 1456 cm-1 and 1414 cm-1 may correspond to CO3
2-. 37 HA-silica 
composites were indentified by the presence of characteristic PO4
3- bands (as above) due to 
the HA core, and characteristic Si-O-Si groups were indentified by Si-O bending at ca. 800 cm-1 
and Si-O asymmetric stretching at ca. 1205 cm-1, 1080 cm-1 due to the silica shell.20 The final 
hollow silica particles (HSP1-4) showed the presence of Si-O-Si groups (as above) and 
disappearance of HA bands, due to the core removal.    
 
Dynamic light scattering (DLS) was used to monitor the colloidal behaviour of the hollow silica 
shells in solution (Table 4.1). Suspensions of the particles were prepared by dispersing 1 
mg/mL in deionised water followed by sonication for 10 minutes. Samples were then analysed 
at 25 oC and pH 7.4 at a measurement angle of 90o. The particle sizes measured for all HSP 
particles were in the range of 1000-2000 nm, suggesting that the nanoparticles formed large 
aggregates in solution. These results were in agreement with the TEM analysis that showed 




















Figure 4.4: EDX spectrometry for HA-silica composites1-4 (left) and HSP1-4 (right). HA-silica samples 
correspond to the presence of Ca, P, Si and O. HSP samples are identified by the removal of the HA core, 








































Figure 4.6: FTIR of HA3, HA4, and their corresponding HA-silica composites and HSP particles (hollow 











Deposition and self 
assembly of 
silica/surfactant layer




Figure 4.7: Schematic representing the formation of nanoporous silica. Potential mechanism based on 




Previous studies have suggested that formation of nanoporous silica occurs initially via the 
development of small irregular clusters of silica/surfactant aggregates which then aggregate 
further or collapse and form larger spherical particles. The surfactant micelles eventually align 
themselves perpendicular to the particle/solution interface, resulting in radially orientated 
pores.38 In the dual templating method, Tan and Ranking have suggested that the small 
silica/surfactant clusters adsorb on the template surface and subsequently adopt hexagonal 
close packed ordering, with the micelles aligning parallel to the shell surface as the particles 
age.9 However, Wang et al. describe the positively charged C16TAC surfactant adsorbing on a 
negatively charged particle surface followed by deposition of silicate species and self assembly 
of a 2D hexagonal silica layer on the particle surface (Figure 4.7).20 To investigate the 
formation of nanoporous silica we used citrate coated HA4 as a template. It was thought that 
the inherent unstable colloidal nature of HA caused aggregation of the core template and the 
subsequent deposition of silica/surfactant was on the core aggregates. The adsorption of 
citrate ions on the HA surfaces has been reported,35 we thought that introducing citrate to the 
HA surface could induce stabilisation via its negative charge. However, in our experiments the 
negatively charged citrate coated particles did not increase colloidal stability and no 
improvement in silica shell aggregation properties were observed for HSP4. Similar problems 
have been observed by Tan and Ranking9 using latex as a core template, suggesting that 




contribution from sonication prior to silica deposition and the positively charged surfactant 
C16TAC are not sufficient to form well defined monodisperse silica shells. In addition, the 
heating process used to remove surfactant may also encourage particles to coalesce.  
 
Porous materials are known to have high surface areas,39 therefore, we thought that the HSP 
structures may provide improved 18F labelling efficiency over the silica gel material tested in 
chapter 2, where ca. 4% 18F-fluoride labelling efficiency was observed. We investigated the 18F 
labelling efficiency of the HSP and HA-Silica composite materials (performed as described in 
chapter 2 18F-fluoride binding survey) (Figure 4.8). The porous silica materials did not increase 
18F-fluoride labelling efficiency % for any of the above silica materials. For the HA-silica 
composites, the 18F-fluoride radiolabel cannot reach the HA core material, despite the silica 
being porous. These results conclude that silica materials are poor 18F-fluoride binding agents 
in water. Although pH was not controlled in these initial binding surveys (to avoid interference 
from competing ions in solution), the poor 18F-fluoride labelling efficiency is presumably a 
consequence of the low isoelectric point of silica (ca. pH 2),40 implying that even at low pH the 
surface charge will remain negative and electrostatically repel the negatively charged fluoride 
ions (Chapter 6 discusses isoelectric points in more detail).  
 
 
Figure 4.8: Graph showing silica 
18
F labelling efficiencies. 
 
In summary, a novel method for the synthesis of porous hollow silica structures, using HA 
nanoparticles as core templates has been developed. Most interestingly, the morphology of 
the hollow silica structures can be controlled and tailored according to the nature of HA 
template. Due to the large surface areas, porous nature, and the control that can be excised 
over their size and shape, these hollow silica shells may have applications in fields such as 




protein and then coated with silica. However, these materials are poor 18F-fluoride binding 
agents and cannot be applied to the pretargeting strategy. Therefore, further development 
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This chapter provides a review of bisphosphonates (BPs) and the development of bifunctional 
BP chelators. The synthesis of a novel bifunctional BP chelator, N,N-
bis(quinoylmethyl)pamidronate-amine-(BQMPA) is described and we have investigated its 
potential as a probe for SPECT and fluorescent imaging. We have presented the synthesis of a 
DOTA like bisphosphonate BPAMD (a literature compound),1 and discussed the preparation of 
its novel 64Cu radiolabelled complex. We aimed to increase the affinity of radiolabelled BPs for 
hydroxyapatite (HA) and other nanoparticles surfaces by using bifunctional BPs. These ligands 
contain separate chelating and bone or HA targeting groups. Traditional radiolabelled BPs 
contain bisphosphonate groups that function as a both the chelator and bone targeting 
moiety, thus each function may impair the other. We aimed to exploit the bifunctional nature 
of these ligands to simultaneously functionalise and radiolabel nanoparticle surfaces. These 
bifunctional ligands have the potential to act as pretargeting or prelabelling nanoparticle 
probes. The high affinity of bisphosphonates for metal oxide and hydroxyapatite surfaces 
provides a simple platform for radiolabelling nanoparticles. Moreover, the versatile nature of 
chelating groups means that they can be applied to a variety of imaging modalities. The 
preparation of 99mTc and Re- BQMPA complexes resulted in the formation of multiple 
products, indicated by NMR, HPLC and TLC. The 64Cu-BPAMD complex was identified as a 
single complex by HPLC and was kinetically stable in serum over 24 h, therefore it may be a 
useful PET imaging or therapeutic agent in its own right.     
 
5.2 Introduction 
In chapter 2, we indentified HA and Alhydrogel (Al(OH)3) as lead materials for development of 
our pretargeting concept, using 18F-fluoride as a simple tracer. In chapter 3 we developed HA 
materials and realised that BPs can act as surface modifiers, potentially linking small 
molecules or peptides for targeting purposes. It is well known that BPs have affinity for HA 
and metal oxides surfaces (discussed below). In this chapter, we discuss the development of 
radiolabelled bifunctional bisphosphonates, producing single well defined complexes. We 
envisaged that radiolabelled BPs can act as chasing tracers in the pretargeting concept, 
exploiting their high affinity for HA and metal oxide surfaces to rapidly and efficiently bind to 




PET), using bifunctional-BP chelators that can form complexes for MRI, fluorescent or SPECT 
imaging, and radionuclide therapy. This approach comes at the expense of an additional 
labelling step to form the BP precursor (compared to simple 18F-fluoride); however, we aimed 
to keep the chemistry of this step rapid and simple. In addition, we aimed to use the 
radiolabelled BP complexes to help understand the BP-nanoparticle interaction and its 
suitability as a tracer or targeting ligand (e.g. for introducing functional groups to 
nanoparticles surfaces). BP-nanoparticle labelling studies are discussed in chapter 6.  
  
Herein we provide review on the development of bisphosphonates as clinical agents for 
treating and imaging bone diseases. This provides an insight to the chemistry and rational of 
BP design. An understanding of the chemistry and concepts behind BPs guides the 
development of new BPs that can be applied to our nanoparticle targeting concept.  
  
5.3 Bisphosphonates 
Bisphosphonates (BPs) have found therapeutic and diagnostic application in the treatment of 
skeletal diseases, such as osteoporosis,2 Paget’s disease,3  and metastatic bone disease.4 
Furthermore, BPs target the high bone mineral turnover occurring in these diseases. 
Bisphosphonates have been used in a clinical setting for over 40 years. Their potential was 
first realised in the 1960s upon the discovery that endogenous pyrophosphate (PPi) is involved 
in the formation and dissolution of hydroxyapatite crystals in vitro.5, 6 This in turn led to the 
development of stable, non-hydrolysable BP analogues.7, 8 It was shown that these orally 
active BP analogues could aid the prevention of bone resorption, and may be useful for 
treating diseases exhibiting high bone mineral turnover.9-12 The BPs used in these early studies 
were dichloromethylene diphosphonate (clodronate),11, 12 methylene diphosphonate 















Figure 5.1: Bisphosphonates used in a clinical setting and under clinical development; simple, non- 
nitrogen-containing bisphosphonates (left), nitrogen containing bisphosphonates (right), typically 
exhibit higher anti-resorptive effects.   
 
Structure-activity relationship studies have defined the essential components for biological 
activity.13-17 The P-C-P moiety is responsible for the strong affinity to HA, often described as 
the “bone hook” (Figure 5.2). In addition, it has been suggested that the bite distance 
between the two phosphate -O------O- (ca. 3.08 Ao) is ideal for chelation of Ca2+ in HA.18  
Altering the “back-bone” to give compounds containing C-N-C or P-C-C-P structures showed 
reduced affinity for bone.19 The replacement of the oxygen contained in pyrophosphate with 
carbon allows for the introduction of various R1 and R2 groups. Varying the R1 and R2 
substituents attached to the C atom can greatly alter both the BP’s affinity for bone and their 
biological activity. Now that the mechanisms of BP action are better understood, rational BP 
design for treating bone diseases can be considered in two phases: the affinity for bone, and 
the inhibitory effect on cellular mechanisms involved in bone resorption. The R1 substituent 




hook” interaction takes place, presumably binding in a tridentate fashion to calcium ions 
rather than a bidentate contribution from the two –O- phosphate moieties.20  
Bisphosphonate group 
can act as a “hook” 
binding in a bidentate
fashion to Ca2+ on 
hydroxyapatite 
surfaces. 
R1 is often an OH group. 
Enhances bone binding activity 
through a tridentate binding 
interaction.  
R2 determines the 
anti-resorption
activity of BP’s, 




Figure 5.2: General structure of bisphosphonates and functional properties. 
 
Recent studies have suggested that altering the R2 side chain has an effect on mineral affinity. 
HA affinity was ranked in the order zoledronate > alendronate > ibandronate > risedronate > 
etidronate > clodronate.21 The effect was attributed to differences in protonation and charge 
of R2 groups.21 For example, BPs with nitrogen moieties that have high pKa values remain 
protonated at physiological pH (e.g. alendronate and zolendronate), increasing positive charge 
on the HA surface. However, BPs such as clodronate have low pKa’s and introduce negative 
charge to the HA surface. The net result is charge induced repulsion for further BP adsorption, 
therefore reducing affinity. Alteration of the R2 substituent appears to have a greater effect 
on the resorption activity (i.e. their ability to prevent the breakdown of bone) of BPs.16 The 
development of BPs can be divided into three generations: the non-nitrogen-containing BPs, 
nitrogen-containing BPs, and heterocyclic nitrogen-containing BPs. The first generation BPs 
include the non-nitrogen containing BPs: clodronate, etidronate, and medronate. The second 
was developed by introducing a basic aminoalkyl group in the R2 position, greatly enhancing 
anti-resorption properties (discussed below).  The first clinically used aminoalkyl BP was 
pamidronate, increasing the anti-resorptive potency 10 and 100 fold in comparison to 
etidronate and clodronate respectively.22 As more BPs were developed, it became evident 
that the distance of the nitrogen atom from the P-C-P group and specific spatial configuration 




to form alendronate further increased potency ca. 8 fold over pamidronate. Increasing the 
chain length beyond alendronate reduced potency.16 The synthesis of several other nitrogen 
containing BPs led to increased potency; including residronate,24 ibandronate,16 
incadronate,24, 25 minodronate,17 and zolendronate16. Bisalkylation of the amine moiety of 
pamidronate to form ibandronate increased potency 50 fold.16 The third generation BPs are 
most potent, introduction of nitrogen containing heterocyclic rings, such as zolendronate 
results in an increase in antiresorptive potency up to 850 fold in comparison to pamidronate.16  
 
The anti-resorptive potency of BP derivatives is related to their mechanism of action.13, 16, 17, 24 
Broadly, the mode of action of BPs can be divided into two groups; non-nitrogen-containing 
BPs or nitrogen- containing BPs.  Non-nitrogen-containing BPs inhibit bone resorption via 
metabolic incorporation into non-hydrolysable analogues of adenosine triphosphate (ATP). 
Intracellular accumulation of these non-hydrolysable analogues in osteoclasts can inhibit their 
function and promote cell death. Ultimately, they could be described as “pro-drugs” being 
converted into active metabolites in vivo.26, 27 The potent nitrogen-containing BPs avoid 
metabolism and target enzymatic pathways involved in the production of osteoclasts.13 , 24, 28 
They specifically inhibit the enzyme farnesyl pyrophosphatesynthase (FPPS)- a key enzyme in 
the mevalonate pathway. FPPS generates isoprenoid lipids required for the post-translational 
modification (prenylation) of small GTP binding proteins essential for osteoclast function. 
Crystallographic studies of FPPS and nitrogen containing BPs reveal that the nitrogen moieties 
interact with amino acid residues via hydrogen bonds within the FPP active site.13, 28 The 
essential phosphonate groups can interact with Asp residues via coordination with divalent 
metal ions, such as magnesium. In addition, bisphosphonates such as ibandronate and 
minodronate contain hydrophobic moieties, which may be stabilised in hydrophobic pockets.  
 
In conclusion, the elucidation of structure-activity relationships and a better understanding of 
molecular mechanisms have paved the way for development of new potent bisphosphonates. 
The development of BPs and replacing existing potent treatments for bone disease may not 
be cost effective. However, BPs remain well researched. Novel BPs are sought after for 
therapeutic applications such as anti-cancer, anti-bacterial and anti-osteoporosis drugs, or 
diagnostic applications such as imaging bone diseases (e.g. BPs bound to radionuclides).  
 
5.4 Bisphosphonates; Versatile Radiolabelled Probes for Nanoparticle Functionalisation 
The high affinity BP interaction is not limited to hydroxyapatite. BPs were first discovered over 




ligands can form complexes with a variety of metals: Ba(II),31-33 Sr(II),31, 33 Mg(II),31,33 Pb(II),32 
Al(III)34, Fe(III),34 Cd(II),35, 36 Zn(II),35, 36 Cu(II),35, 37, 38 Co(II),39 Ni(II),39 UO2(II),
40 and Lanthanide(III) 
Ce, La, Pr, Nd41 and Gd42. In addition, it is well known that phosphonic acids and BPs bind 
strongly to metal oxide surfaces, such as TiO2,
43-47 Al2O3,
43, 45, 48 ZrO2,
43, 46, 49 Fe2O3/Fe3O4,
50-54 
SiO2,
44, 45 AlOOH,55 BaTiO3,
56 stainless steel44 ,and rare earth metal oxides in the form M2O3, 
where M = Eu, Er, Yb, and Gd.53  The sheer number of examples of metal-BP complexes and 
metal oxide-BP interactions highlights the versatile nature of the P-C-P moiety. We aim to 
exploit the traditional hydroxyapatite BP high affinity interactions and explore the potential of 
a range of metal oxide nanoparticle materials for the rapid delivery of bifunctional imaging 
agents in a pretargeting setting. Above we have discussed the properties of BPs that make 
them biologically active antiresorptive agents, which has highlighted characteristic properties 
that are essential for HA binding (e.g. the P-C-P moiety). Herein we review some existing 
radiolabelled BPs and the development of new bifunctional BPs. This review is performed to 
guide our radiolabel BP designs. 
 
5.5 Radiolabelled Bisphosphonates 
99mTc based radiopharmaceuticals are the most widely used in nuclear medicine.57, 58 BPs such 
as MDP(methylene diphosphonate or medronate), HMDP(hydroxymethylene diphosphonate) 
and HEDP(hydroxyethylidene diphosphonate or etidronate) have routinely been used for 
skeletal imaging in the diagnosis of diseases such as primary bone cancers, metastatic bone 
disease, pagets disease and osteoporosis, via coordination of 99mTc,59-65 since the mid 70’s.60 
Due to the analogous nature (e.g. size, oxidation state, geometry) of Tc and Re,  it was thought 
that BPs would be ideal for labelling with the  β- emitting radionuclides 186/188Re for pain relief 
in the treatment of bone metastases.66, 67 However, a significant difference is the ease of 
oxidation of rhenium complexes, thus, oxidation to [ReO4]
- is common in vivo.68, 69 Moreover, 
the in vivo/vitro behaviour of 186/188Re BPs and their 99mTc counterparts is not analogous. For 
example, 186/188Re BPs often require carrier added non radioactive Re to improve bone 
metastases targeting, labelling and kinetic stability.66, 70  
 
Despite their widespread clinical use, very little is known about the structure and formulation 
of radiolabelled BPs. For example, the simplest 99mTc-BP complex, 99mTc-MDP is still poorly 
defined. The general consensus is that 99mTc-MDP consists of a mixture of anionic polymeric 
complexes. Handeland et al. performed high performance column chromatography revealing 
that preparations consist of a series of different anionic complexes.71 The variation of 




differences in bone/muscle uptake ratio. The variations were attributed the use of different 
stabilising agents, e.g. ascorbic acid or gentisic acid.71 Libson et al. have isolated a polymeric 
complex from the reaction of [99TcBr6]
2- with MDP, where MDP can bridge two Tc centres, 
presumably acting as a doubly bidentate ligand, each Tc atom is bound two MDP ligands. A 
hexameric structure has been reported (Figure 5.3).72, 73  An EXAFS study of the Tc-MDP 
complex also identified its polymeric nature.74 In addition, the poor stability of 186/188Re-BP 
complexes makes isolation difficult. In particular, 186Re-HEDP complexes have been reported 
to have polymeric nature.73 
 
Figure 5.3: Right- MDP (methylene diphosphonate). Left- potential polymeric 
99m
Tc-MDP structure. 




In general, the traditional Tc and Re BP complexes are poorly defined. Moreover, studies 
indicate they consist of a mixture of polymeric complexes. Labelling protocols and choice of 
BP can affect the behaviour and biodistribution of BPs in vivo. For example, Davis et al. 
reviewed various BP-99mTc complexes, such as HEDP and MDP, noting that differences in 
biological distribution exist.75 This highlights the complex nature of chemistry and biological 
mechanisms involved with radiolabelled BPs.   
 
Little is known about the mechanism of uptake of radiolabelled BPs.76, 77 It is generally 
assumed that BPs accumulate at sites of active bone metabolism. An additional problem 
encountered by some 99mTc-BPs, such as MDP, is their relatively slow blood clearance.60, 75, 78 
Often, an interval of 2-6 h is needed between injection and bone imaging, thus slowing down 
bone scanning procedures in clinical centres. 
 
The limited knowledge of structure and formulation hinders the development and design of 
new diagnostic and therapeutic bone seeking agents. The uncertainty of chemical properties, 
such as the inconsistent polymeric nature of complexes, raises questions in the reliability and 
reproducibility of results. With these issues in mind, there is scope for developing new Tc and 




bisphosphonate group has dual function; as a chelator, and a bone targeting group. The two 
functions interfere with each other, for example bisphosphonates are not ideal chelators for 
Tc, while Tc chelation may impair bone interactions. A logical approach to improve BP design 
is to develop bifunctional chelators. For example, the targeting molecule will contain two 
separate moieties, one for bone targeting (e.g. the BP group) and one for radiolabel chelation. 
In theory, well defined monomeric complexes, where the BP function is not hindered by metal 
chelation, can be produced. Some recent examples adopting this approach are reviewed 
herein. 
  
5.6 Bifunctional Bisphosphonates for Imaging 
5.6.1 Diethylenetriaminepentaacetic Acid-BP (DTPA-BP)  
El-Mabhouh et al. described the synthesis of a bifunctional 99mTc and 188Re labelled 
diethylenetriaminepentaacetic acid-BP (DTPA-BP) for selective bone delivery for diagnosis and 
therapy of bone metastases.79, 80 The synthesis is described in (Figure 5.4). Briefly, an ethyl 
protected amino BP was coupled to DTPA via amide bond formation. The product was purified 
by flash chromatography and removal of the BP ethyl protection groups was achieved in the 
presence of bromotrimethylsilane, in a relatively high yield coupling reaction (67%).  High 
radiochemical yields of 92% and 92-100% were reported for 99mTc and 188Re and complexes 
respectively. The 99mTc and 188Re complexes were studied in vivo with mice and compared to 
their MDP and HEDP counterparts respectively. The blood clearance and bone uptake values 
were relatively similar for all complexes. No significant degradation to perrhenate (ReO4)
- or 
pertechnetate (TcO4)
- was observed up to 8 h. However, 99mTc-DTPA-BP complexes did show 
increased liver and kidney accumulation, which could be attributed to colloidal impurities, 
such as tin colloid, a by-product of the reducing agent SnCl2. The liver uptake of 
188Re-DTPA-
BP, was unremarkable. In summary, these complexes show promising bone seeking 
properties; however, no real benefit can be observed over their MDP and HEDP counterparts. 
In addition, there is no clear identification that the DTPA moiety is indeed being labelled 






Figure 5.4: Synthesis of DTPA BP (2-[2-[2-(bis(carboxymethyl)amino)ethyl-(carboxymethyl)amino]ethyl-
[2-(diphosphonomethylamino)-2-oxo-ethyl]amino]acetic acid). (i) DMF/ 50-60 
o
C 9, RT 2 h.  (ii) TMBS/ RT 
5 h.  
 
5.6.2 MAG3, HYNIC and MAMA-Bisphosphonates 
Ogawa et al. have published a series of papers reporting a number of bifunctional chelators 
for skeletal imaging and therapy.81-86 An early paper reports a 186Re-
mercaptoacetylglycylglycylglycine(MAG3)-bisphosphonate and 186Re-MAG3-HBP (Figure 5.5). 
186Re-MAG3-HBP was prepared and compared to 186Re-HEDP. The BP moiety was conjugated 
to a TFP (tetrafluorophenol) activated MAG3 ligand, using TEA (triethylamine) as a base, in a 
yield of 34.5%. The reaction scheme is shown in Figure 5.5. 186Re-MAG3-HBP was prepared in 
a radiochemical yield of 76%. The exclusivity of 186Re binding to the MAG3 chelator, rather 
than BP moiety was confirmed via HPLC using non radioactive Re analogues. In vitro stability 
in buffer solution showed that 186Re-MAG3-HBP complex remained stable over 24 h (95% 
intact). In comparison, the 186Re-HEDP complex was only 30% intact after 24 h. The in vivo bio-
distribution data showed faster blood clearance, 49.7 mL/h and 15.6 mL/h for 186Re-MAG3-
HBP and 186Re-HEDP respectively. The bone uptake was significantly higher, the % injected 
dose per gram (% ID/g) found in the femur after 24 h was 711% and 342% for 186Re-MAG3-
HBP and 186Re-HEDP respectively. The slower blood clearance of 186Re-HEDP was attributed to 
its in vivo instability,i.e. its conversion to perrhenate (ReO4)
-. The higher bone accumulation of 
186Re-MAG3-HBP was attributed to the higher affinity of the unlabelled, free BP moiety. The 
bifunctional nature of 186Re-MAG3-HBP complex appears to enhance its in vivo properties, and 







Figure 5.5: Synthesis of MAG3-HBP (i) NHS, DCC (ii) glycylglycylglycine (iii) TFP, DCC (iv) Et3N (v) TFA, 
Triethylsilane. 
 
In addition, a 99mTc-MAG3-HBP complex has been evaluated, where significant increase in 
bone uptake was observed in comparison to 99mTc-HMDP. However, its use as a bone imaging 
agent may be limited by its slow blood clearance, attributed to high serum protein binding of 
the complex.86 In the same study Ogawa et al. report the synthesis of a novel 99mTc-HYNIC-HBP 
(Figure 5.6). The HYNIC-BP conjugate was prepared in a similar approach to the MAG3-BP 
conjugate; an activated  2,3,5,6-Tetrafluorophenyl 6-(tert-butoxycarbonyl)-hydrazinopyridine-
3-carboxylate(Boc-HYNIC-TFP) molecule was reacted with Alendronate in the presence of 
triethylamine (TEA), followed by HPLC purification and BOC deprotection. The HYNIC ligand 
used is a pyridine derivative, reported to have higher stability and less serum protein binding. 
The blood clearance of 99mTc-HYNIC-HBP was significantly faster than 99mTc-MAG3-HBP, 
attributed to lower serum protein binding. However, blood clearance was similar to 99mTc-
HMDP, but the bone uptake was increased. Therefore, a higher bone-blood ratio is observed 









Another study by Ogawa et al. describes the synthesis of 186Re-monoaminemonoamidedithiol 
(MAMA) chelates, (186Re-MAMA-BP) and (186Re-MAMA-HBP) (Figure 5.7), where BP and HBP 
are 4-amino-butylidenebisphosphonate and 4-amino-1-hydroxybutylidene-1,1-
bisphosphonate (Alendronate) respectively. The aim was to investigate the effect of a 
hydroxyl group on the P-C-P carbon and the stability of the 186Re-MAMA complexes in 
comparison to 186Re-HEDP.82,84 The MAMA-BP conjugate was synthesised from a 
bisphosphoric tetraethyl ester coupled with MAMA in the presence of DCC. The synthesis of 
MAMA-HBP followed the activated TFP routes described above, to meet the water solubility 
requirements of HBP. The radiochemical yields of (186Re-MAMA-BP) and (186Re-MAMA-HBP) 
were 32% and 54% respectively. Both 186Re-MAMA-BP and 186Re-MAMA-HBP complexes were 
stable in buffered solutions over 24 h, 82% and 74% intact respectively. In contrast, 186Re-
HEDP was less than 30% intact.  
 
The in vivo biodistribution studies in mice showed increased bone accumulation and faster 
blood clearance for 186Re-MAMA-HBP, in comparison to 186Re-MAMA-BP. Overall the MAMA-
BP complexes showed much higher bone/blood ratios than 186Re-HEDP, with ca. 1204, 713, 
327 (bone/blood ratios of % ID/g) after 24 h for 186Re-MAMA-HBP, 186Re-MAMA-BP and 186Re-
HEDP respectively. However, a side effect of using the MAMA ligand is an increase in 
lipophilicity, in turn, leading to a greater liver uptake of the MAMA-BP complexes, 4.7% and 
0.4% ID/g after 1 h for 186Re-MAMA-HBP and 186Re-HEDP respectively. In addition, an extra 
HPLC purification step is required after formation of the 186Re-MAMA-BP complexes, 
extending the preparation time. This step has been required in all of the Ogawa preparations 
described above. In conclusion, the bifunctional nature of the MAMA-BP complexes improves 
bone uptake and blood clearance. However, the increased liver exposure must also be 






Figure 5.7: Structure of Re-MAMA-BP (left) and Re-MAMA HBP (right). 
 
5.6.3 Pyrazolyl-Diamine Bisphosphonates 
Palma et al. prepared bifunctional BPs containing pyrazolyl-diamine type chelators (Figure 
5.8).87,88 The tridentate N,N,N atom set of the pyrazolyl-diamine (pz) moiety forms stable 
complexes with the organo-metallic precursor fac-[99mTc(CO)3(H2O)3]
+(discussed in more detail 
below). Two pyrazolyl-diamine containing BPs, pz-PAM (pamidronate) and pz-
ALN(alendronate) were prepared and their radioactive counterparts [99mTc(CO)3(pz-PAM)]
- and 
[99mTc(CO)3(pz-ALN)]
- were assessed in vitro/vivo.  
 
The pz-PAM ligand was prepared via a coupling reaction, using N-hydroxysuccinimide/DCC to 
activate the carboxylic acid of the pz(Boc)–COOH precursor, followed by the coupling of 
pamidronate in CH3CN/borate buffer (pH 9.5) using triethylamine as a base. The pz-ALN ligand 
was prepared via a HOBt/HBTU coupling reaction and using 4-methylmorpholine as a base, in 
a DMF/H2O mixture. After deprotection and purification, the pz-PAM and pz-ALN products 
were achieved in yields of 30% and 12% respectively.  The [99mTc(CO)3(pz-PAM)]
- and 
[99mTc(CO)3(pz-ALN)]
- complexes were prepared using fac-[99mTc(CO)3(H2O)3]
+ as a precursor, at 
100 oC in saline for 30 minutes, a radiochemical purity > 95% was achieved for both 
complexes. The specific reaction of the tricarbonyl core with the pyrazolyl-diamine moiety was 
identified by comparison with non-radioactive Re tricarbonyl complexes via HPLC.  The 
[99mTc(CO)3(pz-PAM)]
- and [99mTc(CO)3(pz-ALN)]
- biodistributions studies in mice were 
compared to 99mTc-MDP. The bone uptake of all complexes was similar, 18.3%, 17.3%, and 
17.1% ID/g per at 1 h post injection for [99mTc(CO)3(pz-PAM)]
-, [99mTc(CO)3(pz-ALN)]
- and 99mTc-
MDP respectively. However, the blood clearance of [99mTc(CO)3(pz-PAM)]
- and [99mTc(CO)3(pz-
ALN)]- was significantly faster than 99mTc-MDP. Thus, increasing bone/blood ratios. The 
[99mTc(CO)3(pz-PAM)]
- and [99mTc(CO)3(pz-ALN)]
- complexes were described as highly stable in 






-  in comparison to 99mTc-MDP. The 
reduced liver uptake is surprising, given the expected increase in lipophilic nature of these 
ligands compared to MDP. However, the lipophilic nature is not the only contributor to 
increase liver uptake, for example, the polymeric nature of 99mTc-MDP may increase liver 
uptake.  The results suggest that the organo-metallic precursor fac-[99mTc(CO)3(H2O)3]
+ can be 
exploited to selectively label bifunctional BP complexes. Palma et al. have reported an 
additional example of ligands containing pz phosphonic acid and BP groups with similar fac-
[99mTc(CO)3(H2O)3]
+ labelling properties.87 
 
Figure 5.8: Structures of [M(CO)3(pz-ALN)]
-
 (left) and [M(CO)3(pz-PAM)]
-
 (right), where M= 
99m
Tc or Re. 
 
5.6.4 Dipicolylamine-Alendronate (DPA-Ale) and Dithiocarbamate-BP (DTCBP) 
Dipicolylamine-alendronate (DPA-Ale) is a new bifunctional chelator that has been developed 
within our group.89-91 The BP conjugate consists of an alendronate BP moiety (for bone 
affinity) and a separate dipicolylamine (DPA) moiety for chelation of metals. The 
dipicolylamine moiety consist of a tridentate N,N,N donor atom set and forms stable 
complexes with fac-[M(CO)3]
+ (M= Tc and Re). Distinct 99mTc(CO)3-DPA-Ale and 
188Re(CO)3-DPA-
Ale complexes were prepared, ensuring exclusive radiolabelling of the DPA moiety(Figure 5.9). 
The complexes displayed promising in vivo biodistribution for imaging bone disease and 











Rosales et al. have also prepared a bifunctional 64Cu–bis(dithiocarbamate bisphosphonate) 
(Figure 5.10).53 The dithiocarbamate (dtc) group is used to coordinate copper, bridging across 
two dtc ligands to form a bis-BP complex. The dithiocarbamate-BP  (DTCBP) (Figure 5.10) was 
prepared by the reaction of an N-methylamino-BP with CS2. The DTCBP ligand was mixed with 
a solution of 64Cu(OAc)2 to form the 
64Cu–bis(dithiocarbamatebisphosphonate) in a 
radiochemical yield of 100%, using DTCBP concentrations > 0.15 mM. The exclusivity of copper 
binding to dithiocarbamate moieties was confirmed by UV and IR spectroscopic studies.  
 
Figure 5.10: Preparation of  
64
Cu–Bis(dithiocarbamatebisphosphonate). Dithiocarbamate-BP (DTCBP) 
(left) and  
64
Cu– (DTCBP)2 (Right). (i) 
64
Cu(OAc)2, 50 mM carbonate buffer (pH 9). 
 
The high affinity of BPs for metal oxide surfaces has been exploited for 64Cu–Bis(DTCBP) and   
99mTc(CO)3-DPA-Ale complexes.
53,54 Both complexes have been used to functionalise and label 
iron oxide nanoparticles (Fe3O4, Endorem
TM) with PET (64Cu) and SPECT (99mTc) as promising 
dual modality MRI-PET or MRI-SPECT imaging agents. Radiolabelled nanoparticles were 
prepared by heating iron oxide nanoparticles with radiolabelled ligands at 100 oC for 15 
minutes, with radiochemical yields of 95% and 55% for 64Cu-Bis(DTCBP)-Endorem and 
99mTc(CO)3-DPA-Ale-Endorem respectively. The 
99mTc(CO)3-DPA-Ale-Endorem interaction was 
stable in vitro for at least two days in serum. SPECT/CT imaging confirmed the in vivo stability 
of the 99mTc(CO)3-DPA-Ale-Endorem interaction; high spleen and liver uptake was observed 
with negligible bone uptake after 1 h. The 64Cu-Bis(DTCBP)-Endorem interaction was stable in 




application. Furthermore, 64Cu–Bis(DTCBP) has displayed high affinity for other materials, such 
as rare-earth metal oxides in the form M2O3 ( where M= Gd, Er, Eu, Yb) or Al2O3. 
 
In conclusion, 64Cu–Bis(DTCBP)-Endorem and 99mTc(CO)3-DPA-Ale-Endorem complexes 
highlight the high affinity BP- metal oxide interaction with iron oxide nanoparticles. They form 
highly stable BP-nanoparticle conjugates for potential in vivo application. 
 
5.6.5 Bifunctional Macrocyclic-Bisphosphonates 
Bifunctional BPs containing macrocyclic compounds offer an attractive platform for 
developing imaging or therapeutic agents. A wide variety of macrocyclic compounds form 
stable complexes with a range of transition metals and lanthanides; thus, presenting vast 
potential as MRI agents, radiopharmaceuticals and luminescent probes for biomedical 
imaging.92-94 The concept of using macrocyclic compounds in bifunctional molecules is well 
known. The NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid), DO3A (1,4,7,10-
tetraazacyclododecane-1,4,7-triacetic acid), DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid) and TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic 
acid)chelators form the basis of many of the bifunctional chelator designs.95-98 For example, 
many antibody DOTA conjugates have been explored for radio-immunotherapy and tumour 
targeting, including 111In and 90 Y labelled conjugates.99-101 In addition, macrocycles have been 
conjugated to peptides for tumour targeting such 68Ga-DOTA-TOC and 68Ga-DOTA-TATE.102  
 
Recently, it was thought that the synthesis of macrocyclic-BP bifunctional ligands would be a 
useful design for imaging probes. Most interest has been driven by the synthesis of DOTA-BP 
ligands(Figure 5.11b-g), where DOTA has been used to chelate Gd (for MRI),103-105 90Y and 111In 
(for pain relief),81,106 and 68Ga (for PET imaging).107,108 Lanthanides, Eu and 160Tb have been 
used to elucidate structural and functional information in DOTA-BP complexes.103, 104, 109, 110 
Recently, a NOTA-BP ligand, for chelating 68Ga has been described.111 Phosphorous containing 
macrocycles, such as DOTP (Figure 5.11H), where phosphorus acid arms replace the acetic 
arms in DOTA structures, have been reviewed.110, 112-116 Complexes of DOTP, such as 111In,  
153Sm and Gd have shown high accumulation in bone and calcified tissues.117 However, upon 
binding to bone, the Gd complex becomes MRI silent due to expulsion of water molecules on 
adsorption.117 Moreover, a kinetic study comparing, lanthanide complexes of DOTP and a 
DOTA-BPs (Figure 5.11B-E) revealed that DOTA-BPs exhibited much higher affinity for 
hydroxyapatite surfaces.110 Presumably, due to the well known higher affinity of BPs 




macrocycle interaction; therefore it should be exclusively available for hydroxyapatite binding, 
unlike the DOTP phosphonate arms that are involved in metal chelating interactions. It is 
reasonable to suggest that bifunctional macrocycle-BPs, where the BP is separate from the 


























Herein, a specific example, the DOTA-like ligand, ((4-[[(bis(phosphonomethyl))carbamoyl] 
methyl]-7,10-bis(carboxymethyl)-1,4,7,10- tetraazacyclododec-1-yl)acetic acid, (BPAMD) is 
discussed (Figure 5.11b). Kubicek et al. have produced a series of papers discussing the 
synthesis and application of the BPAMD ligand.103, 105, 107, 109, 118 The BPAMD ligand was first 
designed for application as an MRI contrast agent, forming  a Gd complex. The synthesis of the 
ligand will be discussed in detail later in this chapter. Briefly, an aminomethyl-
bis(phosphonate) containing a chloroacetylamide moiety was reacted with a tris(tertbutyl 
ester) of DO3A, followed by deprotection to yield BPAMD. Lanthanide(III) complexes were 
prepared, the distances between metal centre Ln(III) cations and phosphonate P atoms was 
measured, indicating that phosphonate groups are not bound to the metal centre cation. For 




that the Ln-BPAMD complex is nine coordinated. The relaxivity of Gd-BPAMD was 5.34 s-1mM-1 
at 20 MHz (298K, pH 7.5), comparable to that of Gd-DOTA complexes. Sorption experiments of 
160Tb-BPAMD on HA showed that binding was reversible, and the affinity was ca. 2 orders of 
magnitude higher than MDP and HEDP. An adsorption study compared BPAMD, simple BPs 
and DOTA-like BPs containing differing BP arm lengths, such as BPAPD and BPPED (Figure 
5.11). The maximum adsorption capacity of simple BPs (e.g. pamidronate or etindronate) was 
determined by their charge, whereas adsorption of DOTA-like ligands was determined by their 
size. Computer modelling revealed the surface area occupied by DOTA-BPs was similar to the 
experimental values measured. However, for simple BPs, the experimental measurements 
were much higher than the modelled values, 20-30 Å2 and 80-100 Å2 for modelled and 
experimental measurements respectively. The observation was attributed to interactions 
between charged groups of the BP, such as pamidronate amine and the HA surface. The 
affinity constants of the DOTA-like BPs were dependent on the BP arm length. The high 
affinities of BPAMD and BPPED were attributed to a shorter spacer limiting the access of 
water molecules due to steric hindrance of the bulky substituent and/or hydrophobicity, 
presuming that water molecules are involved in the adsorption/desorption mechanism.109 
Surprisingly, there is no discussion of HA surface interaction with the DOTA carboxylic acid 
groups.   
 
Recently, the first in human study of the 68Ga complex of BPAMD was performed. PET/CT was 
used to image osteoblastic bone metastases in a patient with known bone metastases of 
prostate cancer. There was intense accumulation in osteoblastic lesions, higher than 18F-
fluoride. Metastases were detected in the whole skeleton with a maximal standardised uptake 
value (SUV max) of 77.1% and 62.1% in the 10th thoracic and L2 vertebra vs. 39.1% and 39.2% 
for 18F-fluoride, respectively. 68Ga-BPAMD showed high target/tissue ratio and fast blood 
clearance.  BPs can interfere with the metabolic pathway of osteoclast function, therefore,  
the 68Ga-BPAMD tracer may be a better choice for detecting osteoclastic lesions or managing 
other bone diseases in comparison to 18F-fluoride. In this study, there is no comparison to 
traditional bone imaging BPs, such as 99mTc-MDP. However, the reported fast clearance of 
68Ga-BPAMD, presumably offers favourable properties compared to the relatively slow 
clearance of 99mTc-MDP discussed previously. In conclusion, the high kinetic stability of DOTA 
metal complexes and avidity of BPs for HA and other metal oxide surfaces make a bifunctional 





In this chapter we have reviewed the development of BPs for the treatment and imaging for 
bone diseases.  The review has highlighted that P-C-P moiety in the BP structure is essential 
for HA affinity. In addition, introducing hydroxyl groups in R1 position (Figure 5.2) is often 
associated to high HA affinity. Traditional radiolabelled BP complexes are poorly defined, and 
their function is complicated by the fact the BP group has dual function, acting as a bone 
targeting group and metal chelator. The two functions can interfere with each other, thus, the 
concept of bifunctional BPs has been proposed. Bifunctional BPs separate the chelating and 
BP bone targeting groups, so that each can function exclusively for their purpose. 
Radiolabelled bifunctional BPs have shown increased bone accumulation in comparison to 
their older BP counterparts (where the BP is dual functioning), suggesting that the concept 
improves affinity for bone. We aimed to exploit and apply the bifunctional BP concept to 
radiolabel nanoparticles (e.g. HA nanoparticles), with high loading rate, affinity, capacity and 
stability for potential in vivo application. 
 
We envisaged that the BP-nanoparticle interaction will occur in vivo, and might be applicable 
to our pretargeting concept. Radiolabelling HA nanoparticles with BPs will also help 
understand their behaviour with regard to their functioning as linkers for introducing disease 
targeting ligands in active nanoparticle targeting strategies (BP-nanoparticles labelling studies 
are discussed in chapter 6). 
 
In this chapter we have described the synthesis of a novel bifunctional BP chelator, N,N-
bis(quinoylmethyl)pamidronate-amine-(BQMPA) and investigated its potential as a 
multimodal probe for fluorescence microscopy (as its rhenium tricarbonyl complex) and 
radionuclide imaging (as its 99mTc-tricarbonyl complex). We have discussed the synthesis of a 
DOTA like bisphosphonate, BPAMD, as described by Kubicek et al.1 and discussed the 
preparation and in vitro behaviour of its novel 64Cu radiolabelled complex. 
 
Experimental Aims 
 Prepare a novel bifunctional BP chelator, N,N-bis(quinoylmethyl)pamidronate-amine-
(BQMPA) and investigate its potential as multimodal probe for fluorescence 
microscopy and radionuclide imaging. 
 Prepare the DOTA like ligand BPAMD and its novel 64Cu radiolabelled complex.  






All chemicals used in these experiments were obtained from commercial sources as analytical 
reagents and used without further purification unless otherwise indicated.  Deionised water 
(Type I, 18.2 MΩ·cm) was obtained from an ELGA Purelab Option-Q system. Human serum, 
male AB plasma (H4522) was purchased from Sigma-Aldrich UK. Isolink TM kits (Mallinckrodt 
Medical B.V.) were generously provided by Covidien, Petten, The Netherlands. Pamidronate, 
alendronate and dipicolylamine-alendronate (DPA) were prepared in house, supplied by Dr 
Rafael Torres (KCL).89 The macrocyclic t-Bu3DO3A ligand was provided by Dr Maite Jauregui-
Osoro (KCl). Dittmer-Lester’s TLC reagent for the detection of phosphorus was prepared 
following the original literature protocol.119 [Re(CO)3(H2O)3]




Reverse phase (RP) HPLC analyses were carried out using an Agilent 1200 series system 
equipped with a quadruple pump, a UV detector set at 254 nm and a radiodetector (Lablogic) 
gamma rays. For RP studies, an Agilent Zorbax Eclipse XDB-C18 column (5 μm, 4.6 x 150 mm) 
was used. TLC plates were scanned with a Mini-Scan TLC Scanner equipped with a FC3600 
detector optimised for gamma or beta detection (Lablogic, UK). Radioactivity in samples was 
measured with a CRC-25R dose calibrator (Capintec, USA) or a 1282 CompuGamma gamma 
counter (LKB Wallac, Finland). [99mTcO4+Na was supplied by the radiopharmacy at Guy’s and St 
Thomas’ Hospital NHS trust, London, UK, obtained from a Drytec generator (GE Healthcare, 
Amersham, UK). 64Cu was produced at the PET Imaging Centre, St. Thomas’ Hospital, London, 
UK. 64Ni (99.6 % isotopically enriched) was purchased from CK GAS products Ltd. (Hampshire, 
UK). High-resolution mass spectra (HRMS) were obtained at the Division of Imaging Sciences 
using an Agilent 6500 Accurate-Mass Q-TOF LC-MS system using electrospray ionisation. 
MALDI-TOF mass spectra were obtained at the EPSRC National Mass Spectrometry Service 
Centre at Swansea University using a Voyager-DE-STR system with Linear and reflectron 
analysers. NMR spectra were obtained in a 400 MHz Bruker Avance III (Germany).  1H chemical 
shifts are referenced with respect to the residual solvent peaks (δH 4.79 ppm, D2O; 7.26 ppm 
CDCl3). 
 31P resonances were referenced to an external solution of 85% H3PO4 (δP 0 ppm). 
  13C 
chemical shifts were referenced to the residual solvent peak (δC 77.16 ppm, CDCl3) or left 
unreferenced (D2O). Elemental analyses were carried out at the elemental analysis service at 
London Metropolitan University. IR spectra were obtained in a Perkin-Elmer Spectrum 100 







Preparation of  [99mTc(CO)3(OH2)3]
+ 
[99mTcO4]
-  was converted to [99mTc(CO)3(OH2)3]
+ using an Isolink™ kit (Mallinckrodt Medical 
B.V.) as described by the manufacturer’s instructions.  Briefly, 1 mL of *99mTcO4]
-  (500 MBq) 
was added to the kit and the vial was heated at 100 oC for 20 minutes.  After cooling to room 
temperature, the contents were neutralised with 120 μL of 1M HCl and analysed by HPLC 




Production of 64Cu 
 64Cu was produced at the PET Imaging Centre, St. Thomas’ Hospital, London, UK by proton 
bombardment of 10-15 mg of 64Ni, plated onto a gold disc, at 25 μA for 4-6 hours in a CTI RDS 
112 11 MeV cyclotron using purpose-built targetry. Purification of 64Cu was undertaken using 
established procedures.121 Radionuclidic purity was confirmed by gamma-ray spectroscopy 
(Ortec DSPEC Plus HPGe gamma-ray spectrometer) to be >99 %. 64CuCl2 was then obtained in 
HCl solution and was transformed into 64Cu(OAc)2 by evaporation of the solution to a small 
volume and titrating it with small aliquots of a 1 M sodium acetate solution (99.995 % trace 
metal basis) until the pH of the solution reached 5.5. Purity was confirmed by TLC (Rf = 0.66) 
with silica gel plates using 15 mM EDTA in 10% ammonium acetate/MeOH (50/50) as the 
mobile phase. 
 
Reverse Phase HPLC Methods 
The following method was employed using the stated conditions.  
 
Method A: 
Solvent A: Water 
Solvent B: Acetonitrile 
 
Time (min) Flow rate (mL/min)  A (%)  B (%) 
0 1  100 0 
3 1  100 0 






Solvent A: 0.05M TEAP (triethylammonium phosphate) pH 2.25. 
Solvent B: MeOH 
Time (min) Flow rate (mL/min)  A (%)  B (%) 
0 1 100 0 
5 1 100 0 
6 1 75 25 
9 1 66 34 
20 1 0 100 
30 1 0 100 
31 1 100 0 
35 1 100 0 
 
Radio TLC Methods:  
Method A: TLC was performed using silica gel 60 F-254 glass backed plates (Merck, 
Germany), spotting line at 1.5 cm and solvent front at 7 cm. 
Mobile Phase: MeOH in 0.1%HCl  
Method B: TLC was performed using silica gel 60 F-254 aluminium backed plates (Merck, 
Germany) spotting line at 1.5 cm and solvent front at 7 cm. 
 Mobile Phase: 50 mM ethylenediaminetetraacetic acid (EDTA) in 10% NH4OAc/MeOH (50/50). 
 
5.10.1 Synthesis of N,N-Bis(Quinoylmethyl)Pamidronate-Amine (BQMPA) (1) 
To a solution of pamidronate disodium (100 mg, 358 µM, 1 eq) in H2O (12 mL) was added  
NaOH ( 57 mg, 1.43 mM, 4 eq) and the mixture was stirred at RT for 10 min.  Next, 2-
(chloromethy)quinoline hydrochloride was added (153.4 mg, 716 µM, 2eq).  The mixture was 
heated at 65 oC overnight with stirring.  The pH of the mixture reduced from 12.3 to 10.3. To 
ensure the reaction was complete additional NaOH (14 mg, 1eq) was added to the reaction 
mixture and stirred at 65 oC overnight. The reaction was stopped and washed with DCM (10 
mL x 3). The aqueous layer was collected and dried in vacuo. To purify, the crude product was 
dissolved in H2O (10 mL) and passed through a C-18 Sep Pak cartridge (1 g). The cartridge was 
flushed first with H2O (10 mL) followed by acetonitrile (10 mL), collecting (ca. 1.5 mL) 
fractions. Product-containing fractions were identified under UV light (254 nm), collected and 
analysed via NMR to confirm product-yielding fractions. The product was lyophilised, yielding 




1H NMR (400 MHz, D2O) δ = 7.61 (d, J=8.5, 2H, q-H
8), 7.48 (m, 4H, q-H4,H7), 7.39 (d, J=8.1, 2H, 
q-H5), 7.30 (m, 2H, q-H6), 7.22 (d, J=8.5, 2H, q-H3), 4.02 (s, 4H, q-CH2-N) 3.31 (br, 2H, -N-CH2-
CH2-),  2.42, (br, 2H, (-CH2-C(PO3)2(OH)).  
13C NMR (100 MHz, D2O) δ 159.09 (2C, q), 145.58 (2C, 
q) , 136.59 (2CH, q) 129.75 (2CH, q), 127.45(2C, q) , 126.72 (2CH, q), 126.60 (2CH, q) , 126.37 
(2CH, q), 122.19 (2CH, q), 73.81 ((t, JC-P = 128.2 Hz, CH2-C(PO3)2(OH)), 61.86 (-CH2-), 54.68 (2C,  
q-CH2-N-), 30.14 (-CH2-C(PO3)2(OH).  
31P NMR (162 MHz, D2O) δ 15.47 (s). ESI/MS(+) Calculated 











        M= Re, 99mTc     
 







5.10.2 Synthesis of M(CO)3-Bis(Quinoylmethyl)Pamidronate-Amine (BQMPA) (2)  
 
Titration of N,N-Bis(Quinoylmethyl)Pamidronate-Amine (BQMPA) (1) with [Re(CO)3(H2O)3]
+   
BQMPA (1) was titrated with [Re(CO)3(H2O)3]
+ to assess the formation of (2).  BQMPA (1) (10.1 
mg, 19.5 µM) was dissolved in 800 µL of 100 mM sodium carbonate  buffer (pH 9) in D2O.  The 
mixture was incubated with increasing molar equivalents of [Re(CO)3]
+ for 30 minutes at 100 
oC. After cooling, each solution was analysed by RP-HPLC using method A and 1H NMR. 
 
Radiolabelling of N,N-Bis(Quinoylmethyl)Pamidronate-Amine (1) with [99mTc(CO)3(H2O)3]
+   
[99mTc(CO)3(H2O)3]
+ was prepared according to manufactures instructions. To establish the 
minimum concentration at which (1) could be efficiently labelled with [99mTc(CO)3(H2O)3]
+  four 
solutions of different concentrations of (1) were prepared (1.9x10-3 M, 1.9x10-4 M, 1.9x10-5 M 
and 1.7x10-6 M) in 100 mM sodium carbonate buffer (pH 9). An aliquot of the BQMPA (1) 
solution (75 μL) was mixed with [[99mTc(CO)3(OH2)3]
+ (ca. 37.5MBq in 75 μL) before being 
heating in a sealed vial for 30 minutes at 100 oC. The purity of the newly formed complex was 
assessed by RP-HPLC (method B) and radio TLC (method A). 
 
Binding of 99mTc(CO)3-BQMPA to HA1 
To ascertain whether 99mTc(CO)3-BQMPA formed at a concentration of 1.9x10
-4 M ligand (1) 
retained hydroxyapatite affinity, an aliquot of the radiolabelled mixture (20 µL, 1 MBq) was 
added to a 500  µL suspension of HA1 (1 mg/mL) in 50 mM TRIS-HCl buffer pH 7.4.  The 
mixture was incubated for 30 minutes at RT. The sample was tested in triplicate and 
nanoparticle free standards were used to measure the baseline supernatant activity and any 
non specific binding to centrifuge tubes. To measure the binding of radioactivity to 
particulates, the solution was centrifuged (5 min at 14000 rpm). An aliquot of each sample 
supernatant 100 μL was removed and counted for activity using a gamma counter. The 
amount of activity associated to the particles was calculated as a percentage of the total input 
activity (Equation 1). In addition, aliquots of [99mTc(CO)3(H2O)3]
+ and free TcO4
-  (20 µL, 1 MBq) 
were incubated with HA1 nanoparticles (as above) to assess their binding affinity and ensure 
and activity associated to the particles was related to 99mTc(CO)3-BQMPA. 
 
Labelling efficiency % = [1- (Activity in supernatant aliquot/ activity in standard 
aliquot)]x100   





5.10.3 Synthesis of (4,7-Bis-carboxymethyl-10-[[(hydroxyphosphinoyl-phosphono-methyl)-









Figure 5.13: Synthesis of BPAMD. (i)N2 atmosphere, 160 °C; (ii) H2, Pd/C, EtOH, reflux; (iii) ClCH2C(O)Cl, 




The BPAMD ligand was prepared as described in a literature protocol by Kubicek et al. 103 For 
completeness, the experimental details are reported herein. 
 
Synthesis of [Dibenzylamino-(Diethoxy-Phosphoryl)-Methyl]-Phosphonic Acid Diethyl Ester 
(3) 
Triethyl orthoformate (10.6 g, 71 mmol) diethyl phosphate (25.6 g, 186 mmol) and 
dibenzylamine (11.6 g, 59 mmol) were mixed and heated under reflux (150 oC) for 5 h under 
an inert atmosphere. The reaction mixture was heated at 160 oC for 24 h. The solution was 
cooled and diluted with DCM (300 mL).  The mixture was washed with 5% NaOH (3 x 60 mL) 
and brine (2 x 75 mL). The organic phase was dried over MgSO4 and concentrated in vacuo. 




bypurified by flash chromatography (100 % hexane through to 100% ethanol), yielding a 
yellow oil (1.56 g) Yield= 41% of purified crude.    (Hexane:EtOAc, 1:1,Rf = 0.4-0.5) 
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.11 (m, 10H, Ar-H ), 4.28 – 4.08 (m, 8H, O- CH2-), 4.09 – 
3.96 (m, 4H N- CH2-Ph), 3.55 (t, J = 25.1, 1H, P-CH-P), 1.43 – 1.17 (m, 12H, CH3) 
31P NMR (162 
MHz, CDCl3) δ 20.11 (d, JHP = 24.9,) 
 
Synthesis of [Amino-(Diethoxy-Phosphoryl)-Methyl]-Phosphonic Acid Diethyl Ester (4) 
(3) (1.5g, 3.1mmol) and 10% Pd/C (0.3 g) was added to anhydrous ethanol (20 mL). The 
mixture was hydrogenated for 3 days at RT under pressure using a hydrogenator. The reaction 
mixture was filtered and concentrated in vacuo. The resultant product was a colourless oil.  
Yield 0.89 g (95 %)  
1H NMR (400 MHz, CDCl3) δ 4.29 – 4.17 (m, 8H, O- CH2-), 3.43 (t, J = 20.6, 1H, P-CH-P), 1.46 – 
1.31 (m, 12H, CH3). 
31P NMR (162 MHz, CDCl3) δ 20.25 (s)  
 
Synthesis of [(2-Chloro-Acetylamino)-(Diethoxy-Phosphoryl)-Methyl]-Phosphonic Acid Ethyl 
Ester Methyl Ester (5) 
A solution of (4) (800 mg ,2 mmol) in DCM (20 mL) was slowly dropped into a solution of DIEA  
(270 mg, 2.05 mmol) and chloroacetyl chloride (326 mg, 2.05 mmol) in DCM (20 mL), cooled 
to -40 oC  before addition. The mixture was allowed to warm to RT and stirred overnight. The 
organic phase was washed with 2 x H2O (40mL)), 2 x 0.1N NaHCO3 (40 mL)) and 2 x H2O 
(40mL). The organic phase was dried over MgSO4 , filtered and concentrated in vacuo. Excess 
chloroacetyl chloride was removed via repeated evaporation with toluene. The product was 
obtained as a yellow oil in a yield of 750mg (75%).  
1H NMR (400 MHz, CDCl3) δ 6.98 (d, J = 10.3, 1H, NH), 4.95 (td, J = 10.1, 21.4, 1H, P-CH-P), 4.15 
(s, 8H, O-CH2), 4.17 – 4.05 (m, 2H, Cl-CH2-CO), 1.33 (dt, J = 7.2, 14.1, 12H, -CH3) 
31P NMR (162 
MHz, CDCl3) δ 15.46 (s) 
 
Synthesis of [4-([[Bis-(diethoxy-phosphoryl)-methyl]-carbamoyl]-methyl)-7,10-bis-tert-
butoxycarbonylmethyl-1,4,7,10tetraaza-cyclododec-1-yl]-acetic acid test-butyl ester (6) 
A solution of (5) (750 mg, 0.95 mmol) in acetonitrile (20 mL) was slowly dropped into a 
solution of t-Bu3DO3A (850 mg) in a suspension of K2CO3 (2.5 eq) in dry acetonitrile (20 mL), 
and then stirred for 48 h at 60 oC. The reaction mixture was treated with charcoal, filtered and 
concentrated in vacuo. The crude was purified via flash chromatography (conc. ammonia-




identified. The product was a yellow oil. ESI/MS(+) Calculated for C37H73N5O13P2 M= 857.5, 
Observed 858.3 (M +H+) 
 
Synthesis of (4,7-Bis-carboxymethyl-10-[[(hydroxyphosphinoyl-phosphono-methyl)-
carbamoyl]-methyl]-1,4,7,10 tetraaza-cyclododec-1-yl)-acetic acid (BPAMD) (7) 
(6) was dissolved in 30% HBr in dry AcOH and stirred for 24 h at RT.  Volatiles were removed 
via repeated rotary evaporation. The solid was dissolved in methanol and suspended in ether 
(20 mL) and dried in vacuo x3.  The resultant beige solid was dissolved in water and purified 
on a strongly acidic cation exchange resin (Dowex 50x4), eluted with water followed by 10% 
aqueous pyridine. After rotary evaporation, excess pyridine was removed with a weakly acidic 
cation exchange resin (Amberlite GC50, eluted with water). The product was concentrated in 
vacuo and lyophilised to dryness yielding an off-white powder, 150mg (15%).  
1H NMR (400 MHz, D2O) δ = 5.13 (t, J=19.1 Hz, 1H, N-CH(PO3)2, 4.64 (bs, 4H, -N-CH2-pendant), 
4.46 (bs, 2H, -N-CH2-pendant), 4.21 (bm, 10H, -cyclen- CH2-N (8H) and N-CH2-pendant (2H)) 
(bs, 4H, cyclen- CH2-N) 3.94 (bs, 4H, cyclen- CH2-N)  
13C NMR (100 MHz, D2O) δ = 188.65 (1C, -
COO-), 180.77 (2C,-COO-), 173.28 (1C, -CON-), 59.84 (3C, -N-CH2-pendant), 58.80 (1C, -N-CH2-
pendant), 57.34 (8C, cyclen-CH2-N) 52.66 (dd, C JC-P = 30.2, 344.2 Hz, N-CH(PO3)2. 
31P NMR (162 
MHz, D2O) δ= 13.66 (s) MALDI/MS Calculated for C17H33N5O13P2M= Calculated 577.2 Observed 
578.4 (M+H) Purity confirmed by RP-HPLC using method B (Rt= 3.17 min). 
 
5.10.4 Radiosynthesis of 64Cu-BPAMD 
The preparation of 64Cu(OAc)2 is described above. To establish the minimum concentration at 
which (7) could be efficiently labelled with 64Cu(OAc)2 five solutions of different  
concentrations of (7) were prepared (1.73x10-3 M, 1.73x10-4 M, 1.73x10-5 M, 1.73x10-6 M and 
1.73x10-7 M) in 100 mM acetate buffer (pH 5.5). An aliquot of the BPAMD (7) solution (75 μL) 
was mixed with 64Cu(OAc)2 (ca. 20MBq in 75 μL) before being heating in a sealed vial for 1 h at 
100 oC. The purity of the newly formed complex was assessed by RP-HPLC (method B) and 
radio TLC (method B). 
 
Preparation of Cu-BPAMD 
BPAMD (5.1 mg, 8.8 µmol) was dissolved in 500 μL of 100 mM acetate buffer (pH 5.5). Next, 
CuCl2.2H2O (1.5 mg, 1 eq) was added, resulting in the solution turning to a light blue colour. 
After 1 h stirring at 100 oC, the solution was freeze-dried to yield the product as a pale blue 
powder. The product was assessed by FTIR and to confirm that Cu(II) was coordinated to the 





Kinetic Stability of 64Cu-(BPAMD) in Serum and PBS 
64Cu-BPAMD was prepared as describe above using a BPAMD concentration of 1.73x10-4 M. To 
assess the in vitro stability of 64Cu BPAMD, 50 μL of 64Cu-BPAMD (ca. 6 MBq) were incubated 
in PBS or human serum (500 μL) at 37 oC and constant shaking for 24 h. Aliquots (2 μL) were 
taken at 1, 16 and 24 h after mixing and analysed by TLC (method B).  
 
Protein Binding of 64Cu-(BPAMD) in Serum 
64Cu-BPAMD was prepared as describe above using a BPAMD concentration of 1.73x10-4 M. To 
assess the in vitro binding of 64Cu-(BPAMD) to proteins in human serum, 10 μL of 64Cu-BPAMD 
(ca. 1 MBq) was incubated in human serum (500 μL) at 37 oC and constant shaking for 6 h. The 
mixture was filtered with repeated washing with PBS (500 μL), using a Vivaspin 2 filter with a 5 
KDa molecular weight cut-off membrane, until no further activity could be observed in the 
filtrate. A solution of 64Cu-BPAMD in PBS was also prepared as a control and subjected to the 
same filtering process. The radioactivity in the filtrate and retentate (serum protein fraction) 
was measured to determine the 64Cu-BPAMD bound to serum proteins. 
 
5.11 Results and Discussion 
5.11.1 Synthesis of N,N-bis(quinoylmethyl)pamidronateamine-(BQMPA) (1) 
The BQMPA ligand (1) was prepared to function as a bifunctional bisphosphonate chelator for 
fluorescence microscopy (as its rhenium tricarbonyl complex) and radionuclide imaging (as its 
99mTc-tricarbonyl complex). Fluorescent probes are useful for determining the in vitro fate of 
compounds at a cellular and sub cellular level, helping to elucidate and understand biological 
mechanisms. In addition, their radiolabelled counterparts can be used to image biomolecular 
processes in vivo. Radiopharmaceutical probes often require additional structural modification 
to incorporate fluorescent dyes,122,123 potentially altering their physicochemical properties and 
in vitro behaviour. Therefore, isostructural fluorescent and radionuclide imaging probes are 
desirable. Due to the analogous nature (e.g. size and lipophillicity) of Tc and Re, 
complimentary fluorescent and radionuclide imaging probes may be designed. The tridentate 
N,N,N donor atom set has been exploited to form stable isostructural complexes of 99mTc and 
β- emitting radionuclides 186/188Re.87-90, 124-129 Furthermore, Re(I) complexes can be used to 
prepare luminescent probes with favourable fluorescent properties. In particular, the 
bis(quinoylmethyl)amine donor atom has been used to prepare stable Re and 99mTc , 
fluorescent  and radiolabelled probes.124,128 To this end, it was thought that a bifunctional 




derivatise nanoparticles with isostructural counterparts, thus retaining similar 
physicochemical properties for in vitro and in vivo studies for fluorescent and radioimaging 
studies. In addition, the bifunctional bis(quinoylmethyl)amine bisphosphonate probe may be a 
useful bone imaging or therapeutic agent in its own right.   
 
The bis(quinoylmethyl)amine moiety consists of a tridentate N,N,N donor atom set,  including 
two sp2 N-heterocycles, ideal for forming stable complexes with fac-[M(CO)3]
+ (M= Tc  and 
Re).124, 128, 130 The M(I) tricarbonyl core was chosen because of a number of favourable 
properties. For example, the aqua ligands in the fac-[M(CO)3(H2O)3]
+  complex are labile, and 
can be substituted by donor groups such as tridentate N,N,N atom sets. The fac-[M(CO)3]
+ 
group is highly stable due to its d6 low spin electron configuration that makes it useful for 
further chemical modification. In addition, the preparation of the fac-[M(CO)3(H2O)3]
+  core is 
available in kit form.  A variety of complexes involving the substitution of halo or aqua ligands, 
while maintaining the fac-[M(CO)3]
+ core have been reported, including six-coordinate Tc(I) 
and Re(I) tricarbonyl complexes, pioneered by Alberto et al..131-140 Herein, we choose to focus 
on the favourable properties of N,N,N tridentate ligands. For example, the bifunctional 
dipicolylamine (DPA) bisphosphonate ligand has shown highly selective and stable 
coordination of fac-[M(CO)3]
+  ( M=99mTc and 188Re) with the dipicolylamine (DPA) moiety.89, 90  
In addition, the versatile nature of tridentate chelators means that they can be modified to 
afford different pharmacokinetic properties of complexes.  
 
The bis(quinoylmethyl)pamidronate amine conjugate (1) was prepared via a simple one step 
method, based on the preparation of the bifuntional BP, DPA-Ale (Figure 5.12).89, 90 2-
(chloromethy)quinoline hydrochloride was reacted with pamidronate via nucleophilic 
substitution. Notably, the insolubility of pamidoronate in organic solvents required the use of 
water, complicating the conjugation reaction. For the amine group of pamidronate to act as a 
nucleophile, it must be deprotonated. Pamidronate contains five ionisable protons, two on 
each phosphonate group and one on the primary amine. The last deprotonation occurs on the 
amine group, consistent with the high pKa of the pamidronate -NH2 (13.1).
141 To ensure the 
reaction proceeded, a strong base was required to promote nucleophilic attack. The reaction 
proceeded using NaOH, maintaining pH >12 at 65 oC for 36 h. Additional heat was required to 
solubilise 2-(chloromethy)quinoline hydrochloride. After Sep-Pak purification, a yield of 32% 
was achieved. Presumably, hydrolysis of the 2-(chloromethy)quinoline contributes to the 
relatively low yield. The purity of the compound was confirmed by RP-HPLC using method B, a 
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Figure 5.15: Titration of BQMPA (1) with [Re(CO)3(H2O)3]
+
 , monitored by RP-HPLC (method B), indicating 
the formation of multiple products. Where (1) = BQMPA (1 eq) + (X) equivalents of 
[Re(CO)3(H2O)3]
+
added in titration. 
 
To assess the complexation of (1) with fac-[Re(CO)3]
+, a series of titrated solutions with 
increasing quantities of  [Re(CO)3(H2O)3]
+ were monitored by HPLC and NMR. The aim was to 
determine if fac-[Re(CO)3]
+ exclusively coordinates with the bis(quinoylmethyl)amine moiety. 
The addition of [Re(CO)3(H2O)3]
+  resulted in a colour change; the mixture turned from 
colourless to a pale orange solution. In addition, a small amount of red precipitate was 
observed. RP-HPLC (Figure 5.15) and NMR (Figure 5.16) studies indicate that multiple products 
were formed at all concentrations of [Re(CO)3(H2O)3]
+. 31P NMR (Figure 5.16) studies reveal 
multiple peaks, even at 0.17 eq of [Re(CO)3(H2O)3]
+, indicating that there is an interaction with 
the metal centre and the BP group. Moreover, interaction with the bis(quinoylmethyl)amine 
moiety is not stoichiometric, indicated by multiple peaks present in the aromatic region of the 
1H NMR spectrum at 1 eq, implying a mixture of coordinated and uncoordinated 
bis(quinoylmethyl)amine species. RP-HPLC analysis also revealed the presence of multiple 






Figure 5.16: Titration of BQMPA (1) with [Re(CO)3(H2O)3]
+
 monitored by 
1
H NMR  (aromatic region) (Left) 
and 
31
P NMR (Right).  [Re(CO)3(H2O)3]
+
 was sequentially added to BQMPA, the number of equivalents is 
denoted on the spectra.  
 
The radiosynthesis of 99mTc(CO)3- bis(quinoylmethyl)pamidronate amine was assessed by radio 
HPLC and TLC. Since the concentration of ligand is several orders greater than that of the 
radionuclide, it was thought that the complexation properties may be different to those seen 




concentrations of (1) and were incubated with [99mTc(CO)3(H2O)3]
+  to establish binding 
properties, and the minimum concentration for efficient radiolabelling was determined. RP-
HPLC (method B) revealed the formation of multiple species at ligand concentrations below 
1.9 x 10-4 M (Figure 5.17).  Using a concentration of 1.9 x 10-3 M BQMPA, a single peak at 15.2 
min (>95%) can be seen, indicating that at higher concentrations of ligand and low 
radionuclide concentrations it is possible to form a single distinct radiolabelled species. 
However, radio TLC analysis also indicated the formation of multiple products, even at 1.9x10-
3 M (Figure 5.18). The peak near the baseline (Rf = 0.14) may correspond to the desired 
bis(quinoylmethyl)amine coordinated species.  As the concentration of ligand (1) decreases, 
the % of peaks at (Rf= 0.41) and (Rf = 0.87) increases, which may correspond unbound 
[99mTc(CO)3(H2O)3]
+  and pertechnetate respectively. There is a large increase in % for peaks at 
(Rf = 0.41) and (Rf = 0.87) observed at 1.9 x 10
-5 M. However, a relatively low % of 
[99mTc(CO)3(H2O)3]
+ species is observed in the corresponding RP-HPLC; therefore, implying that 
the peaks observed at (Rf = 0.41) and (Rf = 0.87) may not  be exclusively associated with 
[99mTc(CO)3(H2O)3]
+  and pertechnetate. 
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To ascertain whether the complex mixture formed at a concentration of 1.9x10-4 M ligand (1) 
retained hydroxyapatite affinity, an aliquot of radiolabelled mixture was incubated with 1 
mg/mL HA1 nanoparticles.  After incubation for 30 minutes, over 80% of the activity remained 
associated to the HA1 nanoparticles. In addition, [99mTc(CO)3(H2O)3]
+ and free TcO4
-  were 
incubated with HA1 nanoparticles under the same conditions; less than 6% of the activity 
remained associated to the nanoparticles. The results imply that even if multiple 99mTc(CO)3 –
BQMPA products are present, they have high affinity for hydroxyapatite. In addition, 
[99mTc(CO)3(H2O)3]
+ and free TcO4





Figure 5.19: Binding of 
99m







low binding efficiencies to HA1. 
 
5.11.2 Synthesis of (4,7-Bis-carboxymethyl-10-[[(hydroxyphosphinoyl-phosphono-methyl)-
carbamoyl]-methyl]-1,4,7,10tetraaza-cyclododec-1-yl)-acetic acid (BPAMD) (7) 
The high stability of DOTA metal complexes and avidity of BPs for HA and metal oxide 
surfaces, makes bifunctional DOTA BPs an interesting prospect for labelling nanoparticles to 
be used in a variety of imaging modalities. Herein, we discuss the preparation of BPAMD, a 
literature compound, as prepared by Kubicek et al.,103 and its potential as a ligand for labelling 
nanoparticle surfaces using 64Cu as the metal ion centre. To our knowledge, the 64Cu-DOTA-BP 
ligand is a novel complex.  
 
Copper-64 has emerged as an important isotope for PET and radionuclide therapy, due to its 
favourable decay properties (half-life = 12.7 h, β- (40%), and β+ (19%), electron capture (41%) 
).142 A number of reviews have described the chemistry of copper and its potential to form 
stable complexes for diagnostic imaging and radiotherapy.142-145 The coordination chemistry of 
copper is dominated by two oxidation states, (I) and (II). A third oxidation state, (III) is 
attainable, but is rare and requires strong π-donating ligands. Almost always, the copper is 
delivered in the oxidation state(II), because it binds strongly to many ligands, providing a 
range of stable complexes. Copper(II) is a d9 metal, favouring four, five and six coordination 
numbers;  forming square-planar, distorted square-planar, trigonal-pyramidal, square-
pyramidal, and distorted octahedral geometries. For example, the crystal structure of Cu(II)-
DO3A reveals a cis-octahedron.143 Cu(II) is bound to the four macrocylic nitrogens and two of 




other Cu-N and Cu-O bonds. A consequence of Jahn-Teller distortions, often observed in six-
coordinate Cu(II) complexes, resulting in distorted octahedral structures.143  
 
Two of the most important Cu(II) chelators are the macrocyclic polyaminocarboxylates, 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA).  For example, stable bifunctional 
chelators containing disease targeting peptides such as 64Cu-DOTA-octreotate and 64Cu-TETA-
octreotide have been prepared.96, 146 These macrocyclic systems offer enhanced stability over 
acyclic chelating systems, due to the “macrocyclic effect”, presumably a result of geometric 
constraints from the ligand cage.147 The in vivo kinetic inertness of the 64Cu(II) complexes is 
paramount to avoid copper dissociation. Since not all of the carboxylate groups of DOTA or 
TETA based ligands are required to form stable 64Cu complexes, there is an opportunity to 
modify them to form bifunctional chelators. Herein we discuss the preparation of a literature 
compound, the DOTA-like BP ligand (BPAMD), reported by Kubicek et al.,103 and to our 
knowledge, its novel 64Cu complex. The high stability of DOTA metal complexes and avidity of 
BPs for HA and metal oxide surfaces, makes bifunctional DOTA BPs an interesting prospect for 
labelling nanoparticles to be used in a variety of imaging modalities.  
 
The synthesis of the DOTA-like ligand (BPAMD) is discussed. The BPAMD ligand was prepared 
as described by Kubicek et al.103 The same group has produced a series of papers discussing 
the synthesis and application of the BPAMD ligand.103, 105, 107, 109, 118 The BPAMD ligand has 
been used to form stable complexes with Gd and 68Ga for application as an MRI contrast agent 
and PET imaging probe respectively.103, 107  Recently, the first in human study of the 68Ga-
BPAMD complex has shown promising application in imaging metastatic bone disease.107  
The synthesis of the ligand proceeded as described in figure 5.13.103  Briefly, the reaction of 
dibenzylamine, triethylorthoformate and diethylphosphite gave the benzylprotected product 
(3). Benzyl groups were removed via hydrogenation using H2 and Pd/C as a catalyst yielding 
(4). The reactive chloroacetylamide intermediate (5) was produce via a substitution reaction 
of (4) with chloroacetyl chloride in the presence of DCM and DIEA as base.  (5) was used to 
alkylate t-Bu3DO3A (6), followed by hydrolysis in the presence of 30% HBr in acetic acid to give 
(BPAMD) (7). The final product was confirmed by 1H NMR, 13C NMR and 31P NMR (Figure 5.20); 
MS and RP-HPLC.  Differences in the reported NMR patterns can be attributed to changes in 
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The radiosynthesis of 64Cu-BPAMD was assessed by radio HPLC (method B) (Figure 5.23) and 
TLC (method B) (Figure 5.24). To establish the minimum concentration at which (7) could be 
efficiently labelled by 64Cu(OAc)2, a series of solutions containing different concentrations of 
(7) were prepared (1.73x10-3 M, 1.73x10-4 M, 1.73x10-5 M, 1.73x10-6 M and 1.73x10-7 M) in 
100 mM acetate buffer (pH 5.5). An aliquot of the BPAMD (7) solution (75 μL) was mixed with 
64Cu(OAc)2 (ca.  20MBq in 75 μL) before heating in a sealed vial for 1 h at 90 
oC. RP-HPLC 
analysis (Figure 5.21) shows the free ligand appears at (Rt = 3.17 min), while free copper 
acetate can be seen at (Rt= 1.33 min) (Figure 5.23a). At the lowest concentrations (1.73x10-6 
M and 1.73x10-7 M) only free copper acetate can be observed in the radio HPLC traces. At the 
intermediate concentration (1.73x10-5 M), multiple peaks are observed in the radio HPLC 
trace, indicating multiple products are present. At higher concentrations (1.73x10-3 M, 
1.73x10-4 M) a clear peak at (Rt= 6.41 min) with radiochemical purity > 97% is observed. 
Notably, this peak is significantly shifted from the free BPAMD ligand (Rt= 3.17 min). This 
implies that the interaction of Cu(II) with the macrocycle increase the lipophillic nature of 
BPAMD ligand. The HPLC UV chromatogram of the “non radioactive” Cu-BPAMD, reveals a 
broad peak at (Rt= 6.50), comparable to the Rt observed for the radiolabelled complex (Figure 
5.22 ).  
 
 
Figure 5.21: RP-HPLC chromatogram of BPAMD “free” ligand. (Rt = 3.17 minutes). 
 
 







Figure 5.23: Radio RP-HPLC trace of  BPAMD labelling with 
64
Cu(OAc)2 (A) control 
64
Cu(OAc)2.(B-F) 
labelling at various concentrations of BPAMD, (B) 1.73x10
-7
 M  (C) 1.73x10
-6
 M, (D) 1.73x10
-5
 M (E) 
1.73x10
-4




At the same time, the radiosynthesis of 64Cu-BPAMD was monitored by radio TLC method B 
(Figure 5.24). TLC analysis was performed using silica gel TLC, with 50 mM 
ethylenediaminetetraacetic acid (EDTA) in 10% NH4OAc/MeOH (50/50) as a mobile phase. The 
“free” copper moves with an Rf= 0.65, whereas the 
64Cu-BPAMD has a value of  Rf = 0.01. At 
the lowest concentrations (1.73x10-6 M and 1.73x10-7 M) “free” copper is predominantly 
observed (Rf = 0.65). In addition, a small peak is observed (ca. 20%) at Rf = 0.40 for 1.73x10
-7 M 




M, 1.73x10-4 M and 1.73x10-5 M) all activity appears at Rf = 0.01, indicating that all of the 
64Cu 
is associated with the BPAMD ligand. However, in conjunction with the radio HPLC studies we 
observed multiple products at 1.73x10-5 M. Under these conditions, the additional products 
also appear near the TLC baseline. In conclusion, this TLC analysis cannot confirm product 
purity alone.   
 
 
Figure 5.24: Radio TLC of 
64
Cu-BPAMD labelling. (A) Control 
64
Cu(OAc)2.(B-G) labelling at various 
concentrations of BPAMD: (B) 1.73x10
-3
 M  (C) 1.73x10
-4
 M, (D) 1.73x10
-5
 M (E) 1.73x10
-6







The stability of the 64Cu-BPAMD  complex was assessed in PBS and human serum over a period 
of 24 h. Incubation at 37 oC in these media showed no decomposition to “free” copper during 




serum bound copper will dissociate under these conditions. Furthermore, the complex does 
not decompose under the TLC conditions used (up to 50 mM EDTA), thus demonstrating high 
inertness towards ligand substitution. To assess whether 64Cu-BPAMD binds to serum 
proteins, the labelled ligand was incubated in human serum for 6 h. The mixture was filtered 
with repeated washing, using a Vivaspin 2 filter with a 5 KDa molecular weight cut-off 
membrane, until no further activity could be observed in the filtrate. A solution of 64Cu-
BPAMD in PBS was also prepared as a control and subjected to the same filtering process. The 
radioactivity in the filtrate and retentate (serum protein fraction) was measured to determine 
the 64Cu-BPAMD bound to serum proteins. An average of 62% and 6% activity was observed in 
the retentate for serum and PBS fractions respectively, indicating that the 64Cu-BPAMD 
complex is highly bound to the serum proteins.  
 
 
Figure 5.25: Stability of 
64
Cu-BPAMD in PBS and Serum. Radio TLC of in serum after 24 h (Left) and PBS 
after 24h (Right) no free copper is observed..   
 
FTIR analysis of the “cold” (non radioactive) Cu(II)BPAMD complex was performed to ensure 
that Cu(II) was exclusively coordinated to the DOTA macrocycle and not the bisphosphonate 
group (Figure 5.26). Characteristic BP bands were observed in the free BPAMD ligand at 914 
and 1016 cm-1, attributable to symmetrical and asymmetrical P-O vibrations, and at 1045 cm-1 
for n(P=O) vibrations.148 The frequency of these vibrations remains unchanged after copper 
coordination, forming Cu-BPAMD. Coordination of Cu(II) with carboxylic acid pendant arms 
was confirmed by prominent asym(COO) bands due to coordinated carboxylate at 1411 cm–1, 

















Figure 5.26: FTIR of Cu(II)-BPAMD complex.(Top) Cu-BPAMD (Middle) BPAMD (Bottom) Alendronate. 
Green line highlights bands corresponding to phosphate are similar in both Alendronate and Cu-BPAMD, 
indicating bisphosphonate groups are not interacting with copper.     
 
5.12 Conclusions 
In conclusion, the bisphosphonate ligand, bis(quinoylmethyl)pamidronate-amine has been 
prepared. However, its application as a multimodal bifunctional chelating agent may be 
limited by the poorly defined nature of its complexes. Labelling with [Re(CO)3(H2O)3]
+ and 
[99mTc(CO)3(H2O)3]
+ ligands implied the formation of multiple complexes. The coordination of 
the fac-[M(CO)3]
+ (M= Tc  and Re) may be sterically hindered by the bulky nature of the 
bis(quinoylmethyl)amine groups; thus, encouraging interactions with bisphosphonate groups. 
The binding of 99mTc(CO)3-BQMPA to HA1 indicated that the mixed complexes retain affinity 
for HA; therefore, the BQMPA ligand might be useful as a bone imaging agent. However, our 
aim was to produce a well defined imaging agent, to ensure consistent in vitro and in vivo 
behaviour for pretargeting nanoparticles. Undefined radiolabelled polymeric complexes, such 
as 99mTc-MDP, have already shown variable results for in vivo bone imaging. For this reason, 
we will exploit a ligand that gives a well-defined single technetium complex, dipicolylamine-
alendronate (DPA-Ale), for the basis of BP-nanoparticle binding experiments within this thesis 
(Chapter 6). Moreover, DPA-Ale has been prepared within our group, thus, it is readily 
available.89 
 
A novel 64Cu-BPAMD complex has been prepared from the literature compound, BPAMD.103 
RP-HPLC analysis revealed that the BPAMD can be labelled with 64Cu(OAc)2 at concentrations 
as low as 173 µM. FTIR analysis indicated exclusive labelling of the macrocyclic moiety and not 
the bisphosphonate group. The 64Cu-BPAMD complex was stable in serum and PBS over 24 h; 
dissociation to “free” copper was not observed. In addition, the 64Cu-BPAMD was highly 
bound to serum proteins. The results indicated that a kinetically stable 64Cu-BPAMD complex 




radiotherapy for the diagnosis and treatment of bone diseases. Promising “first in human” 
studies with 68Ga-BPAMD have already highlighted the potential of the BPAMD ligand.107 Thus, 
we propose the 64Cu-BPAMD complex warrants further investigation due to its PET imaging 
and radiotherapy potential. However, within the scope of this thesis we are interested in 
developing a pretargeted nanoparticle concept. Therefore, we will focus on the ability to label 
nanomaterials with the bifunctional 64Cu-BPAMD complex. The 64Cu-BPAMD complex provides 
a platform to investigate binding properties of the BPAMD ligand with various materials. 
Moreover, the BPAMD ligand has the potential to form a stable Gd(III) complex for MRI, 
reported in literature.103,150 Therefore, the BPAMD ligand could act as a scaffold to produce 
labelled nanoparticles across a range of imaging modalities. Chapter 6 will investigate the 
binding capabilities of 99mTc(CO)3-DPA-Ale  and  
64Cu-BPAMD to various materials, with a view 
to in vivo application. Further studies with the BQMPA ligand were halted due to the poorly 
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A Survey of 99mTc(CO)3-DPA-Ale and 
64Cu-BPAMD Avidity for Inorganic 
and Biocompatible Materials 
 
6.1 Overview  
It is well known that bisphosphonates have high affinity for a variety of metal oxide surfaces. 
In this chapter we aimed to identify biocompatible materials with optimal BP binding 
properties. The investigation began with a comparison between the clinically used 99mTc-MDP 
and a novel bifunctional chelator, 99mTc(CO)3-DPA-Ale. We also investigated the binding 
properties of the novel 64Cu-BPAMD complex with a variety of materials. The avidity of BP 
ligands for inorganic materials was explored with two concepts in mind: the functionalisation 
of particles for targeting or stabilisation purposes, and the use of radiolabelled BPs as 
pretargeting probes for SPECT or PET imaging. We have indentified that 99mTc(CO)3-DPA-Ale 
and 64Cu-BPAMD bind to a wide range of metal oxide materials with high efficiency. 
Hydroxyapatite (HA) and Alhydrogel were chosen as lead materials for further in vitro and in 
vivo investigations. The BP-HA and –Alhydrogel interaction was robust in biological media. In 
addition, functionalised HA particles can be loaded with radiolabelled BPs in high efficiency.  
 
6.2 Introduction  
The research in this chapter is conducted using the bifunctional chelator DPA-Alendronate, 
kindly supplied by Dr Rafael Torres (KCL).1-3 It was preferred over the BQMPA chelator 
described in chapter 5, as the structures of its complexes are well defined. For example, single 
distinct radiolabelled products of 99mTc(CO)3-DPA-Ale and 
188Re(CO)3-DPA-Ale, have been 
prepared.1-3 In contrast, multiple products were identified in the attempted coordination of 
fac-[M(CO)3]
+ with the BQMPA chelator. To introduce this chapter a summary of the published 
DPA-Alendronate papers1-3 is given to outline its properties and potential as a ligand for 
radiolabelling nanoparticles, such as HA.  
 
6.2.1 Dipicolylamine-Alendronate (DPA-Ale) 
A novel bifunctional BP chelator, dipicolylamine-alendronate (DPA-Ale) has been developed 
within our research group (described briefly in Chapter 5).1-3 The BP conjugate consists of an 
Alendronate BP moiety (for bone affinity) and a separate dipicolylamine (DPA) moiety for 
chelation of metals. The dipicolylamine moiety consists of a tridentate N,N,N donor atom set,  
including two sp2 N-heterocycles, ideal for forming stable complexes with fac-[M(CO)3]
+ (M = 
Tc and Re) (see Chapter 5 for discussion on fac-[M(CO)3]
+ ). The fac-[M(CO)3]




kinetically due to its d6 low spin electron configuration. Moreover, the preparation of the fac-
[M(CO)3(H2O)3]
+ core is convenient, since it is available in kit form. The dipicolylamine-
alendronate conjugate was prepared via a simple one step method (Figure 6.1). 2-picolyl 
chloride was reacted with alendronate via nucleophilic substitution in water. The reaction 
proceeded in a yield > 90% by HPLC.  
 




Re) (i) NaOH (pH 12), H2O, 
RT, 36 h (ii) [M(CO)3(H2O)3]
+
  , H2O, 100 
o
C, 30 min. 
 
A distinct, non-radioactive Re(CO)3-DPA-Ale complex was prepared from fac-[Re(CO)3(H2O)3]
+. 
1H/31P-NMR, and RP-HPLC confirmed the presence of a single species, where the fac-
{Re(CO)3}
+
 species complex coordinated exclusively to the  DPA moiety. The 
188Re(CO)3-DPA-
Ale and 99mTc(CO)3-DPA-Ale complexes were prepared in high radiochemical yields, >96% and 
>98% respectively.  High serum stability and low serum protein binding was observed of both 
complexes in vitro, in contrast to their 188Re-HEDP and 99mTc-MDP counterparts. In addition, 
188Re-HEDP exhibited decomposition to [ReO4]
-. Biodistribution studies in mice revealed 
99mTc(CO)3-DPA-Ale had similar bone uptake compared to 
99mTc-MDP. The 188Re(CO)3-DPA-Ale 
complex had a higher bone uptake than 188Re-HEDP, 21.2% and 13.4% ID/g at 48 h 
respectively. The high bone uptake was attributed to increased stability and affinity for bone. 
More recently, the DPA-Ale ligand has been used to prepare radiolabelled iron oxide 
nanoparticles (99mTc(CO)3-DPA-Ale-Endorem) for potential use as dual modality MRI-PET 




In summary, distinct radiolabelled dipicolylamine-alendronate complexes were prepared with 
promising properties for imaging and radiotherapy of bone disease, and nanoparticle 




The aim of this chapter was to radiolabel nanoparticles (e.g. HA nanoparticles) with 
radiolabelled bisphosphonates, and identify materials with high loading rate, affinity, capacity 
and stability for potential in vivo application. We envisaged that the BP-nanoparticle 
interaction will occur in vivo, and might be applicable to our pretargeting concept. We aimed 
to gain better understanding of BP-nanoparticle binding properties, such as loading capacity 
and stability with a view to their use as functionalising or radiolabelling agents.  We begun our 
search for BP affine materials with a survey and aimed to select promising materials for 
further binding studies. The basic format of this chapter is a reflection of the 18F-fluoride 
binding studies in chapter 2, except 18F-fluoride is replaced by radiolabelled BPs.  
 
Experimental Aims 
 Indentification and selection of materials that have high 99mTc-DPA-Ale loading rate, 
affinity, capacity and stability for potential in vivo application. 
 Comparison of the clinically used 99mTc-MDP, nanoparticle binding properties. 
 Investigate 64Cu-BPAMD nanoparticle binding properties.  
 Investigate the binding properties of radiolabelled bisphosphonate on functionalised 
nanoparticles (prepared in chapter 3).   
 
6.4 Materials 
All chemicals used in these experiments were obtained from commercial sources as analytical 
reagents and used without further purification unless otherwise indicated.  Deionised water 
(Type I, 18.2 MΩ·cm) was obtained from an ELGA Purelab Option-Q system. Human serum, 
male AB plasma (H4522) was purchased from Sigma-Aldrich. Trizema base, sodium phosphate, 
sodium chloride, sodium carbonate, sodium hexametaphosphate, sodium fluoride, 
cetyltrimethylammonium chloride (25%) were all purchased from Sigma-Aldrich. Sodium 
citrate dihydrate was purchased from Fischer Scientific.  IsolinkTM kits (Mallinckrodt Medical 
B.V.) were generously provided by Covidien, Petten, The Netherlands. Alendronate and 





Reverse phase (RP) HPLC analyses were carried out using an Agilent 1200 series system 
equipped with a quadruple pump, a UV detector set at 254 nm and a radiodetector (Lablogic) 
optimised for the detection of gamma-rays. For RP studies, an Agilent zorbax eclipse XDB-C18 
column (5 μm, 4.6 x 150 mm) was used. TLC plates were scanned with a Mini-Scan TLC 
Scanner equipped with a FC3600 detector optimised for gamma detection (Lablogic,UK). 
Radioactivity in samples was measured with a CRC-25R dose calibrator (Capintec, USA) or a 
1282 CompuGamma gamma counter (LKB Wallac, Finland). [99mTcO4]Na and 
99mTc-MDP were 
supplied by the radiopharmacy at Guy’s and St Thomas’ Hospital NHS Trust, London, UK, 
obtained from a Drytec generator and Amerscan Medronate II, (GE Healthcare, Amersham, 
UK)respectively. 
 
Table 6.1: Particulate and bulk materials surveyed for 
99m
 Tc(CO)3 DPA-Alendronate and 
99m
Tc MDP 
binding;  origin and particle size stated by manufacturer except, 
a
measured by transmission electron 
microscopy,
 b 
measured by dynamic light scattering. 
 
 
Material Origin Particle size 
CeO2 Sigma-Aldrich  (544841) < 25 nm 
ZrO2 Sigma-Aldrich  (544760) <100 nm 
Co3O4 Sigma-Aldrich  (637025) < 50 nm 
MgO Sigma-Aldrich  (549649) < 50 nm 
Bi2O3 Sigma-Aldrich  (637871) 90-210 nm 
Y2O3 Sigma-Aldrich  (206168)  
Fe2O3 Sigma-Aldrich  (544884) < 50 nm 
HA1 Sigma-Aldrich  (677418) <200 nm 
HA2 This work 41.6± 1.8 nm
a
 
HA3 This work 107.5 ± 6.2 x 25.8 ± 0.9 nm
a
 
Dy2O3 Sigma-Aldrich  (289264)  
Al2O3 Sigma-Aldrich  (544833) < 50 nm 
CaCO3 Acros (40381100)  
Ho2O3 Sigma-Aldrich  (229679)  
Yb2O3 Sigma-Aldrich  (246949)  
ZnO Sigma-Aldrich  (544906) < 100 nm 
Al(OH)3-Alhydrogel Brenntag Biosector 1211 ± 64 nm
b
 
CaHPO4 Sigma-Aldrich  (100931751)  
Ca3P2O8 Fluka (2318408)  
TiO2, Rutile/Anatase 
mixture 
Sigma-Aldrich  (6346620) < 100 nm 
CaC2O4 Acros (403880050)  
SnO2 Sigma-Aldrich  (549657) < 250 nm 
CuO Sigma-Aldrich  (544868) < 50 nm 
Sb2O3 Sigma-Aldrich  (537173) < 100 nm 
Gd203 Alfa Aesar (11290)  
Mn2O3 Alfa Aesar (87791) <45  µm 
In2O3 Sigma-Aldrich  (632317) < 100 nm 





Reverse Phase HPLC Method 
The following method was employed using the stated condition.  
 
Method A 
Solvent A: 0.05M TEAP (triethylammonium phosphate) pH 2.25 
Solvent B: MeOH 
Time (min) flow rate (mL/min)  A (%)  B (%) 
0 1 100 0 
5 1 100 0 
6 1 75 25 
9 1 66 34 
20 1 0 100 
30 1 0 100 
31 1 100 0 
35 1 100 0 
 
Radio TLC 
Method A: TLC was performed using silica gel 60 F-254 glass backed plates (Merck, 
Germany), spotting line at 1.5 cm and solvent front at 7 cm. 
Mobile Phase: MeOH in 0.1% HCl  
 
 Preparation of 99mTc(CO)3-dipicolylamine-Ale 
 
99mTc(CO)3-dipicolylamine-alendronate was prepared according to the published protocol.
1 
Briefly, a solution of dipicolylamine-alendronate (DPA) (2.3 x 10-4 M) in carbonate buffer (100 
mM) at pH 9 was prepared. An aliquot of the DPA solution (75 μL) was mixed with 
[[99mTc(CO)3(OH2)3]
+ (ca.  37.5MBq in 75 μL) (prepared as described in chapter 5) before being 
heated in a sealed vial for 30 minutes at 100 oC. The purity and quality control of the newly 
formed complex was assessed by HPLC (Method A) and TLC (Method A). The solution was 
diluted to 1.5 mL with saline.  
 
 Preparation of 99mTc-methylene-diphosphonate 
99mTc-MDP was prepared from an Amerscan Medronate II kit, (GE Healthcare, Amersham) as 
described by manufactures procedures. The 99mTc-MDP (0.3 mL, 200 MBq) supplied contained 






Preparation of 64Cu-BPAMD 
 
A stock solution of 64Cu-BPAMD was prepared as described in chapter 6. Briefly, an aliquot of 
the BPAMD solution [1.73x10-4 M] (75 μL) was mixed with 64Cu(OAc)2 (75 μL, 20 MBq) before 
being heating in a sealed vial for 1 h at 100 oC. The solution was diluted to 1.5 mL with saline. 
The format of the binding experiments described within this chapter is based on experiments 
discussed in chapter 2. Herein, some sections of the experimental text are duplicated in 
chapter 2. For clarity, we have described the full experimental details within this chapter, as 
experimental conditions are not identical.   
 
6.6.1 Initial Survey for 99mTc(CO)3-dipicolylamine-Ale and 
99mTc-methylene-diphosphonate 
Binding  
For comparison and contrast a material binding survey was conducted using 99mTc(CO)3-
dipicolylamine-alendronate (99mTc(CO)3-DPA) and 
99mTc-methylene-diphosphonate (99mTc-
MDP). Initial labelling studies were performed on HA nanoparticles, assessing optimal 
conditions for incubation time and media type. Either 99mTc(CO)3-DPA (20 µL, 0.5-1 MBq)  or 
99mTc-MDP (20 µL, 0.5-1 MBq) were added to a 1 mg/mL suspension of HA in water (0.5 mL) or  
50 mM TRIS-HCl buffer (pH 7.4) (0.5 mL). The suspensions were incubated for up to 360 
minutes with continuous shaking at RT. To ensure binding equilibrium was reached, a 
standard incubation time of 30 minutes was selected for all samples, in 50 mM TRIS-HCl buffer 
(pH 7.4) (See table 6.1 for materials tested). 50 mM TRIS-HCl buffer (pH 7.4) was used as the 
suspension medium throughout, unless otherwise stated. Each sample was tested in triplicate 
and nanoparticle-free standards were used to measure the baseline supernatant activity and 
any non specific binding to centrifuge tubes. To measure the binding of radioactivity to 
particulates, the solution was centrifuged (5 min at 14000 rpm). An aliquot of each sample 
supernatant (100 μL) was removed and counted for activity using a gamma counter. The 
amount of activity associated to the particles was calculated as a percentage of the total input 
activity (Equation 6.1). 
 
Labelling efficiency % = [1- (Activity in supernatant aliquot/ activity in standard 
aliquot)]x100   
Equation 6.1: Equation to calculate particle labelling efficiency. 
 
 
Since the binding properties of HA and Alhydrogel were promising, and because they have 
already been studied within this thesis for 18F-fluoride binding, subsequent experiments 




To assess binding capabilities of small quantities (i.e. injectable in vivo quantities) of HA (HA1) 
or Alhydrogel that could sufficiently bind 99mTc(CO)3-DPA-Ale, a series of different particle 
concentrations (0.0001 mg/mL – 2 mg/mL), were incubated with 99mTc(CO)3-DPA-Ale.  
The radiolabelled compounds and stock solutions were prepared as above. 99mTc(CO)3-DPA-
Ale (20 μL) was added to each suspension of particulate material (0.5 mL) in 50 mM TRIS-HCl 
buffer (pH 7.4). The mixture was incubated at room temperature with continuous shaking for 
30 minutes. To measure the binding of radioactivity to the particulates the solution was 
centrifuged (5 min at 14000 rpm). An aliquot of each sample supernatant (100 μL) was 
removed and counted for activity using a gamma counter. Labelling efficiency was calculated 
using equation 6.1. 
  
A semi quantitative method for assessing and comparing the 99mTc(CO)3-DPA-Ale binding 
affinity for different materials was developed in Chapter 2 and is applied herein: particle 
concentration at which half-maximal % binding occurred after 30 min incubation with 
99mTc(CO)3-DPA-Ale in suspensions containing different concentrations of particles. The data 
were fitted to Equation 6.2, a sigmoid function from which the maximum binding (Bmax) and 
the particle concentration at half-maximal % binding (Kd) were obtained, using OriginLab Pro 




Equation 6.2: Sigmoid function fitted to binding efficiency data.  Y = labelling efficiency (%), X = particle 
concentration mg/mL), Bmax= Maximum binding, Kd= concentration of NPs at half-maximal % binding. 
 
6.6.2 Competition Studies 
For the principle of pretargeting to work, the nanoparticle- radiolabel interaction must take 
place rapidly and efficiently in vivo. Inhibition of binding could occur via competition from the 
bodies’ abundant endogenous proteins, peptides and circulating ions. HA (HA1) or Alhydrogel 
(1 mg) (unless stated otherwise) was suspended in water (0.5 mL). Potential competitor 
solutions in water (0.5 mL) were added to the suspension. At the same time, an aliquot of  
99mTc(CO)3-DPA-Ale  (20 μL, ca. 1MBq) was added to each suspension of 
particulate/competitor material. The mixture was incubated at room temperature with 
continuous shaking for 30 minutes. To measure the binding of radioactivity to the particulates, 
the solution was centrifuged (5 min at 14000 rpm ). An aliquot of each sample supernatant 
(100 μL) was removed and counted for activity using a gamma counter. Labelling efficiency 




To study the DPA-Ale loading capacity on HA (HA1) or Alhydrogel, particle solutions of 
different concentrations (0.1, 0.5, 1 mg/mL) were labelled in the presence of a series of cold 
(non-radioactive) DPA-Ale solutions of different concentrations. Labelling was performed as 
described for the competition experiments described above. 
 
6.6.3 Kinetic Profile of 99mTc-DPA Binding in Different Medium 
A series of time course experiments in different media were carried out to assess the kinetic 
profile and behaviour of 99mTc(CO)3-DPA-Ale in the presence of potential binding competitors. 
HA (HA1) or Alhydrogel (1 mg) was suspended in series of different media (1 mL) (serum, PBS, 
TRIS, or H2O). An aliquot of 
99mTc(CO)3-DPA-Ale (20 μL) was added to each suspension of 
particulate material. The mixture was incubated at room temperature with continuous 
shaking for 5 ,30, 60, 180,and 360 minutes. To measure the binding of radioactivity to the 
particulates the solution was centrifuged (5 min at 14000 rpm). An aliquot of each sample 
supernatant (100 μL) was removed and counted for activity using a gamma counter. Labelling 
efficiency was calculated using equation 6.1. 
 
6.6.4 Kinetic Stability in Serum 
HA (HA1) or Alhydrogel (1mg) were suspended in 50 mM TRIS-HCl buffer (pH 7.4) (1 mL).  
99mTc(CO)3-DPA-Ale (20 μL)  was added to the solution. The mixture was incubated at room 
temperature with continuous shaking for 30 minutes. To measure the binding of radioactivity 
to the particulates, the solution was centrifuged (5 min at 14000 rpm). An aliquot of each 
sample supernatant (100 μL) was removed and counted for activity using a gamma counter. 
Labelling efficiency was calculated via equation 6.1. The remaining supernatant was 
discarded. The labelled particles were collected and washed with water (1 mL) via 
centrifugation x4 (5 min at 14000 rpm). The pellets were resuspended in human serum (1 mL). 
The resuspended pellets were divided into 200 μL aliquots. The mixtures were incubated at 
37oC with continuous shaking for 30, 60, 120, 360, 1080 minutes. Samples were prepared in 
triplicate for each time point. To measure the radioactivity associated with the particulates, 
the solution was centrifuged (5 min at 14000 rpm). An aliquot of each sample supernatant 
(100 μL) was removed and counted for activity. The percentage binding was calculated with 
respect to the standard input activity using equation 6.1.  The input activity was 200 μL of the 






6.6.5 Kinetic Stability in Water 
To ensure that the 99mTc(CO)3-DPA-Ale-nanoparticle labelling interaction was stable in water, 
the activity associated with particles during a washing procedure was measured.  HA (HA1) or 
Alhydrogel (1mg) was suspended in water (1 mL) and labelled in triplicate with 99mTc(CO)3-
DPA-Ale, as described above. The particles were pelleted via centrifugation (5 min at 14000 
rpm) and 100 μL of the supernatant was collected for labelling efficiency measurements 
(Equation 6.1). The remaining supernatant was discarded and pellets were subjected to a 
washing protocol. The labelled particles were resuspended in water (1 mL) and incubated at 
room temperature with continuous shaking for 5 minutes. The particles were collected via 
centrifugation (5 min at 14000 rpm). At each washing step, 100 μL of supernatant was 
removed and counted for activity. The washing procedure was repeated x 4. The input activity 
was represented as the total initial activity on the nanoparticles, before washings. The % 
activity associated to the particles after washings was calculated using equation 6.3.  
 
 
Labelling efficiency % =  [1- ((Activity in washing aliquot x10)/ activity of standard 
nanoparticles)]x 100 
Equation 6.3: Equation to calculate kinetic stability in water. 
 
 
6.6.6 Binding Properties of Functionalised Hydroxyapatite 
A series of functionalised HA materials (Table 6.4 and chapter 3 for functionalisation details) 
were also assessed for 99mTc(CO)3-DPA-Ale binding. The particles were labelled with 
99mTc(CO)3-DPA-Ale, as described in the initial screening protocol above. In addition, the 
kinetic stability in serum and water were also assessed as described above.  
 
6.6.7 64Cu-BPAMD Binding Experiments 
All 64Cu-BPAMD binding experiments were performed as described for 99mTc(CO)3-DPA-Ale, 
except 99mTc(CO)3-DPA-Ale was replaced with 
64Cu-BPAMD (ca. 20 µL, 0.5 MBq).  
 
6.7 Results and Discussion 
6.7.1 Initial Survey of 99mTc(CO)3-DPA-Ale and 
99mTc-MDP Binding 
Preliminary binding studies using HA (HA1) and 99mTc(CO)3-DPA-Ale in water revealed the 
general trend that binding equilibrium was reached within 5 minutes in solutions of 1 mg/mL. 
However, when using 50 mM TRIS-HCl buffer (pH 7.4) as a suspension medium, equilibrium 




significantly alter the 99mTc(CO)3-DPA-Ale labelling efficiency. 50 mM TRIS-HCl buffer (pH 7.4) 
was chosen as a suspension medium to ensure pH remained constant.  Thus, for subsequent 
screening experiments an incubation time of 30 minutes was adopted for all materials. The 
materials (Table 6.1) were chosen based on the known bisphosphonate affinity for metal 
oxides, with additional materials included for comparison and contrast. Some examples of 
metal ions (also listed in Chapter 5) to which bisphosphonates are known to bind include 
Ba(II)4-6, Sr(II)4, 6, Mg(II)4, 6, Pb(II)5, Al(III)7, Fe(III)7, Cd(II)8, 9, Zn(II)8, 9, Cu(II)8, 10, 11, Zn(II)12, Co (II)13, 
Ni(II)13, UO2(II)
14,and Lanthanide(III) Ce, La, Pr, Nd15 and Gd16. In addition it is well known that 
phosphonic acids and BPs bind strongly to metal oxides surfaces, such as TiO2
17-21, Al2O3
17, 19, 22, 
ZrO2
17, 20, 23, Fe2O3/Fe3O4
2, 24-27, SiO2
18, 19, AlOOH28, BaTiO3
29, stainless steel18 ,and rare earth 
metal oxides in the form M2O3, where M = Eu, Er, Yb, and Gd
27. Since many of these materials 
are available in nanoparticle form, we suggested that we could exploit this interaction to 
derivatise nanoparticles for in vivo targeting (such as BP-peptide conjugate) or as secondary 
pretargeting radiolabelled probes (such as 99mTc(CO)3-DPA-Ale). An initial survey of 
99mTc(CO)3-
DPA-Ale and 99mTc-MDP binding properties is displayed in figures 6.3 and 6.4.  
 
For 99mTc(CO)3-DPA-Ale, HA showed very high binding efficiency while surprisingly, the affinity 
for other calcium salts was greatly reduced. This could be related to the large surface area 
expected for HA nanoparticles in contrast to bulk materials tested for other calcium salts. The 
BP interaction with HA surfaces is described in Chapter 5. Briefly, BPs can to bind to Ca2+ in a 
bidentate fashion, where the distance between the two phosphates -O------O- (ca. 3.08 Ao) is 
ideal for chelation of Ca2+ in HA.30 In contrast, the labelling efficiency of HA with 99mTc-MDP 
was significantly reduced in general, there is a loss of labelling efficiency for all materials when 
using 99mTc-MDP.  This observation can be attributed to the polymeric nature of 99mTc-MDP 
complexes, the larger polymeric complexes may block and sterically hinder further adsorption 
of BPs to the particle surfaces.31-34 In addition, the affinity of 99mTc-MDP for NP surfaces is 
likely to be reduced as the BP group is also involved in 99mTc chelation. The binding properties 
of 99mTc-MDP will not be discussed further in this section. Herein, the discussion is based on 
99mTc(CO)3-DPA-Ale, unless otherwise stated. 
 
Alhydrogel and aluminium oxide also have very high % binding. The high affinity of 
phosphonates and phosphonic acids for AlOOH and Al2O3 surfaces has been reported.
17, 19, 28 
There is a high % binding measured across a broad range of metal oxides, including Fe2O3, 
MgO, and rare earth metal oxides such as CeO2. Most notable is the decrease in surface 




phosphonate or phosphonic acid binding surfaces.18-20 However, these results may be 
explained well by considering particle surface charge. The charge of a metal oxide surfaces in 
aqueous solution is largely dependent on the dissociation of the hydroxyl groups. For 
example, the charge of the surface may be altered depending on pH (Figure 6.2). There is a 
point at which there is no net surface charge, referred to as the isoelectric point (IEP) or zero 
point of charge (zpc). The pH at which this occurs is related to the electronic character of the 
metal oxide bond and surface stoichiometry.35, 36 
 
            
low pH High pH   




The pH of media is an important factor influencing the surface chemistry of the particles in 
solution. The IEPs of SiO2 and TiO2 are typically between pH ca. 2, and ca. 5 respectively. At a 
pH above the IEP point, the surface will remain negatively charged.35 Our binding studies were 
performed at pH 7.4, therefore, the resulting interaction with the negatively charged 
bisphosphonate groups and the negative metal oxide surface will be weakened due to 
electrostactic repulsion. Conversely, the IEPs of Alhydrogel, Fe2O3, MgO, and HA are ca. pH 9, 
7, 12, and 8 respectively, corresponding to higher % binding (Figure 6.5 and table 6.2). 
However, the IEP is not the only factor to consider for adsorption of BPs. For example, CuO 
materials typically have an IEP ca. pH 9.5.35 The large reduction in % binding is surprising given 
the high IEP and known interaction of Cu2+ and bisphosphonates.10, 11 The reduced binding 
could be related to dissolution of CuO particles or surface contamination. Furthermore, it is 
important to remember that the IEPs presented in Table 6.2 are only a rough guide. These 
values represent similar, but not identical materials. Different values of IEP are often reported 
for materials with the same chemical formula.37 The IEP is dependent on the nature of the 
solid and the concentrations of solutes. In addition, the temperature, pressure and solvent 
also influence IEP.37 For example, solutions with high ionic strengths (e.g. >0.1 M) can shift the 
IEPs.37 
  
Based on these initial results and our previous 18F-fluoride investigations (Chapter 2), HA and 
Alhydrogel (Al(OH)3) were chosen for further investigation with 




particles were selected for both high 18F-fluoride and 99mTc(CO)3-DPA-Ale binding potential. 
Investigating the binding properties of BPs on these surfaces could lead to a better 
understanding of their ability to function as surface modifiers for nanoparticle stabilisation or 
as targeting moieties. In addition, BPs have the potential to act as secondary pretargeting 
binding probes (e.g. replacing the use of 18F-fluoride described in chapter 2).  Moreover, the 
affinity of BPs appears more versatile than 18F-fluoride, with high % binding over a range of 
materials. Thus, there is great potential to exploit the positive physical and chemical 
properties of many nanoparticulate materials and develop new imaging agents.  
 
 
Figure 6.3: Survey of 
99m
Tc(CO)3DPA-Ale binding materials. 
 
Figure 6.4: Survey of
 99m


























































Figure 6.5: Plot of 
99m
Tc(CO)3DPA-Ale labelling efficiencies and published isoelectric points (IEP). 
 
Material Labelling efficiency (%) Isoelectric point (IEP) pH Ref 
HA1 91.8 8.1 
38
 
Alhydrogel 91.6 11.1 
39
 
Al2O3 87.9 9 
35
 
CeO2 85.6 11.2 
40
 
ZrO2 85.0 7.6 
41
 
Co3O4 83.1 7.2 
42
 
MgO 82.0 12 
35
 
In2O3 81.9 9 
40
 
Y2O3 79.3 9 
35
 
Fe2O3 78.7 6.8 
42
 
Dy2O3 72.1 7.7 
43
 
ZnO 60.8 7.5 
42
 
TiO2 43.0 4.7 
35
 
SiO2 22.2 2 
35
 
SnO2 21.3 3.5 
38
 




Table 6.2: Comparison of 
99m







Our 18F-fluoride and 99mTc(CO)3DPA-Ale binding surveys in chapter 2 and this chapter 
respectively,  have selected HA and Alhydrogel as lead materials for further study within this 
thesis. HA materials have been discussed in chapter 3. Until now, Alhydrogel has not been 
described, herein we summarise the properties of Alhydrogel with a view towards tracer 
binding and in vitro/vivo application.  
 
Alhydrogel is a biocompatible clinically approved vaccine adjuvant.44-47 Structural studies 
report that Alhydrogel consists of poorly crystalline aluminium oxyhydroxide (AlOOH or 
boehmite).48-50The primary particles have been reported as needle like structures, 
approximately 2 nm in diameter.48 These particles form stable aggregates with diameters of 1-
10 µm in suspension.45, 48 The high surface area reported is consistent with its high protein 
adsorption capacity,48 while pH dependant charge characteristics also play an important role 
in protein adsorption. The zero point of charge (zpc) for Alhydrogel is pH 11.1,39, 51 below this 
pH the particles will possess a positive charge, ideal for electrostatic attraction of negatively 
charged proteins. Furthermore, the presence of competing anions, such as phosphate, 
sulphate and citrate adsorbing on the Alhydrogel results in a less positive surface charge, 
subsequently reducing electrostatic attractions between its surface and negatively charged 
proteins.52 It has also been reported that high concentrations of citric acid can result in the 
dissolution of Alhydrogel.53-55 The concept of negatively charged ions binding to the surface of 
Alhydrogel in high capacities can be applied to the high adsorption of negatively charged 
fluoride ions and BPs. Within this thesis we have chosen not to develop aluminium hydroxide 
nanoparticles and use the Alhydrogel formulation as received for perspective in vitro and in 
vivo radiolabelling experiments. Although not strictly a nanoparticle formulation we aimed to 
exploit its high loading capacities and biocompatibility for initial in vivo studies and 
pretargeting proof of concept.  
 
6.7.3 Binding Efficiency of Hydroxyapatite and Alhydrogel in TRIS-HCl Buffer (pH 7.4) 
Several preparations of HA nanoparticles were synthesised (discussed in Chapter 3). 
Commercially available (HA1) and calcined (HA2) were examined for 99mTc(CO)3-DPA-Ale 
binding. The hydrothermally treated preparation (HA3) was omitted from these studies due to 
sample constraints and the lower affinity constant observed in the 18F-fluoride studies 
(Chapter 2). The effect of preparation on 99mTc(CO)3-DPA-Ale binding properties of HA was 
assessed for HA1 and HA2. In addition, commercially available Alhydrogel was tested for 
99mTc(CO)3-DPA-Ale binding properties. For comparison and contrast, 




for binding affinity to HA2. To provide an objective measure of 99mTc(CO)3-DPA-Ale affinity, 
allowing a semi-quantitative comparison between materials, a particle concentration at half-
maximal % binding after 30 minutes incubation with 99mTc(CO)3-DPA-Ale was adopted. It was 
assumed that the system was close to equilibrium based on time course experiments 
(discussed later). Note that this measurement ignores differences in surface area and depends 
on mass. The data were fitted to equation 6.2, using OriginLab Pro 8.5 curve fitting software. A 
sigmoid function was used, where maximum binding (Bmax) and concentration of NPs at half-
maximal % binding (Kd) can be obtained.  
                                                                
Y= Bmax (X
n) /(Kd
n + Xn) 
Equation 6.2: Sigmoid function fitted to binding efficiency data.  Y = labelling efficiency (%), X = particle 
concentration mg/mL), Bmax= Maximum binding, Kd= concentration of NPs at half-maximal % binding. 
 
The concentration of the particles was varied between 0.001 and 2 mg/mL,  (Figures 6.6-6.9 
and table 6.3)  for results. A high (Kd) value implies low affinity (weak binding), a low (Kd) value 
implies high affinty (strong binding).The results showed that the binding affinity did not vary 
greatly depending on HA sample used. However, the binding affinity of 99mTc-MDP for HA2 
was over 7 times weaker than measured for 99mTc(CO)3-DPA-Ale. Moreover, the Bmax is greatly 
reduced to ca. 61%. These results highlight favourable binding properties of 99mTc(CO)3-DPA-
Ale compared to 99mTc-MDP for HA (i.e. the affinity is reduced by chelation of 99mTc to the BP 
group, therefore interfering with the HA interaction) . Surprisingly, the binding affinity of 
99mTc(CO)3-DPA-Ale measured for Alhydrogel was ca. 11 times weaker (high Kd) than HA2. 
These results are in contrast to those observed for 18F-fluoride in chapter 2 (Table 6.3),where 
the binding affinities of 18F-fluoride for HA1, HA2 and Alhydrogel were all comparable with 
each other. Moreover, the highest affinty (low Kd) was observed for 
99mTc(CO)3-DPA-Ale on 
HA1 and HA2. The binding affinity measured for 99mTc(CO)3-DPA-Ale  is almost 8 times stronger 
than 18F-fluoride for HA2. These results imply that the DPA-Ale has extremely high affinity 
(strong binding) for HA materials, possibly enhanced by the high affinity Ca2+ interaction with 
BPs. The binding mechanisms of BPs to HA and Alhydrogel surfaces may be considered 
different. For example, Alhydrogel binding may involve weaker interactions, such as hydrogen 
bonding. Furthermore, high 18F-fluoride binding efficiency has been observed in the presence 
of high BP concentrations (seen in chapter 2) indicating both may have the ability to bind at 









































Tc(CO)3-DPA 93.44 0.011 1.77 0.9251 
HA2 
99m
Tc(CO)3-DPA 93.01 0.005 1.23 0.9327 
Alhydrogel 
99m





61.12 0.037 1.43 0.9097 
HA1 
18
F-fluoride 92.04 0.038 1.43 0.9700 
HA2 
18
F-fluoride 100 0.042 1.24 0.9976 
HA3 
18
F-fluoride 100 0.113 1.31 0.9266 
Alhydrogel 
18
F-fluoride 92.47 0.038 1.23 0.9836 
 





F-fluoride (results from chapter 2). Kd is the nanoparticle concentration at half-maximal % binding; 
Bmax is the maximal % binding. A high Kd value implies weak binding, a low value implies strong 
binding. 
 
To assess the loading capacity of DPA-Alendronate on the particles, the free ligand (non 
radioactive) DPA-Alendronate was used as a competitive inhibitor. The DPA-Alendronate 
loading capacities of HA1 and Al(OH)3 were measured using varying concentrations of free 
ligand (non-radioactive) DPA-Alendronate and particulates. Despite the high affinity of DPA-
Alendronate for HA; the loading capacity of Alhydrogel and HA1 was remarkably similar at the 
same particle concentrations. The DPA-Alendronate loading capacity of HA1 and Alhydrogel 
was ca. 0.1 µmol/mg (Figures 6.10 and 6.11), equivalent to (43.1 g/kg). 
 
The fluoride binding capacity (measured in chapter 2) of Alhydrogel was approximately 10 
µmol/mg or (190 g/kg), about 2 orders of magnitude higher than that measured for DPA-
Alendronate on Alhydrogel and HA1. The fluoride binding capacity of HA1 (measured in 
chapter 2) was approximately the same as  DPA-Alendronate loading capacities for both HA1 
and Alhydrogel, ca. 0.1 µmol/mg. The comparable BP loading capacity is remarkable given the 
large size of the BP ligand in contrast to the small fluoride ion.  At these levels of affinity and 
capacity it is clear that for both HA and Alhydrogel, at quantities likely to be used in vivo (e.g. 
























6.7.4 Binding of 99mTc(CO)3-DPA-Ale to Hydroxyapatite and Alhydrogel in the Presence of 
Competitors 
The binding of  99mTc(CO)3-DPA-Ale to nanoparticles must take place in the presence of a 
number of competing substances, to ensure potential competitors will not affect labelling 
properties in vivo. A series of potential competing solutions were prepared and 99mTc(CO)3-
DPA-Ale binding was assessed in their presence (Figures 6.12 and 6.13). The solutes included 
simple anions (chloride, phosphate, carbonate, and citrate) and components which could be 
used for particle stabilisation, such as and sodium hexametaphosphate (SHMP) and cetyl 
trimethylammonium bromide (CTAB).  
 
An incubation time of 30 minutes was chosen for comparison to previous results in water and 
TRIS-HCl buffer (pH 7.4). The normal serum concentrations for Cl- , HCO3
2-, and HPO4
2-are ca. 
103, 27, and 1 mM respectively,56 therefore, the concentration of competitor was studied in 
the range 0.0001M-0.1 M. The binding of 99mTc(CO)3-DPA-Ale in the presence of NaCl, 
carbonate and TRIS-HCl buffer had little or no effect at concentrations up to 0.1 M for 
Alhydrogel and HA1. The carbonate results were surprising, given the relatively high inhibitory 
effect previously observed for 18F-fluoride (chapter. 2). A moderate inhibitory effect was 
observed for phosphate at concentrations up to 0.01 M. Interestingly, the inhibitory effect of 
citrate was marked for Alhydrogel binding at concentrations up to 0.001 M, but in contrast, 
was only moderate at high concentrations (e.g. 0.1 M) for HA. The citrate may be inhibiting BP 
binding through strongly interacting with the Al(OH)3 surface, or encouraging dissolution. The 
dissolution of Alhydrogel in citrate solutions has been suggested as a possible cause of serum 
instability of the 18F-fluoride-Alhydrogel interaction, reported in chapter 2.  
 
The inhibitory effect observed for the stabilising agent CTAB was modest, with half maximal 
binding observed at a concentration of 0.1 M. The greatest inhibitory effect was observed in 
the presence of SHMP, even at low concentrations (0.0001 M), only ca. 40% labelling 
efficiency was observed for HA1. This can be explained by anionic nature of SHMP and the 
high affinity of phosphate groups for HA surfaces. SHMP has previously been exploited to 
stabilise HA particles in solution through its high affinity HA interaction.57 Conversely, the 
inhibitory effect of SHMP on Alhydrogel binding was insignificant, even at concentrations as 
high as 0.1 M, suggesting that 99mTc(CO)3-DPA-Ale has higher affinity for Alhydrogel than 
SHMP. In addition, this result implies the BP binding mechanisms on HA and Alhydrogel 








For these materials to be used in vivo, binding must occur rapidly and efficiently in biological 
conditions. The biological environment may contain components that exhibit inhibitory 
effects.  A series of time course experiments were performed in different media to assess the 
kinetic profile of 99mTc(CO)3-DPA-Ale binding on HA and Alhydrogel (Figures 6.14 and 6.15). 
The binding efficiency was measured at time points up to 1 h and 6 h for Alhydrogel and HA1 




within 5 minutes of incubation. There was little change over a period of 6 hours. The binding 
of 99mTc(CO)3-DPA-Ale in TRIS-HCl buffer had a small effect on the kinetic profile, reaching 
equilibrium within 30 minutes for HA1. The kinetic profile of 99mTc(CO)3-DPA-Ale binding to 
HA1 in PBS is significantly slowed or inhibited, even after 6 hours the % binding was only 2/3 
of the maximal binding observed in water. The result is unremarkable, since PBS is a 
phosphate containing buffer (ca. 10 mM), and phosphate is a known inhibitor of 99mTc(CO)3-
DPA-Ale HA binding (see above). The 99mTc(CO)3-DPA-Ale binding to HA1 in human serum is 
markedly slower than water, although given time the binding % becomes that comparable to 
water. The human serum used contained a mixture of amino acids, proteins and inorganic 
salts. Therefore, the slow binding kinetic profile was unsurprising, since HA is well known for 
its protein binding capabilities. However, most significant was the high % binding and rapid 
equilibrium observed for 99mTc(CO)3-DPA-Ale binding to Alhydrogel in serum, especially since 
the human serum used in these experiments contains added citrate (10 mM). This result is in 
contrast to the slow 18F-fluoride labelled Alhydrogel kinetic profile in serum. These results 
suggested that the Alhydrogel may not be subject to dissolution in serum while in the 




Figure 6.14: Binding of 
99m
Tc(CO)3-DPA-Ale to HA1 in different media over time. (A) H2O (B) TRIS-HCl 







Figure 6.15: Binding of 
99m
Tc(CO)3-DPA-Ale to Alhydrogel in different media over time. (A) H2O (B) 
human serum. 
 
6.7.5 Kinetic Stability of 99mTc(CO)3-DPA-Ale Labelled  HA and Alhydrogel 
For radiolabelled nanoparticles to be used for in vivo imaging the nanoparticle-BP interaction 
must be sufficiently stable and remain intact in biological media. Repeated washing of 
99mTc(CO)3-DPA-Ale labelled HA1 and Alhydrogel nanoparticles with water did not remove a 
significant fraction of radiolabel (Figure 6.16).  The stability of labelled HA and Alhydrogel was 
measured in serum; after 18 hours minimal 99mTc(CO)3-DPA-Ale dissociation was observed. 
The high Alhydrogel-99mTc(CO)3-DPA-Ale stability in serum was remarkable, in contrast to the 
severe loss of fluoride from labelled Alhydrogel, where almost 50% loss was observed in 30 
minutes (Chapter 2).  
 
 
Figure 6.16: Kinetic stability in water wash and incubation in serum of 
99m
Tc(CO)3-DPA-Ale-NPs. (Top) 




6.7.6 Labelling Efficiency and Kinetic Stability of Functionalised HA Particles 
Our pretargeting concept requires nanoparticles that have disease targeting capabilities whilst 
simultaneously retaining sufficiently high affinity for a secondary radiolabelled chasing probe. 
Thus, we have proposed that bisphosphonates can provide a platform for both. For example, 
BPs can act as linkers on HA surfaces to conjugate small molecules or peptides for targeting 
purposes (Chapter 3). In addition, BPs can be used to radiolabel HA surfaces with high affinity 
and stability (see above). Herein, we discuss the 99mTc(CO)3-DPA-Ale radiolabelling of 
pamidronate, phytate, SHMP, and PEGBP-functionalised particles (Figure 6.17 and 6.18). For 
comparison and contrast, aminosilane functionalised particles are also discussed (the 
preparation of these particles is discussed in chapter 3). 
 
A list of the materials tested is provided in Table 6.4. The effect on % binding by PEGBP 
functionalisation of HA was small. There is unremarkable difference between the different 
PEGBP preparations, all measuring between 5-10% below the maximum binding % seen for HA 
in 50 mM TRIS-HCl buffer (pH 7.4). These results suggest that under these conditions PEGBP 
does not saturate or block BP binding sites to any significant extent. Furthermore, DLS particle 
size studies on the PEGBP treated particles revealed that they retained their stability (same 
hydrodynamic size) after radiolabelling, indicating that there was limited loss or exchange of 
the PEGBPs with 99mTc(CO)3-DPA-Ale on radiolabelling. The effect of SHMP functionalised 
particles on binding % was moderate. The greatest effect was observed with HA1HMP10, with 
less than half the maximal binding observed for HA1 in 50 mM TRIS-HCl buffer. Presumably, 
the greater inhibitory effect was due to the higher SHMP content. Our previous competition 
studies have shown that concentrations of HMP as low as 0.0001 M in solution can 
significantly inhibit BP binding. Moreover, it was remarkable that HA particles saturated in 
HMP solutions retain any BP binding properties. DLS particle size studies indicated that the 
particles retained stability (same hydrodynamic size) after radiolabelling. Particles derivatised 
with phytic acid, a hexaphosphonic acid, also experienced a moderate effect (decrease) on 
binding %.  
 
 A series of Alendronate loaded HA particles with increasing amounts BP were prepared 
(Chapter 3). The increase in BP loading corresponded well to binding inhibition. HA-Ale 
prepared in 1% and 0.5% wt/vol solutions of Alendronate were sufficient to saturate the HA 
surface and prevent further BP binding. The Alendronate concentration required a 5 fold 
reduction 0.1% wt/vol to achieve high binding %. These results suggested that the surface can 




interaction. Finally, a series of 3-aminopropyltriethoxysilane (APTES) derivatised particles 
were prepared. 3-aminopropyltriethoxysilane has frequently been used to functionalise HA 
and silica surfaces.58, 59 Hydrolysis of silanes results in a network of silica-particle bound layers 
via siloxane bond formation. Given the low binding efficiency measured for silica particles 
(presumably due to low IEP, discussed above), the very low binding % that was observed for 
APTES coated HA is expected. This result suggested that organosilane derivatisation of HA 
particles was not suitable for our pretargeting concept. The introduction of a silica network on 
the HA surfaces restricts the BP tracer from binding. Therefore we suggest that BPs, when 
loaded in suitable concentrations, provide a better platform for simultaneously functionalising 
(with targeting or stabilising moieties) and radiolabelling nanoparticles. The SHMP and PEGBP 
modified HA particles were most promising, since they have shown colloidal stability 
(preventing aggregation) and retain high 99mTc(CO)3-DPA-Ale binding %. The kinetic stability in 
serum was studied for HA1HMP1, HA1PEGBP1, HA2HMP1 and HA2PEGBP1, with a view 
towards in vivo pilot studies in mice. Repeated washing of 99mTc(CO)3-DPA-Ale labelled HA-
HMP and HA-PEGBP samples did not remove a significant fraction of radiolabel (Figure 6.19). 
The particles were stable in human serum, after 18 h only minimal 99mTc(CO)3-DPA-Ale 
dissociation was observed(Figure 6.18). 
Particle  Labelling efficiency (%) Particle size (nm) 
HA1PEGBP1 81.0 ±1.0 203 ±5.0 
HA1PEGBP0.1 90.6 ±0.2 491.7 ±8.4 
HA1PEGBP0.01 86.3 ±0.2 1141.3 ±8.0 
HA1HMP10 40.6 ±0.2 140 ±1.5 
HA1HMP1 52.6 ±0.4 195.7 ±6.8 
HA1HMP0.1 60.7 ±0.3 276.7 ±9.0 
HA2PEGBP10 82.1 ±0.1       589.2 ±10.2 
HA2PEGBP1 82.2 ±0.2       355.3 ±11.1 
HA2PEGBP0.1 86.6 ±0.5       765.3 ±58.6 
HA2HMP10 68.8 ±0.8 298.7 ±5.8 
HA2HMP1 69.3 ±0.6 198 ±1.7 
HA2HMP0.1 72.6 ±1.1 775 ±51 
HA1APTES4 8.2 ±1.2 1734.1 ±150.1 
HA1APTES2 6.4 ±3.8 2057.86 ±232.6 
HA1APTES1 11.7 ±1.9 1937.8 ±42.3 
HA1Ale1 5.1 ±2.2 790 ±17.2 
HA1Ale0.5 3.2 ±1.2 1061.3 ±32.9 
HA1Ale0.1 79.6 ±4.5 1201.3 ±53.9 
HA1Ale0.01 93.7 ±0.2 1269.7 ±22.7 
HA1Phytic10 58.9 ±0.4 391 ±7.2 
 



















Figure 6.19: kinetic stability of HA functionalised particles in water wash. 
 
 
6.7.7 Binding Survey for 64Cu-BPAMD 
In chapter 5 we presented the synthesis of the 64Cu-BPAMD  ligand. Herein we conducted an 
initial binding survey with a variety of inorganic materials (Figure 6.20).  Preliminary binding 
studies using HA (HA1) and 64Cu-(BPAMD) in 50 mM TRIS-HCl buffer (pH 7.4) indicated that 
binding equilibrium was reached within 10 minutes in solutions of 1 mg/mL (Figure 6.21). 
However, for consistency and comparison with the 99mTc(CO)3-DPA-Ale we chose an 
incubation time of 30 minutes for all 64Cu-(BPAMD) studies. Binding studies were performed 
as 99mTc(CO)3-DPA-Ale protocols, replacing the radiotracer with 
64Cu-(BPAMD).  The survey 
revealed high labelling efficiency across a wide range of materials, a similar trend was 
observed for 99mTc(CO)3-DPA-Ale. However, in general the % binding observed over the whole 
trend was generally higher, most notable for materials such as TiO2 and ZnO, increasing from 
ca. 45 and 60% to ca. 75 and 80% respectively. The binding % observed for SiO2 and CuO 
remained very low.  The general higher labelling efficiency observed may be attributed to 
interactions of the uncoordinated carboxylic acid pendant arms the DOTA- like moiety with 
the particle surface.      
 
Given the promising labelling results observed for HA nanoparticles, HA1HMP1 and 
HA1PEGBP1 using 99mTc(CO)3-DPA-Ale as a radiolabel, we investigated their 
64Cu-BPAMD 
binding properties. Their binding in 50 mM TRIS-HCl buffer (pH 7.4), kinetic stability in water 
washes and serum was assessed as described for 99mTc(CO)3-DPA-Ale (Figure 6.22). The 
binding properties of HA1 were also examined. The labelling efficiency of HA1HMPBP1 
(69.4%) was moderately reduced and no significant change was observed for HA1PEGBP1 
(86.4%), in comparison to HA1 (88.5%). For HA1, HA1PEG1 and HA1HMP1, there was no 







Figure 6.20: Survey of 
64
Cu-(BPAMD) binding materials. 
 
 
Figure 6.21: Binding of 
64





Figure 6.22: Kinetic stability of 
64




We have identified that 99mTc(CO)3-DPA-Ale can bind efficiently to a wide range of metal oxide 
materials. The binding efficiency was significantly greater than 99mTc-MDP for corresponding 
materials. Our aim was to exploit the BP interaction for multiple purposes: radiolabelling, 
stabilising, and attachment of targeting moieties. The concept can be applied to developing 
directly labelled nanoparticles (radiolabelled prior to injection) or pretargeted nanoparticles 
(radiolabelled BP chases nanoparticles in vivo). 
 
The binding of  99mTc(CO)3-DPA-Ale to metal oxide surfaces was achieved in a simple one step 
reaction,  in aqueous solution, without the need for complicated reaction or purification steps. 
Of course, an additional step was required to prepare the radiolabelled BP ligands. HA and 
Alhydrogel were identified as promising biocompatible materials, continuing from the 
promising 18F-fluoride binding results (Chapter 2.). They have bound 99mTc(CO)3-DPA-Ale 
efficiently at low concentrations applicable to in vivo studies. Moreover, the affinity of 




greater than that observed with 18F-fluoride.  Efficient labelling has been achieved in the 
presence of various biological and potential competitors. In particular, the 99mTc(CO)3-DPA-
Ale-HA and Alhydrogel interactions have proven robust under biological conditions, with only 
minor dissociation seen over time in serum. In addition, there is potential to moderately load 
HA nanoparticles with functionalising BP ligands, leaving sufficient space for radiolabelled BPs 
to bind in with high efficiency. More specifically, stabilised HAHMP and HAPEGBP particles can 
be labelled with high efficiency and biological stability. BP functionalised HA particles have the 
potential to operate as a platform for radiolabelling with either 18F-fluoride (Chapter 2) or 
99mTc(CO)3-DPA-Ale, introducing a multifunctional nanoparticle platform for radionuclide 
delivery.  
 
Preliminary binding studies with the 64Cu-(BPAMD) complex have also identified that it can 
bind efficiently to a wide range of metal oxide materials. We have shown that the 64Cu-
(BPAMD)-HA binding interaction occurs rapidly in 50 mM TRIS-HCl buffer (pH 7.4) and was 
robust in biological conditions. Stabilised HA1HMP1 and HA1PEGBP1 particles were labelled 
with high efficiency and biological stability. In future experiments we intend to conduct 
comprehensive binding studies with the 64Cu-BPAMD ligand, as performed with 99mTc(CO)3-
DPA-Ale within this chapter. However, time constraints have restricted these within this 
thesis.  
 
Further work in this thesis will focus on the preliminary in vivo studies with HAHMP, HAPEGBP 
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Pretargeting Studies and the in Vitro and in Vivo Behaviour of 18F, 99mTc 
and 64Cu Labelled Nanoparticles 
 
7.1 Overview  
In this chapter we have discussed in vitro and in vivo biological behaviour of 18F-fluoride and 
99mTc(CO)3-DPA-Ale labelled hydroxyapatite (HA) and Alhydrogel. Since macrophages 
contribute significantly to the removal and clearance of nanoparticles in vivo, a series of in 
vitro cell studies with macrophages were conducted. The aim was to assess the in vitro uptake 
of nanoparticles using electron microscopy and radiotracers. Macrophages were treated with 
nanoparticles then incubated with radiotracer to assess the intracellular binding properties of 
nanoparticles sequestered within cells. 
  
Preliminary in vivo investigations were performed in normal mice. The biological behaviour of 
HA2PEGBP1 and HA2HMP1, and Alhydrogel was studied with a view towards the pretargeting 
strategy. Initial SPECT-CT studies with 99mTc(CO)3-DPA-Ale labelled nanoparticles were 
performed to elucidate the in vivo fate and stability of these particles. These studies were 
followed by in vivo pretargeting experiments. Unlabelled particles were injected into normal 
mice and chased by a second injection with 99mTc(CO)3-DPA-Ale radiotracer. The results have 
been discussed and compared to in vitro/vivo 18F-fluoride studies with HA and Alhydrogel 
labelled particles, reported elsewhere.1 In addition, the in vivo behaviour of 64Cu-BPAMD and  
64Cu-BPAMD  labelled HA1PEGBP1 was  studied by PET-CT imaging.   
 
HA1, HA2 and Alhydrogel particles were sequestered within phagosomes inside macrophages. 
The in vitro radiolabelling studies of particles that were sequestered within cells, were 
inconclusive. 99mTc(CO)3-DPA-Ale labelled HA2PEGBP1, HA2HMP1 showed high uptake in the 
liver and spleen, and less lung uptake compared to untreated HA2 (observed in previous 
work).1 Presumably a consequence of disaggregation of HA2 in the HMP and PEG treated 
particles. There was no translocation of activity to the bone after 3 hours. 99mTc(CO)3-DPA-Ale 
labelled HA2PEGBP1 and Alhydrogel showed highest uptake within the spleen, attributed to 
the spleen filtration mechanism.  Preliminary pretargeting  studies with 99mTc(CO)3-DPA-Ale 
have indicated that it was possible to label Alhydrogel particles in vivo, either while circulating 
in blood or trapped within the spleen. The liver and spleen uptake was significantly increased 






When considering nanoparticle biodistribution in vivo, surface chemistry, size, charge and 
morphology play important roles in the interaction with cells and tissues of the body.2-5  In 
addition, the route of administration must also be considered. Strict control of particle 
properties is essential for producing a homogenous radiolabelled product with well 
characterised biodistribution. To overcome problems of aggregation leading to large and 
uncontrolled particle size, we have prepared HA particles functionalised with sodium 
hexametaphosphate (SHMP) and polyethyleneglycol (PEG) ligands to improve colloidal 
stability and homogeneity (Chapter 3). Some of the typical properties influencing the in vivo 
biodistribution of nanoparticles are discussed in chapter 1.  
 
Following intravenous injection, nanoparticles are exposed to blood and serum proteins that 
can bind to their surface. Proteins called opsonins promote recognition at macrophage cell 
surfaces and help internalise and remove nanoparticles from circulation.3, 6-8 Macrophages are 
predominately found in the liver, spleen and bone marrow, and a major constituent of the 
reticuloendothelial system (RES), thus, enhanced particle uptake is expected in these organs.  
The binding of serum proteins is influenced by particle properties such as surface charge and 
hydrophobicity.8-10 Moreover, the type of protein adsorbed can be influenced. For example, 
positively charge particles promote adsorption of albumin, while negatively charged particles 
can adsorb immunoglobulins such as IgG antibodies.8, 10 The adsorption of proteins can 
influence the biodistributrion of nanoparticles, since proteins such as IgG are believed to 
promote uptake by the RES system,9, 10 while albumin is believed to prolong circulation in 
blood.11 In addition, nanoparticles can be manipulated to restrict protein binding. For 
example, we have introduced a PEG ligand onto the surface of HA to increase hydrophilicity 
and colloidal stability, a technique that has routinely been used to increase blood circulation 
times of nanoparticles.6, 8, 12 The increased hydrophilicity and stability of PEG modified 
particles can restrict the binding of serum proteins, thus inhibiting the process of macrophage 
uptake by the RES. Nanoparticle size and shape also has a major influence on their in vivo 
behaviour.13-20 The size and shape of a particle determines its velocity in the bloodstream, and 
its capacity for diffusion across and adhesion to blood vessels, airways and the extracellular 
matrix (Chapter 1).   
 
7.3 Aims 
In this chapter we aimed to assess the in vitro behaviour of HA and Alhydorgel nanoparticles 




clearance mechanism of nanoparticles. In the pretargeting concept, we envisaged that 
untargeted nanoparticles will predominantly clear via the RES. We suggested that particles 
sequestered within macrophages in the RES will be inaccessible to the secondary radiolabelled 
chasing probe. This will reduce background interference from the major components of the 
RES (e.g. liver, spleen and bone marrow) and allow the tracer to track the targeted 
nanoparticles elsewhere. We aimed to test this theory in vitro by using a two step method; 
nanoparticles were incubated with macrophages (allowing macrophages to internally 
sequester the particles), then the internalised particles were chased by addition of a tracer. 
The aim was to identify if tracer can traverse the cell membrane and bind to internalised 
nanoparticles. 
 
Initial in vivo studies focused on prelabelled nanoparticles. These experiments were 
conducted to determine the in vivo fate of the nanoparticles. We envisaged that nanoparticles 
functionalised with ligands to prevent aggregation (HA2HMP1 and HA2PEGBP1) would alter 
their in vivo behaviour compared to untreated HA2 (which is largely aggregated and 
accumulates in the lungs).1 Ultimately we aimed to produce particles with prolonged blood 
half-life for targeting purposes. Finally, pretargeting experiments are discussed. This involved 
injecting unlabelled nanoparticles, then chasing them with a tracer injection some time later. 
In this context, the particles were untargeted. These initial studies were performed to assess if 
particles trapped in organs such as the liver and spleen are assessable to tracer.     
 
Experimental Aims 
 Investigate the in vitro behaviour and uptake of HA and Alhydrogel nanoparticles in 
macrophages. 
 Perform preliminary in vivo studies with prelabelled (99mTc(CO)3-DPA-Ale and 
64Cu-
BPAMD), functionalised HA and Alhydrogel.  
  Perform preliminary pretargeting experiments, using 99mTc(CO)3-DPA-Ale for initial 
proof of concept. 
 
7.4 Methods and Materials 
The radiotracers 18F-fluoride and 99mTc(CO)3-DPA-Ale were prepared as described in chapters 2 
and 4. The preparation of HA1, HA2, HA1PAMFITC, HA2HMP1, HA2PEGBP1 and HA1PEGBP1 






7.4.1 In Vitro Macrophage Studies 
 
Cell Culture Conditions  
Media and reagents were obtained from PAA (Yeovil, UK). The J774.1 cell line (macrophage, 
derived from a tumour in a female BALB/c mouse, kindly provided by Dr. Helen Collins, King’s 
College London) and grown in a humidified incubator at 37 °C with 5% CO2 in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% foetal calf serum (FCS), 10 mM 
HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine and penicillin/streptomycin. 
 
(i) Phagocytic Uptake of Hydroxyapatite Nanoparticles – Electron Microscopy 
Phagocytic uptake of HA nanoparticles was demonstrated by transmission electron 
microscopy as follows. J774.1 cells were seeded in 6 well plates at a density of 5 × 105 cells per 
well in the above medium (2 mL) and incubated in a humidified incubator at 37 °C with 5% 
CO2 for 48 h. HA1 and HA2 (2 mL, 100 μg/mL) in phosphate buffered saline (PBS) were added 
to the cells and incubated at 37 °C, 5% CO2 for 4 h. Cells were washed three times with PBS (2 
mL) and detached from the wells by scraping. The cells were pelleted by centrifugation at 
1500 rpm for 5 minutes and resuspended in piperazine-N,N′-bis(2-ethanesulfonic acid) buffer 
(PIPES) 0.1 M (1 mL). Cells were then fixed by adding 4% glutaraldehyde (1 mL) and incubating 
for 1 h before washing twice and resuspending in 0.1 M PIPES buffer (1 mL), post fixed in 1% 
aqueous osmium tetroxide and dehydrated through a graded series of ethanol and embedded 
in TAAB resin. Sections 70 nm thick were cut using a Leica ultracut E ultra microtome (Leica, 
Milton Keynes, UK), mounted on 200 mesh Cu grids (Agar Scientific, Stansted, UK), and stained 
with 1.5% uranyl acetate in 50% ethanol and 0.15% lead citrate before viewing on a Tecnai 
T12 electron microscope (FEI, the Netherlands). Images were captured using a Gatan Bioscan 
792 camera (Gatan, Abingdon Oxon, UK). 
 
(ii) Confocal Microscopy  
Phagocytic uptake of fluorescent HA nanoparticles was demonstrated by confoncal 
microscopy as follows. J774.1 cells were seeded in 6 well plates containing glass coverslips at a 
density of 5 × 105 cells per well in the above medium (2 mL) and incubated in a humidified 
incubator at 37 °C with 5% CO2 for 48 h. HA1PAMFITC (2 ml, 100 μg/mL) in phosphate 
buffered saline (PBS) were added to the cells and incubated at 37 °C, 5% CO2 for 4 h. Cells 
were washed three times with PBS (2 mL). Next, cells were fixed by adding 4% 
paraformaldehyde (1 mL), incubating for 10 min at RT, and washed three times in PBS (2 mL) , 
followed by washing three times in H2O (2 mL). Coverslips were carefully removed and 




mounting media. The slides were analysed by fluorescent microscopy using a Leica SP5 II 
microscope.   
 
(iii) In Vitro Radiolabelling of Macrophages Treated with Nanoparticles 
The uptake of 18F-fluoride and 99mTc(CO)3-DPA-Ale in macrophage cells treated with HA and 
Alhydrogel nanoparticles was measured. The aim was to elucidate whether the “free” 
radiolabelled ligand could traverse the cell membrane and bind to the intracellular 
sequestered nanoparticles.  Cells were seeded in 50 mL flasks, split 1:20 and incubated in the 
above medium (30 mL) in a humidified incubator at 37 °C with 5% CO2 for 72 h. Cells were 
washed three times with PBS (30 mL) and detached from the flask by scraping. The cells were 
pelleted by centrifugation at 1500 rpm for 5 minutes and resuspended in PBS (2 mL).  The cells 
were divided into suspensions containing 10 X 106 cells in PBS (9 mL) in Falcon tubes (50 mL).  
A solution containing 1 mg/ mL nanoparticles (HA1, HA2, or Alhydorgel) in PBS (1 mL) was 
added to the suspension. The particle containing cell suspension was incubated with 
continuous shaking at 37 °C for 4 h. The cells were pelleted by centrifugation at 1500 rpm for 
5 minutes and resuspended in PBS (7 mL). The cells were carefully placed on Percoll (23% 
W/W) (7 mL) in 15 mL Falcon tubes. The layered suspension was centrifuged at 1700 rpm for 
15 minutes. Cells remain at the Percoll/ PBS interface while unbound nanoparticle material 
was pelleted. The cell containing layer was carefully removed by pipette and washed three 
times with PBS (5 mL). Cells (2 x 106) were resuspended in PBS (0.5 mL), and incubated with 
18F-fluoride or 99mTc(CO)3-DPA-Ale (20 µL, 1-2 MBq) at 37 
oC for 30 min. The fraction of activity 
associated with cells was calculated via equation 7.1. Control samples containing 
nanoparticle-free cells were prepared to eliminate any non-specific uptake of radiolabel.   
 
Labelling efficiency %  =  [1- (Activity in supernatant aliquot/ activity in standard 
aliquot)]x100   
Equation 7.1: Equation to calculate cell labelling efficiency. 
 
7.4.2 In Vivo Studies 
Animal studies were carried out in accordance with UK research councils’ and medical 
research charities’ guidelines on responsibility in the use of Animals in Bioscience Research, 
under a UK home office license. Female BALB/c mice (aged 7–14 weeks) were purchased from 





(i) In Vivo Biodistribution and Imaging of Labelled Nanoparticles 
99mTc(CO)3-DPA-Ale Labelled Nanoparticles 
 
For HA2PEGBP1, HA2HMP1 and Alhydrogel, mice received i.v. (tail vein) injections of 
approximately 20 MBq of 99mTc(CO)3-DPA-Ale-labelled nanoparticles (1mg/mL), (prepared as 
described in chapters 6 and 7) suspended in 75 μl saline. With the mouse under isofluorane 
anaesthesia in a Minerve imaging chamber, SPECT/CT scans were acquired from 30 min to 3 h 
using a NanoSPECT/CT animal scanner (Bioscan Inc.). Whole-body SPECT images were 
obtained in 20 projections over 30 minutes using a 4-head scanner with 4 × 9 (2 mm) pinhole 
collimators in helical scanning mode and CT images with a 45 kVP X-ray source, 1000 ms 
exposure time in 180 projections over 7.5 minutes. Images were reconstructed in a 256 × 256 
matrix using HiSPECT (ScivisGmbH), a reconstruction software package, and images were 
fused using proprietary Bioscan InVivoScope (IVS) software. After 3 h, the mice were culled by 
cervical dislocation and the following organs were dissected: femur, pancreas, kidneys, heart, 
stomach, spleen, intestine, liver, lung, muscle, and a sample of blood. Each sample was 
weighed and counted with a gamma counter ((Wallac 1282-001 Compugamma CS), together 
with standards prepared from a sample of the injected material. The percent of injected dose 
per gram of tissue was calculated for each tissue type. 
 
64Cu-BPAMD Labelled Nanoparticles and 64Cu-BPAMD 
For HA1PEGBP1, mice received i.v. (tail vein) injections of approximately 10 MBq of 64Cu-
BPAMD labelled nanoparticles (1mg/mL) (prepared as described in chapters 6 and 7) 
suspended in 75 μl saline. With the mouse under isofluorane anaesthesia in a Minerve 
imaging chamber.  PET /CT scans were acquired at 45 and 75 minutes with a NanoPET-CTTM 
preclinical animal scanner (Mediso Ltd., Bioscan Inc.). Image acquisition took place in list 
mode format. Acquisition time was 30 min. List-mode data were sorted into 400-600 keV 
energy-window, 5 ns time-window; crystal-efficiency correction was applied. Reconstruction 
method was OSEM (6 subsets, 8 iterations, 0.29 mm pixel size, 0.585 mm axial thickness) 
based on SSRB 2D LOR rebinning (linear interpolation, 16 span-size). The CT images were 
obtained with 55 kVp tube voltage, 1200 ms exposure time in 360 projections. The two 
modalities (PET and CT) were fused using InVivoScope (Bioscan)software. After 3 h, the mice 
were culled by cervical dislocation and the following organs were dissected; femur, pancreas, 
kidneys, heart, stomach, spleen, intestine, liver, lung, muscle and a sample of blood. Each 
sample was weighed and counted with a gamma counter ((Wallac 1282-001 Compugamma 
CS), together with standards prepared from a sample of the injected material. The percent of 




For 64Cu-BPAMD (without nanoparticles) the protocol was as above, except 64Cu-BPAMD 
labelled nanoparticles were replaced with 10 MBq of 64Cu-BPAMD suspended in 75 μl saline. 
 
(ii) In Vivo Biodistribution and Imaging of Pretargeted Nanoparticles 
Pretargeting Studies with 99mTc(CO)3-DPA-Ale  
For HA2PEGBP1 and Alhydrogel, mice received two sequential  i.v. (tail vein) injections; firstly, 
“unlabelled” nanoparticles (1mg/mL) suspended in 75 μl saline, secondly, after a period of 
either 20 or 2 minutes approximately 20 MBq  of 99mTc(CO)3-DPA-Ale, suspended in 50 μl 
saline. With the mouse under isofluorane anaesthesia in a Minerve imaging chamber, 
SPECT/CT scans were acquired from 30 min to 3 h using a NanoSPECT/CT animal scanner 
(Bioscan Inc.). For second injections after 20 minutes,  whole-body SPECT images were 
obtained in 20 projections over 30 minutes using a 4-head scanner with 4 × 9 (2 mm) pinhole 
collimators in helical scanning mode and CT images with a 45 kVP X-ray source, 1000 ms 
exposure time in 180 projections over 7.5 minutes. For second injections after 2 minutes, 
SPECT/CT images of the liver and spleen region were collected over 5 minutes, a whole body 
SPECT/CT image was taken at 1 h over a period of 30 minutes.  Images were reconstructed 
and mice were culled at 3 h and dissected for biodistribution data as the described in the 
above SPECT/CT protocol. 
 
7.5 Results and Discussion 
7.5.1 In Vitro Cell Studies 
The reticulendothelial system (RES) has a major influence on the ultimate in vivo fate and 
clearance of nanoparticles.13, 21, 22 Phagocytic cells- macrophages found in the liver, spleen and 
bone marrow are a key component of the RES. Macrophages, such as Kupffer cells in the liver, 
induce the body’s immune response to foreign nanoparticles, and sequester them. Although 
HA is a well known biocompatible material, relatively little is known about the in vivo 
behaviour of these particles. Recent interest in the biological behavior of HA nanoparticles has 
been driven by their potential as drug delivery agents.23 The uptake of HA nanoparticles by 
macrophages in vitro has been discussed.24, 25 In summary, these authors found that HA 
nanoparticles were sequestered by the phagocytic pathway and dissolved in lysosomes over 
time. The uptake of HA was highly dependent on particle properties, such as size, shape and 
surface charge. For example, positively charged rod-like HA particles showed high uptake in 
macrophages, in comparison to negatively charged spherical particles. Furthermore, relatively 
high quantities of HA nanoparticles were required to induce toxicity (e.g.>250 µg/mL).25 




mechanisms.26 We have therefore studied the interaction of the HA and Alhydrogel particles 
with cultured macrophages (J774.1).  
 
To demonstrate the macrophage uptake of HA nanoparticles (HA1, HA2) and Alhydrogel we 
have analysed samples via TEM (Figure 7.1). The phagocytic uptake of HA particles was 
confirmed by the presence of aggregates of HA particles and Alhydrogel within endosomes in 
the cytoplasm of the cells. Dissolution of the particles was not observed within the acidic 
environment of lysosomes. However, it is expected the dissolution process requires more time 
than 4 h, for example, 24 h observed by Motskin et al.25 In addition, fluorescently labelled 
HA1PAMFITC particles were incubated with macrophages under similar conditions. The z-stack 
confocal images (Figure 7.2) showed punctuate fluorescent spots within the mocrophages, 
indicating that the fluorescent particles were also located within endosome compartments. 
These examples demonstrated that macrophages uptake HA nanoparticles by phagocytosis, 
hence providing a mechanism for clearance of nanoparticles from circulation in vivo. In some 
instances macrophage uptake would be an advantage while in others it must be protected 
against. For example, particle clearance is essential to achieve high target-to-background ratio 
for targeted nanoparticles. In contrast, extensive and rapid macrophage uptake could reduce 
nanoparticle availability and blood half-life for active targeting protocols.  
 
We proposed that nanoparticles taken up by macrophages will be invisible in the pretargeted 
nanoparticles system. The sequestered nanoparticles should mask them from the chasing 
radiotracer, thus reducing interference from the RES organs, and improving signal-to-
background ratios. To benefit from the proposed “invisibility” of phagocytically-cleared 
nanoparticles, it is essential that nanoparticles located within macrophages are inaccessible to 
the radiotracer, so that radiotracer will only bind in vivo to nanoparticles not located within 
cells.  
 
A series of in vitro radiolabelling experiments were conducted to assess whether radiotracer 
could traverse the cell membrane of macrophages and bind to intracellular nanoparticles 
(Figure 7.3). Macrophages were incubated with HA or Alhydrogel, washed and resuspended in 
cell media. Next, radiotracer was added to the cell media mixture and incubated for 30 
minutes at 37 oC. Initial experiments were inconclusive because it could not be shown that 
radioactivity binding was due to intracellular rather than extracellular nanoparticles. The 
experiment was refined to separate extracellular nanoparticles from intact cells containing 




HA1, HA2 and Alhydrogel nanoparticles as described above. Free nanoparticles were 
separated from the treated macrophages using a Percoll gradient and washed with PBS. The 
nanoparticle treated cells were then incubated with 18F-fluoride or 99mTc(CO)3-DPA-Ale, along 




Figure 7.1: TEM images of nanoparticle uptake in murine macrophages J744.1. (A) HA1  (B) HA2  (C) 
Control, (D) Alhydrogel*. The images show internalisation of HA nanoparticles via non specific 
endocytosis. Nanoparticle aggregates can be seen in endosome compartments, traversing though the 
cytosol. * Image D was provided by Dr Arnaud Glaria, KCL and shows large granular Alhydrogel being 

















Figure 7.2: Confocal Z-Stack images of HA2FITCBP uptake in murine macrophages J744.1. The blue 
regions are associated with the nuclear stain (DAPI), green regions in the cytosol are punctuate and can 
be attributed to phagocytosed HA2FITCBP nanoparticles within endosomes. 
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Figure 7.3: Accumulation of 
99m
Tc(CO)3-DPA-Ale  (Top) and  
18
F-fluoride (Bottom) in particle treated 
macrophages (J774.1). 
 
Untreated macrophages showed low uptake of radiotracer, 0.5% and 4% for 18F-fluoride or 
99mTc(CO)3-DPA-Ale respectively. Macrophages treated with nanoparticles showed an increase 
in uptake of 18F-fluoride; 12, 20 and 5% for HA1, HA2 and Alhydrogel respectively. When 
99mTc(CO)3-DPA-Ale was introduced into cell media containing treated macrophages, a 
remarkably high fraction of activity was associated with the macrophages; 68, 80 and 87% for 
HA1, HA2 and Alhydrogel respectively. These results implied that 99mTc(CO)3-DPA-Ale could 
efficiently bind to intracellular HA and Alhydrogel, while loaded nanoparticles are relatively 
shielded from 18F-fluoride. The high binding observed for 99mTc(CO)3-DPA-Ale may be related 
to the efficient endocytosis of bisphosphonate molecules,27, 28 in contrast to relatively slow 
fluoride uptake observed in cells.28, 29 In addition, the differences in binding results could be 
explained by the lower affinity of 18F-fluoride for HA (Chapters 2 and 6), while the 




related to instability of the 18F-Alhydrogel interaction in biological media. To summarise, the 
results shown were inconclusive, since intracellular nanoparticle concentrations were not 
defined and presence of extracellular nanoparticles able to bind radiotracers has not been 
completely ruled out by analytical methods after the Percoll gradiant separation.  
 
Additional studies involving the uptake of labelled particles performed in our laboratory are 
reported elsewhere.1 Briefly, prelabelled 18F-HA and -Alhydrogel, and 18F-fluoride as a control, 
were incubated with J774.1 cells. 18F-fluoride was not significantly taken up by macrophages 
(<0.2%), whereas the 18F-fluoride-labelled HA showed progressive association with cells 
reaching over 70% uptake by 3 h. Uptake of labelled Alhydrogel was much less marked during 
this period, which could be explained by rapid uptake and rapid release of free fluoride, due 
to the instability of the 18F-Alhydrogel interaction under these conditions.  
 
7.5.2 In Vivo Studies  
The promising colloidal stability and high labelling efficiency of HA2PEGBP1 and HA2HMP1 has 
prompted in vivo studies to elucidate the biological behaviour of these particles. In addition, 
Alhydrogel was studied since it has routinely and safely been used as a clinical adjuvant in vivo 
and has shown promising labelling properties.   
 
The kinetic stability of 99mTc(CO)3-DPA-Ale labelled HA2PEGBP1, HA2HMP1 and Alhydrogel 
nanoparticles in biological media, such as serum indicated that the in vivo fate of the 
nanoparticles, and the in vivo stability of the radiolabel, can be monitored in vivo by SPECT 
imaging. The latter is possible because 99mTc(CO)3-DPA-Ale released from the nanoparticle 
surface in vivo would show characteristic uptake in the joints of the skeleton. Labelled 
particles were administered by intravenous injections in normal mice. The observed 
biodistribution of 99mTc(CO)3-DPA-Ale labelled HA2PEGBP1, HA2HMP1 nanoparticles was 
dependant on their surface chemistry, charge and state of aggregation. SPECT/CT images 






Figure 7.4: SPECT/CT images of intravenously injected 
99m
Tc(CO)3-DPA-Ale–Alhydrogel in normal mice at 




Figure 7.5: SPECT/CT images of intravenously injected 
99m
Tc(CO)3-DPA-Ale–HA2PEG1 in normal mice at 
30 minutes (Left) and 3 h (Right) High liver and spleen uptake, less lung uptake than previously observed 
for untreated HA2 particles,
1





Figure 7.6: SPECT-CT images of intravenously injected 
99m
Tc(CO)3-DPA-Ale–HA2HMP1 in normal mice at 
30 minutes (Left) and 3 h (Right) High liver and spleen uptake, less lung uptake than previously observed 
for untreated HA2 particles,
1
 but more than the HA2PEGBP1 particles above. Less aggregated than HA2 
but more aggregated than HA2PEGBP1. 
 
After intravenous injections, the labelled HA2HMP1 and HA2PEGBP1 particles accumulated in 
the liver and spleen and to a lesser extent the lungs. There was also significant renal excretion, 
indicating that some particles are small enough to (i.e < 10 nm) to be filtered by the kidneys.2, 
5, 30 After 3 h there was no translocation of activity to the bone, indicating that the radiotracer 
remained nanoparticle bound or trapped within phagocytic cells. The average particle sizes of 
HA2PEGBP1 and HA2HMP1 in solution were ca. 355 and 198 nm respectively, measured by 
DLS (Chapter 3). Given the size of these particles it is expected they will accumulate mainly in 
the liver and spleen.13, 21, 22  
 
For HA2HMP1 a marked fraction of activity is observed in the lungs, suggesting larger 
aggregates of particles were trapped by embolisation in the lungs. The lung uptake of 
HA2PEGBP1 was significantly reduced, indicating better colloidal stability in vivo. Major 
differences were observed between spleen and liver accumulation, depending on the 
nanoparticles used. HA2PEGBP1 had very high spleen uptake (ca. 200% ID/g), whereas 
HA2HMP1 was much lower (ca. 50% ID/g). The spleen to liver ratios were 2.3 and 0.5 for 
HA2PEGBP1 and HA2HMP1 respectively (Figure 7.8), highlighting the preferential spleen 
uptake of HA2PEGBP1 particles. This observation can be explained by variation in surface 




stabilisation, thus, hindering adsorption of proteins responsible for inducing phagocytic 
uptake mechanisms in the RES. However, instead of increased blood half-life we observe 
increased spleen uptake. The observed biodistribution can be explained by a size dependant 
filtration system in the spleen. Uptake in the liver is highly dependant on phagocytic 
mechanisms (relatively non size dependant), thus the pegylated particles can evade liver 
accumulation. However, it has been shown that the interendothelial slits within the spleen are 
ca. 200-500 nm, therefore allowing only particles smaller than 200 nm to pass through.31-34 
The HA2PEGBP1 particles appear large enough to be trapped in this fashion. Once trapped in 
the spleen the particles will eventually succumb to phagocytic uptake. In contrast, the 
negatively charged surface of HA2HMP1 could induce the adsorption of proteins or antibodies 
to promote phagocytic uptake in the liver, such as IgG.9, 10 For comparison, the biosdistribution 
of 99mTc(CO)3-DPA-Ale (nanoparticle free) at 3 h, is shown in figure 7.9.  
 
After intravenous injection of 99mTc(CO)3-DPA-Ale labelled Alhydrogel, the particles 
accumulated in the liver and spleen. No translocation of activity to the skeleton was observed, 
implying the radiolabel-nanoparticle interaction remains intact or trapped in macrophages. As 
with HA2PEGBP1 particles, uptake was predominately observed in the spleen. Alternatively, 
the observed biodistribution may be explained by surface charge rather than surface 
chemistry. The Alhydrogel nanoparticles carry a positive surface charge. This has been related 
to adsorption of serum proteins such as albumin, which is known to prolong blood half-life, 
presumably through evading macrophage uptake.11 However, the Alhydrogel particles are 
known to be ca. 2000 nm as measured by DLS, therefore, they will be subject to the same 


















Figure 7.7: Biodistribution of intravenously injected, radiolabelled nanoparticles in normal mice at 3 h, 
where n=1.  
99m






Figure 7.8: Biodistribution spleen/liver ratios of intravenously injected, radiolabelled nanoparticles in 
normal mice at 3 h, 
99m
Tc(CO)3-DPA-Ale – Alhydrogel, HA2HMP1 and  HA2PEG1.    
 
 
Figure 7.9: Biodistribution of intravenously injected 
99m
Tc(CO)3-DPA-Ale in  normal mice at 3 h, where 
n=3 mice. 
 
The high splenic uptake of radiolabelled HA2PEGBP1 and Alhydrogel could be described as 
passive targeting as the particles are being trapped by virtue of their size. We envisaged that 
we could exploit the high splenic uptake of these particles to assess our in vivo pretargeting 
strategy. Given that 99mTc(CO)3-DPA-Ale accumulates almost exclusively in the bone, we 
propose nanoparticles trapped, or sequestered in spleen macrophages, may be accessible for 
binding radiotracer injected as a chasing agent. Any radiotracer that accumulates in the spleen 







                                                                                
 
 
Figure 7.10: Whole body SPECT/CT images of attempted pretargeting in normal mice at 1 h post 
radiotracer injection. Unlabelled nanoparticles were intravenously injected, then chased by i.v. injected 
tracer  (
99m
Tc(CO)3-DPA-Ale) 20 min later. (Left) Alhydrogel (Right) HA2PEGBP1. High bone uptake of the 
tracer is observed in both images, suggesting particles trapped in the liver and spleen are not accessible 
to the tracer. 
 
HA2PEGBP1 and Alhydorgel nanoparticles were injected intravenously, followed by a chasing 
intravenous injection of 99mTc(CO)3-DPA-Ale 20 minutes later. The SPECT/CT images are 
displayed in figure 7.10. Characteristic bone scans are observed in all SPECT/CT images at 1 h, 
showing little uptake in the liver or spleen and significant renal excretion, although images 
could be manipulated to show spleen and liver uptake. The corresponding biodistribution data 
at 3 h (Figure 7.11) shows increased levels of activity in the spleen compared to 99mTc(CO)3-
DPA-Ale (without nanoparticle pre-administration). The spleen uptake was 1.9 and 5.6% ID/g, 
compared to 0.6% ID/g for pretargeted HA2PEGBP1, Alhydrogel, and 99mTc(CO)3-DPA-Ale 
(without nanoparticles preadministration) respectively, where animals were culled at 3 h. The 
spleen uptake of radiotracer for the pretargeted Alhydrogel experiment was increased almost 
10-fold. However, the change was not significant and difficult to observe by SPECT/CT (Figure 
7.10), spleen uptake is only visible if images are manipulated to show it. It was thought that 
Alhydrogel sequestered in macrophages at the 20 minute time point may be invisible to 
radiotracer. We thought that reducing the time gap between particles and chasing radiotracer 








Figure 7.11: Biodistribution of attempted pretargeting in normal mice at 3 h post radiotracer injection. 
Unlabelled nanoparticles were intravenously injected, then chased by i.v. injected tracer (
99m
Tc(CO)3-
DPA-Ale) 20 min later. (Top) Alhydrogel  (Bottom) HA2PEGBP1 (n=3 mice in both experiments). 
 
Alhydrogel was selected for further investigation, since the highest spleen accumulation was 
observed. Alhydrogel nanoparticles were injected intravenously, followed by a chasing 
intravenous injection of 99mTc(CO)3-DPA-Ale 2 minutes later. The SPECT/CT images (Figures 
7.12 and 7.13) and biodistribution data (Figure 7.14) are discussed. High spleen and liver 
uptake was observed in SPECT/CT images as early as 6 minutes post injection of radiotracer, 
indicating accumulation was rapid. The whole body SPECT/CT scan at 1 h shows spleen, liver 
and bone uptake.  The biodsitribution data showed significant increase in spleen (25.9% ID/g) 
and liver (21.8% ID/g) uptake, and similar bone accumulation (15.6% ID/g), compared to 
spleen (0.6% ID/g), liver (4.1% ID/g) and bone (16.2% ID/g) uptake observed for 99mTc(CO)3-




of % ID/g are displayed in figure 7.15. Most notable was the high spleen/liver and spleen/bone 
ratio observed for the pretargeted Alhydrogel experiment at 2 minutes. From the observed 
biodistribution and SPECT/CT, we can attribute the spleen and liver accumulation to an in vivo 
interaction with the Alhydrogel. The interaction is stable in vivo for up to 1 h. However, since 
we do not know the in vivo fate of the unlabelled nanoparticles at <2 minutes (before the 
chasing injection), we cannot confirm the binding interaction occurs in the spleen. It may be, 
at this short time point, that a significant fraction of nanoparticles remain in the blood pool, 
and radiolabelling may occur here. Without further studies, the targeting of nanoparticles 
trapped in the spleen is not conclusive. Nevertheless the images showed conclusively that the 
radiotracer can effectively bind to the nanoparticles in vivo and thereby demonstrate their 





Figure 7.12: Whole body SPECT/CT images of attempted pretargeting in normal mice at 1 h post 
radiotracer injection. Unlabelled Alhydrogel was intravenously injected, then chased by i.v. injected 
tracer (
99m
Tc(CO)3-DPA-Ale) 2 min later. High bone, liver and spleen uptake is observed. Uptake in the 
liver and spleen indicates in vivo binding of 
99m










Figure 7.13: Sequential SPECT/CT images of attempted pretargeting in normal mice at (A) 6 min (B) 12 
min (C) 18 min (D) 24 min (E) 30 min (F) 36 min post radiotracer injection. Unlabelled Alhydrogel was 
intravenously injected, then chased by i.v. injected tracer (
99m
Tc(CO)3-DPA-Ale) 2 min later. High uptake 
is observed in the liver and spleen within 6 minutes, indicatating that the in vivo binding of 
99m
Tc(CO)3-




Figure 7.14: Biodistribtuion of attempted pretargeting in normal mice at 3 h post radiotracer injection. 
Unlabelled Alhydrogel was intravenously injected, then chased by i.v. injected tracer (
99m
Tc(CO)3-DPA-








Figure 7.15: Biodistribution spleen/liver and spleen/bone ratios of intravenously injected nanoparticles 
(Alhydrogel and HA2PEGBP1) chased by 
99m
Tc(CO)3-DPA-Ale (2 or 20 minutes later),  in normal mice at 3 
h post radiotracer injection. Includes ratios for nanoparticle free 
99m
Tc(CO)3-DPA-Ale(without 
preadministration of nanoparticles). 
 
 
7.5.3 64Cu-BPAMD in Vivo Studies 
First-in-man studies with 68Ga-BPAMD have shown excellent bone targeting properties.35 To 
our knowledge no 64Cu complex of BPAMD has been prepared. Replacing 68Ga with 64Cu in the 
BPAMD complex could incorporate therapeutic properties to the bone targeting BPAMD 
ligand. The 64Cu-BPAMD complex may be a useful tool for diagnosis and treatment of bone 
disease. However, within this thesis we aim to exploit the 64Cu-BPAMD complex to radiolabel 
nanoparticles for application in the pretargeting strategy. The BPAMD ligand offers an 
alternative to the 99mTc-DPA-Ale complexes discussed above. The versatile nature of the DOTA 
ligand offers a useful platform to expand the choice of radionuclide used in the pretargeting 
strategy, for example the 64Cu radionuclide may be used for therapeutic applications. Herein 
we discuss preliminary in vivo studies, in mice; first with the 64Cu-BPAMD ligand and next with 
64Cu-BPAMD labelled HA1PEGBP1 nanoparticles. The in vitro kinetic stability of 64Cu-BPAMD 
(nanoparticle free) and 64Cu-BPAMD labelled HA1PEGBP1 nanoparticles in serum indicated 
that their in vivo fate of can be monitored by PET imaging (Chapter 6).  
 
After intravenous injection of 64Cu-BPAMD, a characteristic bone scan with high joint uptake 
was observed at 45 and 75 minutes (Figure 7.17). There was also significant renal excretion. 
The biodistribution data (Figure 7.16) for mice culled at 3 h shows significant uptake in the 
bone (ca. 11% ID/g) and  low liver, spleen, kidney and stomach accumulation (ca. <2% ID/g), 
comparable to values observed for 99mTc-DPA-Ale (Figure 7.9). After intravenous injection of 
64Cu-BPAMD-HA1PEGBP1 (prelabelled particles), particles accumulated in the liver and spleen, 




observed in the PET/CT images, indicating that some particles are small enough to be filtered 
by the kidneys (Figure 7.18).2 ,5, 30 After 3 h there was no translocation of activity to the bone, 
indicating that radiotracer remains nanoparticle bound or trapped within phagocytic cells, 
unless free copper is released from the DOTA complex, where accumulation would be 
expected in the liver and gut. As seen with the 99mTc-DPA-Ale-HA2PEGBP1 particles (see 
above) accumulation in the spleen was highest with a similar spleen/liver uptake ratio (1.9 for 
64Cu-BPAMD-HA1PEGBP1 and 2.3 for 99mTc-DPA-Ale-HA2PEGBP1), presumably trapped by the 
spleen filtration mechanism described above. There was also a marked decrease in lung 
accumulation, compared to 99mTc-DPA-Ale-HA2PEGBP1. This can be attributed to the 
improved colloidal stability of the pegylated HA1 over HA2 particles, observed in chapter 3 
DLS studies.   
 
Figure 7.16: (Top) Biodistribution of Intravenously injected 
64
Cu-BPAMD in  normal mice at 3 h, where 
n=3 mice..(Bottom) Biodistribution of intravenously injected 
64
Cu-BPAMD labelled HA1PEGBP1 at 3 h, 







Figure 7.17: PET/CT images of intravenously injected 
64
Cu-BPAMD in normal mice at 45 minutes (Left) 





Figure 7.18: PET/CT images of intravenously injected 
64
Cu-BPAMD-HA1PEGBP1 nanoparticles in normal 






7.6 18F-fluoride In Vivo Studies  
Additional studies investigating the in vivo fate of 18F-fluoride labelled HA and Alhydrogel have 
been conducted by other members of our group. The results are published elsewhere,1 and 
the findings are summarised herein for comparison. Four different nanoparticles preparations 
were labelled with 18F-fluoride: HA2, HA4, HA4-PEG0.1, and Alhydrogel.  HA2 and Alhydrogel 
correspond to the materials discussed within this thesis, while HA4 is a less aggregated 
untreated HA and HA4-PEG0.1 is a pegylated preparation of HA4.  
 
The promising high labelling efficiency and stability in vitro suggested that the in vivo fate of 
the nanoparticles could be monitored by PET imaging.  It was thought that since 18F-fluoride 
has high affinity for bone, any free or dissociated radioactivity would be displayed by 
distinctive uptake in the skeleton.  Labelled particles were administered by the sub-cutaneous, 
intramuscular and intravenous routes. The observed biodistribution of 18F-labelled HA 
nanoparticles in normal mice was dependant on the route of administration and the state of 
aggregation of the particles. Labelled particles injected sub-cutaneously and intramuscular 
showed that all activity remained at the site of injection over a period of 4 h. There was no 
translocation of activity to the skeleton, indicating high in vivo stability. After intravenous 
injection of 18F-HA2, most activity was trapped by embolisation in the lungs, corresponding to 
its highly aggregated nature. The activity remained associated to the particles trapped in the 
lungs over a period of 4 h. The less aggregated forms of HA, (HA4 and HA4-PEG0.1) showed 
much less lung uptake, and significant spleen and liver accumulation. The lungs were by-
passed by these preparations, due to their smaller particle sizes.  After 30 minutes, particles 
that were trapped in the liver and spleen released progressive amounts of radioactivity that 
accumulated in the skeleton, presumably associated with phagocytic dissolution of the 
particles, releasing the radiolabel.  
 
For 18F-Alhydrogel nanoparticles injected sub-cutaneously and intramuscularly, PET scans 
showed that the majority of activity remained at the sight of injection over a period of 4 h. 
There was slight evidence of translocation to the skeleton, indicating moderate in vivo 
stability. After intravenous injection of 18F-Alhydrogel, the particles accumulated in the liver 
and spleen, with some renal excretion. The translocation of activity to the skeleton was more 
rapid than that observed for intravenously injected HA and faster than for sub-cutaneous and 
intramuscular injected Alhydrogel, implying rapid release of radioactivity occurs mainly in the 
liver and spleen. A large amount of radioactivity appears to accumulate rapidly in the bladder, 




fragments small enough for renal filtration, without releasing free fluoride, since minimal joint 
uptake was observed in the 30 min PET-CT scan. Release of free fluoride is associated to 
skeletal uptake observed later than the initial renal excretion. 
 
In comparison to the modified HA labelled with 99mTc(CO)3-DPA-Ale reported within this 
chapter, the in vivo stability of liver and spleen trapped nanoparticles is significantly different, 
the exact mechanism cannot yet be explained. The retention of radioactivity for 99mTc(CO)3-
DPA-Ale-NPs in the liver and spleen could be attributed to increased stability of the BP-NP 
interaction, whereas the fluoride interaction rapidly dissociates when taken up by the 
macrophages, presumably a consequence of the acidic environment within macrophage 
lysosomes. Alternatively, dissociated 99mTc(CO)3-DPA-Ale might remain trapped within cells, or 
dissociate to smaller HA particle fragments that are excreted renally.   
 
7.7 Conclusion 
In this chapter we have confirmed that HA and Alhydrogel particles are sequestered within 
macrophages using transmission electron microscopy. In addition, it was possible to track the 
in vitro fate of HA nanoparticles labelled with a fluorescent FITC tag. Moreover, the 
HA1PAMFITC nanoparticles were sufficiently stable in vitro to be used for this purpose. In vitro 
studies suggested that it is possible to efficiently label intracellular nanoparticles with 
99mTc(CO)3-DPA-Ale. However, these results were not conclusive since extracellular binding of 
tracer to the nanoparticle could not be ruled out.  
 
The in vivo studies in normal mice showed that 99mTc(CO)3-DPA-Ale-HA2HMP1, HA2PEGBP1 
and Alhydrogel particles were highly stable and can be monitored by SPECT/CT. The in vivo 
biodistribution of HA nanoparticles was influenced by surface modifications, controlling size, 
surface chemistry and charge. The highly aggregated HA2 nanoparticles, labelled with 18F-
fluoride, have been shown to accumulate in the lungs.1 The introduction of stabilsing ligands 
to HA directed uptake to the liver or spleen, corresponding to reduced aggregation. 
Furthermore, the particles could be tailored to accumulate in either the liver or spleen. The 
introduction of hydrophilic PEG ligands helped to bypass liver phagocytosis and trap particles 
(> 200 nm) in the spleen, presumably via a filtration mechanism. Negatively charged 
HA2HMP1 and positively charged Alhydrogel (30 mV, measured at pH 7.4 as in chapter 3) 
were directed towards liver and spleen uptake respectively. The in vivo stability 99mTc(CO)3-





The in vivo PET/CT studies in normal mice with 64Cu-BPAMD indicated that it may be a useful 
bone imaging agent, as it displayed high bone uptake of the tracer and relatively low liver and 
spleen accumulation at 3 h.  The 64Cu-BPAMD labelled HA1PEGBP1 nanoparticles had a 
preference for spleen uptake and no translocation of activity to bone was observed, indicating 
high in vivo stability of the 64Cu-BPAMD-HA interaction, unless free copper was released from 
the DOTA complex, which would accumulate in the liver and gut (M. Cooper, unpubilished 
results).  
 
Preliminary pretargeting  studies with 99mTc(CO)3-DPA-Ale have indicated that it is possible to 
label Alhydrogel particles in vivo, either while circulating in blood or trapped within the 
spleen. The liver and spleen uptake was significantly increased when the chasing injection was 
rapid (2 minutes after particle injection). This might correlate to in vivo labelling of 
unphagocytosed particles in the spleen and liver. However, labelling of nanoparticles in the 
blood pool cannot be ruled out. In contrast, there was much lower uptake seen in liver and 
spleen for pretargeting experiments with a chasing injection at 20 minutes, associated to 
inaccessible phagocytosed particles. 
 
In conclusion, these experiments have indicated that the 99mTc(CO)3-DPA-Ale-HA and -
Alhydrogel interaction are highly stable in vivo. In addition it was possible to label Alhydrogel 
particles in vivo, whether the labelling occurs in the liver, spleen or blood is not yet concluded.  
The results were very encouraging for future studies since it confirms the 99mTc(CO)3-DPA-Ale-
Alhydrogel interaction can occur in vivo and compete with characteristic bone uptake of the 
free radiolabelled ligand. Preliminary in vivo studies have also demonstrated the bone 
targeting capabilities of the 64Cu-BPAMD ligand and in vivo stability of the 64Cu-BPAMD-HA 
interaction. Future studies will focus on pretargeting experiments with 18F-fluoride, 64Cu-
BPAMD and further 99mTc(CO)3-DPA-Ale studies. Ultimately, strategies that actively target 
nanoparticles to disease sites will be required for proof of the pretargeting strategy in vivo. 
Before this can be achieved, HA preparations or other nanoparticles require a reduction in size 
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Summary of Work 
In this thesis, we aimed to identify nanoparticle materials with high intrinsic affinity for simple 
radionuclide probes, such as 18F-fluoride and 99mTc-bisphosphonates, and exploit them in a 
novel pretargeting strategy. Conventional particulate radiopharmaceuticals in routine use are 
limited to passive targeting strategies, often associated with poor homogeneity, with variable 
radiolabelling and particle properties. In contrast, modern radiolabelled nanoparticle designs 
often aim to actively target disease sites. However, they typically involve complicated labelling 
protocols with multiple steps. We aimed to directly label nanoparticle surfaces without the 
need for complex reactions or purification steps.  Designing new molecular imaging agents 
based on nanoparticles requires a material that satisfies a number of criteria: efficient and 
rapid labelling under facile conditions, functionalisable for targeting and stabilising purposes, 
homogenous nature to provide consistent labelling and biodistribution, means of attaching a 
stable radiolabel, and biocompatibility. 
 
Key conclusions: 
 Chapter 1: Requirement for a novel radiolabelling strategy  
 Chapter 2: Alhydrogel and hydroxyapatite nanoparticles selected as promising 18F-
fluoride binding materials.  
 Chapter 3: Calcination and hydrothermal post-synthesis treatments controlled 
hydroxyapatite particle morphology and size. Bisphosphonates can be used to 
functionalise HA surfaces.  
 Chapter 4: Hollow porous silica shells prepared via a novel templating method, using 
HA as a core material. 
 Chapter 5: Synthesis of a novel bifunctional bisphosphonate bis(quinoylmethyl)- 
pamidronate-amine (BQMPA). Preparation of a 64Cu labelled macrocycle-
bisphosphonate, 64Cu-BPAMD. 
 Chapter 6: Alhydrogel and hydroxyapatite nanoparticles selected as promising 99mTc-
DPA-Ale binding materials. Bisphosphonate functionalised nanoparticles can be 
radiolabelled.  






18F-Fluoride Binding Studies 
Initial studies focused on 18F-fluoride because of its simplicity and availability. We investigated 
the 18F-fluoride binding properties of nanoparticulate materials under various conditions. Our 
initial survey identified hydroxyapatite (HA) and Alhydrogel as promising materials, providing 
facile rapid labelling with 18F-fluoride. They have bound 18F-fluoride efficiently at low particle 
concentrations, applicable for in vivo studies. Efficient labelling was achieved in the presence 
of various biological and potential competitors. In particular, the 18F-HA interaction has proven 
robust under biological conditions, with only minor dissociation seen over time in serum. 
However, the serum stability of 18F-fluoride bound to Alhydrogel appeared less robust, and 
may only be suitable for shorter molecular imaging studies, unless further modified to curtail 
degradation. 
 
Preparation of Hydroxyapatite 
HA materials were prepared via wet chemical precipitation. Synthesis temperature did not 
greatly affect particle properties, while calcination and hydrothermal post-synthesis 
treatments controlled particle morphology and crystallinity. Hydrothermally treated particles 
were rod-like and highly crystalline while calcined particles were crystalline and possessed a 
rounded irregular morphology. Size measurement studies revealed that unfunctionalised HA 
particles: HA1, HA2 and HA3 were highly aggregated in solution (ca. 2-4 µm). The particles 
were stabilised in 0.1% sodium hexametaphosphate (SHMP) solutions leading to reduced 
aggregate size, and HA1, HA2, and HA3 were measured at 224, 105 and 145 nm respectively. 
Furthermore, particles functionalised with SHMP and PEGBP (polyethyleneglycol–
bisphosphonate) were stable in solutions over a period of 24 h and 1 h for HA1 and HA2 
respectively. X-ray photoelectron spectroscopy (XPS) analysis indicated that peptide 
conjugation via pamidronate amine groups on HA surfaces is possible. Therefore, 
bisphosphonates provide a potential, simple two step method for functionalisation of HA 
surfaces, with small molecules or peptides. This approach provides a valuable pathway for 
derivatising HA nanoparticles for in vivo targeting purposes. 
 
Prepartion of Porous Hollow Silica  
Porous hollow silica particles were prepared via a novel templating method, using the HA 
nanocrystals as a core material. The morphology of the hollow silica structures was controlled 
and tailored according to the nature of HA template. Due to the large surface areas, porous 
nature, and the control that can be exercised over their shape, these hollow silica shells may 




materials were highly aggregated and 18F-fluoride showed poor affinity for them. Therefore, 
further studies, with a view to pretargeting were not pursued with these materials and their 
applications may lie in other areas.     
 
Bisphosphonate Synthesis 
We aimed to exploit the high affinity bisphosphonate-HA interaction for multiple purposes: 
radiolabelling, stabilising, and attachment of targeting moieties. The concept can be applied to 
developing directly labelled nanoparticles (radiolabelled prior to injection) or pretargeted 
nanoparticles (radiolabelled bisphosphonate “chases” nanoparticles in vivo). A novel 
bifunctional bisphosphonate chelator - bis(quinoylmethyl)pamidronate-amine - was prepared 
with a view towards fluorescent and radionuclide in vitro and in vivo  imaging studies. Its 
application as a multimodal bifunctional chelating agent is limited by the poorly defined 
nature of its complexes. Labelling with [Re(CO)3(H2O)3]
+ and [99mTc(CO)3(H2O)3]
+ ligands 
identified the formation of multiple complexes. However, the binding of 99mTc(CO)3-BQMPA to 
HA1 indicates that the mixed complexes retain high affinity for HA, therefore, the BQMPA 
ligand might be useful as a bone imaging agent. However, our aim within this thesis was to 
produce a well defined imaging agent, ensuring consistent in vitro and in vivo behaviour for 
pretargeting nanoparticles. For this reason, we chose to exploit a ligand that gives a well-
defined single technetium complex, dipicolylamine-alendronate (DPA-Ale) (a literature 
compound), for the basis of bisphosphonate-nanoparticle binding experiments within this 
thesis (discussed below), instead of BQMPA.  
 
A novel radiolabelled DOTA-bisphosphonate derivative, 64Cu-BPAMD complex has been 
prepared from the literature compound, BPAMD, and was labelled with 64Cu(OAc)2 at 
concentrations as low as 173 µM. FT-IR analysis indicated exclusive labelling of the 
macrocyclic moiety and not the bisphosphonate group. The 64Cu-BPAMD complex was stable 
in serum and PBS over 24 h, while dissociation to “free” copper was not observed. The results 
indicated that a kinetically stable 64Cu-BPAMD complex was prepared. The in vivo 
biodistribution of this 64Cu-BPAMD complex showed its potential for use in PET imaging and 
radiotherapy for the diagnosis and treatment of bone diseases in its own right. However, 
within the scope of this thesis, developing a pretargeted nanoparticle concept was the aim. 
The 64Cu-BPAMD complex provides a platform to investigate binding properties of the BPAMD 
ligand with various materials. Moreover, the BPAMD ligand has the potential to form stable 
Gd(III) and Eu(III) complexes for MRI and optical imaging, reported in literature.  Therefore, 




imaging modalities. Preliminary nanoparticle binding studies with the 64Cu-BPAMD complex 
identified that it can bind efficiently to a wide range of metal oxide materials.  Labelling 
studies showed that 64Cu-BPAMD-HA binding interaction occurs rapidly in 50 mM TRIS buffer 
(pH 7.4) and is robust in biological conditions. Stabilised HA1HMP1 and HA1PEGBP1 particles 
were labelled 64Cu-BPAMD in high efficiency and biological stability.  
 
 In vivo PET/CT studies in normal mice with 64Cu-BPAMD indicated that it may be a useful bone 
imaging agent in its own right, displaying high bone uptake of the tracer and relatively low 
liver and spleen accumulation at 3 h. 64Cu-BPAMD labelled HA1PEGBP1 nanoparticles showed 
high spleen uptake with and no translocation of activity to bone, indicating high in vivo 
stability of the 64Cu-BPAMD-HA interaction, unless free copper is released from the DOTA 
complex, which is expected to accumulate in the liver and gut.  
 
Bisphosphonate Binding Studies 
A material binding survey revealed that 99mTc(CO)3-DPA-Ale can bind efficiently to a wide 
range of metal oxide materials. The binding efficiency was significantly greater than 99mTc-
MDP for corresponding materials. The binding of  99mTc(CO)3-DPA-Ale to metal oxide surfaces 
was achieved in a simple one step reaction, in aqueous solution, without the need for 
complicated reaction or purification steps. An additional step was required to prepare the 
radiolabelled bisphosphonate ligand. HA and Alhydrogel were identified as promising 
biocompatible materials, continuing from the promising 18F-fluoride binding results. They have 
bound 99mTc(CO)3-DPA-Ale efficiently at low concentrations applicable to in vivo studies. 
Efficient labelling has been achieved in the presence of various biological and potential 
competitors. The 99mTc(CO)3-DPA-Ale-HA and Alhydrogel interactions were proven robust 
under biological conditions, with only minor dissociation seen over time in serum. In addition, 
there is potential to moderately load HA nanoparticles with functionalising bisphosphonate 
ligands, leaving sufficient space for radiolabelled bisphosphonates to bind with high efficiency. 
More specifically, stabilised HAHMP and HAPEGBP particles were labelled with high efficiency 
and biological stability. Bisphosphonate functionalised HA particles have the potential to 
operate as a platform for radiolabelling with either 18F-fluoride or 99mTc(CO)3-DPA-Ale, 
introducing a multifunctional nanoparticle platform for radionuclide delivery.  
 
In Vivo Pretargeting Studies   
A series of in vitro and in vivo studies with prelabelled and pretargeted HA and Alhydrogel 




phagosomes inside macrophages. It was possible to track the in vitro fate of HA nanoparticles 
labelled with a fluorescent FITC tag. In vitro studies investigating the radiolabelling of 
intracellular nanoaparticles with 99mTc(CO)3-DPA-Ale and 
18F-fluoride were inconclusive since 
extracellular binding of tracer to the nanoparticle cannot be ruled out. The HA and Alhydrogel-
99mTc(CO)3-DPA-Ale particle-radiolabel interaction remains intact and is highly stable in vivo. 
Therefore, the in vivo fate of these radiolabelled nanoparticles can be monitored by SPECT/CT. 
Specifically, in vivo studies in normal mice showed that the biodistribution of HA nanoparticles 
can be controlled by surface modifications, controlling size, surface chemistry and charge. The 
highly aggregated HA2 nanoparticles, labelled with 18F-fluoride, have been shown to 
accumulate in the lungs. The introduction of stabilising ligands directed uptake to the liver or 
spleen, corresponding to reduced aggregation. Furthermore, the particles can be tailored to 
accumulate in either the liver or spleen by functionalisation with SHMP or PEGBP ligands 
respectively.  
 
Preliminary pretargeting  studies with 99mTc(CO)3-DPA-Ale have indicated that it is possible to 
radiolabel Alhydrogel particles in vivo, although whether the labelling occurs in the liver, 
spleen or blood has not been concluded. The liver and spleen uptake was significantly 
increased when the chasing injection was rapid (2 minutes after particle injection), potentially 
correlated to in vivo labelling of unphagocytosed particles trapped in the spleen and liver. In 
contrast, there was much lower uptake seen in liver and spleen for pretargeting experiments 
with a chasing injection at 20 minutes, possibly relating to already phagocytosed particles 
being relatively inaccecssible. This inaccessibility of sequestered particles can be considered 
beneficial with respect to the pretargeting concept. Macrophages within the 
reticulendothelial system provide a clearance mechanism for untargeted nanoparticles, when 
the particles are engulfed by macrophages they could be invisible to the radiolabel probe, 
thereby reducing background interference from untargeted nanoparticles. Both HA and 
Alhydrogel provide a promising nanoparticle base, with biocompatibility and low toxicity, for 
the development of new molecular imaging agents 
 
Future Work 
Preliminary pretargeting studies within this thesis have identified that it is possible to 
radiolabel Alhydrogel particles with 99mTc(CO)3-DPA-Ale in vivo. The work within this thesis 
can be divided into four phases- (1) selection of nanomaterials (2) development of 
nanomaterials (3) development of functionalisation methodology and (4) Proof of the 




fine tuning of nanoparticles properties for application in the pretargeting concept. This thesis 
started with a review of 18F-fluoride labelling properties of nanomaterials and progressed to 
the use 99mTc(CO)3-DPA-Ale as a pretargeting radiolabel probe. 
99mTc(CO)3-DPA-Ale was 
selected for initial pretargeting studies since its interaction with HA and Alhydorgel was robust 
in biological media, in contrast to the 18F-Alhydrogel interaction, which dissociates more 
rapidly. However, as a direct continuation form this work, a set of preliminary pretargeting 
experiments with 18F-fluoride, and HA and Alhydrogel nanoparticles should be carried out.  
Preliminary pretargeting studies will continue with 99mTc(CO)3-DPA-Ale and Alhydrogel. In 
these studies, further pretargeting timepoints (e.g. between 2 and 20 min) will be 
investigated, to gain a better understanding of the in vivo binding interaction. To aid these 
studies, prelabelled 99mTc(CO)3-DPA-Ale-Alhydrogel will help identify the biodistribuition of the 
particles at early time points.  
 
A major component of the pretargeting study that is yet to be investigated, within the scope 
of this thesis, is the development of targeted nanoparticles. We have identified that it is 
possible to link small molecules (e.g. amino acids) through bisphosphonate ligands on the 
surface of HA nanoparticles. In conjunction with this work, methodology for derivatising 
nanoparticles surfaces utilising the bisphosphonate ligands is underway. Preliminary studies 
(not reported within this thesis) involving the development of a maleimide bisphosphonate 
molecule have shown good promise for linking small molecules or peptides to HA surfaces (P. 
Williamson, unpublished work) In addition, development of a polyethyleneglycol maleimide 
bisphosphonate, which would provide particle stabilisation in aqueous solution and means for 
linking peptides, via the maleimide moiety is underway. Proof of the pretargeting concept for 
targeted particles in vivo will be studied. Initially, the ability to passively target tumours, 
exploiting enhanced permeability and retention (EPR) effect, using tumour models such as 
glioblastoma and the Alhydrogel and HA particles will be investigated. However, it is 
envisaged that the large size of these particle will limit the tumour accumulation via the EPR 
effect. Therefore it is anticipated that further development of the nanoparticles will be 
required. The preliminary in vivo results from chapter 7 suggest that even the PEG stabilised 
HA nanoparticles are large enough to be rapidly trapped within the spleen via its filtration 
mechanism.  Therefore we suggest that particles with smaller sizes (e.g. < 100 nm) should be 
developed.  Moreover, the choice of nanoparticles is not limited to HA and Alhydrogel, as 
identified by the radiolabel binding surveys in chapters 2 and 6. Further studies should aim to 




earth metal oxides in the form M2O3, where M = Eu, Er, Yb, and Gd. However, the 
biocompatibility and toxicity issues related to these materials must be considered.  
 
This thesis has provided evidence that nanoparticles can be radiolabelled in vivo. This is a 
major step forward in the development of a pretargeted nanoparticle strategy for molecular 
imaging. In addition, it is possible to pre-label (label prior to injection) HA and Alhydrogel 
nanoparticles with simple radiolabelled probes (e.g. 18F-fluoride and 99mTc-bisphosphonates) 
with high loading rates, efficiencies, and biological stability. The simple one step (18F-fluoride ) 
and two step (99mTc-bisphosphonates) labelling protocols for prelabelled nanoparticles offers 
an interesting alternative platform for developing radiolabelled nanoparticles for targeted 
molecular imaging, without pretargeting. The use of bisphosphonates as bifunctional 
chelators widens the choice of imaging modality and radionuclide that can be exploited for 
the both pretargeting and prelabelled nanoparticles, extending their potential to radionuclide 












Figure 2.10: Survey of 18F-fluoride binding materials 
Material Labelling efficiency (%) Standard error 
Alhydrogel 95.28327 0.216511 
HA1 92.24 0.3392 
CeO2 86.55177 0.63796 
Er2O3 85.82446 0.074015 
Al2O3 64.45972 1.067489 
Y2O3 62.2262 2.606082 
MgO 38.87417 3.233004 
Eu2O3 34.25282 1.321575 
Dy2O4 23.54106 0.775335 
Co3O4 11.90524 0.359309 
Ca2O7P2 11.77792 1.33812 
Mn2O3 11.71174 0.429507 
Yb2O3 10.93284 0.46475 
CaO 10.8229 0.436966 
TiO2 10.1953 1.283689 
CaHPO4 7.866781 1.559478 
Fe2O3 7.848719 1.672394 
Ag 7.64569 0.682949 
ZrO2 7.357295 1.117395 
Ho2O3 6.00316 1.161501 
CaCo3 5.137228 1.212308 
SiO2 4.687102 0.98249 
Al 4.504383 1.734149 
Sn2O3 4.261018 1.1075 
In2O3 4.109893 0.911139 
SiO2-Al 3.772384 0.274658 




CuO 3.312615 1.485552 
Sb2O3 2.817235 1.518394 
ZnO 2.063755 1.098709 
Gd2O3 1.769478 1.000533 
Bi2O3 0.631968 1.384373 
HA2 96.77 0.0027 
HA3 98.93 0.2193 
CeO2 86.55177 0.63796 
 
Figure 2.12: 18F-fluoride binding affinity curve for hydroxyapatite, HA1 
Concentration 
mg/mL 
Labelling efficiency (%) Standard error 
0.05 27.34171 1.58244 
0.1 56.46395 1.56016 
0.4 76.52766 2.9558 
0.2 66.27884 0.65245 
0.5 81.2282 0.4458 
0.3 73.96559 0.82647 
0.7 86.21138 7.25162 
0.6 81.10108 0.7888 
0.8 87.29032 0.27136 
0.9 88.44285 0.53502 
1 89.03703 0.41952 
1.5 92.17651 2.13612 
2 93.57756 0.81879 
 
Figure 2.13: 18F-fluoride binding affinity curve for Hydroxyapatite, HA2 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
2 99.57903 0.08343 
1.5 98.82028 0.20648 
1 98.38603 0.13934 




0.75 95.99266 0.68427 
0.25 90.22167 1.10758 
0.1 64.31543 0.87239 
0.05 43.89112 2.43004 
0.01 14.89835 0.22279 
1E-3 4.80163 0.77491 
 
Figure 2.14: 18F-fluoride binding affinity curves for Hydroxyapatite, HA3 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
1 99.67696 0.118 
0.75 97.56083 0.29197 
0.5 83.25763 0.63057 
0.25 70.74497 0.64437 
0.1 50.34805 0.70685 
0.05 24.88651 0.85107 
0.01 17.48278 0.74734 
1E-3 3.95171 0.54389 
 
Figure 2.15: 18F-fluoride binding affinity curve for Alhydrogel (Al(OH)3) 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
0.025 34.20333 1.028163 
0.05 42.67305 2.588471 
0.1 73.04662 0.624474 
0.2 80.37497 0.67147 
0.3 84.51055 1.667687 
0.4 86.81483 1.85152 
0.5 88.50567 0.374999 
0.6 87.78402 0.558839 
0.7 89.11738 1.633021 
0.8 89.14491 0.674946 
0.9 90.93395 0.233453 

























deviation   
 1 mg/mL 
Standard 
deviation   
 0.5 mg/mL 
Standard 
deviation   
 0.1 mg/mL 
-8 89.9 85.16038 38.3653 0.23 0.746697 0.94771 
-7 86.56993 82.75898 36.43736 0.391511 0.356699 0.762171 
-6 72.26059 61.08651 24.08539 0.34523 1.481164 1.824683 
-5 35.08094 20.68357 6.653421 0.958892 1.353875 1.568011 
-4 8.669011 8.406318 3.746505 0.614714 0.432739 0.7418 
-3 2.215673 5.342921 2.562973 0.72052 0.16353 0.996222 
-2 0.688035 3.864893 1.70962 0.52861 0.324846 0.193047 
 



















deviation   
 1 mg/mL 
Standard 




deviation   
 0.1 
mg/mL 
-5 91.84164 86.5319 69.59865 0.32637 1.117148 0.44034 
-4 91.51927 86.23915 67.13664 0.580115 0.311388 1.337181 
-3 90.08114 82.55555 51.90286 0.840602 0.550924 1.52591 
-2 84.87306 56.39389 17.65279 1.344027 0.683321 2.332449 
-1 23.98089 12.07901 1.864755 0.422655 0.751393 1.076971 
 
Figure 2.18: Binding of 18F-fluoride to Hydroxyapatite (HA1) and in the presence of competitors 
Log competitor Concentration 
 
Labelling efficiency (%) Standard error 
Tris -1 60.9594 0.453203 
Tris -2 76.36108 0.580835 
Tris -3 83.89139 0.155967 




NaH2PO4 -1 3.414839 0.658326 
NaH2PO4 -2 8.348741 1.430103 
NaH2PO4 -3 27.54702 0.738087 
NaH2PO4 -4 81.45112 0.506117 
NaCl -1 85.31462 0.891626 
NaCl -2 83.76973 1.730428 
NaCl -3 85.14999 0.787721 
NaCl -4 84.56488 0.37488 
CaCO3 -1 13.93981 0.472248 
CaCO3 -2 28.35732 0.679079 
CaCO3 -3 52.7686 0.512814 
CaCO3 -4 82.6469 0.851853 
HMP -1 43.67699 0.082184 
HMP -2 24.21031 0.77864 
HMP -3 19.92409 1.116411 
HMP -4 33.24283 1.751471 
BP -1 58.98674 0.754084 
BP -2 73.20632 0.466301 
BP -3 73.42723 0.44583 
BP -4 76.54862 1.986229 
Citrate -1 42.6933 0.962617 
Citrate -2 49.8052 0.909299 
Citrate -3 61.14174 0.354734 
Citrate -4 76.39019 0.421816 
 
Figure 2.19: Binding of 18F-fluoride to Alhydrogel in the presence of competitors 
Log competitor Concentration Labelling efficiency (%) Standard error 
NaCl 0 98.6 0.8 
NaCl-0.3 97.8 0.6 
NaCl-1 98.5 0.1 
HMP-1 7.5 1.6 




HMP-3 77.2 0.5 
HMP-4 89.8 0.4 
Citrate-1 10.4 0.7 
Citrate-2 20.1 0.8 
Citrate-3 39.5 0.9 
Citrate-4 87.4 0.5 
Citrate-5 90.2 0.5 
BP-1 68.8 0.3 
BP-2 69.4 0.5 
BP-3 80.5 1.2 
BP-4 86.8 1.6 
BP-5 88 1.1 
 
Figure 2.20: Binding of 18F-fluoride to hydroxyapatite competitors over time HA1  
Media Time (min) Labelling efficiency (%) Standard error 
Water 60 98.29 0.28 
 20 99.72 0.0714 
 10 99.45 0.07 
 5 98.93 0.2193 
Tris-HCl 60 82.6 1.83 
 20 74.47 1.971 
 10 87.36 0.7 
 5 61.16 0.343 
PBS 60 89.48 0.61 
 20 77.46 1.11 
 10 74.38 1.5 
 5 68.57 0.73 
DMEM 60 68.27 1.11 
 20 45.91 3.47 
 10 36.4 1.42 
 5 32.39 3.13 




 20 68.74 1.683492 
 5 65.06179 2.789987 
 
Figure 2.20: Binding of 18F-fluoride to hydroxyapatite competitors over time HA2  
Media Time (min) Labelling efficiency (%) Standard error 
Water 60 97.52 0.19 
 20 96.9 0.7337 
 10 95.99 0.0858 
 5 96.77 0.0027 
Tris-HCl 60 80.88 3.31 
 20 91.45 0.345 
 10 86.92 0.32 
 5 87.25 0.325 
PBS 60 72.66 1.27 
 20 68.54 0.73 
 10 63.18 0.36 
 5 85.96 0.34 
DMEM 60 53.68 1.43 
 20 47.08 1.65 
 10 49.89 2.95 
 5 43.17 3.22 
Serum 60 76.25 2.556668 
 20 58.42 4.653305 
 5 71.93912 0.849834 
 
Figure 2.20: Binding of 18F-fluoride to hydroxyapatite competitors over time HA3 
Media Time (min) Labelling efficiency (%) Standard error 
Water 60 94.3 0.74 
 20 89.05 0.4195 
 10 92.36 0.4196 
 5 92.24 0.3392 




 20 75.89 1.777 
 10 76.38 0.45 
 5 69.6 0.9956 
PBS 60 80 1.24 
 20 72.24 1.07 
 10 70 3.75 
 5 92.31 0.22 
DMEM 60 72.24 1.28 
 20 50.12 0.81 
 10 49.55 1.97 
 5 41.05 2.83 
Serum 60 89.57 1.165551 
 20 66.33 3.006177 
 5 64.22775 1.602764 
 
Figure 2.21: Kinetic stability of 18F-fluoride labelled  HA1 in serum 
Time (min) Labelling efficiency (%) Standard error 
30 97.77331 0.584947 
60 96.84056 0.431037 
180 97.82401 0.161096 
 
Washing stabilty of 18F-fluoride labelled  HA1 in water 
Wash number Labelling efficiency (%) Standard error 
W1 93.84734 0.137449 
W2 94.89734 0.334038 
W3 96.18406 0.033195 












Examples of typical XPS survey scans 
 
Example of a wide scan, HA1. wide scans were taken on each sample, surveying the elements 




Typical set of high resolution scans for HA1 (charge corrected to C 1s at 285eV) The red line is 
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1H NMR [(2-Chloro-acetylamino)-(diethoxy-phosphoryl)-methyl]-phosphonic acid ethyl ester 
methyl ester (5) 
13C NMR of N,N-bis(quinoylmethyl)pamidronate-amine-(BQMPA) 
 
 





RP-HPLC of BQMPA using method B,  Rt = 15.31 min.  
 




































Absorbance spectrum of Cu-BPAMD. Absorption peak centered at 716 nm.  
 
Chapter 6 
Figure 6.3: Survey of 99mTc(CO)3DPA-Ale binding materials 
Material Labelling efficiency (%) Standard error 
HA2 92.97284 0.103499 
HA1 91.8339 1.172312 
Alhydrogel 91.63961 0.106983 
Al2O3 87.88514 0.435878 
CeO2 85.56593 0.717605 
ZrO2 84.95505 0.095393 
Co3O4 83.1396 0.273974 
MgO 82.01617 0.691259 
In2O3 81.88399 0.487814 
Bi2O3 81.61713 0.264229 
Y2O3 79.29344 0.696188 
Fe2O3 78.65016 1.041995 
Dy2O3 72.10864 0.501948 
CaCO3 68.34856 1.386144 
Ho2O3 67.85715 0.155876 
Yb2O3 63.52682 0.6405 
ZnO 60.79506 14.22171 
Ca3(PO4)2 45.17834 1.71713 
TiO2 43.03571 4.598656 
CaC2O4 23.44961 0.354988 
SiO2 22.23979 1.995161 




CuO 18.30065 2.454009 
Sb2O3 8.684245 4.040544 
Ag -0.05773 1.189685 
 
Figure 6.4: Survey of 99mTc-MDP binding materials 
Material Labelling efficiency (%) Standard error 
MgO 84.94763 7.5852 
Al2O3 79.42658 1.683196 
Y2O3 73.253 1.586605 
HA2 65.3035 0.475468 
Bi2O3 64.50136 1.373819 
HA1 51.77747 4.500366 
ZnO 50.64044 2.765263 
CeO2 46.24574 0.413278 
ZrO2 43.61113 1.506517 
Fe2O3 40.36039 2.899776 
In2O3 30.60128 1.28634 
HA3 28.38953 0.884616 
Dy2O3 24.75219 0.816434 
Ho2O3 24.16322 1.296542 
Gd2O3 21.02671 1.106655 
SnO2 8.005298 0.658788 
Yb2O3 5.5098 1.882481 
TiO2 5.467026 0.195596 
Co3O4 0.006043 0.508976 
Ag 0.000876 0.70326 
CuO -0.58731 0.351011 









Figure 6.6: 99mTc(CO)3-DPA-Ale binding to HA1 at various concentrations 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
2 93.55992 0.05242 
1.5 93.30405 0.0644 
1 91.8339 1.17231 
0.75 91.47464 0.46787 
0.5 92.47085 0.32751 
0.1 89.95837 1.67646 
0.05 88.36079 0.48505 
0.01 41.88655 0.92068 
0.005 23.64741 1.57992 
 
Figure 6.7: 99mTc(CO)3-DPA-Ale binding to HA2 at various concentrations 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
2 93.38178 0.10699 
1.5 92.4417 0.76756 
1 92.97284 0.1035 
0.75 92.01869 0.523 
0.5 91.39122 0.65587 
0.25 89.63172 0.48129 
0.1 89.12021 0.14881 
0.05 88.32293 0.16529 
0.01 66.46204 0.75681 
0.005 36.95901 1.17613 
 
Figure 6.8: 99mTc(CO)3-DPA-Ale binding to Alhydrogel at various concentrations 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
1 91.63961 0.10698 
0.75 91.24777 0.12986 
0.5 90.55599 0.92402 
0.25 85.75408 4.0058 




0.05 42.02298 6.94531 
0.01 6.16416 0.99877 
0.005 0.63031 0.25164 
1E-3 1.33292 0.41204 
5E-4 0.86625 1.06949 
 
Figure 6.9: 99mTc-MDP binding to HA2 at various concentrations 
Concentration (mg/mL) Labelling efficiency (%) Standard error 
0.0125 27.80086 7.93892 
0.05 36.49731 1.44999 
0.1 46.07535 1.99833 
0.2 60.70138 1.46256 
0.3 58.10178 1.69472 
0.4 58.31411 1.17823 
0.5 58.49304 1.19346 
0.6 59.66508 0.96569 
0.8 61.16943 1.22166 
1 60.66729 2.22402 
 
 










HA (no DPA) HA 1mg/mL 93.43031 0.208433 
0 HA 0.5mg/mL 90.71549 0.32115 
0 HA 0.1mg/mL 90.26189 0.536334 
-1 HA 1mg/mL 5.358489 2.624691 
-1 HA 0.5mg/mL -1.8779 0.394515 
-1 HA 0.1mg/mL -3.83758 7.270905 
-2 HA 1mg/mL 37.29339 1.019279 
-2 HA 0.5mg/mL 0.888667 5.293694 




-3 HA 1mg/mL 58.01973 9.927076 
-3 HA 0.5mg/mL 34.63566 11.94999 
-3 HA 0.1mg/mL 21.46633 1.569534 
-4 HA 1mg/mL 91.60069 0.472545 
-4 HA 0.5mg/mL 90.47734 0.215359 
-4 HA 0.1mg/mL 86.9689 0.764011 
-5 HA 1mg/mL 91.41004 1.073743 
-5 HA 0.5mg/mL 90.0894 0.214985 
-5 HA 0.1mg/mL 88.74671 0.824268 
-6 HA 1mg/mL 92.94726 0.409468 
-6 HA 0.5mg/mL 91.38115 0.228801 
-6 HA 0.1mg/mL 89.07116 1.028341 
-7 HA 1mg/mL 93.22178 0.217103 
-7 HA 0.5mg/mL 91.482 0.18087 
-7 HA 0.1mg/mL 90.9459 0.338546 
-8 HA 1mg/mL 93.1258 0.411253 
-8 HA 0.5mg/mL 91.59978 0.052495 
-8 HA 0.1mg/mL 91.53311 0.461591 
 
Figure 6.11: Binding of 99mTc(CO)3-DPA-Ale to Alhydrogel (1 mg/mL) in the presence of DPA-
Ale  
Log DPA-Ale concnetration Labelling efficiency (%) Standard error 
-1 -0.17132 1.11179 
-2 0.155407 0.676626 
-3 10.2334 1.248589 
-4 95.17651 0.077061 
-5 95.37789 0.091332 
-6 95.4131 0.072845 
-7 95.412 0.043284 







Figure 6.12: Binding of 99mTc(CO)3-DPA Ale to HA1 (1 mg/mL) in the presence of competitors 
Log competitor Concentration Labelling efficiency (%) Standard error 
Citrate -1 53.24229 1.765824 
Citrate -2 86.08511 4.171231 
Citrate -3 93.18321 0.0861 
Citrate -4 88.48514 4.868112 
Citrate -5 89.53603 4.726021 
Carbonate -1 91.59926 0.169726 
Carbonate -2 93.41409 0.177954 
Carbonate -3 94.23892 0.148375 
Carbonate -4 93.29637 0.623245 
Carbonate -5 92.34889 1.817328 
HMP -1 -2.48196 0.998956 
HMP -2 -1.93123 1.294369 
HMP -3 4.014189 0.259524 
HMP -4 44.4628 11.61401 
HMP -5 92.74701 0.251626 
CTAB -1 47.29101 2.005635 
CTAB -2 84.49049 0.397682 
CTAB -3 87.21778 0.807686 
CTAB -4 87.73373 0.20762 
CTAB -5 82.59147 0.985919 
Phosphate -1 12.14151 0.50737 
Phosphate -2 70.68954 0.371654 
Phosphate -3 82.77689 0.612317 
Phosphate -4 84.30354 0.478282 
Phosphate -5 84.09379 0.893835 
NaCl -1 53.93461 1.101867 
NaCl -2 74.9977 0.514353 
NaCl -3 76.7668 2.804621 
NaCl -4 80.31382 0.376606 





Figure 6.13: Binding of 99mTc(CO)3-DPA-Ale to Alhydrogel (1 mg/mL) in the presence of 
competitors 
Log competitor Concentration Labelling efficiency (%) Standard error 
Tris -1 91.96203 0.153422 
Tris -2 92.36393 0.060101 
Tris -3 93.70598 0.023797 
Tris-4 94.25356 0.007187 
NaH2PO4 -1 23.04986 1.45998 
NaH2PO4 -2 76.48608 0.052075 
NaH2PO4 -3 91.72475 0.124882 
NaH2PO4 -4 93.97631 0.118455 
NaCl -1 93.69013 0.164689 
NaCl -2 93.88145 0.024899 
NaCl -3 94.12306 0.140684 
NaCl -4 93.71134 0.135746 
CaCO3 -1 89.81196 0.403497 
CaCO3 -2 92.68909 0.057228 
CaCO3 -3 93.25072 0.071628 
CaCO3 -4 93.9707 0.062841 
Citrate -1 0.931626 0.670555 
Citrate -2 1.216423 0.754923 
Citrate -3 8.452183 5.889141 
Citrate -4 90.21147 0.193851 
HMP -1 86.68066 0.266159 
HMP -2 92.75843 0.094987 











Figure 6.14: Binding of 99mTc(CO)3-DPA-Ale to HA1 in different media over 















serum  5 45.86311 0.847337 Tris 5 85.31778 2.825872 
serum 30 62.04094 0.442697 Tris 30 92.10919 0.162167 
serum 60 64.49259 0.827684 Tris 60 91.0458 0.898468 
serum 180 72.47432 0.296348 Tris 180 92.09319 0.367297 
serum 360 74.91424 0.438689 Tris 360 88.20745 0.514489 
H20 5 91.27 0.617357 PBS 5 36.61481 0.238337 
H20 30 92.29499 0.38355 PBS 30 46.29631 0.551122 
H20 60 92.67373 0.437575 PBS 60 50.87347 0.488679 
H20 180 93.53246 0.094958 PBS 180 56.01365 1.258295 
H20 360 88.72672 0.465524 PBS 360 59.30895 0.533363 
 
Figure 6.16: Kinetic stability of 99mTc(CO)3-DPA-Ale-HA1 in water wash 
Wash number Labelling efficiency (%) Standard error 
w1 99.3795 0.10158 
w2 99.08631 0.125798 
w3 98.31352 0.200733 
w4 96.93527 0.508728 
 
Figure 6.16: Kinetic stability of 99mTc(CO)3-DPA-Ale-HA1 in serum 
Time (min) Labelling efficiency (%) Standard error 
1hr 97.99128 0.12371 
2hr 97.97443 0.128291 
6hr 98.45514 0.035845 
18hr 98.6493 0.0523 
 
Figure 6.16: Kinetic stability of 99mTc(CO)3-DPA-Ale-Alhydrogel in water wash 
Wash number Labelling efficiency (%) Standard error 




W2 98.38512 0.351679 
W3 99.63512 0.594856 
 
Figure 6.16: Kinetic stability of 99mTc(CO)3-DPA-Ale-Alhydrogel in serum 
Wash number Labelling efficiency (%) Standard error 
1hr 94.66748 0.271284 
3hr 88.80966 2.542266 
18hr 90.50472 2.514626 
 
Figure 6.20: Survey of 64Cu-(BPAMD) binding materials 
Material Labelling efficiency (%) Standard error 
CeO2 96.43572 0.490729 
HA2 95.86406 0.174056 
HA3 94.6057 0.134026 
Fe2O3 93.77037 0.48937 
Co3O4 93.59101 0.183795 
Al2O3 92.38767 0.794576 
In2O3 91.94106 0.12142 
HA1 89.42077 0.02045 
Bi2O3 89.30429 0.11941 
Dy2O3 89.11207 0.278686 
CaCO3 88.88872 0.139811 
Y2O3 88.86769 0.475852 
ZnO 87.26562 0.14234 
Ho2O3 86.23735 1.355687 
Yb2O3 77.11799 0.898252 
TiO2 76.07682 0.332331 
Ca3(PO4)2 45.43355 0.538834 
Mn2O3 33.60701 2.676925 
SiO2 31.27823 0.499892 
CuO 29.61899 1.208031 




ZrO2 10.97653 0.618595 
SiO2 4.765478 1.019564 
Ag 4.741182 0.43864 
Sb2O3 0.90822 0.341182 
 
Figure 6.21: Binding of 64Cu-BPAMD to HA1 in different media over time in TRIS-HCl buffer 
(pH 7.4) 
Time (min) Labelling efficiency (%) Standard error 
10 88.96435 0.098309 
20 89.02304 0.119638 
30 88.31873 0.109934 
60 88.88189 0.223404 
120 88.16948 0.446541 
 
Figure 6.22: kinetic stability of 64Cu-BPAMD labelled HA1, HA1HMP1 and HA1PEGBP1 in 
water washing 
Wash number Labelling efficiency (%) Standard error 
W1-HA1 99.22662 0.214524 
W2-HA1 97.27522 0.036999 
W3-HA1 98.98171 0.015926 
W4-HA1 98.90365 0.026712 
W1-HA1HMP1 91.4303 1.554629 
W2-HA1HMP1 88.8726 0.440435 
W3-HA1HMP1 87.05029 0.095627 
W4-HA1HMP1 85.64355 0.052459 
W1-
HA1PEGBP1 97.99979 0.146892 
W2-
HA1PEGBP1 97.20636 0.116772 
W3-
HA1PEGBP1 96.04085 0.037678 
W4-





Figure 6.22: kinetic stability of 64Cu-BPAMD labelled HA1, HA1HMP1 and HA1PEGBP1 in 
serum  
HA1 1 hr 91.64892 0.184189 
HA1 24 hr 90.10453 0.754773 
HA1HMP1 1 hr 93.00698 0.319382 
HA1HMP1 24 
hr 91.46872 0.331574 
HA1PEGBP1 1 
hr 91.10482 0.356127 
HA1PEGBP1 
24 hr 90.55638 0.105066 
 
Chapter 7 
Figure 7.7: Biodistribution of intravenously injected, radiolabelled nanoparticles in normal 
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Figure 7.7: Biodistribution of intravenously injected, radiolabelled nanoparticles in normal 
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Figure 7.7: Biodistribution of intravenously injected, radiolabelled nanoparticles in normal 
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Figure 7.9: Biodistribution of intravenously injected 99mTc(CO)3-DPA-Ale in  normal mice at 3 
h, where n=3 mice 
Organ %ID/g Standard deviation 
Intestine 2.861306 2.054781 
Spleen 0.564448 0.2279 
Stomach 1.259237 1.20833 
Kidneys 2.520874 0.586673 
Liver 4.084063 1.505516 
Heart 0.343807 0.087651 
Lung 0.40313 0.22178 
Blood 0.469052 0.174268 
Muscle 0.478881 0.530062 





Figure 7.11: Biodistribution of attempted pretargeting in normal mice at 3 h post radiotracer 
injection. Unlabelled nanoparticles were intravenously injected, then chased by i.v. injected 
tracer  (99mTc(CO)3-DPA-Ale) 20 min later. Alhydrogel  (n=3 mice) 
Organ %ID/g Standard deviation 
Intestine 2.466711941 1.6545608 
Spleen 5.625855742 2.0926554 
Stomach 1.274937316 0.4881987 
Kidneys 2.015167164 0.03786707 
Liver 3.840580746 0.14959843 
Heart 0.388209338 0.18730337 
Lung 0.976321213 0.19987284 
Blood 0.211178228 0.06727384 
Muscle 0.070963486 0.02998459 
Femur 19.39994428 3.2277588 
 
Figure 7.11: Biodistribution of attempted pretargeting in normal mice at 3 h post radiotracer 
injection. Unlabelled nanoparticles were intravenously injected, then chased by i.v. injected 
tracer  (99mTc(CO)3-DPA-Ale) 20 min later. HA2PEGBP1 (n=3 mice) 
organ %ID/g Standard deviation 
Intestine 2.868819 1.844889 
Spleen 1.891258 0.815694 
Stomach 1.206849 0.423299 
Kidneys 2.275344 0.208697 
Liver 3.25459 1.045203 
Heart 0.321179 0.055884 
Lung 1.574028 1.388851 
Blood 0.249222 0.166541 
Muscle 0.203818 0.248882 
femur 21.62872 8.205147 
 
Figure 7.14: Biodistribtuion of attempted pretargeting in normal mice at 3 h post radiotracer 
injection. Unlabelled Alhydrogel was intravenously injected, then chased by i.v. injected 
tracer (99mTc(CO)3-DPA-Ale) 2 min later (n= 3 mice) 
Organ %ID/g Standard deviation 




Spleen 25.84411 8.710354 
Stomach 1.173161 0.869461 
Kidneys 2.526619 0.357425 
Liver 21.76554 6.503959 
Heart 0.290482 0.052772 
Lung 1.144441 0.056215 
Blood 0.383276 0.098329 
Muscle 0.047575 0.020624 
femur 15.60404 4.965014 
 
Figure 7.16; (Top)Biodistribution of Intravenously injected 64Cu-BPAMD in  normal mice at 3 
h, where n=3 mice. (Bottom) Biodistribution of intravenously injected 64Cu-BPAMD at 3 h, 
where n= 3 mice 
Organ %ID/g Standard deviation 
Intestine 1.365464893 0.08477634 
Spleen 0.226957266 0.02033706 
Stomach 1.112847199 0.07124883 
Kidneys 1.529600668 0.24023609 
Liver 2.289601931 0.24402644 
Heart 0.308544663 0.04961398 
Lung 0.899384661 0.09024 
Blood 0.099714655 0.01314286 
Muscle 0.069409556 0.00692561 
Femur  10.57999645 0.76483313 
 
Figure 7.16: (Top)Biodistribution of Intravenously injected 64Cu-BPAMD in  normal mice at 3 
h, where n=3 mice.(Bottom) Biodistribution of intravenously injected labelled HA1PEGBP1 
at 3 h, where n= 3 mice 
Organ %ID/g Standard deviation 
Intestine 3.798590535 0.51736894 
Spleen 64.45593796 27.1312151 
Stomach 2.011371127 1.24467238 
Kidneys 3.391189187 0.60928029 




Heart 1.484286307 0.15750767 
Lung 5.359640346 1.06054518 
Blood 0.480461913 0.21977948 
Muscle 0.281775144 0.03760536 
Femur 2.198827036 0.27592652 
 
 
